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1.1 Transition Metal-Catalyzed C–H Functionalizations 
Transition metal-catalyzed cross-coupling reactions of organic electrophiles and organometallic reagents have 
emerged as a tremendously powerful synthetic tool, and the development has reached a level of sophistication 
that allows for a wide range of coupling partners to be combined efficiently.
[1]
 The importance of this general 
class of reactions was recognized by awarding of the Nobel Prize in chemistry to Richard Heck, Ei-ichi 
Negishi, and Akira Suzuki “for palladium-catalyzed cross-couplings in organic synthesis”. Despite the 
enormous advances achieved by cross-coupling reactions, limitations still need to be addressed. For traditional 
cross-coupling reactions, a prefunctionalisation of substrates is necessary. These pre-functionalisation steps, 
along with the cross-coupling itself, are each accompanied by the generation of stoichiometric amounts of 
byproducts. In recent decades, the direct functionalization of otherwise inert C–H bonds was recognized as a 




Scheme 1. C–H Functionalization versus functional group interconversions. 
For the key C–H  metalation step, several different mechanistic pathways have so far been  widely  accepted.
[3]
 
They are: a) oxidative addition with electron-rich, low-valent late-transition metal catalysts, such as iridium, 
platinum and ruthenium; b) σ-bond metathesis with early transition metals and lanthanoids; c) 1,2-addition to 
unsaturated M=X bonds, where a heteroatom is a hydrogen acceptor, for some early or mid-transition metals; 
d) electrophilic substitution with late-transition metals in higher oxidation states; e) base-assisted 
deprotonation, for example, using secondary phosphine oxides or carboxylates as an internal base (Scheme 2). 
Based on a six-membered transition state, the last pathway has been called either concerted metalation-
deprotonation (CMD)
[4]
 or ambiphilic metal ligand activation (AMLA).
[3c, 5]
 Whereas a four membered 
transition state is proposed in case of an internal electrophilic substitution (IES), which was found to be most 
likely for C–H activations enabled by complexes with alkoxy ligands.
[6]
 A novel base-assisted internal 








Scheme 2. Plausible mechanistic pathways for C–H activation. 
An important issue in C−H activation chemistry is the chemo- and site-selectivity. The organic molecules of 
interest usually possess many C–H bonds with similar dissociation energies. Therefore, achieving chemo- and 
regio-selective functionalization is challenging. In order to differentiate between various chemically similar 
C–H bonds, several strategies have been developed. These include a) differentiation through assistance of a 
Lewis-basic directing group (DG) within the substrate, b) differently electronically activated C–H bonds,
[8]
 




Scheme 3. Strategies for site-selectivity in C–H functionalization. 
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1.2 Ruthenium-Catalyzed C–H Arylation 
Substituted (hetero)biaryls are central structural motifs in various compounds with activities of relevance to 
different areas, such as pharmaceutical or material sciences.
[10]
 A variety of industrially important 




Figure 1. Representative examples for bioactive biaryls. 
In the past decades, traditional cross-coupling reactions have emerged as reliable methodologies for the 
preparation of biaryl compounds.
[12]
 However, these transformations usually require prefunctionalized 
substrates, which involve a number of synthetic operations. Therefore, direct arylation reactions through the 
cleavage of an otherwise inert C‒H bond represent an economically and environmentally more attractive 
strategy.
[13]
 Importantly, catalytic C–H arylation improves the step- and atom-economy of the cross-coupling 
process.  
1.2.1 Ruthenium Catalyzed C–H Arylation with Aryl Boronates 
In 2003, Kakiuchi and co-workers reported the ruthenium(0)-catalyzed direct arylation of ketones 1 with aryl 
boronates 2 as the coupling partners (Scheme 4).
[14]
 Thus, a series of aryl ketones 1 were efficiently arylated in 
pinacolone as the solvent. The detailed mechanistic studies by Kakiuchi, Chatani et al. suggested that the 
solvent pinacolone served as a sacrificial oxidant (Scheme 5).
[15]
 Subsequently, this protocol was also applied 




 The efficiency of this strategy was further 




Scheme 4. Ruthenium-catalyzed direct arylation with boronate. 
 




Scheme 5. Proposed mechanism for ruthenium-catalyzed direct arylation with boronates. 
In addition to the above mentioned aryl boronates, more atom-economical aryl boronic acids could also be 
utilized as effective arylating reagents when the appropriate oxidants were employed under ruthenium(II)-




Scheme 6. Ruthenium-catalyzed C–H arylation with aryl boronic acids as arylating reagents. 
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1.2.2 Ruthenium-Catalyzed C–H Arylation with Aryl (pseudo)Halides and Their Derivatives 
In early reports, Oi and Inoue et al. developed a catalytic system consisting of [RuCl2(C6H6)]2 and PPh3. The 
direct arylation of 2-phenylpyridine derivatives with aryl bromides or iodides was achieved with this protocol 
(Scheme 7).
[19]
 In the next few years, this strategy was further applied to a series of other N-containing 
directing groups, such as imine, oxazoline, imidazoline, pyrazole and purine.
[20]
 However, it was found that 





Scheme 7. Ruthenium-catalyzed arylation with phosphine ligand. 
Compared to aryl bromides or iodides, aryl chlorides 8 are undoubtedly the most useful aryl halides as a single 
class of electrophilic substrates due to their lower cost and wider diversity.
[22]
 However, aryl chlorides were 
generally unreactive under the catalytic system developed by Oi and Inoue. The lower reactivity of aryl 
chlorides is usually attributed to the higher bond strength of the C–Cl bond (bond dissociation energies for 
Ph–X: Cl: 96 kcal/mol; Br: 81 kcal/mol; I: 65 kcal/mol), which leads to a reluctance of aryl chlorides to 




Scheme 8. Ruthenium-catalyzed direct arylation with aryl chlorides. 
The first generally applicable method for intermolecular direct arylation with inexpensive aryl chlorides 8 was 
reported by Ackermann (Scheme 8).
[24]
 In this case, the air-stable adamantyl-substituted secondary phosphine 
oxide (SPO) (1-Ad)2P(O)H was used as the preligand, which enabled the unprecedented ruthenium-catalyzed 
diarylation of pyridines 9 and mono-arylation of imines 10 via C–H activation using diversely substituted aryl 
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chlorides 8. With the assistance of HASPO ligands,
[2q]





 proved to be viable (pro)electrophiles for similar transformations. 
In 2008, Ackermann et al. first described the beneficial effect of a substoichiometric amount of carboxylic 
acid ligands in the ruthenium-catalyzed direct arylation of arenes, enabling reactions to occur even in the 
apolar solvent toluene (Table 1).
[27]
 As shown in the Table 1, both (HA)SPO and carboxylate ligands showed 
high catalytic efficiency (entries 4 and 7). The authors proposed that the activation mechanisms were similar 
in both cases, proceeding via a base-assisted metalation process (Scheme 9). 
[27]
  
Table 1. Ruthenium-catalyzed direct arylation of triazole 13 in PhMe. 
 
Entry Cocatalyst Isolated yield (%) 
1 --- --- 
2 IPr·HCl 9 
3 PPh3 20 
4 (1-Ad)2P(O)H 85 
5 t-BuCO2H 66 
6 i-PrCO2H 69 
7 MesCO2H 93 
 
 
Scheme 9. Base-assisted ruthenation with a) Phosphinous acid and b) Carboxylate assistance. 
Stoichiometric experiments were carried out for mechanistic studies subsequently.
[28]
 The well-defined 
ruthenium(II) biscarboxylate complex 16 was easily prepared by the treatment of [RuCl2(p-cymene)]2 with 
MesCO2H. The complex 16 proved to be catalytically competent even in the apolar solvent toluene, and 
displayed a remarkably broad substrates scope in the direct arylation of arenes. Importantly, no oxidative 
addition of p-chloroanisole 8a to the ruthenium complex 16 was observed even at elevated temperature; 
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contrarily, cyclometalation of arene 9a occurred easily, thereby yielding catalytically competent 
cyclometalated complex 17 (Scheme 10).   
 
Scheme 10. Stoichiometric experiments with well-defined ruthenium complex 16.  
Based on these observations, a catalytic cycle was proposed as follow: First, complex 16 undergoes an initial 
reversible cyclometalation through a carboxylate-assisted deprotonation. Thereafter, complex 19 reacts in the 
rate-limiting step with aryl halide 8 to yield intermediate 20. Finally, reductive elimination delivers the final 




Scheme 11. Proposed mechanism of carboxylate-assisted ruthenium-catalyzed direct arylations. 
Subsequently, various important carboxylate-assisted ruthenium-catalyzed directed C–H arylation reactions 
were reported by Ackermann and coworkers (Scheme 12).
[2f, 2l, 18b, 29]
 




Scheme 12. Selected products of carboxylate assisted ruthenium-catalyzed directed C–H arylation. 
1.3 Transition Metal-Catalyzed C–H Alkynylations 
Alkynylarenes are versatile building blocks in organic synthesis.
[30]
  As a consequence, the development of 
efficient strategies for the construction of alkynes continues to be an important goal.
[31]
  The most frequently 
utilized method for the preparation of alkynylarenes is the Sonogashira-Hagihara  reaction,  in  which  
C(aryl)–C(sp) bonds are constructed by the palladium/copper-catalyzed cross-coupling of aryl halides with 
terminal alkynes.
[32]
 However, in recent years, transition metal-catalyzed C–H functionalization has emerged 
as a powerful alternative for the direct introduction of the alkynyl moiety.
[33]
  
Early examples of direct C–H alkynylation reactions were reported by Yamaguchi et al. using GaCl3 as 
catalyst (Scheme 13).
[34]
 However, these transformations usually proceeded under harsh reaction conditions 
and highly reactive organolithium reagents are required. Thus, a variety of valuable functional groups were 
not compatible with this system. 
 
Scheme 13. GaCl3-catalyzed ortho-ethynylation reaction of phenols and N-alkylanilines. 
In 2007, Gevorgyan and cowokers reported a mild and effective method for palladium-catalyzed C–H 
alkynylation of electron-rich heterocycles (Scheme 14).
[35]
 Thus, a series of heterocycles such as indolizine, 
pyrroloquinoline, pyrroloisoquinoline, pyrrolooxazole, and bis-pyrrolo-pyrimidine were successfully 
alkynylated. It was shown that a variety of functional groups at the bromoalkyne, such as alkyl, alkenyl, aryl, 
silyl, and ester, were perfectly tolerated. The authors proposed that this transformation operated via an 
electrophilic substitution pathway, analogous to that previously postulated for palladium(0)-catalyzed 
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arylation of electron-rich heterocycles.
[36]
 Under similar conditions, the palladium-catalyzed C3 alkynylation 




Scheme 14. Palladium-catalyzed C–H alkynylation of electron-rich heterocycles. 
In 2009, the first chelation-assisted palladium-catalyzed direct C–H alkynylation of acetylanilide derivatives 
was reported by Chatani (Scheme 15).
[38]
 Preliminary mechanistic studies indicated that the reaction proceeds 
through a pathway distinctly different from the previously reported alkynylation of electron-rich heterocycles. 
However, a stoichiometric amount of silver salt was necessary for this transformation, and the scope regarding 
the bromoalkyne component proved to be limited. Afterwards, a variety of effective C–H alkynylation 





















Scheme 15. Palladium-catalyzed alkynylation of aromatic C–H bonds with bromoalkyne 33a. 
Meanwhile, new alkynylation reagents also emerged. In 2014, Loh reported the ortho C–H alkynylation of 
aromatic amides taking advantage of the hypervalent iodine reagent
[48]
 38 as the alkyne source (Scheme 
16).
[41f]
 The reaction showed high efficiency in furnishing only monoalkynylated products in excellent yields 
at ambient temperature. A variety of synthetically useful functional groups was well-tolerated. The synthetic 
utility of this protocol was illustrated by the late stage functionalization towards complex molecule 39g. 




Scheme 16. Rhodium-catalyzed alkynylation of aromatic C–H bonds with the hypervalent iodine reagent 38. 
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1.4 Cobalt Catalyzed C−H Functionalization 
Over the past few decades, considerable progress has been achieved in transition metal-catalyzed C−H 
functionalization.
[2a-c, 2f, 2l, 49]
 Until recently, most of catalyzed C−H functionalizations were realized by using 
expensive second- or third-row transition metals.
[2c, 50]
 The development of catalysts based on more naturally 
abundant and cost-effective first row transition metal complexes, represents an attractive alternative.
[2k, 51]
 In 




Given the success of precious 4d and 5d transition metals, numerous efforts have been made to explore easily 
accessible cobalt complexes for C−H activation.
[53]
 As a key step of C−H cobaltation, Klein and coworkers 
isolated the cyclometalated cobalt complex 55 by treating azobenzene (54) with [Co(CH3)(PMe3)4].
[54]
 








 donor groups also 
proved to be suitable substrates to form cyclocobaltated complexes. Indeed, the cyclometalation was not 
restricted to the formation of five- or six-membered cobaltacycles, but the formation of a less favourable four-
membered cobaltacycle 51 was also possible (Scheme 17).  
 
Scheme 17. Cyclocobaltated compounds by stoichiometric C−H or C−F cleavage using [Co(CH3)(PMe3)4]. 
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Murahashi reported the first example of a cobalt-catalyzed chelation-assisted C−H functionalization reaction. 
In this case, aldimine 56 or azobenzene 54 undergoes carbonylative cyclization delivering indazolone 57 or 
phthalimidine 58, respectively (Scheme 18).
[59]
 Further applications of these reactions were however limited 
due to harsh reaction conditions. 
 
Scheme 18. Early examples of cobalt-catalyzed chelation-assisted C−H functionalization. 
1.4.1 Low-Valent Cobalt Catalyzed C−H Activation 







 The catalytic system for these transformations 
usually contains a cobalt precatalyst, a ligand (such as phosphine or N-heterocyclic carbene (NHC)) and a 
Grignard reagent to generate the active low-valent cobalt species. These novel catalysts promoted a series of 
pyridine- and imine-directed hydroarylation reactions of alkynes and olefins at mild reaction temperatures. 
The combination of a cobalt−NHC catalyst and a Grignard reagent allows directed aromatic C−H 
functionalizations with electrophiles such as aldimines, aryl chlorides, as well as alkyl chlorides or bromides.  
 
Scheme 19. Cobalt-catalyzed hydroarylation of alkynes 59. 
In 2010, Yoshikai and coworkers introduced a ternary catalytic system consisting of CoBr2, a phosphine 
ligand (PMePh2) and a stoichiometric reductant (MeMgCl) which efficiently catalyzed the hydroarylation of 
unactivated internal alkynes with arylpyridines (Scheme 19).
[62]
 By utilizing a quaternary catalytic system 
consisting of a cobalt salt, a triarylphosphine ligand, a Grignard reagent, and pyridine, Yoshikai and 
coworkers further achieved the hydroarylation of ketimines or aldimines with unactivated internal alkynes at 
ambient temperature (Scheme 20).
[63]
 A series of potentially sensitive functional groups, including chloride, 
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bromide, nitrile and tertiary amide, were well-tolerated. The reaction also displayed a unique regioselectivety. 
Thus, the presence of substituents such as methoxy, halogen, and cyano groups at the meta-position of the 
imino group led to selective C−C bond formation at the more sterically hindered C2-positions. 
 
Scheme 20. Cobalt-catalyzed hydroarylation of imine 10. 
The catalytic cycle for the cobalt-catalyzed hydroarylation was proposed as follows: The active low-valent 
cobalt complex is generated from the cobalt(II) precatalyst and an excess t-BuCH2MgBr (Scheme 21). 
Precoordination of the alkyne 59 to the active cobalt species is followed by oxidative addition into the ortho 
C−H bond of imine 10 to give cobalt complex 63. Intramolecular hydrocobaltation of complex 63 and 
subsequent reductive elimination of the intermediate 64 delivers product 61 and regenerates the active cobalt 
species.  




Scheme 21. Cobalt-catalyzed hydroarylation of imine 10. 
On the basis of the remarkable high efficiency of the alkyne hydroarylation,
[62-64]
 hydroarylation of olefins 
also proved to be possible by utilizing low valent cobalt catalysis. In 2010, Yoshikai developed a switchable 
protocol for the hydroarylation of styrenes 65 giving linear or branched hydroarylation products largely by the 




Scheme 22. Cobalt-catalyzed hydroarylation of imine 28. 
Until 2011, low valent cobalt catalysis was mainly used for addition reactions to unsaturated substrates. 
Nakamuru reported a cobalt-catalyzed ortho-alkylation protocol using alkyl chlorides as organic electrophiles 
(Scheme 23).
[60]
 Here, by employing DMPU as the ligand, the alkylation of secondary benzamides was 
achieved with various alkyl chlorides 68. Subsequently, arylpyridines, N-pyri(mi)dylindoles
[61c]
 as well as 
ketimines
[66]
 also proved to be viable substrates for this transformation by the choice of NHC preligands. 




Scheme 23. Cobalt-catalyzed hydroarylation of imine 10. 
Apart from alkylations, Ackermann and coworkers showed that low valent cobalt-catalysis could be applied to 
the challenging C−H arylation of arenes.
[61b-d]
 Thus, the direct arylation of arylpyridines 9 as well as 2-
pyri(mi)dylindoles was accomplished with organic electrophiles, such as aryl chlorides 8, phenol derived aryl 
carbamates 70 or sulfamates 71.
[61c, 67]
 The scope of this reaction was further extended to ketimines 10 by 
Yoshikai group.
[68]
 Thus, valuable biarylketones were easily accessible after hydrolysis.  
 
Scheme 24. Cobalt-catalyzed C−H arylations with aryl carbamates 70, sulfamate 71 and chlorides 8. 
Mechanistic studies suggested that these transformations involve a radical intermediate. Thus, the catalytic 
cycle was proposed as follows (Scheme 25).
[53e]
 First, cyclometalation of aryl imine 10 with an alkylcobalt 
species generated in situ from the cobalt precatalyst and the Grignard reagent delivers intermediate 72. Then, 
single electron transfer (SET) from the cobalt center to alkyl halide 68 occurs. Finally, radical C−C coupling 
affords the product, and transmetalation of the resulting cobalt halide species with the Grignard reagent 
regenerates the alkylcobalt species. 
 




Scheme 25. Proposed catalytic cycle for ortho-alkylation with alkyl halide. 
In 2015, weakly coordinating amides were also shown to be a suitable directing groups for the direct arylation 
by low valent cobalt catalysis.
[61d]
 In this case, ICy·HCl (1,3-dicyclohexyl-1H-imidazol-3-ium chloride) (149g) 
was used as the optimal preligand. This reaction displayed a broad substrate scope for benzamides 67 as well 
as aryl chlorides 8. It is noteworthy that by treating the products with PCl5 and sodium azide, biaryl tetrazoles 
75, which are highly important building blocks in medicinal chemistry, could easily be accessed (Scheme 26).  
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1.4.2 Cobalt-Catalyzed Oxidative C−H Activation 
Since Daugulis introduced the 8-aminoquinoline auxiliary for palladium catalyzed C−H activation in 2005,
[69]
 
it became one of the most widely used and versatile directing groups in C−H functionalization chemistry.
[2e, 70]
 
In 2014, Daugulis utilized this directing group for cobalt-catalyzed oxidative alkyne annulation reactions and 
achieved excellent results (Scheme 28).
[71]
 The reaction showed remarkable functional group tolerance under 
mild conditions, both internal and terminal alkynes were competent substrates for these transformation. The 
picolinamide also proved to be reactive under the same conditions, albeit with diminished yield.  
 
Scheme 27. Cobalt-catalyzed C−H annulations by 8-aminoquinoline auxiliaries. 
Utilizing a similar catalytic system, Daugulis and coworkers further achieved the hydroarylation of 
unactivated alkenes (Scheme 28).
[72]
 Thus, a series of dihydroisoquinolinone derivatives was obtained step-





 were also shown to be possible. 
 
Scheme 28. Cobalt-catalyzed hydroarylation of unactivated alkenes. 
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Another interesting result in this field was reported by Ackermann and coworkers. They identified a 
complementary oxidative coupling reaction with electron-deficient olefins that provides expedient access to 
synthetically useful isoindolin-1-ones (Scheme 29).
[75]
 A wide range of functional groups, such as methoxy, 
halogen, cyano or even nitro substituents, were well tolerated.  
 
Scheme 29. Cobalt-catalyzed isoindolinone synthesis. 
A possible catalytic cycle was proposed as follows: The oxidative alkene annulation proceeds via a kinetically 
relevant, carboxylate-assisted C−H cobaltation. Subsequent migratory insertion of the olefin 65, followed by 
β-hydride-elimination, delivers the alkenylated benzamide 84, which finally undergoes an intramolecular 
alkene hydroamidation to furnish the desired isoindolinones 81 (Scheme 30). 




Scheme 30. Proposed catalytic cycle for cobalt-catalyzed isoindolinone synthesis. 
In 2014, Song and coworkers employed 2-aminopyridine-1-oxide (PyO) as a removable N,O-bidentate-type 
directing group in copper-mediated direct aryloxylation of benzamides.
[76]
 Later, this directing group was 
utilized in cobalt catalyzed C(sp
2
)−H alkoxylation reactions (Scheme 31).
[77]
 The reaction proceeded under 
mild conditions using inexpensive Co(OAc)2·4H2O as the catalyst. However, a stoichiometric amount of silver 
oxide was required as oxidant in this transformation.  
 
Scheme 31. Cobalt-catalyzed C−H alkoxylation. 
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1.4.3 High Valent Cobalt(III)-Catalyzed C−H Activation 
In recent years, C−H activation using Cp*Rh(III) catalysts has underwent an remarkable development. 
[2c, 2i, 50e, 
78]
 A variety of C−C and C−heteroatom bond-forming reactions by means of C−H activation have been 
achieved in both oxidative and redox-neutral manners. Although Cp*Rh(III)-catalyzed processes are useful 
and versatile, the need for expensive and precious rhodium sources is economically and environmentally 




In 2013, Matsunaga, Kanai, and co-workers disclosed a major breakthrough in the analogous Cp*Co(III) 
catalysis, identifying a cationic Co(III) complex, [Cp*Co(C6H6)(PF6)2], as a competent catalyst for the 
addition of 2-arylpyridines to N-sulfonylimines and enones via a C−H activation process (Scheme 32).
[80]
 
Among several cyclopentadienyl–cobalt(III) complexes (Figure 2), the [Cp*Co-(benzene)] complex (88) 
showed the highest activity. The reason could be that this complex showed the best balance between reactivity 
and stability.  
 
Figure 2. Structure of cationic high-valent cyclopentadienyl cobalt(III) complexes.  
 
Scheme 32. Addition of 2-arylpyridines to N-sulfonyladimines or α,β-unsaturated ketones. 
Complex 88 also showed a unique reactivity in the reaction of N-carbamoylindole with an internal alkyne.
[81]
 
A C2-selective indole alkenylation/annulation sequence proceeded smoothly with catalytic amounts of 
cobalt(III) complex 88 and KOAc. By tuning the carbamoyl group and the reaction conditions, the product 
selectivity can be easily controlled to deliver either alkenylation or annulation products (Scheme 33). 
Interestingly, when Cp*Rh(III) complexes were used, only the alkenylation product was formed. This clear 
difference highlighted the unique nucleophilic nature of the organocobalt species. 




Scheme 33. Reaction of N-carbamoylindole 97 and alkyne 59b leading to pyrrolo-indolone 101 or 2-
alkenylindole 98. 
In an effort to expand the scope of Cp*Co(III) catalysis, Kanai successfully applied the bench-stable 
[Cp*CoI2(CO)] complex 104, which was first prepared by Li and Jin as early as 2004,
[82]
 for the C2-selective 
C−H amidation of indole 102 (Scheme 34).
[83]
 This in situ generated Cp*Co(III) catalyst showed significant 
potential for C−H functionalization and attracted an increasing attention in the past few years.  
 
Scheme 34. Cobalt-catalyzed C2 selective amidation of indoles. 
It is well known that Cp*Co(III)-catalyzed reactions easily proceed via cyclocobaltation and addition onto 
multiple bonds. These addition reactions were mainly restricted to alkynes and conjugated double bonds. 
However, Ellman disclosed a cobalt-catalyzed addition of C−H bonds to carbonyl compounds.
[84]
 Thus, 
azobenzenes 54 as well as α,β-unsaturated oximes 109 were efficiently transformed into indazoles 108 or 
furans 110, respectively, via insertion of aromatic aldehydes 106 and trapping of the thus-formed alcohols by 
nucleophilic attack (Scheme 35).  




Scheme 35. Condensation of azobenzene or α,β-unsaturated oximes with aldehyde 106.  
In 2015, the Ackermann group reported the first example of cobalt-catalyzed direct C−H cyanations of 2-
arylpyridines, N-pyrimidylindoles and related (hetero)arenes by utilizing the readily available N-cyano-N-
phenyl-p-toluenesulfonamide (NCTS) as cyanating reagent (Scheme 36a).[85] Thereafter, Glorius and co-
workers also achieved C−H cyanation under similar conditions in an independent study.
[86]
 The scope of 
Cp*Co(III)-catalysis was further extended to C−H allylations and halogenations by using pivalic acid instead 
of acetate salt as a key catalyst component (Scheme 36 b and c).
[87]
 It is noteworthy that both the silver and the 
carboxylate additive were crucial for these transformations, presumably for the generation of a cationic Co(III) 
carboxylate species.  
 
Scheme 36. Cobalt-catalyzed C−H cyanation, iodination and allylation. 
Ackermann and co-worker developed the first cobalt(III)-catalyzed aminocarbonylation of aryl pyrazoles 117 
(Scheme 37).
[88]
 The aminocarbonylation with isocyanates 118 as the electrophiles gave optimal results with 
  Introduction  
23 
 
[Cp*Co(CO)I2] (104) as the precatalyst, along with AgSbF6 and AgOPiv as the additives. The reaction 
showed high functional group tolerance and remarkable site selectivity with meta-substituted arenes 117. As 
isocyanates could be generated in situ from acyl azides via a Curtius rearrangement, acyl azides 120 could 
also be used as suitable coupling partners.
[2g, 89]





Scheme 37. Cobalt(III)-catalyzed aminocarbonylation of aryl pyrazole 117. 
The isoquinoline framework is an important structural motif found in a series of biologically active natural 
products and pharmaceuticals.
[91]
 In 2015, a cobalt(III)-catalyzed C−H/N−O functionalizations for the redox-







research groups independently (Scheme 38). Although annulation reactions of oxime derivatives 122 and 
alkynes 59 by C−H activation to give isoquinolines 123 without the use of any external oxidants have been 
developed using various transition metal catalysts, the substrate scope was however limited to internal alkynes 
in all the previous reports.
[95]
 Notably, the Cp*Co(III)-catalyst exhibited much higher site selectivity for meta-
substituted O-acyl oximes and higher reactivity towards terminal alkynes than the Cp*Rh(III) catalyst.  
 
Scheme 38. Cobalt(III)-catalyzed C−H/N−O functionalization.




Biaryls are core structural motifs in biologically active compounds, which are of great importance for the 
agrochemical and pharmaceutical industries.
[11]
  Transformations of unactivated C−H bonds have emerged as 
an attractive alternative to conventional cross-coupling approaches, enabling step-economical biaryl syntheses 
with minimal byproduct formation.
[13]
 Major advances have been accomplished by means of ruthenium(II)-
catalyzed reactions with easily accessible electrophilic aryl halides.
[2f, 28-29, 29d, 96]
 Despite these undisputable 
advances, ruthenium(II)-catalyzed C−H arylations with organic electrophiles are limited to strongly 
coordinating nitrogen-containing directing groups, which are difficult to remove or modify. 
[29d, 97]
 Therefore, 
the development of ruthenium(II)-catalyzed C−H arylations of weakly-O-coordinating
[98]
 benzoic acids is 
highly desirable (Scheme 39). 
 
Scheme 39. Ruthenium(II)-catalyzed C–H arylation by weakly coordinating benzoic acids. 
Arylalkynes are versatile building blocks in organic synthesis. As a consequence, the development of efficient 
strategies for the construction of alkynes is an important goal, often being achieved by the conventional 
Sonogashira–Hagihara cross-coupling reaction.
[32]
 Recently, transition metal-catalyzed C−H functionalization 
has emerged as a powerful alternative for the direct introduction of alkynyl moieties.
[25, 30a, 40a, 44-47]
 Despite this 
undisputable progress, ruthenium-catalyzed C–H alkynylations of weakly-O-coordinating substrates have 
proven elusive.
[43]
 In consideration of the unique synthetic utility of substituted alkynes, we thus became 
attracted to devise an unprecedented ruthenium(II)-catalyzed C−H alkynylation of weakly-O-coordinating 
benzoic acids (Scheme 40). 
 
Scheme 40. Ruthenium(II)-catalyzed C–H alkynylation by weakly coordinating benzoic acids. 
The past decade has witnessed the emergence of C–H activation as an increasingly powerful tool in natural 
product synthesis,
[99]
 with considerable recent progress being achieved by versatile ruthenium(II) catalysts. In 
2013, Ackermann and coworkers reported a versatile pyrrole synthesis through ruthenium(II)-catalyzed 
oxidative C–H/N–H functionalizations.
[100]
 In continuation of these studies, and given the antibiotic, anti-
cancer and anti-malaria activities of pyrrole-containing lamellarin alkaloids,
[101]
 it was therefore one goal of 
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this work to conduct a comparative study on the performance of various transition metal catalysts in the 
preparation of naturally-occurring lamellarins 129 (Scheme 41). 
 
Scheme 41. Ruthenium(II)-catalyzed C–H/N–H activation for the assembly of lamellarin alkaloids. 
In consideration of the natural abundance and low costs of 3d transition metals, the focus in catalytic C‒H 
activation has shifted in the recent years towards the use of base metal catalysis, with major advances 
accomplished by versatile cobalt catalysts.
[2k, 51, 79]





achieved C‒H arylations with organic halides by the use of low-valent cobalt catalysis. Recently, the 
functionalization of otherwise unreactive C–H bonds in oxazolines has gained interest,
[20e, 25, 103]
 as modified 
oxazolines were found to exhibit biological activity.
[104]
  Hence, studying cobalt-catalyzed C‒H arylation of 
oxazolines by a modifiable directing group
[105]
 strategy was an important target of this thesis (Scheme 42). 
 
Scheme 42. Cobalt-catalyzed C‒H arylation by oxazoline assistance. 
Substituted oxazolines are omnipresent structural motifs of numerous bioactive compounds of relevance to 
crop protection and medicinal chemistry.
[106]
 As a consequence, there is a continued strong demand for 
flexible methods that provide general access to substituted oxazolines. So far, catalytic C−H amidations on 
aryl oxazolines are restricted to the use of precious rhodium and iridium catalysts, as elegantly developed by 
Chang, among others.
[107]
 Therefore, it is of great significance to develop a new versatile protocol for 
cobalt(III)-catalyzed C−H amidations of synthetically useful aryl oxazolines by the action of dioxazolones as 
user-friendly amidating reagents (Scheme 43). 




Scheme 43. Cobalt-catalyzed oxazolinyl-assisted C−H amidation. 
Although remarkable progress has been achieved with low-valent cobalt catalysis, these catalytic systems 
usually require sub-stoichiometric or stoichiometric amounts of Grignard reagents as the reductant and the 
base.
[53d-g]
 Therefore, a variety of valuable functional groups were not tolerated under these reaction conditions, 






 developed the 
oxidative cobalt-catalyzed alkyne and alkene annulation reactions. Based on these considerable recent 
advances, we set out to develop the first general protocol by cobalt oxidase-type reactions with molecular 
oxygen as the sole oxidant (Scheme 44).   
 
Scheme 44. Cobalt-catalyzed oxidase C−H functionalization.
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3 Results and Discussion 
3.1 Ruthenium(II)-Catalyzed C–H Functionalizations on Benzoic Acids with Aryl and Alkenyl Halides 
by Weak-O-Coordination 
Biaryls are ubiquitous in natural products, pharmaceuticals, agrochemicals, ligands, polymers and organic 
materials.
[10-12]
 Recently, direct arylation of otherwise inert C–H bonds has emerged as an attractive alternative 
to conventional cross-coupling strategies, enabling the regiospecific introduction of aryl groups in 
unfunctionalized positions.
[13]
 However, this great conceptual advantage is often offset by the structural 
complexity of the required directing groups. Only recently, various functional groups with low coordinating 
ability,
[97, 110]
 such as carboxylates, have successfully been used as directing groups for ortho C–H 
arylations.
[111]
 The key benefit of carboxylate groups is that they can be tracelessly removed by 
protodecarboxylation or utilized as leaving groups in a rapidly growing number of decarboxylative coupling 
reactions.
[112]
 As a result, we started to explore the possibility of developing unprecedented C−H arylations of 
benzoic acids by reasonably priced ruthenium(II) catalyst. 
3.1.1 Optimization Studies 
We initiated our studies by testing a series of different ligands for the envisioned ruthenium(II)-catalyzed C–H 
arylation of weakly O-coordinating benzoic acids 124a (Table 2). The typical N-heterocyclic carbene 
precursors (entries 2–3) or SPO (entries 4–7) ligands were not effective in providing access to arylated 
benzoic acid product 125aa. To our delight, moderate conversion was obtained when PPh3 was employed 
(entries 8–14). The yield could be further improved to 81% when the PCy3 ligand was used (entry 14). The 
control experiments showed that there was no reaction in the absence of ruthenium catalyst or K2CO3 (entries 
15-16). The aryl chlorides 8 proved to be unreactive under the current conditions (entry 17). It is noteworthy 
that the well-defined [RuCl2(PCy3)(p-cymene)] was also identified as a user-friendly single component 
catalyst, allowing for the preparation of the ortho-arylated benzoic acid 125aa with comparable levels of 
efficiency (entry 18). The catalytic performance was further improved by exploiting carboxylate assistance 
with the aid of the well-defined ruthenium(II)biscarboxylate complex 16 (entry 19). Probing different solvents 
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entry [Ru] ligand 125aa (%)
 b
 
1 [RuCl2(p-cymene)]2 --- (11) 
2 [RuCl2(p-cymene)]2 IPr·HCl (<5) 
3 [RuCl2(p-cymene)]2 IMes·HCl (<5) 
4 [RuCl2(p-cymene)]2 tBu2POH 16 
5 [RuCl2(p-cymene)]2 Cy2POH (<5) 
6 [RuCl2(p-cymene)(PhtBuPOH)] --- (<5) 
7 [RuCl2(p-cymene)(nBu2POH)] --- (6) 
8 [Ru(O2CMes)2(p-cymene)] X-Phos (7) 
9 [RuCl2(p-cymene)]2 DavePhos (<5) 
10 [RuCl2(p-cymene)]2 JohnPhos (8) 
11 [RuCl2(p-cymene)]2 P(n-Bu)(Adamantyl)2 20 
12 [RuCl2(p-cymene)]2 P(t-Bu)3 (22) 
13 [RuCl2(p-cymene)]2 PPh3 (51) 
14 [RuCl2(p-cymene)]2 PCy3 81 
15
c
 [RuCl2(p-cymene)]2 PCy3 n.d. 
16 --- PCy3 n.d. 
17
d
 [RuCl2(p-cymene)]2 PCy3 (5) 
18 [RuCl2(p-cymene)(PCy3)] --- 75 
19 [Ru(O2CMes)2(p-cymene)] (16) PCy3 87 
20
e
 [Ru(O2CMes)2(p-cymene)] (16) PCy3 54 
21
f
 [Ru(O2CMes)2(p-cymene)] (16) PCy3 n.d. 
22
g
 [Ru(O2CMes)2(p-cymene)] (16) PCy3 (32) 
a
 Reaction conditions: 124a (0.50 mmol), 14a (0.75 mmol), [Ru] (10 mol %), ligand (10 mol %), 
K2CO3       (2.0 equiv), and NMP (2.0 mL), 120 ºC, 16 h. 
b
 Yields of isolated product; in parentheses: GC 
conversion after esterification with K2CO3 (2.0 equiv) and MeI (5.0 equiv) in MeCN (3.0 mL) with 1,3,5-
trimethoxybezene as internal standard. 
c
 Without K2CO3. 
d 
Using 4-chloroanisole 8a instead of 4-bromoanisole 
14a. 
e 
DMA (2.0 mL) as solvent. 
f
 PhMe (2.0 mL) as solvent. 
g
 DMPU (2.0 mL) as solvent. 
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3.1.2 Scope of Ruthenium(II)-Catalyzed C–H Arylation  
3.1.2.1 Scope of Aryl Bromides in the Ruthenium(II)-Catalyzed C–H Arylation 
With the optimized catalytic system in hand, we tested its versatility in the C–H arylation of differently 
substituted aryl bromides 2 (Scheme 45). Here, a representative set of synthetically useful functional groups, 
such as halides, activated alkenes and esters were well tolerated by the optimized catalyst at para or meta 
positions of the aryl electrophiles. Moreover, electron-deficient as well as typically more demanding electron-
rich aryl halides 14 were efficiently converted. Even the heterocyclic substrate 3-bromoquinoline 14g gave 
moderate yield of the corresponding product. 
 
Scheme 45. Scope of aryl bromides in the ruthenium(II)-catalyzed C–H arylation. 
However, some substrates also turned out to be incompatible with the current catalytic conditions (Scheme 46). 
Typical heterocycles, such as 3-bromopyridine 14h and 2-bromothiophene 14i, were unreactive. The sterically 
hindered ortho substituted aryl bromide 14j proved unsuitable as well under the current condition. Moreover, 
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aryl bromide 14k, which is functionalized with a chiral tertiary amide moiety, gave unsatisfactory result, 
delivering a complex mixture of unidentified products. 
 
Scheme 46. Limitations of the ruthenium(II)-catalyzed C–H arylation with regard to aryl bromides. 
3.1.2.2 Scope of Benzoic Acids 
Subsequently, we explored the scope of viable benzoic acids in the ruthenium(II)-catalyzed C–H arylation 
reaction (Scheme 47). Thus, various weakly-coordinating benzoic acids 124 could be converted with high 
catalytic efficiency and excellent positional selectivity by the phosphine-modified biscarboxylate complex 16. 
Although in some cases (124d-e, 124i-j) only moderate yield could be obtained, to our delight, the yields 
could be improved to an excellent level when aryl iodide 14a´ was employed instead of aryl bromide 14a. 




Scheme 47. Scope of the ruthenium(II)-catalyzed C–H arylation with regard to benzoic acid 124.
a
 
Benzoic acid 124m containing a strong electron-withdrawing nitro group, unfortunately delivered no product. 
Also the ortho choloro- or benzamide-substituted substrates 124n-o were unreactive and failed to provide the 
desired products. Heterocyclic benzoic acids, such as furan, thiophene or pyridine, were so far incompatible 
with the current catalytic conditions (124p-r) (Scheme 48). 




Scheme 48. Challenging benzoic acids 124 in the ruthenium(II)-catalyzed C–H Arylation.  
3.1.3 Weak O-Coordination for C–H Alkenylation 
To our delight, the unique utility of our ruthenium(II) catalysis was further demonstrated by enabling the 
olefination of benzoic acid 124 with alkenyl halide 135 (Scheme 49). Thus, a series of ortho alkenylated 
benzoic acid derivatives were easily accessible. 
 
Scheme 49. Weak O-coordination for C–H alkenylation.  
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3.1.4 Mechanistic Studies 
3.1.4.1 Intermolecular Competition Experiments 
In consideration of the unique efficiency of the ruthenium(II) catalysis regime, we performed a series of 
experiments to rationalize its mode of action. Intermolecular competition experiments between aryl bromides 
14l and 14a revealed the electron-deficient aryl bromide 14l to be inherently more reactive (Scheme 50).  
 
Scheme 50. Intermolecular competition experiment between aryl bromides 14l and 14a.  
We further performed an intermolecular competition experiment between benzoic acid 124c and strongly 
coordinating triazole 13b (Scheme 51). It turned out that the strongly N-coordinating 1,2,3-triazole
[113]
 
substrate 13b reacted preferentially. This result further demonstrated the challenging nature of the C–H 
arylation with weakly coordinating benzoic acids 124.  
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3.1.4.2. C–H Arylation in the Presence of Isotopically Labelled Cosolvent 
Moreover, a significant H/D scrambling upon the addition of an isotopically labelled cosolvent under 
otherwise identical reaction conditions was observed. This finding showed that the C–H metalation is most 
likely reversible (Scheme 52). 
 
Scheme 52. Facile C–H arylation in the presence of isotopically labelled cosolvent. 
3.1.4 3. Ruthenacycle  for C–H Arylation 
Additionally, we prepared the potential intermediate ruthenacycle 137a, which was previously employed for 
oxidative alkyne annulations by Ackermann and coworkers.
[114]
 Notably, the cyclometalated complex 137a 
showed a similar activity compared to catalyst 16 and afforded the corresponding arylation product 125ga in 
moderate yield (Scheme 53). This result indicated that the cyclometalated complex 137a could be a key 
intermediate for this transformation. 
 
Scheme 53. Ruthenacycle 137a as catalyst in the C–H arylation. 
3.1.4.4 Proposed Catalytic Cycle 
Based on these mechanistic studies, we proposed a plausible catalytic cycle for this arylation protocol. First, 
the initial C–H bond activation enables a reversible carboxylate-assisted cycloruthenation of benzoic acid 124 
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to form ruthenacycle 137, which then undergoes an oxidative addition with the assistance of electron-rich 
phosphine ligand PCy3.
[115]
 Finally, reductive elimination of 139 releases the arylated product 125 and 
regenerates the active ruthenium catalyst (Scheme 54). 
 
Scheme 54. Plausible catalytic cycle for benzoic acid-directed C–H arylation. 
  
 Results and Discussion 
36 
 
3.2 Ruthenium(II)-Catalyzed C−H Alkynylation of Weakly-Coordinating Benzoic Acids 
In recent years, robust ruthenium(II) carboxylate catalysis has proven particularly powerful for redox-neutral 
C−H transformations with organic electrophiles.
[2f, 116]
 Despite these considerable advances, ruthenium-
catalyzed C–H alkynylations of weakly-O-coordinating benzoic acids have proven elusive.
[43]
 In consideration 
of the unique synthetic utility of substituted alkynes, 
[41f, 45-47]
 one part of this thesis focused on the 
development of ruthenium(II)-catalyzed C−H alkynylation of weakly-O-coordinating benzoic acids. 
3.2.1 Optimization Studies for Ruthenium(II)-Catalyzed C−H Alkynylation  
We initiated our studies by probing various reaction conditions for the envisioned C−H alkynylation of 
weakly coordinating benzoic acid 124t with bromoalkyne 33a using the single-component ruthenium(II) 
biscarboxylate catalyst 16 (Table 3). Among a variety of bases, the weak base K2CO3 proved to be optimal 
(entries 1−6). No product was observed when the carboxylate-free complex [RuCl2(p-cymene)] was used in 
combination with AgSbF6 as the additive (entry 7). The presence of typical phosphine ligand did not improve 
the catalytic efficiency (entry 8). Then, the solvent effect was tested and 1,4-dioxane was shown to be the 
most suitable solvent for this transformation. The desired C−H alkynylation also proceeded when the 
corresponding alkynyl chlorides 33a´ or iodides 33a´´ were employed, albeit with lower yields (entries 16 and 
17). 
Table 3. Optimization of ruthenium(II)-catalyzed C–H alkynylation with benzoic acid 124t.
a 
 
entry base solvent 126ta (%)
b
 
1 K2CO3 NMP 63 
2 NHCy2 NMP 55 
3 DBU NMP (47) 
4 NaHCO3 NMP 47 
5 KOAc NMP (22) 
6 K3PO4 NMP 33 
 Results and Discussion 
37 
 
7 K2CO3 NMP ---
 c
 
8 K2CO3 NMP 46
d
 
9 K2CO3 DMA (52) 
10 K2CO3 DMF 72 
11 K2CO3 DMPU (57) 
12 K2CO3 GVL (47) 
13 K2CO3 1,4-Dioxane 88 
14 K2CO3 CH3CN 85 
15 K2CO3 PhMe 53 
16 K2CO3 1,4-Dioxane 39
e
 




Reaction conditions: 124t (0.50 mmol), 33a (0.65 mmol), 16  (10 mol %), 
Base (2.0 equiv), Solvent (1.0 mL), 120 °C, 16 h; then K2CO3 (2.0 equiv) 
and MeI (5.0 equiv) in MeCN (3.0 mL). 
b
 Yields of isolated products; in 
parentheses: 
1
H-NMR conversion after esterification with 1,3,5-
trimethoxybezene as the internal standard.
 c 
[RuCl2(p-cymene)]2    (5.0 mol 
%), AgSbF6 (20 mol %); 
d
 10 mol % Xphos as additive; 
e
 Using alkynyl 
chloride 33a´; 
f
 Using alkynyl iodine 33a´´.  
3.2.2 Scope of C–H Alkynylation by Weak Coordination 
With the optimized reaction conditions in hand, we explored its versatility in the ruthenium(II)-
biscarboxylate-catalyzed C−H alkynylation with weakly coordinating benzoic acids 124 (Scheme 55). Thus, 
the utility of the ruthenium(II)-catalyzed C−H activation was demonstrated by tolerating electron-rich as well 
as electron-deficient benzoic acids 124. A variety of synthetically useful functional groups, including ether, 
fluoro, chloro, bromo and ketone, were well accepted. Notably, not only the TIPS substituted alkyne 31a was 
a viable substrate, but also the TBDMS substituted alkyne 31b could be transformed to the corresponding 
product 126jb in synthetically meaningful yield. The current strategy allowed the double alkylynation for 
substrates 124k, 124z and 124aa being devoid of ortho substituent. Thus, a series of fully substituted aryl 
alkynes were synthesised efficiently (126za-126aaa). For substrate 124d bearing a bulky acetyl group at the 
meta position the alkynylation took place at the sterically less hindered position. 




Scheme 55. Scope of C–H alkynylation by weak coordination. 
The synthetic impact of this methodology was further demonstrated by the facile preparation of a series of 
ortho-alkynylated free benzoic acid derivatives 126´(Scheme 56).  




Scheme 56. Scope of C–H alkynylation of free benzoic acids 124 by weak coordination. 
 
3.2.3 C−H Alkynylation/Cyclization Cascade 
The versatility of the ruthenium(II) catalysis manifold was highlighted by a C−H alkynylation/addition 
sequence of substrates 124 and 33a in the presence of the X-Phos ligand (Scheme 57). Thus, the exo-
methylene phthalides 140a-c were obtained with high yields in a step-economical manner. 
 
Scheme 57. C−H Alkynylation/cyclization cascade. 
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3.2.4 Product Diversivications  
Finally, we uncovered an unprecedented decarboxylative C−H alkynylation to assemble the meta-alkynylated 
arene 141 (Scheme 58). Importantly, the decarboxylative ortho-C−H alkynylation proved viable in the 
absence of copper(I) or silver(I) additives, which were typically required for decarboxylative palladium- or 




Scheme 58. Decarboxylative C−H alkynylation. 
The synthetic utility of the ruthenium(II)-catalyzed C−H alkynylation was reflected by the facile removal of 





 are to be easily realized. 
 
 
Scheme 59. Removal of silyl-group. 
3.2.5 Mechanistic Studies 
A set of experiments towards elucidation of the mechanistic aspects were performed. First, C−H alkynylation 
was performed in the presence of the isotopically labelled cosolvent CD3OD. A significant H/D exchange 
could be observed in the reisolated substrate [D]n-124aa. This result can be rationalized in terms of a 
reversible carboxylate-assisted C−H activation (Scheme 60a). Furthermore, the introduction of stoichiometric 
amounts of typical radical scavengers did not significantly decrease the efficacy of the C−H alkynylation, 
which indicates that a radical mechanism is unlikely (Scheme 60b). Moreover, an intermolecular competition 
experiment showed electron-rich aryl bromide to be preferentially converted (Scheme 60c). This outcome 
could be rationalized by a facile base-assisted internal electrophilic substitution-type (BIES) C−H activation.  




Scheme 60. Mechanistic studies of ruthenium-catalyzed C−H alkynylation. 
Based on these mechanistic studies, a plausible catalytic cycle was proposed as follow: First, the initial C–H 
bond activation involves a reversible carboxylate-assisted cycloruthenation of carboxylic acid 124 to form 
ruthenacycle 137, which was then coordinated by the TIPS alkyne. Subsequent oxidative addition and 
reductive elimination forms the desired product and regenerates the active ruthenium(II) catalyst (Scheme 61). 
 




Scheme 61. Proposed catalytic cycle for ruthenium-catalyzed C−H alkynylations. 
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3.3 Concise Synthesis of Lamellarin Alkaloids by C–H/N–H Activation 
Lamellarins are polycyclic marine alkaloids that contain a central pyrrole moiety (Figure 3).
[119]
 Since the first 
discovery of lamellarins A−D from Lamellaria sp. by Faulkner and co-workers in 1985,
[120]
 more than 50 




Figure 3. Structure of lamelarins type 1a, 1b and 2. 
Given the antibiotic, anti-cancer and anti-malaria activities
 
of pyrrole-containing lamellarin alkaloids,
[101a-f, 101h]
 
various synthetic routes for the preparation of lamellarins have been developed.
[122]
 These syntheses basically 
can be classified into two major categories; one utilizes ring-formation reactions using appropriately 
substituted acyclic precursors, while the other employs the functionalization of preexisting pyrroles.
[123]
 In 
2013, Ackermann and cowockers reported a versatile ruthenium(II) catalyzed oxidative C–H/N–H 
functionalization of enamides (Scheme 62a).
[100]
 This strategy set the stage for a step-economical pyrrole 
synthesis. In continuation of this study, we became attracted to conduct a step-economical lamellarin alkaloid 
synthesis (Scheme 62b). 
 
Scheme 62. Ruthenium(II)-catalyzed C–H/N–H activation for the assembly of lamellarin alkaloids. 
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3.3.1 Retrosynthetic Analysis 
Our studies were inspired by identifying pyrrole 143 as the key intermediate for a C–H activation-based 
lamellarin synthesis. Starting from the diaryl-substituted pyrrole 128 which derived from the metal-catalyzed 
C–H/N–H activation strategy, the annelation of the D-ring can be achieved by Suzuki-Miyaura coupling and 
intramolecular esterification. Finally, the construction of the B-ring could be accomplished by a two-step 
Pomeranz−Fritsch-type cyclization
[122c, 122e, 122g]
 protocol (Scheme 63). 
 
Scheme 63. Retrosynthetic analysis for lamellarin alkaloids 4. 
3.3.2 Optimization for the Preparation of Key Intermediate 128a 
We initiated our studies by testing the efficiency of different transition metal complexes
[100, 124]
 in the 
envisioned C–H/N–H functionalization of enamides 127 with alkyne 59c (Table 4). The desired products were 
not observed in the absence of typical transition metal catalysts (entry 1). However, trace amounts of products 




 were  used  as the  catalyst  
(entries 2 and 4). In contrast, rhodium(III)
[124g]
 and less expensive ruthenium(II)
[100, 124f]
 complexes proved to 
be significantly more powerful (entries 3 and 5), delivering the desired products in synthetically meaningful 
yields. We then focused on the inexpensive ruthenium(II) complexes and screened various solvents and 
additives systematically. We found that the chemoselectivity towards the NH-free pyrrole 128a was strongly 
influenced by the silver(I) additive and the solvents (entries 5-10).
[124f]
 Finally, the optimal conditions are 
determined as shown in entry 10. In the presence of AgSbF6 additive, the desired NH-free pyrrole 128a was 
obtained in almost quantitative yield in a mixture of DCE and MeOH in the ratio of 2:1.  
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Entry [TM] solvent 
128a (%) 
R = H 
128a´ (%) 
R = Ac 
1 --- MeOH/DCE --- --- 
2 
Cp*Co(CO)I2 
MeOH/DCE --- --- 
3 [Cp*RhCl2]2 
MeOH/DCE 94 trace 
4 
Pd(OAc)2 
MeOH/DCE 15 --- 
5 [RuCl2(p-cymene)]2 PEG-400
b
 32 59 
6 [RuCl2(p-cymene)]2 PEG-400/H2O
b
 44 34 
7 [RuCl2(p-cymene)]2 t-AmOH
b
 13 80 
8 [RuCl2(p-cymene)]2 t-AmOH 68 23 
9 [RuCl2(p-cymene)]2 t-AmOH
/
DCE 95 trace 
10 [RuCl2(p-cymene)]2 MeOH/DCE 97 --- 
a
 Reaction conditions: 59c (0.50 mmol), 127 (0.55 mmol), [TM] (10 mol %), AgSbF6 
(20 mol %), Cu(OAc)2·H2O (2.0-3.0 equiv), solvent (1.5 mL), 110-120 °C, 24 h, yield 
of isolated products; 
b
 in the absence of AgSbF6. 
 
3.3.3 Synthesis of Lamellarin D/H 
With the optimized conditions being identified, we then explored the scalability of the C–H/N–H activation 
with a gram-scale reaction. To our delight, the large scale reaction delivered the desired key intermediate 
pyrrole 128a in comparably high yield (Scheme 64). 




Scheme 64. Gram-scale synthesis by C–H/N–H activation. 
Subsequently, reaction of key intermediate pyrrole 128a with NBS gave the expected C3-brominated pyrrole 
144a selectively in excellent yield by a judicious choice of solvent.
[122e]
 Next, the Suzuki-Miyaura cross-
coupling of 144a with arylboronic ester 2a afforded the tetra-substituted pyrrole 145. With a regioselective 
route to 3,4,5-arylated pyrrole-2-carboxylates 145 established, we focused on their conversion to the 
lamellarin scaffold. Thus, compound 145 was treated with p-TsOH in methanol to give lactone 146a, which 
was alkylated with commercially available bromoacetaldehyde dimethyl acetal 147 using Cs2CO3 as base to 
afford 148a in 81% yield. Finally, The N-alkylated intermediate 148a was transformed into isoquinoline 129c 
in a TfOH-mediated Pomeranz-Fritsch cyclization in 94% yield. The selective deprotection of the isopropyl 
groups in 148a with BCl3 afforded lamellarin D 129b in 96% yield. Meanwhile, lamellarin H 129a could be 
obtained by the cleavage of both methyl and isopropyl groups simultaneously with BBr3 (Scheme 65).
[122f]
 




Scheme 65. Synthesis of lamellarins H (129a) and D (129b). 
3.3.4 Synthesis of Lamellarin Derivatives 129d and 129e  
With the concise synthetic route to lamellarins H and D being established, we subsequently prepared the novel 
lamellarin derivative 129d being devoid of oxygenation elements at one β-aryl motif in only three steps from 
the the C3-brominated pyrrole 144a (Scheme 66). To our delight, by utilizing the ortho hydroxyl phenyl 
boronic acid 2b, we could access the annulated lactone 146 in one step by combining the Suzuki-Miyaura 
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coupling and intramolecular lactonizaiton. Finally, lamellarin derivative 129d was again obtained by 
Pomeranz-Fritsch cyclization. 
 
Scheme 66. Synthesis of lamellarin analogue 129d.
 
The strategy of combining the ruthenium(II)-catalyzed C–H/N–H activation with the palladium-catalyzed one-
pot annulation further set the stage for the preparation of truncated lamellarin analogue 129e (Scheme 67), 
highlighting the modular nature of our approach. 
 
Scheme 67. Synthesis of lamellarin analogue 129e. 
 Results and Discussion 
49 
 
3.4 Cobalt-Catalyzed C‒H Functionalizations by Imidate Assistance with Aryl and Alkyl Chlorides 
The vast majority of direct C‒H arylations has been realized with catalysts of precious 4d transition metals, 
most notably with the assistance of palladium, rhodium and ruthenium complexes.
[96]
 In consideration of the 
natural abundance and low costs of 3d transition metals, the focus in C‒H activation catalysis has shifted in 
the recent years towards the use of base metal catalysis. In this context, Ackermann




 have recently reported on C‒H arylations with organic halides by low-valent cobalt catalysis.  
Oxazolines are valuable intermediates
[105]
 in organic synthesis as well as useful ligands
[126]
 in metal catalysis. 
Therefore, within this thesis studies were performed to develop low valent cobalt-catalyzed C‒H arylations by 
oxazoline assistance. 
3.4.1 Optimization Studies 
We initiated our studies by testing various cobalt salts and ligands for the envisioned C‒H arylation on aryl 
oxazoline 130a with aryl chloride 8a (Table 5). Among a variety of N-heterocyclic carbene (NHC) preligands 
derived from benzimidazolium salts 149a‒b, triazolium salts 149c‒e, and imidazolium salts 149f‒h (entries 
1‒12), dicyclohexyl-substituted imidazolium chloride 149g gave the best result (entry 8). Imidazolinium salt 
149i also showed good reactivity, with however a slightly decreased yield of the desired product 131aa (entry 
10). Interestingly, the typical NHC precursors IMes·HCl and IPr·HCl failed to deliver the desired product 
131aa in good yields (entries 11 and 12). Among a variety of cobalt salts, Co(acac)2 proved to be optimal 
(entries 14‒17). Importantly, no product was formed in the absence of any cobalt salt (entries 13). 
Furthermore, the best metal to ligand ratio was determined to be 1/1 (entries 8 and 18). Surprisingly, the 
reaction proceeded smoothly even at ambient temperature and delivered the desired product in comparable 
yield (entry 19). 
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Table 5. Optimization of cobalt-catalyzed C‒H arylation by oxazoline assistance.
a 
 
entry [Co] (mol %) ligand (mol %) 131aa (%)
b
 
1 Co(acac)2 (5.0) --- < 5 
2 Co(acac)2 (5.0) 149a (5.0) 19 
3 Co(acac)2 (5.0) 149b (5.0) 27 
4 Co(acac)2 (5.0) 149c (5.0) 34 
5 Co(acac)2 (5.0) 149d (5.0) 9 
6 Co(acac)2 (5.0) 149e (5.0) 20 
7 Co(acac)2 (5.0) 149f (5.0) 13 
8 Co(acac)2 (5.0) 149g (5.0) 81 
9 Co(acac)2 (5.0) 149h (5.0) 14 
10 Co(acac)2 (5.0) 149i (5.0) 65 
11 Co(acac)2 (5.0) IMes·HCl (5.0) 13 
12 Co(acac)2 (5.0) IPr·HCl (5.0) 4 
13 --- 149g (5.0) --- 
14 CoCl2 (5.0) 149g (5.0) 74 
15 CoBr2 (5.0) 149g (5.0) 67 
16 CoI2 (5.0) 149g (5.0) 73 
17 Co(acac)3 (5.0) 149g (5.0) 51 
18 Co(acac)2 (5.0) 149g (10.0) 56 




 Reaction conditions: 130a (0.50 mmol), 8a (0.65 mmol), CyMgCl (2.0 
equiv), DMPU (1.0 mL), 60 °C, 16 h. 
b
 Yield of isolated product. 
c
 The 
reaction was performed at 23 °C.  
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3.4.2 Scope of Cobalt-Catalyzed C−H Arylation with Aryl Chlorides 
Once obtained the best conditions, we then explored the versatility of the optimized catalytic system (Scheme 
68). Notably, various aryl chlorides 8 with para-, meta- and even sterically hindered ortho-substituents could 
be efficiently converted. Functional groups such as, ether, halide or tertiary amine, were well tolerated (131ac-
131ae, 131ao). The utility of this method was further demonstrated by the 5 mmol-scale reaction, which 
provided the corresponding product 131ai in 73% yield. 
 
Scheme 68. Scope of cobalt-catalyzed C−H arylation with respect to aryl chlorides 2. 
Subsequently, a variety of cyclic imidates 130 were tested in the ambient-temperature cobalt-catalyzed C‒H 
arylation (Scheme 69). The protocol was applicable to both electron-rich as well as electron-deficient arenes 
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130, thereby delivering the corresponding products 131 with excellent levels of positional selectivity. 
Furthermore, substituted cyclic imidates 130e-g with varying ring size were also well tolerated. 
Heteroaromatic indole
 
substrate 130h also proved to be a viable substrate for this transformation. 
 
Scheme 69. Cobalt-catalyzed C−H arylation of aryl imidates 130. 
Actually, not only C‒H arylations were achieved with this broadly applicable low-valent cobalt-NHC catalyst, 
but also challenging primary and secondary C‒H alkylations were shown to be possible, albeit with moderate 
yields (Scheme 70).  




Scheme 70. Primary and secondary C‒H alkylations. 
3.4.3. Mechanistic Studies 
To delineating the working mode of the transformation, we performed a series of competition experiments 
(Scheme 71). Thus, electron-deficient aryl chloride 8f was preferentially converted, indicating a kinetically 
relevant C‒Cl cleavage step (Scheme 71a). The intermolecular competition experiment with aryl imidates 130 
showed that electron-deficient substrate 130d reacted exclusively (Scheme 71b).  
 
Scheme 71. Intermolecular competition experiments. 
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Furthermore, in the competition experiment between arylating and alkylating reagents 8a and 68a, we 
observed the C‒H arylated product 131aa as the main product, while only traces of the alkylated arene 150a 
was detected. This result demonstrated the challenging nature of the C‒H alkylations. 
Furthermore, independent experiments with substrates 130b and [D]4-130b
 
revealed a kinetic isotope effect 
(KIE) of kH/kD  1.2, indicating that C‒H activation might not be the rate determining step (Scheme 72). 
 
Scheme 72. Kinetic isotope effect study. 
We introduced stoichiometric amounts of typical radical scavengers into the catalytic system, and observed 
that the yield dropped significantly. These results indicated that a single electron transfer (SET)-type process
 
might be operative (Scheme 73). 
 
 
Scheme 73. Cobalt-catalyzed C−H arylation in the presence of radical scavengers. 
3.4.4. Diversification of Biaryl Imidates 131 
Finally, the synthetic utility of our strategy was further demonstrated by the facile diversification
[105b] 
of the 
obtained biaryl oxozolines 131, delivering the alcohols 150, amide 151, arylated benzoic acid 152 and 
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benzochromen-6-one 153 (Scheme 74).
[105d]
 Thereby, a variety of key structural motifs of bioactive 




Scheme 74. Diversification of biaryl imidates 131. 
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3.5 Oxazolinyl-Assisted C−H Amidation by Cobalt(III) Catalysis 
Decorated oxazolines are important structural motifs of various bioactive compounds of relevance to crop 
protection and medicinal chemistry (Figure 4).
[106]
 Moreover, oxazolines are easily accessible and can be 
transformed into a variety of valuable functional groups,
[128]
 which renders them key intermediates in organic 
synthesis and useful ligands in metal catalysis.
[126]
 Consequently, the development of flexible methods that 
provide general access to substituted oxazolines are highly desirable. 
 
Figure 4. Selected bioactive 2-aryl oxazolines. 
In recent years, transition metal-catalyzed C−H functionalization has made important progress for the atom- 
and step-economic diversification of oxazolines.
[20e, 25]
 However, catalytic C−H amidations on aryl oxazolines 
are as of yet restricted to the use of precious rhodium and iridium catalysts, as developed by Chang, among 
others.
[107]
 As a result, in this chapter we started to explore the possibility for cobalt(III)-catalyzed C−H 
amidations of oxazolines by employing dioxazolones
[129]
 as user-friendly amidating reagent. 
3.5.1 Optimization Studies 
At the outset of our studies, we explored the feasibility of the envisioned cobalt-catalyzed C−H amidation of 
aryl oxazoline 130i with dioxazolone 132a (Table 6). Preliminary solvent optimization showed that aprotic 
solvents enabled the desired C−H amidation, with DCE being optimal (entries 1−3). Then a variety of 
additives, including mono protected Amino acid (MPAA), were tested. NaOAc proved to be the most 
effective (entries 3−10). These observations demonstrated the importance of carboxylate assistance in the 
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C−H functionalization regime (entries 3−10). Different cobalt(III) complexes were explored thereafter. While 
CpCo(CO)I2 and CoCl2 proved to be completely unreactive, [Cp*CoI2]2 and [Cp*Co(MeCN)3](SbF6)2 showed 
similar reactivity with Cp*Co(CO)I2, albeit with inferior yields (entries 10−14). A control experiment 
revealed that there was no reaction in the absence of cobalt catalyst (entry 16). The beneficial effect of the 
carboxylate additive was further verified by the result of entry 15. 




Entry [Co] Solvent Additive 133ia 
(%) 1 Cp*Co(CO)I2 TFE NaOAc − 
2 Cp*Co(CO)I2 PhCF3 NaOAc 53 
3 Cp*Co(CO)I2 DCE NaOAc 65 
4 Cp*Co(CO)I2 DCE KOAc 47 
5 Cp*Co(CO)I2 DCE PivOH 58 
6 Cp*Co(CO)I2 DCE PivONa 63 
7 Cp*Co(CO)I2 DCE MesCO2Na 3 
8 Cp*Co(CO)I2 DCE AdCO2Na 44 
9 Cp*Co(CO)I2 DCE Ac-Ile-CO2Na 17 
10 Cp*Co(CO)I2 DCE NaOAc 68
b
 
11 [Cp*CoI2]2 DCE NaOAc 61
b
 
12 CpCo(CO)I2 DCE NaOAc − 
13 CoCl2 DCE NaOAc − 
14 [Cp*Co(MeCN)3](SbF6)2 DCE − 54 
15 Cp*Co(CO)I2 DCE − 35 
16 − DCE NaOAc − 
a 
Reaction conditions: 130i (0.50 mmol), 132a (1.2 equiv), [Co] (5.0 mol %), 
AgSbF6 (10 mol %), additive (10 mol %) solvent (2.0 mL), 100 ºC, 16 h. 
b
AgSbF6 
(20 mol %), NaOAc (20 mol %). 
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3.5.2 Scope of the Oxazolinyl-Assisted C−H Amidation 
 
Scheme 75. Scope of the oxazolinyl-assisted C−H amidation. 
With the optimized conditions identified, we tested the cobalt(III) catalyst in the C−H amidation of various 
aryl oxazolines 130 (Scheme 75). Thus, a remarkable functional group tolerance that included chloro-, bromo-, 
cyano-, ester- and trifluromethyl-substituents was observed, which highlighted the excellent chemo-selectivity 
of this cobalt(III) catalysis (130m-v). For the meta-substituted arenes 130v-w featuring two inequivalent ortho 
C−H bonds an excellent positional selectivity was observed, which was fully controlled by oxazolinyl 
assistance and secondary steric interactions. Thereafter, we tested substrates bearing substituents on the 
oxazoline ring. Thus, oxazolines 130 derived from different β-amino alcohols gave the desired products 
 Results and Discussion 
59 
 
133xa−133za with synthetically meaningful yields. Interestingly, the six-membered ring 1,3-oxazine 130aa 
also smoothly delivered the corresponding product. The efficiency of the protocol was further demonstrated 
by the gram-scale synthesis of amide 133ia in comparable yield.  
 
Scheme 76. Cobalt(III)-catalyzed C−H amidation of indoles and pyrroles. 
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To our delight, apart from oxazolines and oxazines 130, indoles 102 bearing removable pyridyl and pyrimidyl 
directing group also proved to be viable substrates for the Cp*Co(CO)I2-catalyzed C−H amidation (Scheme 
76). Again, the excellent chemoselectivity of the cobalt(III) catalyst was demostrated by a remarkable 
tolerance of valuable electrophilic functional groups, such as fluoro, chloro, bromo, iodo, ester or thiophene 
substituents (154ca−154ga). Meanwhile, aryl, heteroaryl, and alkyl amide moieties could be introduced in a 
step-economical manner by this user-friendly protocol (154bb−154bf). The robustness of the Cp*Co(CO)I2-
catalyzed C−H amidation was illustrated by the gram-scale synthesis of amidated indole 154ba at low catalyst 
loading of only 1.0 mol %. The catalytic system was not only applicable to indole substrates but also enabled 
the cobalt-catalyzed C−H nitrogenation of pyrroles (155aa), pyrozoles (156aa-156ba), phenyl pyridines and 
phenyl pyrimidines (157aa-157ca) as well (Scheme 77). 
 
Scheme 77. Cobalt(III)-catalyzed C−H amidation of other substrates. 
3.5.3 Mechanistic Studies 
Attracted by the robustness of the cobalt(III)-catalyzed C−H amidation, we conducted mechanistic studies to 
elucidate its mode of action. Only a minor loss in catalytic activity was observed when typical radical 
scavengers were introduced into the catalytic system. These findings do not provide support for a radical-
based mechanism (Scheme 78a). Furthermore, a mercury-test experiment confirmed the cobalt catalysis to be 
homogeneous in nature (Scheme 78b). 




Scheme 78. Radical scavenger experiments and mercury test. 
In the absence of the dioxazolinone 132a, reactions performed in the presence of an isotopically labelled 
cosolvent revealed a considerable H/D scrambling (Scheme 79a). However, no H/D exchange was observed in 
the presence of dioxazolinones 132a (Scheme 79b). The kinetic isotope effect (KIE) was determined to be 
kH/kD ≈ 2.3 by independent experiments. This result indicated that the C−H cobaltation step might be 
kinetically relevant. 




Scheme 79. H/D exchange and KIE studies. 
Intermolecular competition experiments between differently substituted substrates revealed electron-rich 
arenes 130m and electron-rich dioxazolones 132b to be converted preferentially (Scheme 80). These results 
could be rationalized in terms of the key C−H activation step occurring by a base-assisted, intermolecular 
electrophilic substitution-type (BIES) C−H activation. 
 
Scheme 80. Competition experiments. 
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3.5.4 Product Diversivications  
The synthetic utility of the cobalt(III)-catalyzed C−H amidation was illustrated by the postsynthetic 
diversification of the obtained amides 133 (Scheme 81). Thus, the liberation of the free primary amine was 
easily accomplished within 30 min by microwave irradiation, and then following a modified procedure, a 
novel quinazolinone 159 could be prepared in a step-economical manner. Moreover, adopting Yu’s protocol 
[130]
 our catalytic product could easily underwent C−H oxygenation process via copper catalysis.  
 
Scheme 81. Diversification of 2-amidoaryloxazolines 133. 
Based on our mechanistic studies and previous reports,
[131]
 we propose a plausible catalytic cycle as follow 
(Scheme 82): First, a kinetically relevant, acetate-assisted C−H cobaltation occurres to form the metallacycle 
160. Subsequent coordination of the dioxazolones 132 forms the intermediate 161, which then undergoes CO2 
extrusion. Finally, proto-decobaltation by the originally formed AcOH regenerates the catalyst cobalt-(III) 
carboxylate and yields the desired product 133.  
 
Scheme 82. Proposed catalytic cycle. 
 Results and Discussion 
64 
 
3.6 Cobalt-Catalyzed Oxidase C−H/N−H Alkyne Annulation 
Recent years have witnessed considerable progress in the development of oxidative C−H/Het−H 
functionalizations for the assembly of bioactive heterocycles,
[2l]
 the vast majority of which require metal 
oxidants, such as antibacterial copper(II) and/or precious silver(I) oxidants. In contrast, oxidase alkyne 
annulations with O2 as the sole oxidant were as of yet only accomplished exploiting precious 4d transition 
metals such as palladium, rhodium, and ruthenium.
[132]
  







 we started to explore the possibilities of using oxygen as the sole oxidant in 
cobalt-catalyzed alkyne annulations.  
3.6.1 Optimization Studies 
We initiated our studies by testing different additives for the envisioned aerobic cobalt-catalyzed C–H 
functionalization of arene 85a, featuring the bidentate 2-pyridyl-N-oxide (PyO) as the directing group (Table 
7). Thus, the envisioned cobalt oxidase reactivity was realized under an atmosphere of ambient air, when 
using PivOH as additive in trifluoroethanol (TFE) at 80 °C (entries 1-2). While high reacting temperature was 
detrimental for the reaction, the most appropriate temperature was determined to be 60 °C (entries 3-4). No 
products were observed when the reaction was conducted under a N2 atmosphere (entry 5), this result clearly 
demonstrated that O2 is sole oxidant in this transformation. The catalyst loading could be further reduced  to 
10 mol % when the reaction was performed under an atmosphere of O2 (entries 6-7). In the absence of either 
cobalt salt or PivOH, no product was detected (entries 8-9). Finally, after N-deoxygenation with PCl3, the 
desired product could be isolated in 84% yield (entry 10). Subsequently, different cobalt sources (entries 11-
16) and solvents (entries 17-19) were tested, Co(OAc)2 and TFE proved to be optimal. It is worth noting that 
the cobalt(III) complexes [Cp*Co(CO)I2], [Co(NH3)6]Cl3, and Co(acac)3 failed to deliver the desired product. 
Furthermore, no reactivity was observed when the PyO directing group was modified to the simple N-pyridyl 
or the N-phenyl group. Importantly, this oxidative C–H/N–H functionalization was realized with the simple 
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       Yield [%] 
 134ad           134ad´
´
 
1 Co(OAc)2 NaOPiv 80 --- --- 
2 Co(OAc)2 PivOH 80 50 25 
3 Co(OAc)2 PivOH 100 trace --- 
4 Co(OAc)2 PivOH 60 69 26 
5
b
 Co(OAc)2 PivOH 60 --- --- 
6
c
 Co(OAc)2 PivOH 60 28 13 
7
c,d
 Co(OAc)2 PivOH 60 69 21 
8 --- PivOH 60 --- --- 
9 Co(OAc)2 --- 60 --- --- 
10
c, d, e
 Co(OAc)2 PivOH 60 --- 84 
11 CoCl2 PivOH 60 --- --- 
12 CoI2 PivOH 60 --- --- 
13 Co(acac)2 PivOH 60 42 10 
14
c
 Co(acac)3 PivOH 60 --- --- 
15
c
 [Co(NH3)6]Cl3 PivOH 60 --- --- 
16
c
 Cp*Co(CO)I2 PivOH 60 --- --- 
17
f
 Co(OAc)2 PivOH 60 trace --- 
18
g
 Co(OAc)2 PivOH 60 --- --- 
19
h
 Co(OAc)2 PivOH 60 --- --- 
a
 Reaction conditions: 85a (0.25 mmol), 59d (1.50 equiv), [Co] (20 mol %), additive (2.0 equiv), 
CF3CH2OH (1.0 mL), under air (1 atm), 16 h, isolated yield. 
b
 under N2. 
c
 [Co] (10 mol %). 
d
 O2 (1 atm). 
e
 
59d (1.2 equiv), isolated after N-deoxygenation with PCl3. 
f
 CF3CH(OH)CF3 (1.0 mL) as solvent. 
g
 EtOH 
(1.0 mL) as solvent. 
h
 DMSO (1.0 mL) as solvent.  
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3.6.2 Scope of Cobalt-Catalyzed Aerobic C−H Functionalization 
3.6.2.1 Scope of Terminal Alkynes 
With the optimized reaction conditions in hand, we then tested the versatility of the cobalt(II) catalyst with a 
representative set of benzamides 85a (Scheme 83) and alkynes. To our delight, a variety of terminal alkynes 
59 were efficiently converted in this aerobic C−H/N−H functionalization process. Alkyl-, aryl-, silyl- and 
ester-substituted terminal alkynes proved to be viable substrates for this transformation. It is worth noting that 
an excellent tolerance of valuable electrophilic functional groups was observed, such as iodo, bromo, ester, 
ketone, and carboxylic acid substituents. Interestingly, this strategy was not restricted to aromatic C−H 
functionalization, but proved applicable to diversification of alkene 85f as well. The synthetic utility of the 
optimized cobalt(II) catalyst was further demonstrated by the gram-scale preparation of isoquinolones 134bi 
and 134aj in comparable yields. 
 
Scheme 83. Scope of cobalt-catalyzed aerobic C−H functionalization with terminal alkynes. 
3.6.2.2 Aerobic C–H/N–H Functionalizations with Internal Alkynes 
The aerobic cobalt-catalyzed C–H/N–H functionalization was not restricted to terminal alkynes 59. Indeed, 
challenging internal alkynes 59d, 59o-q also proved to be viable substrates for this chemoselective annulation 
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of benzamides 85 (Scheme 84). Not only symmetrical aryl and alkyl-substituted alkynes were efficiently 
converted (59o-59q), but the unsymmetrically internal aryl alkyl-alkyne 59b also underwent the desired 
annulation with excellent regio-selectivity, placing the aromatic group proximal to the heteroatom. A variety 
of valuable substituents in the para-, ortho- and meta-positions of benzamides 85 were well accommodated. 
For the meta-substituted benzamides, the annulation occured preferentially at the least hindered position (85j-
85k). 
 
Scheme 84. Scope of cobalt oxidase C−H functionalization with internal alkynes. 
3.6.3 Mechanistic Studies 
Thereafter, we performed experimental mechanistic studies to delineate the working mode of the cobalt 
oxidase catalysis. Intermolecular competition experiments with differently substituted substrates showed that 
electron-deficient benzamides 85h and electron-deficient alkynes 59s are inherently less reactive (Scheme 85).  




Scheme 85. Intermolecular competition experiments. 
Moreover, H/D exchange experiments were performed with D2O as the co-solvent. No deuterium-
incorporation was observed in both the reisolated starting material 85a´ as well as the desired product 134aj. 
These results indicated that the C−H cobaltation might be an irreversible process in this transformation 
(Scheme 86).  
 
Scheme 86. Attempted H/D Exchange experiments using D2O as cosolvents. 
In addition, inter- and intramolecular kinetic isotope effects (KIE) were determined to be kH/kD 1.4 and 1.9, 
respectively, which were suggestive of a kinetically-relevant C−H cobaltation event (Scheme 87). 




Scheme 87. Kinetic isotope effect (KIE) studies. 
For the further understanding of the aerobic nature of this cobalt-catalyzed C−H activation process, O2 up-take 
studies were subsequently carried out (Scheme 88). Impressively, the high catalytic efficiency of the cobalt 
oxidase strategy was demonstrated with 90% conversion of substrate 85a within less than 5 h. Our observation 
clearly showed that O2 served as the sole terminal oxidant in the C−H functionalization process. These results 
also highlighted a short, yet significant induction period.  
 
 




























Scheme 88. Oxygen consumption during cobalt-catalyzed C−H activation.  
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Based on the above mentioned mechanistic studies, a possible catalytic cycle was proposed as follows. The 
oxidative alkyne annulation is initiated by a kinetically relevant, carboxylate-assisted C−H cobaltation, 
followed by subsequent migratory insertion of the alkyne 59, to give the seven membered-caboltacycle 164. 
Finally, the reductive elimination delivers the desired isoquinolone product 134 and regenerates the active 
cobalt species (Scheme 89).  
 
Scheme 89. Plausible catalytic cycle for cobalt catalyzed alkyne anulation. 
3.6.4 Product Diversification 
Finally, the pyridyl-N-oxide moiety was removed in a traceless fashion, which highlighted the considerable 
synthetic potential of the cobalt-catalyzed oxidase C−H/N−H functionalization (Scheme 90a). Furthermore, 
we successfully utilized this strategy for the synthesis of the cytotoxic topoisomerase-I (topo-I) inhibitor 
rosettacin derivative 170 (Scheme 90b). Thus, the aerobic annulation of alkyne 59k by benzamide 85l through 
the C−H/N−H functionalization set the stage for a step-economical access to the anticancer agent 21,22-
dimethoxyrosettacin
[133]
 170 among others. Here, the unique reactivity of the cobalt-catalyzed oxidative 
annulation with terminal alkynes was essential, avoiding tedious reaction sequences for the installation and 
removal of a silyl protecting group on the alkyne moiety.
[134]
 




Scheme 90. Product diversification: (a) Traceless removal of PyO and (b) Step economical synthesis of 21,22-
dimethoxyrosettacin. 
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4 Summary and Outlook 
Catalytic C−H functionalization has emerged as an economically-attractive and environmentally-benign 
alternative to conventional cross-coupling approaches. Thus, major efforts have been made on transformations 
of inert C–H bonds into useful functionalities. The work presented within this thesis mainly focused on the 
development and application of versatile ruthenium- and cobalt-catalyzed direct C−H functionalizations.  
In the first project, a phosphine-modified ruthenium(II) biscarboxylate catalyst enabled C–H arylations of 
benzoic acids with excellent positional selectivity and ample substrates scope. Importantly, the unique 
synthetic utility of the ruthenium(II) catalysis regime also set the stage for site-selective C–H olefinations of 
benzoic acids (Scheme 91).  
 
Scheme 91. Ruthenium(II)-catalyzed C–H arylation and olefination of benzoic acids. 
Inspired by the above mentioned robustness of C–H arylations and olefination of benzoic acids protocol, we 
subsequently achieved the first ruthenium-catalyzed C–H alkynylation of weakly-O-coordinating substrates. 
The reaction proceeded under mild conditions with the weak base K2CO3. The versatility of the ruthenium(II) 
catalysis was illustrated by providing step-economical access to phthalides as well as enabling unprecedented 
decarboxylative ortho-C−H alkynylations (Scheme 92). 
 
Scheme 92. Ruthenium(II)-catalyzed C–H alkynylations of weakly coordinating benzoic acids. 
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In the third project, we investigated the efficiency of various transition metal catalysts in the C–H/N–H 
activation of enamides for the step-economical synthesis of lamellarin alkaloids. Thus, the inexpensive 
ruthenium(II) catalyst proved to be particularly effective for the key oxidative alkyne annulation, which 
provided modular access to the naturally-occurring alkaloids lamellarin D and H (129a-b) as well as truncated 
derivatives 129c-e (Scheme 93). 
 
Scheme 93. Modular synthesis of lamellarin alkaloids by C‒H/N‒H functionalizations. 
Subsequently, we disclosed the first low valent cobalt-catalyzed C‒H arylation and C‒H alkylation by 
oxazoline assistance (Scheme 94). Thus, cobalt catalysts derived from N-heterocyclic carbenes enabled 
positional-selective C‒H arylations and alkylation with inexpensive aryl/alkyl chlorides as electrophiles. 
Thereby, biaryl oxazolines were prepared in a step-economical fashion, which thus far required the use of 
precious metal catalysts. Mechanistic studies suggested a facile C‒H metalation and a kinetically relevant C‒
Cl cleavage. Importantly, the obtained biarylated imidates could be easily transformed to a variety of valuable 
functionalities, which gave expedient access to key structural scaffold of bioactive compounds. 
 
Scheme 94. Cobalt-catalyzed C−H arylation and C−H alkylation by oxazoline assistance. 
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Thereafter, we reported the first cobalt-catalyzed C−H amidation by the assistance of synthetically useful 
oxazolines. Thus, a versatile cobalt(III) catalyst allowed for the direct amidation using robust dioxazolones 
with ample substrate scope, which also proved viable to C−H functionalizations on indoles, pyrroles, 
pyrozoles as well as phenyl pyridines. The synthetic utility of the oxazolinyl-assisted C−H amidation proctol 
was further demonstrated by late-stage diversification and large scale reaction. Mechanistic studies provided 
strong support for a kinetically relevant C−H cobaltation by carboxylate assistance (Scheme 95).  
 
Scheme 95. Cobalt-catalyzed C−H amidation. 
Finally, described herein is the unprecedented cobalt-catalyzed oxidative alkyne annulation by C−H/N−H 
functionalizations with O2 as the sole oxidant. Thus, by utilizing inexpensive Co(OAc)2 as the catalyst, 
isoquinolones were accessed in a step-economical fashion with both terminal and internal alkynes under 
extremely mild conditions. The practical importance of the cobalt oxidase catalysis was illustrated by an 
efficient synthesis of a cytotoxic topoisomerase-I inhibitor 170 (Scheme 96). 
 




Scheme 96. Cobalt-catalyzed oxidase C−H functionalization. 
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5 Experimental Section 
5.1 General Remarks 
Unless otherwise noted, all reactions were performed under an argon or nitrogen atmosphere using pre-dried 
glassware and standard Schlenk techniques.  
Solvents  
All solvents for reactions involving moisture-sensitive reagents were dried, distilled and stored under an inert 
atmosphere (argon or nitrogen) according to the following standard procedures.  
1,2-Dimethoxyether (DME) and tert-amylalcohol (t-AmOH) were used as supplied by Merck or stirred over 
sodium chips for 5 h at 120 °C and then distilled at ambient pressure.  
Water (H2O) was degassed before its use, applying repeated freeze-pump-thaw degassing procedure.  
1,2-Dichloroethane (DCE) and 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU) were dried 
over CaH2 for 8 h, degassed and distilled under reduced pressure.   
Dichloromethane (DCM), N,N-dimethylformamide (DMF) and tetrahydrofuran (THF) were purified 
using a solvent purification system (SPS) from Mbraun.  
N-Methyl-2-pyrrolidone (NMP) was dried over CaH2 for 4 h at 150 °C and subsequently distilled under 
reduced pressure.   
Methanol (MeOH) was distilled from magnesium methanolate.   
Toluene was pre-dried over KH followed by distillation from sodium benzophenone.  
1,4-Dioxane was dried over sodium, benzophenone and distilled afterwards.  
 
Vacuum  
The following pressures were measured on the used vacuum pump and were not corrected: membrane pump 
vacuum (MPV): 0.5 mbar, oil pump vacuum (OPV): 0.1 mbar. 
 
Melting Points (M. p.) 
Melting points were measured, using a Stuart® Melting Point Apparatus SMP3 from Barloworld scientific. 
Reported values are uncorrected.  
 
Chromatography  
Analytical thin layer chromatography (TLC) was performed on 0.25 mm silica gel 60F-plates (Merck) with 
254 nm fluorescent indicator from Merck. Plates were visualized under UV-light or developed by treatment 
with a KMnO4 solution followed by carefully heating. Chromatographic purification of products was 
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accomplished by flash column chromatography on MERCK silica gel, grade 60 (0.040–0.063 mm and 0.063–
0.200 mm).  
Gas Chromatography (GC) 
The conversion of the reactions was monitored by coupled gas chromatography/mass spectrometry using 
G1760C GCDplus with mass detector HP 5971, 5890 Series II with mass detector HP 5972 from HEWLETT-
PACKARD and 7890A GC-System with mass detector 5975C (Triplex-Axis-Detector) from AGILENT 
TECHNOLOGIES equipped with HP-5MS columns (30 m × 0.25 mm, Ø 0.25 m). 
High Performance Liquid Chromatography (HPLC) 
Preparative and analytical separations were performed on an HPLC-System from KNAUER (Smartline Pump 
100, Dynamic Mixing Chamber, Injection-and Control-Valve, Smartline UV Detector 2500). Separation 
normal phase column (250×10 mm) from MACHEREY-NAGEL (MN) was used. Organic solvents of HPLC 
grade were employed. All samples were filtered through Polytetrafluoroethylene Filter from ROTH (Ø 25 mm, 
0.2 μm) or VWR (Ø 13 mm, 0.2 μm) prior to separation.  
 
Nuclear Magnetic Resonance Spectroscopy (NMR) 
Nuclear magnetic resonance (NMR) spectroscopy was performed at 300, 400, 500 or 600 MHz (
1
H NMR), 75, 
100 or 125 MHz (
13
C NMR, APT) and 283 MHz or 471 MHz (
19
F NMR) on BRUKER AM 250, VARIAN 
Unity-300 and Inova 500 instruments. Chemical shifts were reported as δ-values in ppm relative to the 
residual proton peak of the deuterated solvent or its carbon atom, respectively, or the standard trimethylsilyl 
(TMS) peak. For characterization of the observed resonance multiplicities the following abbreviations were 
applied: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), dt (doublet of 
triplet), or analogue representations. The coupling constants J are reported in Hertz (Hz).  
 
Infrared Spectroscopy (IR) 
Infrared spectra were recorded on a Bruker Alpha-P ATR-spectrometer. Liquid probes have been measured as 
films between the plates of NaCl and solid probes neat applying Attenuated Total Reflection (ATR) technique 
which enabled the samples to be examined directly. Analysis of the spectral data has been done by using the 
OPUS 3.1 software from Bruker, respectively OPUS 6. Absorption (ṽ) was given in wave numbers (cm
–1
). 




Mass Spectrometry (MS) 
MS (EI) and HR-MS (EI) were measured on a Time-of-Flight mass spectrometer AccuTOF from JOEL. ESI-
mass spectra were recorded on an Ion-Trap mass spectrometer LCQ from FINNIGAN or on a Time-of-Flight 
mass spectrometer microTOF from BRUKER. ESI-HR-MS spectra were recorded on a BRUKER APEX IV or 
a BRUKER DALTONIC {7T, Fourier Transform Ion Cyclotron Resonance (FTICR)} mass spectrometer. The 
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Chemicals obtained from commercial sources with purity above 95% were used without further purification. 










 2-aryl oxazolines and 2-aryl oxazines 130a-aa,
[138]



















The following compounds were obtained by the generous courtesy of the persons named below: 
Karsten Rauch: [Ru(O2CMes)2(p-cymene)], [RuCl2(p-cymene)]2. 
M. Sc. Joachim Loup: [CpCoI2(CO)]. 
Dr. Svenja Warratz: [RuCl2(p-cymene)(PhtBuPOH)]. 
M. Sc. Torben Rogge: [RuCl2(p-cymene)(nBu2POH)]. 
M. Sc. Zhixiong Ruan: (Bromoethynyl)(tert-butyl)dimethylsilane 32b. 
Dr. Weiping Liu: (Pyridin-2-yl)-1H-indoles and (pyrimidin-2-yl)-1H-indoles 102b-g. 
M. Sc. Qingqing Bu: 2-(1H-Pyrrol-1-yl)pyridine 155a. 
 
5.2 General Procedures 
General Procedure A for Ruthenium(II)-Catalyzed C–H Arylations of Benzoic Acids with Aryl Halides 
by Weak-O-Coordination 
A suspension of   [Ru(O2CMes)2(p-cymene)] (16) (28.1 mg, 10 mol %), PCy3 (14.0 mg, 10 mol %), K2CO3 
(138 mg, 1.00 mmol), 124 (0.50 mmol), and 14 (0.75 mmol, 1.50 equiv) in NMP (2.0 mL) was stirred under 
N2 for 16 h at 120 ºC. At ambient temperature, MeCN (3.0 mL), K2CO3 (207 mg, 1.50 mmol) and MeI (355 
mg, 2.50 mmol) were added and the mixture was stirred at 50 ºC for another 2 h. After cooling to ambient 
temperature, the mixture was diluted with MTBE (120 mL), then washed with H2O (20 mL) and brine (20 mL) 
sequentially. The organic phase was dried over Na2SO4, and concentrated in vacuo. The remaining residue 
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General Procedure B for Ruthenium(II)-Catalyzed C−H Alkynylation of Weakly Coordinating Benzoic 
Acids 
A suspension of   [Ru(O2CMes)2(p-cymene)] (16) (28.1 mg, 10 mol %), K2CO3 (138 mg, 1.00 mmol), 124 
(0.50 mmol), and 33 (0.65 mmol, 1.30 equiv) in 1,4-dioxane (1.0 mL) was stirred under N2 for 16 h at 120 ºC. 
At ambient temperature, MeCN (3.0 mL), K2CO3 (138 mg, 1.0 mmol) and MeI (355 mg, 2.50 mmol) were 
added and the mixture was stirred at 50 ºC for additional 2 h. At ambient temperature, the mixture was dry-
loaded onto silica gel and purified by column chromatography (n-hexane/EtOAc) and HPLC (when required) 
to give products 126. 
 
General Procedure C for Ruthenium(II)-Catalyzed C–H Alkynylation of Benzoic Acids: Access to Free 
Acids 126´ 
A suspension of   [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), K2CO3 (138 mg, 1.00 mmol), benzoic acid 124 
(0.50 mmol), and alkynyl bromide 33 (0.65 mmol, 1.30 equiv) in 1,4-dioxane (1.0 mL) was stirred under N2 
for 16 h at 120 ºC. At ambient temperature, AcOH (2.0 mL) was added, the mixture was dry-loaded onto silica 
gel and purified by column chromatography (n-hexane/EtOAc/AcOH) to give products 126´. 
 
General procedure D for Cobalt-Catalyzed C–H Functionalizations by Imidate Assistance with Aryl 
and Alkyl Chlorides 
A suspension of   Co(acac)2 (6.4 mg, 5.0 mol %), ICy·HCl (149g) (6.7 mg, 5.0 mol %), 130 (0.50 mmol, 1.0 
equiv), 8 (0.65 mmol, 1.3 equiv) and DMPU (1.0 mL) was stirred for 5 min at 0 °C. A solution of CyMgCl in 
2-Me-THF (1.0 M, 1.0 mL, 2.0 equiv) was added dropwise at the same temperature. Then the mixture was 
stirred at 23 °C for 16 h. At ambient temperature, aq. NH4Cl (2.0 mL) and H2O (15 mL) were added. The 
reaction mixture was extracted with MTBE (3 × 20 mL). The combined organic phase was washed with brine 
(20 mL) and dried over Na2SO4. Evaporation of the solvents in vacuo and purification of the remaining 
residue by column chromatography on silica gel (n-hexane/EtOAc 5/1) yielded product 131.  
 
General Procedure E for the Amidation of 2-Phenyloxazolines 
2-Phenyloxazolines 130 (0.50 mmol, 1.0 equiv), dioxazolones 132 (0.60 mmol, 1.2 equiv), [Cp*Co(CO)I2] 
(0.025 mmol, 5.0 mol %), AgSbF6 (0.10 mmol, 20 mol %) and NaOAc (0.10 mmol, 20 mol %) were placed 
into a 25 mL Schlenk tube equipped with a septum under N2 atmosphere. DCE (2.0 mL) was introduced via 
cannula. The reaction mixture was stirred at 100 °C for 16 h. After cooling to ambient temperature, the 
reaction mixture was dry loaded onto silica gel and purified by flash column chromatography (n-
hexane/EtOAc) to afford the desired products 133. 
 
 




General Procedure F for the Amidation of Indoles, Pyrroles, Phenyl Pyridines and Phenyl Pyrazoles  
Indoles or pyrroles 102 (0.50 mmol, 1.0 equiv), dioxazolone 132 (0.60 mmol, 1.2 equiv), [Cp*Co(CO)I2] 
(0.0125 mmol, 2.5 mol %), AgSbF6 (0.025 mmol, 5.0 mol %) and NaOAc (0.025 mmol, 5.0 mol %) were 
placed into a 25 mL Schlenk tube equipped with a septum under N2 atmosphere. DCE (2.0 mL) was 
introduced via cannula. The reaction mixture was stirred at 70 °C for 16 h. After cooling to ambient 
temperature, the reaction mixture was dry loaded onto silica gel and purified by flash column chromatography 
(n-hexane/EtOAc) to afford the desired product 154. 
 
General Procedures G for the Cobalt-Catalyzed Oxidase C−H/N−H Alkyne Annulation 
Under an atmosphere of ambient air, aromatic amides 85 (0.50 mmol, 1.0 equiv), alkynes 59 (0.60 mmol, 1.2 
equiv), PivOH (102 mg, 1.0 mmol, 2 equiv), and Co(OAc)2 (8.9 mg, 10 mol %) were placed in a Schlenk tube. 
The Schlenk tube was evacuated and refilled with O2 three times with a balloon. TFE (2.0 mL) was added via 
a cannula. Then the mixture was stirred in a pre-heated (60 ºC) oil bath for 16 h (with the O2 balloon being 
connected to the Schlenk tube). At ambient temperature, the reaction was stopped by adding saturated aqueous 
NaHCO3 (15 mL). This mixture was extracted with CH2Cl2 (4×10 mL), and dried over Na2SO4. Evaporation 
of the solvent and purification by column chromatography on silica gel afforded the corresponding products. 
 
General Procedure H for the Cobalt-Catalyzed Annulation, and Subsequent N-Deoxygenation with 
PCl3 
Under an atmosphere of ambient air, aromatic amides 85 (0.50 mmol, 1.0 equiv), alkynes 59 (0.60 mmol, 1.2 
equiv), PivOH (102 mg, 1.0 mmol, 2 equiv) and Co(OAc)2 (8.9 mg, 10 mol %) were placed in a Schlenk tube. 
The Schlenk tube was evacuated and refilled with O2 three times with a balloon. TFE (2.0 mL) was added via 
cannula. Then the mixture was stirred in a pre-heated (60 ºC) oil bath for 16 h (with the O2 balloon being 
connected to the Schlenk tube). At ambient temperature, the solvent was removed in vacuo. Under a N2 
atmosphere, the residue was suspended in toluene (5.0 mL), and PCl3 (83 mg, 1.20 equiv) was added. The 
mixture was stirred at 50
 
ºC for 30 min. At ambient temperature, the reaction was stopped by adding saturated 
aqueous NaHCO3 (15 mL) and stirred for 15 min until the solution was clear. This mixture was extracted with 
CH2Cl2 (4×10 mL), and the combined organic phase was dried over Na2SO4. Evaporation of the solvent and 
purification by column chromatography on silica gel using n-hexane/EtOAc yielded the corresponding 
products. 
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5.3 Experimental Procedures and Analytical Data 




Methyl 4'-methoxy-3-methyl-[1,1'-biphenyl]-2-carboxylate (125aa): The general procedure A was 
followed using benzoic acid 124a (68 mg, 0.50 mmol) and aryl bromide 14a (140 mg, 0.75 mmol, 1.5 equiv). 
Purification by column chromatography on silica gel (n-hexane/EtOAc 20:1) yielded 125aa (111 mg, 87%) as 
a white solid.  
M. p. = 69−70 ºC. 
1
H NMR (400 MHz, CDCl3) δ = 7.35–7.25 (m, 3H), 7.21–7.14 (m, 2H), 6.91 (d, J = 8.7 
Hz, 2H), 3.82 (s, 3H), 3.61 (s, 3H), 2.37 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 170.5 (Cq), 159.0 (Cq), 
139.6 (Cq), 135.3 (Cq), 133.3 (Cq), 133.2 (Cq), 129.3 (CH), 129.3 (CH), 128.7 (CH), 127.2 (CH), 113.7 (CH), 
55.2 (CH3), 51.8 (CH3), 19.7 (CH3). IR (ATR): 2946, 2837, 1724, 1510, 1245, 1028, 791 cm
-1
. MS (EI) m/z 
(relative intensity) 256 (100) [M
+
], 225 (90), 209 (30), 197 (15), 182 (30), 153 (40). HR-MS (EI) m/z calcd 
for C16H16O3 [M
+
] 256.1099, found 256.1109. 





4'-Ethyl 2-methyl 3-methyl-[1,1'-biphenyl]-2,4'-dicarboxylate (125ab): The general procedure A was 
followed using benzoic acid 124a (68 mg, 0.50 mmol) and aryl bromide 14b (172 mg, 0.75 mmol, 1.5 equiv). 
Purification by column chromatography on silica gel (n-hexane/EtOAc 20:1) yielded 125ab (134 mg, 90%) as 
a colorless oil.  
1
H NMR (300 MHz, CDCl3) δ = 8.05 (d, J = 8.3 Hz, 2H), 7.40 (d, J = 8.3 Hz, 2H), 7.36–7.31 (m, 1H), 7.26–
7.12 (m, 2H), 4.36 (q, J = 7.1 Hz, 2H), 3.55 (s, 3H), 2.38 (s, 3H), 1.37 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, 
CDCl3) δ = 169.8 (Cq), 166.3 (Cq), 145.4 (Cq), 139.1 (Cq), 135.7 (Cq), 132.9 (Cq), 129.7 (CH), 129.4 (CH), 
129.4 (Cq), 129.3 (CH), 128.1 (CH), 126.9 (CH), 60.9 (CH2), 51.8 (CH3), 19.6 (CH3), 14.2 (CH3). IR (ATR): 
2981, 2950, 1712, 1610, 1460, 1366, 1100, 766 cm
-1
. MS (EI) m/z (relative intensity) 298 (100) [M
+
], 267 









Methyl 3-methyl-3'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxylate (125ac): The general procedure A was 
followed using benzoic acid 124a (68 mg, 0.50 mmol) and aryl bromide 14c (169 mg, 0.75 mmol, 1.5 equiv). 
Purification by column chromatography on silica gel (n-hexane/EtOAc 20:1) yielded 125ac (115 mg, 78%) as 
a colorless oil.  
1
H NMR (300 MHz, CDCl3) δ = 7.66–7.44 (m, 4H), 7.37 (dd, J = 7.6, 7.6 Hz, 1H), 7.28–7.18 (m, 2H), 3.60 (s, 
3H), 2.40 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 169.8 (Cq), 141.6 (Cq), 138.6 (Cq), 135.8 (Cq), 133.2 (Cq), 
131.6 (q, 
4
JC-F = 1.3 Hz, CH), 130.7 (q, 
2
JC-F = 32.2 Hz, Cq), 129.8 (CH), 129.6 (CH), 128.8 (CH), 127.1 (CH), 
125.0 (q, 
3
JC-F = 3.8 Hz, CH), 124.1 (q, 
3
JC-F = 3.8 Hz, CH), 124.0 (q, 
1
JC-F = 272.3 Hz, Cq), 124.0, 51.8 (CH3), 
19.7 (CH3).
 19
F NMR (283 MHz, CDCl3) δ = -62.6 (s). IR (ATR): 2949, 1729, 1483, 1334, 1118, 1065, 703 
cm
-1
. MS (EI) m/z (relative intensity) 294 (40) [M
+
], 263 (100), 243 (5), 235 (10), 215 (20), 193 (5), 165 (40). 
HR-MS (EI) m/z calcd for C16H13F3O2 [M
+
] 294.0868, found 294.0866. 
 
 
Methyl 3',5'-difluoro-3-methyl-[1,1'-biphenyl]-2-carboxylate (125ad): The general procedure A was 
followed using benzoic acid 124a (68 mg, 0.50 mmol) and aryl bromide 14d (145 mg, 0.75 mmol, 1.5 equiv). 
Purification by column chromatography on silica gel (n-hexane/EtOAc 20:1) yielded 125ad (110 mg, 84%) as 
a colorless solid.  
M. p. = 63−64 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 7.37 (dd, J = 7.6, 7.6 Hz, 1H), 7.26 (d, J = 7.6 Hz, 1H), 
7.17 (d, J = 7.6 Hz, 1H), 6.96–6.85 (m, 2H), 6.83–6.75 (m, 1H), 3.67 (s, 3H), 2.40 (s, 3H).
 13
C NMR (75 MHz, 
CDCl3) δ = 169.6 (Cq), 162.7 (dd,
 1,3
JC-F = 248.7, 13.0 Hz, Cq ), 144.1 (t, 
3,3
JC-F = 25.3 Hz, Cq), 137.8 (t, 
4,4
JC-F 
= 2.4 Hz, Cq), 135.8 (Cq), 132.9 (Cq), 130.1 (CH), 129.6 (CH), 126.8 (CH), 111.3 (dd, 
2,4
JC-F = 17.3, 8.1 Hz, 
CH), 102.8 (t, 
2,2
JC-F = 25.3 Hz, CH), 52.0 (CH3), 19.7 (CH3). 
19
F NMR (283 MHz, CDCl3) δ = -(109.8–109.9) 
(m). IR (ATR): 2951, 1726, 1622, 1454, 1337, 1117, 793 cm
-1
. MS (EI) m/z (relative intensity) 262 (60) [M
+
], 
231 (100), 253 (80), 201 (60), 188 (30), 183 (50), 151 (50). HR-MS (ESI) m/z calcd for C15H13F2O2 [M+H
+
] 
263.0878, found 263.0875. 
 




Methyl (E)-4'-(3-methoxy-3-oxoprop-1-en-1-yl)-3-methyl-[1,1'-biphenyl]-2-carboxylate (125ae): The 
general procedure A was followed using benzoic acid 124a (68 mg, 0.50 mmol) and aryl bromide 14e (181 
mg, 0.75 mmol, 1.5 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 20:1) 
yielded 125ae (126 mg, 81%) as a colorless solid.  
M. p. = 91−92 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 7.71 (d, J = 16.0 Hz, 1H), 7.55 (d, J = 8.5 Hz, 2H), 7.41–
7.31 (m, 3H), 7.28–7.18 (m, 2H), 6.47 (d, J = 16.0 Hz, 1H), 3.81 (s, 3H), 3.60 (s, 3H), 2.40 (s, 3H).
 13
C NMR 
(100 MHz, CDCl3) δ = 169.9 (Cq), 167.2 (Cq), 144.2 (CH), 142.9 (Cq), 139.1 (Cq), 135.6 (Cq), 133.3 (Cq), 
132.9 (Cq), 129.5 (CH), 129.4 (CH), 128.7 (CH), 128.0 (CH), 126.9 (CH), 117.8 (CH), 51.8 (CH3), 51.6 (CH3), 
19.6 (CH3). IR (ATR): 2944, 1729, 1708, 1604, 1436, 1270, 1170, 790 cm
-1
. MS (EI) m/z (relative intensity) 
310 (80) [M
+
], 278 (50), 247 (100), 219 (50), 189 (40), 165 (30). HR-MS (ESI) m/z calcd for C19H18O4 [M+H
+
] 
310.1205, found 310.1214. 
 
 
Methyl 3',4',5'-trimethoxy-3-methyl-[1,1'-biphenyl]-2-carboxylate (125af): The general procedure A was 
followed using benzoic acid 124a (68 mg, 0.50 mmol) and aryl bromide 14f (185 mg, 0.75 mmol, 1.5 equiv). 
Purification by column chromatography on silica gel (n-hexane/EtOAc 20:1) yielded 125af (133 mg, 84%) as 
a colorless oil.  
1
H NMR (300 MHz, CDCl3) δ = 7.35–7.30 (m, 1H), 7.25–7.16 (m, 2H), 6.57 (s, 2H), 3.86 (s, 3H), 3.84 (s, 
6H), 3.62 (s, 3H), 2.36 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 170.4 (Cq), 153.0 (Cq), 139.9 (Cq), 137.3 (Cq), 
136.4 (Cq), 135.3 (Cq), 133.1 (Cq), 129.3 (CH), 129.1 (CH), 126.9 (CH), 105.4 (CH), 60.9 (CH3), 56.0 (CH3), 
52.0 (CH3), 19.6 (CH3). IR (ATR): 2942, 2836, 1723, 1577, 1462, 1405, 1120 cm
-1
. MS (EI) m/z (relative 
intensity) 316 (100) [M
+
], 301 (80), 285 (10), 273 (15), 241 (10), 209 (10), 199 (10). HR-MS (EI) m/z calcd 
for C18H20O5 [M+H
+
] 316.1311, found 316.1301. 









Methyl 2-methyl-6-(quinolin-3-yl)benzoate (125ag): The general procedure A was followed using benzoic 
acid 124a (68 mg, 0.50 mmol), aryl bromide 14g (156 mg, 0.75 mmol, 1.5 equiv) and NaI (150 mg, 1.00 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 20:1) yielded 125ag (46 mg, 
33%) as a colorless oil.  
1
H NMR (400 MHz, CDCl3) δ = 8.92 (s, 1H), 8.14–8.12 (m, 2H), 7.83 (dd, J = 8.2, 1.4 Hz, 1H), 7.74–7.70 (m, 
1H), 7.56 (dd, J = 8.2, 6.9 Hz, 1H), 7.44–7.40 (m, 1H), 7.30–7.27 (m, 2H), 3.56 (s, 3H), 2.43 (s, 3H). 
13
C 
NMR (75 MHz, CDCl3) δ = 169.7 (Cq), 150.3 (CH), 147.1 (Cq), 136.5 (Cq), 136.1 (Cq), 134.7 (CH), 133.8 
(Cq), 133.5 (Cq), 130.0 (CH), 129.8 (CH), 129.6 (CH), 129.2 (CH), 128.0 (CH), 127.6 (CH), 127.6 (Cq), 127.0 
(CH), 52.0 (CH3), 19.8 (CH3). IR (ATR): 3063, 2949, 2855, 1721, 1490, 1435, 1264, 1084 cm
-1
. HR-MS (ESI) 
m/z calcd for C18H16NO2 [M+H
+
] 278.1176, found 278.1182. 
 
 
Methyl 3,4'-dimethoxy-[1,1'-biphenyl]-2-carboxylate (125ba): The general procedure A was followed 
using benzoic acid 124b (76 mg, 0.50 mmol) and aryl bromide 14a (140 mg, 0.75 mmol, 1.5 equiv). 
Purification by column chromatography on silica gel (n-hexane/EtOAc 20:1) yielded 125ba (79 mg, 58%) as a 
colorless solid.  
M. p. = 92−93 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 7.43–7.29 (m, 3H), 6.99–6.88 (m, 4H), 3.87 (s, 3H), 3.83 
(s, 3H), 3.66 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 168.7 (Cq), 159.2 (Cq), 156.4 (Cq), 140.8 (Cq), 132.4 
(Cq), 130.4 (CH), 129.3 (CH), 123.0 (Cq), 121.9 (CH), 113.8 (CH), 109.5 (CH), 56.0 (CH3), 55.2 (CH3), 52.1 
(CH3). IR (ATR): 2959, 2860, 1726, 1464, 1238, 1102, 1018, 791 cm
-1
. MS (EI) m/z (relative intensity) 272 
(90) [M
+
], 241 (100), 226 (40), 211 (15), 198 (20), 183 (15), 168 (10). HR-MS (EI) m/z calcd for C16H16O4 
[M
+
] 272.1049, found 272.1045. 




Methyl 4'-methoxy-4-methyl-[1,1'-biphenyl]-2-carboxylate (125ca): The general procedure A was 
followed using benzoic acid 124c (68 mg, 0.50 mmol) and aryl bromide 14a (140 mg, 0.75 mmol, 1.5 equiv). 
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Purification by column chromatography on silica gel (n-hexane/EtOAc 20:1) yielded 125ca (86 mg, 67%) as a 
colorless oil.  
1
H NMR (300 MHz, CDCl3) δ = 7.50 (dd, J = 1.3, 0.6 Hz, 1H), 7.29–7.04 (m, 4H), 6.82 (d, J = 8.7 Hz, 2H), 
3.73 (s, 3H), 3.56 (s, 3H), 2.30 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 169.4 (Cq), 158.8 (Cq), 139.1 (Cq), 
136.5 (Cq), 133.5 (Cq), 131.8 (CH), 130.6 (Cq), 130.5 (CH), 130.1 (CH), 129.4 (CH), 113.4 (CH), 55.1 (CH3), 
51.8 (CH3), 20.8 (CH3). IR (ATR): 2948, 2836, 1715, 1609, 1488, 1289, 1238, 821 cm
-1
. MS (EI) m/z 
(relative intensity) 256 (100) [M
+
], 225 (80), 210 (10), 197 (15), 182 (20), 165 (15), 153 (20). HR-MS (EI) 
m/z calcd for C16H16O3 [M
+
] 256.1099, found 256.1091. 




Methyl 4-acetyl-4'-methoxy-[1,1'-biphenyl]-2-carboxylate (125da): The general procedure A was followed 
using benzoic acid 124d (82 mg, 0.50 mmol) and 1-iodo-4-methoxybenzene (14a
,
) (175 mg, 0.75 mmol, 1.5 
equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 20:1) yielded 125da (115 mg, 




H NMR (400 MHz, CDCl3) δ = 8.32 (dd, J = 1.9, 0.5 Hz, 1H), 8.05 (dd, J = 8.1, 1.9 Hz, 1H), 7.44 (dd, J = 
8.1, 0.5 Hz, 1H), 7.24 (d, J = 8.8 Hz, 2H), 6.92 (d, J = 8.8 Hz, 2H), 3.82 (s, 3H), 3.68 (s, 3H), 2.62 (s, 3H). 
13
C 
NMR (100 MHz, CDCl3) δ = 196.8 (Cq), 168.6 (Cq), 159.5 (Cq), 146.3 (Cq), 135.3 (Cq), 132.3 (Cq), 131.1 (Cq), 
131.0 (CH), 130.5 (CH), 129.9 (CH), 129.4 (CH), 113.7 (CH), 55.2 (CH3), 52.2 (CH3), 26.6 (CH3). IR (ATR): 
2950, 2837, 1719, 1682, 1602, 1518, 1226, 826 cm
-1
. MS (EI) m/z (relative intensity) 284 (90) [M
+
], 269 






Methyl 4'-methoxy-4-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxylate (125ea): The general procedure A 
was followed using benzoic acid 124e (95 mg, 0.50 mmol) and 1-iodo-4-methoxybenzene (2a
,
) (175 mg, 0.75 
mmol, 1.5 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 20:1) yielded 125ea 
(140 mg, 90%) as a colorless oil.  
1
H NMR (300 MHz, CDCl3) δ = 8.04 (dd, J = 1.4, 0.7 Hz, 1H), 7.73 (ddd, J = 8.1, 2.0, 0.8 Hz, 1H), 7.47 (d, J 
= 8.1 Hz, 1H), 7.23 (d, J = 8.8 Hz, 2H), 6.94 (d, J = 8.7 Hz, 2H), 3.84 (s, 3H), 3.69 (s, 3H).
 13
C NMR (75 
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MHz, CDCl3) δ = 168.0 (Cq), 159.5 (Cq), 145.5 (q, 
4
JC-F = 1.6 Hz, Cq), 132.1 (Cq), 131.3 (Cq), 131.3 (CH), 
129.4 (CH), 129.1 (q, 
2
JC-F = 33.1 Hz, Cq), 127.7 (q, 
3
JC-F = 3.6 Hz, CH), 126.8 (q, 
3
JC-F = 3.8 Hz, CH), 123.7 
(q, 
1
JC-F = 272.3 Hz, Cq), 113.8 (CH), 55.2 (CH3), 52.3 (CH3). 
19
F NMR (283 MHz, CDCl3) δ = - 62.6 (s). IR 
(ATR): 2952, 2839, 1726, 1609, 1522, 1334, 1240, 1081 cm
-1
. MS (EI) m/z (relative intensity) 310 (100) [M
+
], 
279 (90), 264 (10), 251 (15), 236 (20), 207 (10), 188 (10). HR-MS (EI) m/z calcd for C16H13F3O3 [M
+
] 
310.0817, found 310.0821. 




The general procedure A was followed using benzoic acid 124f (70 mg, 0.50 mmol) and 1-iodo-4-
methoxybenzene (14a
,
) (175 mg, 0.75 mmol, 1.5 equiv) and K2CO3 (138 mg, 1.00 mmol, 2.0 equiv). 
Purification by column chromatography on silica gel (n-hexane/EtOAc 20:1) yielded 125fa (Colorless oil, 73 
mg, 56%) and the diarylated product 125fa
, 
(Pale yellow solid, 16 mg, 9%).  
Methyl 4-fluoro-4'-methoxy-[1,1'-biphenyl]-2-carboxylate (125fa): 
1
H NMR (400 MHz, CDCl3): δ = 7.51 (dd, J = 9.0, 2.7 Hz, 1H), 7.32 (dd, J = 8.5, 5.5 Hz, 1H), 7.24–7.17 (m, 
3H), 6.93 (d, J = 8.8 Hz, 2H), 3.85 (s, 3H), 3.68 (s, 3H).
 13
C NMR (100 MHz, CDCl3) δ = 167.9 (d, 
4
JC-F = 2.4 
Hz, Cq), 161.3 (d, 
1
JC-F = 247.3 Hz, Cq), 159.0 (Cq), 138.2 (d, 
4
JC-F = 3.4 Hz, Cq), 132.6 (Cq), 132.4 (d, 
3
JC-F = 
7.6 Hz, CH), 132.2 (d, 
3
JC-F = 7.3 Hz, Cq), 129.4 (CH), 118.1 (d, 
2
JC-F = 21.1 Hz, CH), 116.5 (d, 
2
JC-F = 23.4 Hz, 
CH), 113.5 (CH), 55.2 (CH3), 52.1 (CH3).
 19
F NMR (376 MHz, CDCl3) δ = -(115.3–115.4) (m). IR (ATR): 
2951, 2837, 1718, 1608, 1484, 1235, 1175, 822 cm
-1













M. p. = 121−122 ºC. 
1
H NMR (500 MHz, CDCl3) δ = 7.34–7.27 (m, 5H), 7.23–7.20 (m, 1H), 6.96–6.92 (m, 
4H), 3.84 (s, 3H), 3.84 (s, 3H), 3.39 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ = 168.7 (d, 
4
JC-F = 3.3 Hz, Cq), 
158.7 (d, 
1
JC-F = 246.1 Hz, Cq), 159.4 (Cq), 159.1 (Cq), 135.7 (d, 
3
JC-F = 4.1 Hz, Cq), 135.3 (d, 
3
JC-F = 2.7 Hz, 
Cq), 132.0 (Cq), 130.6 (d, 
4
JC-F = 1.4 Hz, CH), 130.2 (d, 
3
JC-F = 8.2 Hz, CH), 129.5 (CH), 127.3 (d, 
2
JC-F = 18.1 
Hz, Cq) 125.4 (Cq), 116.6 (d, 
2
JC-F = 23.2 Hz, CH), 113.8 (CH), 113.7 (CH), 55.2 (CH3), 55.2 (CH3), 51.9 
(CH3).
 19
F NMR (471 MHz, CDCl3) δ = -117.7 (dd, J = 9.2, 5.0 Hz). IR (ATR): 2935, 2837, 1728, 1608, 1514, 
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1463, 1250, 822 cm
-1
. MS (EI) m/z (relative intensity) 389 (100) [M+Na
+
], 335 (10), 278 (5), 219 (10), 203 
(5), 149 (5). HR-MS (ESI) m/z calcd for C22H20FO4 [M+H
+
] 367.1340, found 367.1344. 
 
 
Methyl 2-(4-methoxyphenyl)-1-naphthoate (125ga): The general procedure A was followed using benzoic 
acid 124g (86 mg, 0.50 mmol) and aryl bromide 14a (140 mg, 0.75 mmol, 1.5 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc 20:1) yielded 125ga (114 mg, 78%) as a colorless solid.  
M. p. = 121−122 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 7.99–7.85 (m, 3H), 7.63–7.48 (m, 3H), 7.43 (d, J = 8.8 
Hz, 2H), 6.99 (d, J = 8.8 Hz, 2H), 3.87 (s, 3H), 3.76 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 170.2 (Cq), 
159.2 (Cq), 137.5 (Cq), 133.2 (Cq), 132.1 (Cq), 130.0 (Cq), 129.8 (CH), 129.7 (Cq), 129.6 (CH), 128.1 (CH), 
127.5 (CH), 127.4 (CH), 126.1 (CH), 124.9 (CH), 113.9 (CH), 55.3 (CH3), 52.2 (CH3). IR (ATR): 2937, 1727, 
1608, 1516, 1429, 1231, 1025, 815 cm
-1
. MS (EI) m/z (relative intensity) 292 (98) [M
+
], 261 (100), 246 (10), 
218 (20), 189 (30), 163 (5), 146 (5). HR-MS (EI) m/z calcd for C19H16O3 [M
+
] 292.1099, found 292.1090. 




Methyl 3-benzoyl-4'-methoxy-[1,1'-biphenyl]-2-carboxylate (125ha): The general procedure A was 
followed using benzoic acid 124h (113 mg, 0.50 mmol) and aryl bromide 14a (140 mg, 0.75 mmol, 1.5 equiv). 
Purification by column chromatography on silica gel (n-hexane/EtOAc 20:1) yielded 125ha (92 mg, 53%) as a 
colorless solid.  
M. p. = 108−109 ºC. 
1
H NMR (400 MHz, CDCl3) δ = 7.91–7.79 (m, 2H), 7.63–7.50 (m, 3H), 7.53–7.42 (m, 
3H), 7.31 (d, J = 8.8 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H), 3.84 (s, 3H), 3.45 (s, 3H). 
13
C NMR (100 MHz, CDCl3) 
δ = 196.4 (Cq), 168.9 (Cq), 159.3 (Cq), 141.2 (Cq), 138.5 (Cq), 136.8 (Cq), 133.1 (CH), 132.8 (CH), 132.7 (Cq), 
132.1 (Cq), 130.1 (CH), 129.5 (CH), 129.2 (CH), 128.4 (CH), 127.8 (CH), 113.8 (CH), 55.2 (CH3), 52.1 (CH3). 
IR (ATR): 2950, 2841, 1936, 1730, 1606, 1516, 1247, 1050 cm
-1
. MS (EI) m/z (relative intensity) 346 (100) 
[M
+
], 315 (60), 297 (10), 269 (40), 237 (20), 181 (15), 215 (10). HR-MS (EI) m/z calcd for C22H18O4 [M
+
] 
346.1205, found 346.1194. 
The analytical data are in accordance with those previously reported in the literature.
[111b] 
 




Methyl 4'-methoxy-4,5-dimethyl-[1,1'-biphenyl]-2-carboxylate (125ia): The general procedure A was 
followed using benzoic acid 124i (75 mg, 0.50 mmol) and 1-iodo-4-methoxybenzene (14a
,
) (175 mg, 0.75 
mmol, 1.5 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 20:1) yielded 125ia 
(112 mg, 83%) as a colorless solid.  
M. p. = 82−83 ºC.
 1
H NMR (400 MHz, CDCl3) δ = 7.62 (s, 1H), 7.23 (d, J = 8.8 Hz, 2H), 7.13 (s, 1H), 6.93 
(d, J = 8.8 Hz, 2H), 3.85 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H), 2.32 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 
169.2 (Cq), 158.7 (Cq), 140.3 (Cq), 139.8 (Cq), 135.2 (Cq), 133.8 (Cq), 132.1 (CH), 131.0 (CH), 129.4 (CH), 
127.8 (Cq), 113.3 (CH), 55.2 (CH3), 51.7 (CH3), 19.7 (CH3), 19.2 (CH3). IR (ATR): 2951, 1724, 1607, 1488, 
1443, 1241, 1026, 834 cm
-1
. MS (EI) m/z (relative intensity) 270 (100) [M
+
], 239 (90), 224 (15), 211 (15), 196 
(30), 181 (15), 165 (15). HR-MS (EI) m/z calcd for C17H18O3 [M
+
] 270.1256, found 270.1247. 





Methyl 3,4,4'-trimethoxy-[1,1'-biphenyl]-2-carboxylate (125ja): The general procedure A was followed 
using benzoic acid 124j (91 mg, 0.50 mmol) and 1-iodo-4-methoxybenzene (14a
,
) (175 mg, 0.75 mmol, 1.5 
equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 20:1) yielded 125ja (141 mg, 
93%) as a colorless solid.  
M. p. = 106−107 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 7.27 (d, J = 8.8 Hz, 2H), 7.04 (d, J = 8.5 Hz, 1H), 6.96 
(d, J = 8.5 Hz, 1H), 6.88 (d, J = 8.8 Hz, 2H), 3.89 (s, 3H), 3.87 (s, 3H), 3.80 (s, 3H), 3.67 (s, 3H). 
13
C NMR 
(75 MHz, CDCl3) δ = 168.2 (Cq), 158.9 (Cq), 151.5 (Cq), 146.0 (Cq), 132.2 (Cq), 132.1 (Cq), 129.2 (CH), 128.7 
(Cq), 125.2 (CH), 113.7 (CH), 113.5 (CH), 61.6 (CH3), 56.0 (CH3), 55.2 (CH3), 52.1 (CH3). IR (ATR): 2936, 
2841, 1728, 1480, 1249, 1051, 804, 548 cm
-1
. MS (EI) m/z (relative intensity) 302 (100) [M
+
], 287 (20), 271 
(30), 259 (20), 240 (20), 225 (15), 213 (20). HR-MS (EI) m/z calcd for C17H18O5 [M
+
] 302.1154, found 
302.1146.  
 




The general procedure A was followed using benzoic acid 124k (61 mg, 0.50 mmol), 1-iodo-4-
methoxybenzene 14a
,
 (351 mg, 1.50 mmol, 3.0 equiv) and K2CO3 (276 mg, 2.00 mmol, 4.0 equiv). 
Purification by column chromatography on silica gel (n-hexane/EtOAc 20:1) yielded 125ka (143 mg, 82%) 
and the diarylated product 125ka
,
 (19 mg, 16%).  
Methyl 4,4''-dimethoxy-[1,1':3',1''-terphenyl]-2'-carboxylate (125ka): 
Colorless solid. M. p. = 112−113 ºC. 
1
H NMR (400 MHz, CDCl3) δ = 7.47 (dd, J = 8.2, 7.1 Hz, 1H), 7.39–
7.30 (m, 6H), 6.95 (d, J = 8.9 Hz, 4H), 3.85 (s, 6H), 3.45 (s, 3H).
 13
C NMR (100 MHz, CDCl3) δ = 170.2 (Cq), 
159.1 (Cq), 139.8 (Cq), 132.9 (Cq), 132.7 (Cq), 129.5 (CH), 129.2 (CH), 128.5 (CH), 113.7 (CH), 55.2 (CH3), 
51.8 (CH3). IR (ATR): 2920, 2835, 1730, 1586, 1513, 1246, 1103, 1027 cm
-1
. MS (EI) m/z (relative intensity) 
348 (100) [M
+
], 317 (90), 302 (10), 285 (10), 274 (20), 259 (10), 202 (20). HR-MS (EI) m/z calcd for 
C22H20O4 [M
+
] 348.1362, found 348.1368. 








H NMR (300 MHz, CDCl3) δ = 7.80–7.73 (m, 1H), 7.55–7.43 (m, 1H), 7.38–7.33 (m, 2H), 
7.23 (d, J = 8.8 Hz, 2H), 6.92 (d, J = 8.8 Hz, 2H), 3.83 (s, 3H), 3.65 (s, 3H).
 13
C NMR (75 MHz, CDCl3) δ = 
169.4 (Cq), 158.9 (Cq), 142.0 (Cq), 133.6 (Cq), 131.2 (CH), 130.8 (Cq), 130.7 (CH), 129.7 (CH), 129.4 (CH), 
126.8 (CH), 113.5 (CH), 55.2 (CH3), 51.9 (CH3). IR (ATR): 2949, 2836, 1716, 1610, 1516, 1238, 761 cm
-1
. 
MS (EI) m/z (relative intensity) 242 (95) [M
+
], 211 (100), 196 (10), 183 (15), 168 (30), 139 (40). HR-MS (EI) 
m/z calcd for C15H14O3 [M
+
] 242.0943, found 242.0946. 









The general procedure A was followed using benzoic acid 125l (95 mg, 0.50 mmol), 1-iodo-4-
methoxybenzene (14a
,
) (351 mg, 1.50 mmol, 3.0 equiv) and K2CO3 (276 mg, 2.00 mmol, 4.0 equiv). 
Purification by column chromatography on silica gel (n-hexane/EtOAc 10:1) yielded 125la (108 mg, 52%) 
and the diarylated product 125la
,
 (39 mg, 25%).  
Methyl 4,4''-dimethoxy-5'-(trifluoromethyl)-[1,1':3',1''-terphenyl]-2'-carboxylate (125la): 
Colorless solid. M. p. = 133−134 ºC. 
1
H NMR (400 MHz, CDCl3) δ = 7.56 (d, J = 0.7 Hz, 2H), 7.33 (d, J = 
8.9 Hz, 4H), 6.94 (d, J = 8.9 Hz, 4H), 3.83 (s, 6H), 3.44 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 169.1 (Cq), 
159.6 (Cq), 140.8 (Cq), 135.9 (q, 
4
JC-F = 1.1 Hz, Cq), 131.3 (q, 
2
JC-F = 32.6 Hz, Cq), 131.5 (Cq), 129.5 (CH), 
125.1 (q, 
3
JC-F = 3.7 Hz, CH), 123.7 (q, 
1
JC-F = 272.9 Hz, Cq), 114.0 (CH), 55.3 (CH3), 52.1 (CH3). 
19
F NMR 
(376 MHz, CDCl3) δ = -62.79 (s). IR (ATR): 2943, 2841, 1735, 1609, 1517, 1363, 1120, 809 cm
-1
. HR-MS 
(ESI) m/z calcd for C23H20F3O4 [M+H
+






H NMR (400 MHz, CDCl3) δ = 7.85 (dd, J = 8.6, 0.9 Hz, 1H), 7.64–7.57 (m, 2H), 7.24 (d, J = 
8.9 Hz, 2H), 6.94 (d, J = 8.9 Hz, 2H), 3.84 (s, 3H), 3.68 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 168.4 (Cq), 
159.5 (Cq), 142.5 (Cq), 134.2 (q, 
4
JC-F = 1.0 Hz, Cq), 132.8 (q, 
2
JC-F = 32.6 Hz, Cq), 132.0 (Cq), 130.1 (CH), 
129.4 (CH), 127.4 (q, 
3
JC-F = 3.7 Hz, CH), 123.6 (q, 
4
JC-F = 272.9 Hz, Cq), 123.5 (q, 
3
JC-F = 3.8 Hz, CH), 113.8 
(CH), 55.3 (CH3), 52.3 (CH3). 
19
F NMR (376 MHz, CDCl3) δ = -63.00 (s). IR (ATR): 2953, 2840, 1724, 1610, 
1518, 1244, 1125, 833 cm
-1
. HR-MS (ESI) m/z calcd for C16H14F3O3 [M+H
+
] 311.0890, found 311.0899. 
 
Ruthenium(II)-Catalyzed C–H Alkeynylation 
 
 
Methyl (E)-2-styryl-1-naphthoate    (136a):    A    suspension    of        [Ru(O2CMes)2(p-cymene)]    (16)    
(28.1 mg, 10 mol %), PCy3 (14.0 mg, 10 mol %), K2CO3 (276 mg, 2.00 mmol, 4.0 equiv), benzoic acid 124g 
(86 mg, 0.50 mmol) and (E)-(2-bromovinyl)benzene (135) (275 mg, 1.50 mmol, 3.0 equiv) in NMP (2.0 mL) 
was stirred under N2 for 16 h at 120 ºC. At ambient temperature, MeCN (3.0 mL), K2CO3 (207 mg, 1.50 mmol) 
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and MeI (355 mg, 2.50 mmol) were added and the mixture was stirred at 50 ºC for another 2 h. At ambient 
temperature, the mixture was diluted with MTBE (120 mL), then washed with H2O (20 mL) and brine (20 mL) 
sequentially. The organic phase was dried over Na2SO4, and concentrated in vacuo. The remaining residue 
was purified by column chromatography on silica gel (n-hexane/EtOAc 30:1) to yield the methyl ester 136a 




H NMR (300 MHz, CDCl3) δ = 7.90–7.78 (m, 4H), 7.58–7.43 (m, 4H), 7.41–7.17 (m, 5H), 4.09 (s, 3H).
13
C 
NMR (75 MHz, CDCl3) δ = 169.9 (Cq), 137.0 (Cq), 132.5 (Cq), 132.5 (Cq), 132.0 (CH), 130.1 (Cq), 130.0 
(CH), 129.8 (Cq), 128.7 (CH), 128.1 (CH), 128.1 (CH), 127.4 (CH), 126.8 (CH), 126.3 (CH), 125.4 (CH), 
125.1 (CH), 122.6 (CH), 52.5 (CH3). IR (ATR): 3056, 2948, 1719, 1508, 1434, 1213, 1134, 1032 cm
-1
. MS 
(EI) m/z (relative intensity) 288 (80) [M
+
], 257 (30), 228 (100), 226 (40), 215 (10), 202 (20). HR-MS (ESI) 
m/z calcd for C20H17O2 [M+H
+




Methyl (E)-2-methyl-6-styrylbenzoate  (136b):   A  suspension   of   [Ru(O2CMes)2(p-cymene)]   (16)   
(28.1 mg, 10 mol %), PCy3 (14.0 mg, 10 mol %), K2CO3 (276 mg, 2.00 mmol, 4.0 equiv), benzoic acid 124a 
(68 mg, 0.50 mmol) and (E)-(2-bromovinyl)benzene (135) (275 mg, 1.50 mmol, 3.0 equiv) in NMP (2.0 mL) 
was stirred under N2 for 16 h at 120 ºC. At ambient temperature, MeCN (3.0 mL), K2CO3 (207 mg, 1.50 mmol) 
and MeI (355 mg, 2.50 mmol) were added and the mixture was stirred at 50 ºC for another 2 h. At ambient 
temperature, the mixture was diluted with MTBE (120 mL), then washed with H2O (20 mL) and brine (20 mL) 
sequentially. The organic phase was dried over Na2SO4, and concentrated in vacuo. The remaining residue 
was purified by column chromatography on silica gel (n-hexane/EtOAc 30:1) to yield the methyl ester 136b 




H NMR (300 MHz, CDCl3) δ = 7.57–7.43 (m, 3H), 7.39–7.23 (m, 4H), 7.17–7.00 (m, 3H), 3.95 (s, 3H), 2.34 
(s, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 170.2 (Cq), 137.1 (Cq), 135.2 (Cq), 135.0 (Cq), 132.9 (Cq), 131.3 (CH), 
129.5 (CH), 129.2 (CH), 128.6 (CH), 127.9 (CH), 126.7 (CH), 125.6 (CH), 123.0 (CH), 52.1 (CH3), 19.7 
(CH3). IR (ATR): 3026, 2949, 2862, 1721, 1588, 1436, 1265, 1068 cm
-1
. MS (EI) m/z (relative intensity) 252 
(100) [M
+
], 237 (10), 220 (50), 193 (30), 178 (50), 165 (20). HR-MS (EI) m/z calcd for C17H16O2 [M
+
] 
252.1150, found 252.1148. 
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H/D Exchange Experiments 
 
A  suspension  of   1-bromo-4-methoxybenzene  (14a)  (140 mg, 0.75 mmol), 4-phenylbenzoic acid  (124s) 
(99 mg, 0.50 mmol), [Ru(O2CMes)2(p-cymene)] (16) (28.1 mg, 10 mol %), PCy3 (14.0 mg, 10 mol %), K2CO3 
(138 mg, 1.00 mmol) in a solvent mixture of NMP (2.0 mL) and CD3OD (0.2 mL) was stirred at 120 ºC for 16 
h in a seal tube under a N2 atmosphere. At ambient temperature, MeCN (3.0 mL), K2CO3 (207 mg, 1.50 mmol) 
and MeI (355 mg, 2.50 mmol) were added and the mixture was stirred at 50 ºC for another 2.0 h. At ambient 
temperature, the mixture was diluted with MTBE (120 mL), then washed with H2O (20 mL) and brine (20 mL) 
sequentially. The organic phase was dried over Na2SO4, and concentrated in vacuo. The remaining residue 
was purified by column chromatography on silica gel (n-hexane/EtOAc 20:1) to yield [D]n-124s (48 mg, 45%) 











A suspension of   1-bromo-4-methoxybenzene (14a) (140 mg, 0.75 mmol), benzoic acid (124k) (61 mg, 0.50 
mmol), [Ru(MesCO2)2(p-cymene)] (16) (28.1 mg, 10 mol %), PCy3 (14.0 mg, 10 mol %), K2CO3 (138 mg, 
1.00 mmol) in a solvent mixture of NMP (2.0 mL) and CD3OD (0.2 mL) was stirred at 120 ºC for 16 h in a 
seal tube under a N2 atmosphere. At ambient temperature, MeCN (3.0 mL), K2CO3 (207 mg, 1.50 mmol) and 
MeI (355 mg, 2.50 mmol) were added and the mixture was stirred at 50 ºC for another 2.0 h. At ambient 
temperature, the mixture was diluted with MTBE (120 mL), then washed with H2O (20 mL), and brine (20 
mL) sequentially. The organic phase was dried over Na2SO4, and concentrated in vacuo. The remaining 
residue was purified by column chromatography on silica gel (n-hexane/EtOAc) to yield [D]n-125ka (18 mg, 
16%). The D-incorporation in [D]n-125ka was estimated by 
1
H-NMR spectroscopy. 






Intermolecular competition experiment between benzoic acids 124c and 124e: 
 
A suspension of   1-bromo-4-methoxybenzene (14a) (94 mg, 0.50 mmol), 3-methylbenzoic acid (124c) (82 
mg, 0.60 mmol), 3-(trifluoromethyl)benzoic (124e) (114 mg, 0.60 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 
mg, 10 mol %), PCy3 (14.0 mg, 10 mol %), K2CO3 (138 mg, 1.00 mmol) in NMP (2.0 mL) was stirred under 
N2 for 16 h at 120 ºC. At ambient temperature, MeCN (3.0 mL), K2CO3 (207 mg, 1.50 mmol) and MeI (355 
mg, 2.50 mmol) were added and the mixture was stirred at 50 ºC for another 2 h. At ambient temperature, the 
mixture was diluted with MTBE (120 mL), then washed with H2O (20 mL) and brine (20 mL) sequentially. 
The organic phase was dried over Na2SO4, and concentrated in vacuo. The remaining residue was purified by 
column chromatography on silica gel (n-hexane/EtOAc 20:1) to yield the mixture of 125ca and 125ea (41 mg). 
The ratio was calculated based on 
1
H-NMR analysis. 





Intermolecular Competition Experiment between aryl bromides 14l and 14a: 
 
A suspension of   2-methylbenzoic acid (124a) (68 mg, 0.50 mmol), 1-bromo-4-methoxybenzene (14a) (112 
mg, 0.60 mmol), 1-bromo-4-(trifluoromethyl)benzene (14l) (135 mg, 0.60 mmol), [Ru(MesCO2)2(p-cymene)] 
(16) (28.1 mg, 10 mol %), PCy3 (14.0 mg, 10 mol %), K2CO3 (138 mg, 1.00 mmol) in NMP (2.0 mL) was 
stirred under N2 for 16 h at 120 ºC. At ambient temperature, MeCN (3.0 mL), K2CO3 (207 mg, 1.50 mmol) 
and MeI (355 mg, 2.50 mmol) were added and the mixture was stirred at 50 ºC for another 2.0 h. At ambient 
temperature, the mixture was diluted with MTBE (120 mL), then washed with H2O (20 mL) and brine (20 mL) 
sequentially. The organic phase was dried over Na2SO4, and concentrated in vacuo. The remaining residue 
was purified by column chromatography on silica gel (n-hexane/EtOAc) to yield 125al (79 mg, 54%) and 
125aa (41 mg, 32%). 
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Intermolecular Competition Experiment between Benzoic acid 124c and triazole 13b: 
 
A suspension of   1-bromo-4-methoxybenzene (14a) (94 mg, 0.50 mmol), 3-methylbenzoic acid (124c) (82 
mg, 0.60 mmol), 4-pentyl-1-(m-tolyl)-1H-1,2,3-triazole (13b) (138 mg, 0.60 mmol), [Ru(O2CMes)2(p-
cymene)] (16) (28.1 mg, 10 mol %), PCy3 (14.0 mg, 10 mol %), K2CO3 (138 mg, 1.00 mmol) in NMP (2.0 
mL) was stirred under N2 for 16 h at 120 ºC. At ambient temperature, MeCN (3.0 mL), K2CO3 (207 mg, 1.50 
mmol) and MeI (355 mg, 2.50 mmol) were added and the mixture was stirred at 50 ºC for another 2.0 h. At 
ambient temperature, the mixture was diluted with MTBE (120 mL), then washed with H2O (20 mL) and 
brine (20 mL) sequentially. The organic phase was dried over Na2SO4, and concentrated in vacuo. The 
remaining residue was purified by column chromatography on silica gel (n-hexane/EtOAc) to yield 15b 
(Colorless oil, 94 mg, 56%) and 125ca (5.1 mg, 4%). 
1-(4'-Methoxy-4-methyl-[1,1'-biphenyl]-2-yl)-4-pentyl-1H-1,2,3-triazole (15b): 
1
H NMR (300 MHz, CDCl3) δ =7.41 (s, 1H), 7.36–7.28 (m, 2H), 6.95 (d, J = 8.7 Hz, 2H), 6.90 (s, 1H), 6.77 
(d, J = 8.7 Hz, 2H), 3.75 (s, 3H), 2.60 (t, J = 7.5 Hz, 2H), 2.42 (s, 3H), 1.53 (p, J = 7.5 Hz, 2H), 1.34–1.10 (m, 
4H), 0.84 (t, J = 7.0 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 159.0 (Cq), 147.8 (Cq), 138.2 (Cq), 134.9 (Cq), 
133.6 (Cq), 130.6 (CH), 130.3 (CH), 129.7 (Cq), 129.5 (CH), 127.0 (CH), 122.9 (CH), 113.9 (CH), 55.1 (CH3), 
31.0 (CH2), 28.9 (CH2), 25.2 (CH2), 22.3 (CH2), 20.8 (CH3), 13.8 (CH3). IR (ATR): 2927, 2837, 1609, 1638, 
1493, 1464, 1245, 1018 cm
-1
. MS (EI) m/z (relative intensity) 335 (10) [M
+
], 306 (60), 292 (30), 278 (30), 264 
(30), 250 (100), 237 (30). HR-MS (EI) m/z calcd for C21H25N3O [M
+
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C–H Arylations with Ruthenacycle 137a 
 
A suspension of   1-naphthoic acid (124g) (0.50 mmol, 86 mg), 1-bromo-4-methoxybenzene (14a) (140 mg, 
0.75 mmol), ruthenacycle 137a (24.2 mg, 10 mol %), PCy3 (14.0 mg, 10 mol %), K2CO3 (138 mg, 1.00 mmol) 
in NMP (2.0 mL) was stirred under N2 for 16 h at 120 ºC. At ambient temperature, MeCN (3.0 mL), K2CO3 
(207 mg, 1.50 mmol) and MeI (355 mg, 2.50 mmol) were added and the mixture was stirred at 50 ºC for 
another 2.0 h. At ambient temperature, the mixture was diluted with MTBE (120 mL) then washed with H2O 
(20 mL) and brine (20 mL) sequentially. The organic phase was dried over Na2SO4, and concentrated in vacuo. 
The remaining residue was purified by column chromatography on silica gel (n-hexane/EtOAc 20:1) to yield 
125ga (95 mg, 54%, based on 0.60 mmol) and starting material methyl 1-naphthoate (31 mg, 28%).  
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5.3.2 Ruthenium(II)-Catalyzed C−H Alkynylation of Weakly Coordinating Benzoic Acids 
 
 
Methyl 3,4,6-trimethoxy-2-[(triisopropylsilyl)ethynyl]benzoate (126ta): A suspension of   
[Ru(O2CMes)2(p-cymene)] (16) (56.2 mg, 10 mol %), K2CO3 (276 mg, 2.00 mmol), benzoic acid 124t (212.2 
mg, 1.00 mmol), and alkynyl bromide 33a (339.7 mg, 1.30 mmol) in 1,4-dioxane (2.0 mL) was stirred under 
N2 for 16 h at 120 ºC. At ambient temperature, MeCN (6.0 mL), K2CO3 (276 mg, 2.0 mmol) and MeI (710 mg, 
5.00 mmol) were added and the mixture was stirred at 50 ºC for additional 2 h. At ambient temperature, the 
mixture was dry-loaded onto silica gel and purified by column chromatography (n-hexane/EtOAc 2/1) to give 
product 126ta (349.7 mg, 86%) as a colorless solid. When the reaction was running in 0.50 mmol scale, 88% 
yield was got.  
M. p. = 57−58 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 6.46 (s, 1H), 3.84 (s, 3H), 3.84 (s, 3H), 3.80 (s, 3H), 3.78 
(s, 3H), 1.14−1.04 (m, 21H). 
13
C NMR (75 MHz, CDCl3) δ = 166.7 (Cq), 154.3 (Cq), 152.9 (Cq), 144.8 (Cq), 
118.5 (Cq), 117.0 (Cq), 99.5 (Cq), 99.1 (Cq), 98.2 (CH), 61.0 (CH3), 56.6 (CH3), 56.1 (CH3), 52.3 (CH3), 18.5 
(CH3), 11.2 (CH). IR (neat): 2942, 2864, 2157, 1734, 1585, 1267, 881, 674 cm
-1
. MS (ESI) m/z (relative 
intensity) 429 (10) [M+Na
+
], 407 (100) [M+H
+






Methyl 2,4-dimethoxy-6-[(triisopropylsilyl)ethynyl]benzoate (126ua): The general procedure B was 
followed using benzoic acid 124u (91 mg, 0.50 mmol) and (bromoethynyl)triisopropylsilane (33a) (170 mg, 
0.65 mmol, 1.30 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 5:1) yielded 
126ua (143 mg, 76%) as a pale yellow solid.  
M. p. = 46−47 ºC. 
 1
H NMR (300 MHz, CDCl3) δ = 6.55 (d, J = 2.2 Hz, 1H), 6.41 (d, J = 2.2 Hz, 1H), 3.83 (s, 
3H), 3.77 (s, 3H), 3.76 (s, 3H), 1.14−1.04 (m, 21H). 
13
C NMR (75 MHz, CDCl3) δ = 167.0 (Cq), 161.1 (Cq), 
157.6 (Cq), 123.0 (Cq), 119.4 (Cq), 108.5 (CH), 103.7 (Cq), 99.6 (CH), 94.4 (Cq), 55.9 (CH3), 55.5 (CH3), 52.2 
(CH3), 18.5 (CH3), 11.2 (CH). IR (neat): 2943, 2865, 2150, 1732, 1574, 1267, 1156, 881, 674 cm
-1
. MS (ESI) 
m/z (relative intensity) 399 (20) [M+Na
+
], 377 (100) [M+H
+
]. HR-MS (ESI) m/z calcd for C21H33O4Si [M+H
+
] 
377.2143, found 377.2139. 
 




Methyl 3,6-dimethyl-2-[(triisopropylsilyl)ethynyl]benzoate (126va): The general procedure B was 
followed using benzoic acid 124v (75 mg, 0.50 mmol) and (bromoethynyl)triisopropylsilane (33a) (170 mg, 
0.65 mmol, 1.30 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 4:1) and then 
by HPLC yielded 126va (129 mg, 75%) as a pale yellow oil.  
1
H NMR (300 MHz, CDCl3) δ = 7.11 (d, J = 7.9 Hz, 1H), 7.02 (d, J = 7.9 Hz, 1H), 3.88 (s, 3H), 2.41 (s, 3H), 
2.24 (s, 3H), 1.17−1.02 (m, 21H). 
13
C NMR (75 MHz, CDCl3) δ = 169.4 (Cq), 138.5 (Cq), 136.8 (Cq), 131.9 
(Cq), 130.2 (CH), 129.8 (CH), 120.4 (Cq), 102.7 (Cq), 98.7 (Cq), 52.2 (CH3), 20.6 (CH3), 18.9 (CH3), 18.6 
(CH3), 11.2 (CH). IR (neat): 2943, 2864, 2150, 1734, 1273, 1136, 882, 757, 672 cm
-1
. MS (ESI) m/z (relative 
intensity) 367 (10) [M+Na
+
], 345 (100) [M+H
+







Methyl 2,3-dimethoxy-6-[(triisopropylsilyl)ethynyl]benzoate (126ja): The general procedure B was 
followed using benzoic acid 124j (91 mg, 0.50 mmol) and (bromoethynyl)triisopropylsilane (33a) (170 mg, 
0.65 mmol, 1.30 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 10:1) yielded 
126ja (154 mg, 82%) as a colorless solid.  
M. p. = 74−75 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 7.19 (d, J = 8.6 Hz, 1H), 6.82 (d, J = 8.6 Hz, 1H), 3.87 (s, 
3H), 3.83 (s, 3H), 3.81 (s, 3H), 1.10−1.07 (m, 21H). 
13
C NMR (125 MHz, CDCl3) δ = 166.6 (Cq), 152.9 (Cq), 
145.6 (Cq), 132.0 (Cq), 129.0 (CH), 113.4 (Cq), 113.0 (CH), 103.3 (Cq), 92.5 (Cq), 61.5 (CH3), 55.9 (CH3), 
52.4 (CH3), 18.6 (CH3), 11.3 (CH). IR (neat): 2942, 2863, 2149, 1731, 1463, 1272, 1048, 826, 660 cm
-1
. MS 
(ESI) m/z (relative intensity) 399 (20) [M+Na
+
], 377 (100) [M+H
+
]. HR-MS (ESI) m/z calcd for C21H33O4Si 
[M+H
+
] 377.2143, found 377.2143. 
 
 
Methyl 6-[(tert-butyldimethylsilyl)ethynyl]-2,3-dimethoxybenzoate (126jb): A suspension of   
[Ru(O2CMes)2(p-cymene)] (16) (28.1 mg, 10 mol %), K2CO3 (69 mg, 0.50 mmol), benzoic acid 124j (91 mg, 
0.50 mmol) and (bromoethynyl)(tert-butyl)dimethylsilane (33b) (219 mg, 1.00 mmol, 2.0 equiv) in 1,4-
dioxane (1.0 mL) was stirred under N2 for 8 h at 110 ºC. At ambient temperature, MeCN (3.0 mL), K2CO3 
 Experimental Section  
100 
 
(138 mg, 1.0 mmol) and MeI (355 mg, 2.50 mmol) were added and the mixture was stirred at 50 ºC for 
additional 2 h. At ambient temperature, the mixture was dry loaded onto silica gel and purified by column 
chromatography on silica gel (n-hexane/EtOAc 20:1) yielded 126jb (112 mg, 67%) as a pale yellow oil.  
1
H NMR (300 MHz, CDCl3) δ = 7.21 (d, J = 8.5 Hz, 1H), 6.85 (d, J = 8.5 Hz, 1H), 3.91 (s, 3H), 3.86 (s, 3H), 
3.84 (s, 3H), 0.96 (s, 9H), 0.15 (s, 6H). 
13
C NMR (75 MHz, CDCl3) δ = 166.8 (Cq), 153.2 (Cq), 145.8 (Cq), 
132.2 (Cq), 129.0 (CH), 113.3 (Cq), 113.1 (CH), 102.1 (Cq), 94.6 (Cq), 61.6 (CH3), 55.9 (CH3), 52.4 (CH3), 
26.1 (CH3), 16.6 (Cq), -4.6 (CH3). IR (neat): 2951, 2931, 2152, 1735, 1486, 1274, 1046, 810, 774 cm
-1
. MS 
(ESI) m/z (relative intensity) 357 (70) [M+Na
+
], 335 (100) [M+H
+
]. HR-MS (ESI) m/z calcd for C18H27O4Si 
[M+H
+
] 335.1673, found 335.1675. 
 
 
Methyl 2,3-dimethoxy-6-((tributylsilyl)ethynyl)benzoate (126jc): The general procedure B was followed 
using benzoic acid 124j (91 mg, 0.50 mmol) and (bromoethynyl)triisopropylsilane (33c) (197 mg, 0.65 mmol, 
1.30 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 10:1) yielded 126jc (54 
mg, 26%) as a colorless oil.  
1
H NMR (300 MHz, CDCl3) δ = 6.45 (s, 1H), 3.84 (s, 3H), 3.84 (s, 3H), 3.81 (s, 3H), 3.78 (s, 3H), 1.51–1.25 
(m, 12H), 0.93–0.82 (m, 9H), 0.70–0.56 (m, 6H).
 13
C NMR (75 MHz, CDCl3) δ = 166.6 (Cq), 154.3 (Cq), 
153.0 (Cq), 144.7 (Cq), 118.5 (Cq), 117.0 (Cq), 101.3 (Cq), 98.4 (Cq), 98.2 (CH), 60.9 (CH3), 56.6 (CH3), 56.2 
(CH3), 52.2 (CH3), 26.4 (CH2), 26.1 (CH2), 13.7 (CH3), 12.9 (CH2). IR (neat): 2955, 2919, 2855, 2157, 1722, 
1586, 1428, 1268, 1208 cm
-1
. MS (ESI) m/z (relative intensity) 448 (30) [M
+
], 433 (10), 417 (10), 391 (100), 
377 (30). HR-MS (EI) m/z calcd for C25H40O5Si [M+H
+
] 448.2645, found 448.2649. 
 
 
Methyl 2-methoxy-6-[(triisopropylsilyl)ethynyl]benzoate (126ba): The general procedure B was followed 
using benzoic acid 124b (76 mg, 0.50 mmol) and (bromoethynyl)triisopropylsilane (33a) (170 mg, 0.65 mmol, 
1.30 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 4:1) and then HPLC 
yielded 126ba (135 mg, 78%) as a colorless oil.  
1
H NMR (300 MHz, CDCl3) δ = 7.27 (dd, J = 8.5, 7.8, 1H), 7.09 (dd, J = 7.8, 1.0 Hz, 1H), 6.87 (dd, J = 8.5, 
1.0 Hz, 1H), 3.89 (s, 3H), 3.81 (s, 3H), 1.14–1.08 (m, 21H).
 13
C NMR (75 MHz, CDCl3) δ = 167.1 (Cq), 156.0 
(Cq), 130.2 (CH), 126.4 (Cq), 124.9 (CH), 122.1 (Cq), 111.4 (CH), 103.4 (Cq), 94.7 (Cq), 56.0 (CH3), 52.4 
(CH3), 18.5 (CH3), 11.2 (CH). IR (neat): 2942, 2865, 2152, 1737, 1465, 1261, 1066, 882, 667 cm
-1
. MS (ESI) 
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m/z (relative intensity) 369 (20) [M+Na
+
], 347 (100) [M+H
+
]. HR-MS (ESI) m/z calcd for C20H31O3Si [M+H
+
] 
347.2037, found 347.2033. 
 
 
Methyl 2-ethoxy-6-[(triisopropylsilyl)ethynyl]benzoate (126wa): The general procedure B was followed 
using benzoic acid 124w (83 mg, 0.50 mmol) and (bromoethynyl)triisopropylsilane (33a) (170 mg, 0.65 mmol, 
1.30 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 20:1) yielded 126wa (137 
mg, 76%) as a colorless oil.  
1
H NMR (300 MHz, CDCl3) δ = 7.22 (dd, J = 8.4, 7.8 Hz, 1H), 7.06 (dd, J = 7.8, 0.9 Hz, 1H), 6.84 (dd, J = 
8.4, 0.9 Hz, 1H), 4.02 (q, J = 7.0 Hz, 2H), 3.87 (s, 3H), 1.34 (t, J = 7.0 Hz, 3H), 1.15–1.02 (m, 21H). 
13
C 
NMR (75 MHz, CDCl3) δ = 167.2 (Cq), 155.4 (Cq), 130.1 (CH), 126.9 (Cq), 124.8 (CH), 122.0 (Cq), 112.7 
(CH), 103.5 (Cq), 94.5 (Cq), 64.6 (CH2), 52.3 (CH3), 18.5 (CH3), 14.6 (CH3), 11.2 (CH). IR (neat): 2943, 2865, 
2156, 1738, 1458, 1260, 1065, 669 cm
-1
. MS (EI) m/z (relative intensity) 360 (20) [M
+
], 345 (15), 329 (100). 
HR-MS (EI) m/z calcd for C21H32O3Si [M
 +
] 360.2121, found 360.2111. 
 
 
Methyl 2-phenoxy-6-[(triisopropylsilyl)ethynyl]benzoate (126xa): The general procedure B was followed 
using benzoic acid 124x (107 mg, 0.50 mmol) and (bromoethynyl)triisopropylsilane (33a) (170 mg, 0.65 
mmol, 1.30 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 40:1) and then 
HPLC yielded 126xa (179 mg, 79%) as a pale yellow solid.  
M. p. = 63−64 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 7.38–7.24 (m, 2H), 7.28–7.17 (m, 2H), 7.16–7.03 (m, 1H), 
7.06–6.95 (m, 2H), 6.83 (dd, J = 7.0, 2.4 Hz, 1H), 3.83 (s, 3H), 1.18−1.07 (m, 21H). 
13
C NMR (125 MHz, 
CDCl3) δ = 166.3 (Cq), 156.6 (Cq), 153.9 (Cq), 130.2 (CH), 129.6 (CH), 128.8 (Cq), 127.6 (CH), 123.7 (CH), 
122.7 (Cq), 119.0 (CH), 118.9 (CH), 103.1 (Cq), 95.4 (Cq), 52.4 (CH3), 18.6 (CH3), 11.3 (CH). IR (neat): 2943, 
2865, 2157, 1735, 1453, 1234, 996, 754, 652 cm
-1
. MS (EI) m/z (relative intensity) 408 (20) [M
+
], 393 (20), 
379 (10), 377 (100). HR-MS (EI) m/z calcd for C25H32O3Si [M
+
] 408.2121, found 408.2138. 
 
 
Methyl 3,6-dimethoxy-2-[(triisopropylsilyl)ethynyl]benzoate (126ya): The general procedure B was 
followed using benzoic acid 124y (91 mg, 0.50 mmol) and (bromoethynyl)triisopropylsilane (33a) (170 mg, 
 Experimental Section  
102 
 
0.65 mmol, 1.30 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 4:1) yielded 
126ya (173 mg, 92%) as a pale yellow solid. 
M. p. = 93−94 ºC.
 1
H NMR (400 MHz, CDCl3) δ = 6.78 (s, 2H), 3.86 (s, 3H), 3.77 (s, 3H), 3.73 (s, 3H), 1.10–
1.11 (m, 21H). 
13
C NMR (100 MHz, CDCl3) δ = 166.8 (Cq), 155.0 (Cq), 149.7 (Cq), 127.7 (Cq), 113.1 (CH), 
112.6 (CH), 111.8 (Cq), 99.4 (Cq), 99.4 (Cq), 56.7 (CH3), 56.5 (CH3), 52.3 (CH3), 18.5 (CH3), 11.2 (CH). IR 
(neat): 2942, 2864, 2157, 1732, 1483, 1254, 1055, 673 cm
-1
. MS (ESI) m/z (relative intensity) 399 (20) 
[M+Na
+
], 377 (100) [M+H
+
]. HR-MS (ESI) m/z calcd for C21H33O4Si [M+H
+
] 377.2143, found 377.2142. 
 
 
Methyl 2,6-bis[(triisopropylsilyl)ethynyl]benzoate (126ka): The general procedure B was followed using 
benzoic acid 124k (61 mg, 0.50 mmol) (bromoethynyl)triisopropylsilane (33a) (326 mg, 1.25 mmol, 2.50 
equiv) and K2CO3 (207 mg, 1.50 mmol, 3.0 equiv). Purification by column chromatography on silica gel (n-
hexane/EtOAc 30:1) and then by HPLC yielded 126ka (144 mg, 58%) as a pale yellow solid.  
M. p. = 54−55 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 7.42 (d, J = 7.7 Hz, 2H), 7.25 (t, J = 7.7 Hz, 1H), 3.88 (s, 
3H), 1.13−1.04 (m, 42H). 
13
C NMR (75 MHz, CDCl3) δ = 167.7 (Cq), 139.5 (Cq), 132.3 (CH), 128.9 (CH), 
121.2 (Cq), 103.0 (Cq), 95.4 (Cq), 52.5 (CH3), 18.5 (CH3), 11.2 (CH). IR (neat): 2942, 2863, 2155, 1737, 1458, 
1268, 1113, 882, 669 cm
-1
. MS (EI) m/z (relative intensity) 497 (5) [M+H
+
], 496 (10) [M
+
], 481 (30), 465 
(100), 463 (10). HR-MS (ESI) m/z calcd for C30H49O2Si2 [M+H
+




Methyl 3,4,5-trifluoro-2,6-bis[(triisopropylsilyl)ethynyl]benzoate (126za): The general procedure B was 
followed using benzoic acid 124z (88 mg, 0.50 mmol), (bromoethynyl)triisopropylsilane (33a) (326 mg, 1.25 
mmol, 2.50 equiv) and K2CO3 (207 mg, 1.50 mmol, 3.0 equiv). Purification by column chromatography on 




H NMR (400 MHz, CDCl3) δ = 3.87 (s, 3H), 1.13–1.06 (m, 42H).
 13
C NMR (100 MHz, CDCl3) δ = 165.0 (t, 
4,4
JC-F = 2.6 Hz, Cq), 151.8 (ddd, 
1,2,3
JC-F = 259.7, 11.0, 3.7 Hz, Cq), 140.7 (dt, 
1,2,2
JC-F = 255.8, 15.4 Hz, Cq), 
135.7 (d, 
3
JC-F = 3.5, Cq), 108.2 (dd, 
2,3
JC-F = 12.8, 7.2 Hz, Cq), 103.3 (t, 
3,3
JC-F = 3.3, Cq), 94.0 (d, 
4
JC-F = 3.4, 
Cq), 53.0 (CH3), 18.5 (CH3), 11.1 (CH). 
19
F NMR (376 MHz, CDCl3) δ = -126.6 (d, J = 21.0 Hz), -156.3 (t, J 
= 21.0 Hz). IR (neat): 2944, 2866, 2141, 1749, 1460, 1218, 964, 882, 662 cm
-1
. MS (ESI) m/z (relative 
intensity) 573 (100) [M+Na
+
], 551 (50) [M+H
+









Methyl 3,4,5-trimethoxy-2,6-bis[(triisopropylsilyl)ethynyl]benzoate (126aaa): The general procedure B 
was followed using benzoic acid 124aa (106 mg, 0.50 mmol) (bromoethynyl)triisopropylsilane (33a) (326 mg, 
1.25 mmol, 2.50 equiv) and K2CO3 (207 mg, 1.50 mmol, 3.0 equiv). Purification by column chromatography 
on silica gel (n-hexane/EtOAc 20:1) yielded 126aaa (266 mg, 91%) as a pale yellow solid.  
M. p. = 70−72 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 3.93 (s, 6H), 3.86 (s, 3H), 3.85 (s, 3H), 1.19–1.07 (m, 
42H). 
13
C NMR (125 MHz, CDCl3) δ = 166.9 (Cq), 155.8 (Cq), 147.1 (Cq), 136.7 (Cq), 111.7 (Cq), 99.0 (Cq), 
98.6 (Cq), 61.4 (CH3), 61.4 (CH3), 52.6 (CH3), 18.7 (CH3), 11.4 (CH). IR (neat): 2939, 2863, 2157, 1739, 
1460, 1348, 1025, 660 cm
-1
. MS (ESI) m/z (relative intensity) 609 (40) [M+Na
+
], 587 (100) [M+H
+
]. HR-MS 
(ESI) m/z calcd for C33H55O5Si2 [M+H
+
] 587.3583, found 587.3581. 
 
 
Methyl 2-fluoro-6-[(triisopropylsilyl)ethynyl]benzoate (126aba): The general procedure B was followed 
using benzoic acid 124ab (70 mg, 0.50 mmol) and (bromoethynyl)triisopropylsilane (33a) (170 mg, 0.65 
mmol, 1.30 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 20:1) and then by 
HPLC yielded 126aba (127 mg, 76%) as a pale yellow oil.  
1
H NMR (300 MHz, CDCl3) δ = 7.36–7.25 (m, 2H), 7.11–6.99 (m, 1H), 3.90 (s, 3H), 1.13−1.09 (m, 21H). 
13
C NMR (75 MHz, CDCl3) δ = 164.7 (Cq), 159.3 (d, 
1
JC-F = 252.0 Hz, Cq), 131.1 (d, 
3
JC-F = 9.1 Hz, CH), 
129.0 (d, 
4
JC-F = 3.4 Hz, CH), 124.3 (d, 
2
JC-F = 17.5 Hz, Cq), 123.6 (d, 
3
JC-F = 4.3 Hz, Cq), 116.1 (d, 
2
JC-F = 21.6 
Hz, CH), 102.6 (d, 
4
JC-F = 3.9 Hz, Cq), 96.5 (Cq), 52.7 (CH3), 18.6 (CH3), 11.2 (CH). 
19
F NMR (283 MHz, 
CDCl3) δ = -(114.2–114.3) (m). IR (neat): 2944, 2865, 2156, 1740, 1460, 1276, 997, 882, 667 cm
-1
. MS (ESI) 
m/z (relative intensity) 357 (50) [M+Na
+
], 335 (100) [M+H
+
]. HR-MS (ESI) m/z calcd for C19H28O2FSi 
[M+H
+
] 335.1837, found 335.1840. 
 
 
Methyl 2-chloro-6-[(triisopropylsilyl)ethynyl]benzoate (126na): The general procedure B was followed 
using benzoic acid 124n (78 mg, 0.50 mmol) and (bromoethynyl)triisopropylsilane (33a) (170 mg, 0.65 mmol, 
1.30 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 4:1) and then by HPLC 
yielded 126na (128 mg, 73%) as a colorless oil.  




H NMR (300 MHz, CDCl3) δ = 7.39 (dd, J = 7.5, 1.3 Hz, 1H), 7.32 (dd, J = 8.1, 1.3 Hz, 1H), 7.25 (d, J = 7.6 
Hz, 1H), 3.91 (s, 3H), 1.12−1.08 (m, 21H). 
13
C NMR (75 MHz, CDCl3) δ = 166.4 (Cq), 136.3 (Cq), 130.9 
(CH), 130.7 (Cq), 130.0 (CH), 129.3 (CH), 122.7 (Cq), 102.4 (Cq), 96.3 (Cq), 52.7 (CH3), 18.5 (CH3), 11.2 
(CH). IR (neat): 2944, 2866, 2169, 1744, 1444, 1270, 1109, 902, 670 cm
-1
. MS (EI) m/z (relative intensity) 
349 (10) [M–H
+






Methyl 2-bromo-6-[(triisopropylsilyl)ethynyl]benzoate (126aca): The general procedure B was followed 
using benzoic acid 124ac (100 mg, 0.50 mmol) and (bromoethynyl)triisopropylsilane (33a) (170 mg, 0.65 
mmol, 1.30 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 40:1) and then by 
HPLC yielded 126aca (102 mg, 52%) as a colorless oil.  
1
H NMR (300 MHz, CDCl3) δ = 7.51 (dd, J = 8.1, 1.1 Hz, 1H), 7.45 (dd, J = 7.8, 1.1 Hz, 1H), 7.19 (dd, J = 
8.1, 7.8 Hz, 1H), 3.93 (s, 3H), 1.14−1.08 (m, 21H). 
13
C NMR (75 MHz, CDCl3) δ = 167.0 (Cq), 138.6 (Cq), 
132.4 (CH), 131.4 (CH), 130.1 (CH), 122.8 (Cq), 118.8 (Cq), 102.5 (Cq), 96.4 (Cq), 52.7 (CH3), 18.5 (CH3), 
11.2 (CH). IR (neat): 2943, 2865, 2164, 1741, 1462, 1268, 1104, 878, 666 cm
-1
. MS (ESI) m/z (relative 





] 417.0856, found 417.0850. 
 
 
Methyl 3-[(triisopropylsilyl)ethynyl]-[1,1'-biphenyl]-2-carboxylate (126ada): The general procedure B 
was followed using benzoic acid 126ad (99 mg, 0.50 mmol) and (bromoethynyl)triisopropylsilane (33a) (170 
mg, 0.65 mmol, 1.30 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 25:1) and 




H NMR (400 MHz, CDCl3) δ = 7.52 (dd, J = 7.6, 1.3 Hz, 1H), 7.42–7.28 (m, 7H), 3.63 (s, 3H), 1.16–1.10 (m, 
21H). 
13
C NMR (100 MHz, CDCl3) δ = 168.7 (Cq), 139.9 (Cq), 139.7 (Cq), 136.2 (Cq), 131.6 (CH), 129.6 
(CH), 129.2 (CH), 128.3 (CH), 128.2 (CH), 127.7 (CH), 121.4 (Cq), 103.7 (Cq), 94.9 (Cq), 52.1 (CH3), 18.6 
(CH3), 11.2 (CH). IR (neat): 2943, 2864, 2157, 1736, 1457, 1260, 896, 744, 667 cm
-1
. MS (ESI) m/z (relative 
intensity) 415 (10) [M+Na
+
], 393 (100) [M+H
+










Methyl 2-(trifluoromethyl)-6-[(triisopropylsilyl)ethynyl]benzoate (126aea): The general procedure B was 
followed using benzoic acid 124ae (95 mg, 0.50 mmol) and (bromoethynyl)triisopropylsilane (33a) (170 mg, 
0.65 mmol, 1.30 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 30:1) and then 




H NMR (300 MHz, CDCl3) δ = 7.69 (ddd, J = 7.8, 1.3, 0.6 Hz, 1H), 7.61 (ddd, J = 8.0, 1.3, 0.6 Hz, 1H), 
7.50–7.43 (m, 1H), 3.93 (s, 3H), 1.13–1.11 (m, 21H). 
13
C NMR (125 MHz, CDCl3) δ = 166.7 (Cq), 136.0 (q, 
4
JC-F = 1.1 Hz, CH), 134.9 (q, 
3
JC-F = 2.3 Hz, Cq), 129.3 (CH), 127.6 (q, 
2
JC-F = 32.5 Hz, Cq), 125.6 (q, 
3
JC-F = 
4.6 Hz, CH), 123.0 (q, 
1
JC-F = 273.8 Hz, Cq), 122.6 (Cq), 102.1 (Cq), 97.1 (Cq), 52.9 (CH3), 18.5 (CH3), 11.2 
(CH). 
19
F NMR (282 MHz, CDCl3) δ = -60.47 (s). IR (neat): 2945, 2866, 2157, 1745, 1457, 1321, 1132, 909, 
666 cm
-1
. MS (EI) m/z (relative intensity) 385 (5) [M+H
+
], 365 (60), 353 (100). HR-MS (ESI) m/z calcd for 
C20H27F3 O2SiNa [M+Na
+
] 407.1625, found 407.1619. 
 
 
Methyl 5-acetyl-2-[(triisopropylsilyl)ethynyl]benzoate (126da): The general procedure B was followed 
using benzoic acid 124d (82 mg, 0.50 mmol) and (bromoethynyl)triisopropylsilane (33a) (170 mg, 0.65 mmol, 
1.30 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 30:1) and then by HPLC 
yielded 126da (72 mg, 40%) as a pale yellow solid.  
M. p. = 45−46 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 8.43 (d, J = 1.9 Hz, 1H), 8.00 (dd, J = 8.2, 1.9 Hz, 1H), 
7.66 (d, J = 8.2 Hz, 1H), 3.93 (s, 3H), 2.62 (s, 3H), 1.16−1.10 (m, 21H). 
13
C NMR (75 MHz, CDCl3) δ = 
196.4 (Cq), 166.3 (Cq), 135.9 (Cq), 135.2 (CH), 132.8 (Cq), 130.4 (CH), 130.3 (CH), 127.8 (Cq), 104.4 (Cq), 
101.0 (Cq), 52.4 (CH3), 26.6 (CH3), 18.6 (CH3), 11.3 (CH). IR (neat): 2942, 2864, 2157, 1725, 1684, 1236, 
1072, 880, 605 cm
-1
. MS (ESI) m/z (relative intensity) 381 (100) [M+Na
+
], 359 (60) [M+H
+
]. HR-MS (ESI) 
m/z calcd for C21H31O3Si [M+H
+
] 359.2037, found 359.2046. 
 
 
3,4,6-Trimethoxy-2-[(triisopropylsilyl)ethynyl]benzoic acid (126aa´): The general procedure C was 
followed using benzoic acid 124a (106 mg, 0.50 mmol) and (bromoethynyl)triisopropylsilane (33a) (170 mg, 
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0.65 mmol, 1.30 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc/AcOH 
4:1:0.02) yielded 126aa´ (161 mg, 82%) as a colorless solid.  
M. p. = 177−178 ºC.
 1
H NMR (400 MHz, CDCl3) δ = 6.48 (s, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 3.83 (s, 3H), 
1.12−1.11 (m, 21H). 
13
C NMR (100 MHz, CDCl3) δ = 169.6 (Cq), 155.2 (Cq), 153.8 (Cq), 145.5 (Cq), 118.3 
(Cq), 116.5 (Cq), 101.5 (Cq), 98.9 (Cq), 97.9 (CH), 60.9 (CH3), 56.8 (CH3), 56.2 (CH3), 18.6 (CH3), 11.3 (CH). 
IR (neat): 2942, 2864, 2163, 1699, 1583, 1209, 1096, 691 cm
-1
. MS (ESI) m/z (relative intensity) 415 (30) 
[M+Na
+
], 393 (100) [M+H
+
]. HR-MS (ESI) m/z calcd for C21H33O5Si [M+H
+
] 393.2092, found 393.2092. 
 
 
3-[(Triisopropylsilyl)ethynyl]-[1,1'-biphenyl]-2-carboxylic acid (126ada´): The general procedure C was 
followed using benzoic acid 124ad (99 mg, 0.50 mmol) and (bromoethynyl)triisopropylsilane (33a) (170 mg, 
0.65 mmol, 1.30 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc/AcOH 




H NMR (300 MHz, CDCl3) δ = 10.40 (sbr, 1H), 7.58 (dd, J = 7.6, 1.3 Hz, 1H), 7.47–7.32 (m, 7H), 1.19−1.12 
(m, 21H).
 13
C NMR (75 MHz, CDCl3) δ = 173.4 (Cq), 140.9 (Cq), 139.9 (Cq), 134.2 (Cq), 132.3 (CH), 130.1 
(CH), 129.8 (CH), 128.4 (CH), 128.2 (CH), 127.9 (CH), 122.1 (Cq), 103.7 (Cq), 96.0 (Cq), 18.7 (CH3), 11.3 
(CH). IR (neat): 2942, 2864, 2159, 1693, 1437, 1288, 1275, 880, 665 cm
-1
. MS (ESI) m/z (relative intensity) 
401  (100) [M+Na
+
], 379 (90) [M+H
+
]. HR-MS (ESI) m/z calcd for C24H30O2SiNa [M+Na
+




2-(Trifluoromethyl)-6-[(triisopropylsilyl)ethynyl]benzoic acid (126aea´): The general procedure C was 
followed using benzoic acid 124ae (95 mg, 0.50 mmol) and (bromoethynyl)triisopropylsilane (33a) (170 mg, 
0.65 mmol, 1.30 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc/AcOH 
15:1:0.02) yielded 126aea´ (175 mg, 95%) as a pale yellow solid.  
M. p. = 116−117 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 10.46 (s, 1H), 7.66 (d, J = 8.3 Hz, 1H), 7.57 (d, J = 7.9 
Hz, 1H), 7.46−7.43 (m, 1H), 1.10−0.95 (m, 21H). 
13
C NMR (75 MHz, CDCl3) δ = 171.8 (Cq), 136.3 (CH), 
133.6 (q, 
4
JC-F = 2.1 Hz, Cq), 129.7 (CH), 127.9 (q, 
2
JC-F = 32.7 Hz, Cq), 125.7 (q, 
3
JC-F = 4.6 Hz, CH), 123.0 (q, 
1
JC-F = 273.8 Hz, Cq), 122.8 (Cq), 101.8 (Cq), 98.2 (Cq), 18.5 (CH3), 11.2 (CH). 
19
F NMR (282 MHz, CDCl3) δ 
= -59.8 (s). IR (neat): 2943, 2866, 2160, 1712, 1462, 1323, 1131, 665 cm
-1
. MS (ESI) m/z (relative intensity) 
393 (100) [M+Na
+
], 371 (10) [M+H
+








2-[(Triisopropylsilyl)ethynyl]-1-naphthoic acid (126ga´): The general procedure C was followed using 
benzoic acid 124g (86 mg, 0.50 mmol) and (bromoethynyl)triisopropylsilane (33a) (170 mg, 0.65 mmol, 1.30 
equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc/AcOH 10:1:0.02) yielded 




H NMR (300 MHz, CDCl3) δ = 8.13 (ddd, J = 8.5, 1.8, 0.8 Hz, 1H), 7.90–7.85 (m, 2H), 7.66–7.49 (m, 3H), 
1.21–1.17 (m, 21H). 
13
C NMR (75 MHz, CDCl3) δ = 174.0 (Cq), 133.1 (Cq), 132.7 (Cq), 130.3 (CH), 129.4 
(Cq), 129.0 (CH), 128.2 (CH), 127.8 (CH), 127.1 (CH), 125.2 (CH), 119.9 (Cq), 104.4 (Cq), 97.4 (Cq), 18.7 
(CH3), 11.4 (CH). IR (neat): 2942, 2864, 2128, 1697, 1462, 1256, 820, 744, 648 cm
-1
. MS (EI) m/z (relative 
intensity) 352 (5) [M
+
], 309 (100), 267 (10), 249 (10), 239 (30), 179 (10), 151 (10). HR-MS (EI) m/z calcd for 
C22H28O2Si [M
+
] 352.1859, found 352.1866. 
 
 
2,3-Dimethoxy-6-[(triisopropylsilyl)ethynyl]benzoic acid (126ja´): The general procedure C was followed 
using benzoic acid 124j (91 mg, 0.50 mmol) and (bromoethynyl)triisopropylsilane (33a) (170 mg, 0.65 mmol, 
1.30 equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc/AcOH 4:1:0.02) yielded 
126ja´ (173 mg, 96%) as a colorless solid.  
M. p. = 113−115 ºC. 
1
H NMR (400 MHz, CDCl3) δ = 7.25 (d, J = 8.5 Hz, 1H), 6.88 (d, J = 8.5 Hz, 1H), 3.88 
(s, 3H), 3.87 (s, 3H), 1.14−1.08 (m, 21H). 
13
C NMR (100 MHz, CDCl3) δ = 171.4 (Cq), 153.1 (Cq), 146.2 (Cq), 
130.5 (Cq), 129.5 (CH), 114.0 (Cq), 113.6 (CH), 103.1 (Cq), 93.7 (Cq), 61.7 (CH3), 56.0 (CH3), 18.6 (CH3), 
11.2 (CH). IR (neat): 2941, 2890, 2154, 1703, 1459, 1274, 1045, 812, 676 cm
-1
. MS (ESI) m/z (relative 
intensity) 385 [M+Na
+
] (50), 363 (100) [M+H
+






3,5-Dimethoxy-4-methyl-2,6-bis[(triisopropylsilyl)ethynyl]benzoic acid (126aaa´): The general procedure 
C was followed using benzoic acid 124aa (98 mg, 0.50 mmol) (bromoethynyl)triisopropylsilane (33a) (326 
mg, 1.25 mmol, 2.50 equiv) and K2CO3 (207 mg, 1.50 mmol, 3.0 equiv). Purification by column 
chromatography on silica gel (n-hexane/EtOAc/AcOH 10:1:0.02) yielded 126aaa´ (197 mg, 71%) as a pale 
yellow solid.  
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M. p. = 198−199 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 3.94 (s, 6H), 2.23 (s, 3H), 1.17−1.10 (m, 42H). 
13
C 
NMR (75 MHz, CDCl3) δ = 170.5 (Cq), 161.1 (Cq), 137.6 (Cq), 127.9 (Cq), 112.1 (Cq), 100.2 (Cq), 99.0 (Cq), 
60.7 (CH3), 18.6 (CH3), 11.3 (CH), 9.6 (CH3). IR (neat): 2942, 2865, 2153, 1703, 1450, 1389, 994, 882, 661 
cm
-1
. MS (EI) m/z (relative intensity) 557 (3) [M+H
+
], 556 (5) [M
+
], 537 (10), 515 (15), 514 (40), 513 (100), 
455 (5). HR-MS (EI) m/z calcd for C32H52O4Si2 [M
+
] 556.3404, found 556.3420.  
 
C–H Alkynylation/Cyclization Cascade 
 
 
(Z)-7-Methyl-3-[(triisopropylsilyl)methylene]isobenzofuran-1(3H)-one (140a): A suspension of   
[RuCl2(p-cymene)] (15.3 mg, 5.0 mol %), X-phos (23.8 mg, 10 mol %), K2CO3 (138 mg, 1.00 mmol), benzoic 
acid 124a (68 mg, 0.50 mmol), and (bromoethynyl)triisopropylsilane (33a) (170 mg, 0.65 mmol, 1.30 equiv) 
in NMP (2.0 mL) was stirred under N2 for 16 h at 120 ºC. At ambient temperature, the mixture was diluted 
with MTBE (120 mL), then sequentially washed with H2O (20 mL) and brine (20 mL). The organic phase was 
dried over Na2SO4, and concentrated in vacuo. The remaining residue was purified by column 
chromatography on silica gel (n-hexane/EtOAc 20:1) to yield 140a (125 mg, 79%) as a colorless solid.  
M. p. = 135−136 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 7.61–7.49 (m, 2H), 7.36–7.27 (m, 1H), 5.53 (s, 1H), 
2.69 (s, 3H), 1.41–1.29 (m, 3H), 1.11 (d, J = 7.2 Hz, 18H). 
13
C NMR (75 MHz, CDCl3) δ = 167.6 (Cq), 156.5 
(Cq), 139.7 (Cq), 139.1 (Cq), 133.9 (CH), 131.7 (CH), 122.6 (Cq), 118.2 (CH), 99.7 (CH), 18.8 (CH3), 17.5 
(CH3) 11.7 (CH). IR (ATR): 2940, 2863, 1762, 1637, 1461, 1255, 974 cm
-1
. MS (ESI) m/z (relative intensity) 
339 (90) [M+Na
+
], 317 (100) [M+H
+
]. HR-MS (ESI) m/z calcd for C19H29O2Si [M+H
+
] 317.1931, found 
317.1935. 





(Z)-7-Phenyl-3-[(triisopropylsilyl)methylene]isobenzofuran-1(3H)-one (140b): A suspension of   
[RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), X-phos (23.8 mg, 10 mol %), K2CO3 (138 mg, 1.00 mmol), 
benzoic acid 124ad (99 mg, 0.50 mmol), and (bromoethynyl)triisopropylsilane (33a) (170 mg, 0.65 mmol, 
1.30 equiv) in NMP (2.0 mL) was stirred under N2 for 16 h at 120 ºC. At ambient temperature, the mixture 
was diluted with MTBE (120 mL), then sequentially washed with H2O (20 mL) and brine (20 mL). The 
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organic phase was dried over Na2SO4, and concentrated in vacuo. The remaining residue was purified by 
column chromatography on silica gel (n-hexane/EtOAc 20:1) to yield 140b (91 mg, 48%) as a colorless solid. 
M. p. = 96−97 ºC.
 1
H NMR (400 MHz, CDCl3) δ = 7.77–7.68 (m, 2H), 7.60–7.53 (m, 2H), 7.52–7.39 (m, 4H), 
5.61 (s, 1H), 1.42–1.31 (m, 3H), 1.12 (d, J = 7.4 Hz, 18H).
 13
C NMR (100 MHz, CDCl3) δ = 166.2 (Cq), 156.1 
(Cq), 142.2 (Cq), 140.4 (Cq), 136.2 (Cq), 134.0 (CH), 131.8 (CH), 129.4 (CH), 128.5 (CH), 128.0 (CH), 120.8 
(Cq), 119.6 (CH), 99.8 (CH), 18.8 (CH3), 11.6 (CH). IR (ATR): 2938, 2862, 1772, 1638, 1473, 1238, 976, 879 
cm
-1
. HR-MS (ESI) m/z calcd for C24H31O2Si [M+H
+
] 379.2088, found 379.2091. 
 
 
(Z)-3-[(Triisopropylsilyl)methylene]naphtho[1,2-c]furan-1(3H)-one (140c): A suspension of   [RuCl2(p-
cymene)]2 (15.3 mg, 5.0 mol %), X-phos (23.8 mg, 10 mol %), K2CO3 (138 mg, 1.00 mmol), benzoic acid 
124g (86 mg, 0.50 mmol), and (bromoethynyl)triisopropylsilane (33a) (170 mg, 0.65 mmol, 1.30 equiv) in 
NMP (2.0 mL) was stirred under N2 for 16 h at 120 ºC. At ambient temperature, the mixture was diluted with 
MTBE (120 mL), then sequentially washed with H2O (20 mL) and brine (20 mL). The organic phase was 
dried over Na2SO4, and concentrated in vacuo. The remaining residue was purified by column 
chromatography on silica gel (n-hexane/EtOAc 20:1) to yield 140c (123 mg, 70%) as a colorless solid.  
M. p. = 131−132 ºC.
 1
H NMR (400 MHz, CDCl3) δ = 8.93–8.83 (m, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.92 (d, J 
= 8.2 Hz, 1H), 7.77–7.66 (m, 2H), 7.60 (ddd, J = 8.2, 7.0, 1.3 Hz, 1H), 5.71 (s, 1H), 1.38 (dq, J = 14.3, 7.4 Hz, 
3H), 1.13 (d, J = 7.4 Hz, 18H). 
13
C NMR (100 MHz, CDCl3) δ = 167.6 (Cq), 156.8 (Cq), 139.6 (Cq), 135.4 
(CH), 133.9 (Cq), 129.2 (CH), 128.6 (Cq), 128.4 (CH), 127.6 (CH), 124.2 (CH), 119.2 (Cq), 117.2 (CH), 102.6 
(CH), 18.8 (CH3), 11.7 (CH). IR (ATR): 2940, 2862, 1755, 1633, 1458, 1111, 963, 751 cm
-1
. MS (ESI) m/z 
(relative intensity) 375 (30) [M+Na
+
], 353 (10) [M+H
+
], 117 (100). HR-MS (ESI) m/z calcd for C22H29O2Si 
[M+H
+
] 353.1931, found 353.1938. 
















a) H/D Exchange Experiment 
 
 
A suspension of   3,4,5-trimethoxybenzoic acid (124aa) (159 mg, 0.75 mmol), 
(bromoethynyl)triisopropylsilane (33a) (131 mg, 0.50 mmol), [Ru(O2CMes)2(p-cymene)] (16) (28.1 mg, 10 
mol %), K2CO3 (138 mg, 1.00 mmol) in a solvent mixture of 1,4-dioxane (2.0 mL) and CD3OD (0.1 mL) was 
stirred at 120 ºC for 16 h in a sealed tube under a N2 atmosphere. At ambient temperature, MeCN (3.0 mL), 
K2CO3 (207 mg, 1.50 mmol) and MeI (355 mg, 2.50 mmol) were added and the mixture was stirred at 50 ºC 
for another 2 h. At ambient temperature, the mixture was dry-loaded onto silica gel and purified by column 
chromatography on silica gel (n-hexane/EtOAc 20:1) to yield [D]n-124aa´ (90 mg, 53%) and 126aaa (81 mg, 
18%). Only trace amount of mono-alkynylation product was observed. The D-incorporation in [D]n-124aa 
was estimated by 
1
H-NMR spectroscopy.  
 





b) Probing Radical Intermediates 
 
 
Reaction in the presence of TEMPO 
124t (106 mg, 0.5 mmol, 1.0 equiv), 33a (170 mg, 0.65 mmol, 1.3 equiv), [Ru(O2CMes)2(p-cymene)] (16) 
(28.1 mg, 10 mol %), K2CO3 (138 mg, 1.00 mmol) and TEMPO (78 mg, 0.5 mmol, 1.0 equiv) were placed 
into a 25 mL Schlenk tube equipped with a septum under a N2 atmosphere. 1,4-dioxane (2.0 mL) was 
introduced via cannula. The reaction mixture was stirred at 120 °C for 16 h. At ambient temperature, MeCN 
(3.0 mL), K2CO3 (207 mg, 1.50 mmol) and MeI (355 mg, 2.50 mmol) were added and the mixture was stirred 
at 50 ºC for another 2 h. At ambient temperature, the mixture was dry-loaded onto silica gel and purified by 
column chromatography on silica gel (n-hexane/EtOAc 4:1) to yield 124ta (177 mg, 87%) as an off-white 
solid. 
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Reaction in the presence of BHT 
124t (106 mg, 0.5 mmol, 1.0 equiv), 33a (170 mg, 0.65 mmol, 1.3 equiv), [Ru(O2CMes)2(p-cymene)] (16) 
(28.1 mg, 10 mol %), K2CO3 (138 mg, 1.00 mmol) and 2,6-bis(1,1-dimethylethyl)-4-methylphenol (110 mg, 
0.5 mmol, 1.0 equiv) were placed into a 25 mL Schlenk tube equipped with a septum under a N2 atmosphere. 
1,4-dioxane (2.0 mL) was introduced via cannula. The reaction mixture was stirred at 120 °C for 16 h. At 
ambient temperature, MeCN (3.0 mL), K2CO3 (207 mg, 1.50 mmol) and MeI (355 mg, 2.50 mmol) were 
added and the mixture was stirred at 50 ºC for another 2 h. At ambient temperature, the mixture was dry-
loaded onto silica gel and purified by column chromatography on silica gel (n-hexane/EtOAc 4:1) to yield 
124ta (142 mg, 70%) as an off-white solid. 
 
c) Competition Experiment 
Intermolecular competition experiment between benzoic acids 124ae and 124b. 
 
A suspension of   (33a) (170 mg, 0.65 mmol, 1.3 equiv.), 2-methoxylbenzoic acid (124b) (76 mg, 0.50 mmol), 
2-(trifluoromethyl)benzoic (124ae) (95 mg, 0.50 mmol), [Ru(O2CMes)2(p-cymene)] 16 (28.1 mg, 10 mol %), 
K2CO3 (138 mg, 1.00 mmol) in 1,4-dioxane (1.0 mL) was stirred under N2 for 16 h at 120 ºC. At ambient 
temperature, MeCN (3.0 mL), K2CO3 (207 mg, 1.50 mmol) and MeI (355 mg, 2.50 mmol) were added and the 
mixture was stirred at 50 ºC for another 2 h. At ambient temperature, 1,3,5-trimethoxybenzene (16.8 mg, 0.1 
mmol) was added as internal standard, the yields of 126aea and 126ba were determined based on crude 
1
H-
NMR analysis.  
 





Traceless Removal of Silyl Group 
 
Methyl 2-ethynyl-3,4,6-trimethoxybenzoate (142): 126ta (203 mg, 0.50 mmol) was dissolved in THF (3 mL) 
and TBAF (1.0 M in THF, 1.50 mL) was then added at ambient temperature with constant stirring for 12 h. 
Then, the mixture was concentrated in vacuo. The residue was dissolved in H2O (30 mL) and extracted with 
EtOAc (3 × 5 mL). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered 
and evaporated in vacuo. The crude product was purified by column chromatography to afford the alkyne 142 
(118 mg, 94% yield) as an off-white solid. 
M.p. = 90–91 °C. 
 1
H NMR (300 MHz, CDCl3) δ = 6.54 (s, 1H), 3.91 (s, 3H), 3.90 (s, 3H), 3.87 (s, 3H), 3.84 
(s, 3H), 3.39 (s, 1H). 
13
C NMR (75 MHz, CDCl3) δ = 166.6 (Cq), 154.3 (Cq), 153.1 (Cq), 144.8 (Cq), 118.5 
(Cq), 115.6 (Cq), 98.5 (CH), 84.7 (Cq), 76.5 (CH), 61.0 (CH3), 56.5 (CH3), 56.0 (CH3), 52.3 (CH3). IR (neat): 
3265, 2950, 1721, 1585, 1269, 1208, 1027, 814, 650 cm
-1





]. HR-MS (ESI) m/z calcd for C13H15O5 [M+H
+
] 251.0914, found 251.0922.  
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Decarboxylative C−H Alkynylation 
 
A suspension of   [Ru(O2CMes)2(p-cymene)] (16) (28.1 mg, 10 mol %), K2CO3 (138 mg, 1.00 mmol), benzoic 
acid 124a (106 mg, 0.50 mmol), and alkynyl bromide 33a (170 mg, 0.65 mmol) in 1,4-dioxane (1.0 mL) was 
stirred under N2 for 16 h at 120 ºC. At ambient temperature, the solvent was removed and AcOH (2.0 mL) was 
added under a N2 atmosphere, and the mixture was stirred at 150 ºC for 16 h. At ambient temperature, the 
mixture was dry-loaded onto silica gel and purified by column chromatography (n-hexane/EtOAc) to yield the 
product 141 (132 mg, 76%) as a pale yellow oil and cyclic product 140d
 




H NMR (400 MHz, CDCl3) δ = 6.47 (d, J = 2.9 Hz, 1H), 6.45 (d, J = 2.9 Hz, 1H), 3.83 (s, 3H), 3.80 (s, 3H), 
3.75 (s, 3H), 1.12 (s, 21H). 
13
C NMR (100 MHz, CDCl3) δ = 155.6 (Cq), 153.4 (Cq), 145.4 (Cq), 118.0 (Cq), 
107.2 (CH), 102.8 (Cq), 101.6 (CH), 94.9 (Cq), 61.0 (CH3), 55.9 (CH3), 55.6 (CH3), 18.6 (CH3), 11.3 (CH). IR 
(neat): 2941, 2865, 2152, 1686, 1463, 1153, 1055, 882, 668 cm
-1
. MS (EI) m/z (relative intensity) 349 (15) 
[M+H
+
], 348 (70) [M
+
], 305 (85), 290 (100), 277 (20), 263 (30), 248 (40), 220 (30). HR-MS (EI) m/z calcd 
for C20H32O3Si [M
+
] 348.2121, found 348.2126. 
 (Z)-4,5,7-Trimethoxy-3-[(triisopropylsilyl)methylene]isobenzofuran-1(3H)-one (140d): 
 
M.P. = 146–147 ºC; 
1
H NMR (300 MHz, CDCl3) δ = 6.48 (s, 1H), 5.95 (s, 1H), 3.95 (s, 3H), 3.94 (s, 3H), 
3.82 (s, 3H), 1.39–1.21 (m, 3H), 1.06 (d, J = 7.3 Hz, 18H). 
13
C NMR (125 MHz, CDCl3) δ = 164.7 (Cq), 159.4 
(Cq), 155.1 (Cq), 153.6 (Cq), 137.8 (Cq), 132.0 (Cq), 105.4 (CH), 104.8 (Cq), 97.8 (CH), 59.9 (CH3), 56.6 (CH3), 
56.4 (CH3), 18.8 (CH3), 11.6 (CH). IR (neat): 2938, 2863, 1763, 1602, 1505, 1323, 1231, 1043, 967 cm
-1
. MS 
(EI) m/z (relative intensity) 393 (30) [M+H
+
], 392 (80) [M
+
], 391 (15), 378 (20), 377 (100), 361 (30). HR-MS 
(EI) m/z calcd for C21H33O5Si [M
+
] 393.2092, found 393.2099. 
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5.3.3 Concise Synthesis of Lamellarin Alkaloids by C−H/N−H Activation 
 





4-Iodo-2-methoxyphenol (172): Guaiacol (12.4 g, 100 mmol) was dissolved in MeOH (200 mL), then NaI 
(22.5 g, 149.5 mmol) and NaOH (6.25 g, 150 mmol) were added. Aqueous NaClO solution (15%, 200 mL, 
145 mmol) was added dropwise over 40 min at –4 ºC. The mixture was stirred for additional 30 min at this 
temperature. The mixture was acidified with a HCl solution (4 M) to pH = 7, then Na2S2O3 (10%, 60 mL) was 
added. MeOH was removed under reduced pressure and the aqueous phase was extracted with EtOAc (3×150 
mL). The combined organic phase was washed with saturated aqueous NaHCO3 (2×100 mL) and brine (100 
mL), dried over Na2SO4 and concentrated. The residue was filtrated through a short pad of silica gel and 




H NMR (300 MHz, CDCl3) δ = 7.16 (dd, J = 8.3, 1.9 Hz, 1H), 7.09 (d, J = 1.9 Hz, 1H), 6.66 (d, J = 8.3 Hz, 
1H), 5.54 (s, 1H), 3.86 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ = 147.3 (Cq), 145.6 (Cq), 130.4 (CH), 119.7 
(CH), 116.4 (CH), 80.9 (Cq), 56.2 (CH3). IR (neat): 3489, 2941, 2838, 1601, 1491, 1440, 1218, 1020 cm
-1
. 
MS (EI) m/z (relative intensity) 250 (100) [M
+
], 234 (50), 206 (30), 179 (5), 126 (10), 108 (10). HR-MS (ESI) 
m/z calcd for C7H7IO2 [M
+
] 249.9491, found 249.9495.  




4-Iodo-1-isopropoxy-2-methoxybenzene (173): To a suspension of   172 (12.5 g, 50 mmol) and K2CO3 
(13.8 g, 100 mmol) in DMSO (200 mL) was added i-PrBr (9.20 g, 75 mmol) at ambient temperature and the 
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mixture was heated at 55 ºC for 16 h. At ambient temperature, the mixture was diluted with EtOAc (500 mL) 
and washed with H2O (4×100 mL) and brine (100 mL). The organic phase was dried over Na2SO4 and 
concentrated. The residue was purified by column chromatography (n-hexane/EtOAc, 20/1) to give the 
product 173 (13.7 g, 94%) as a colorless oil.  
1
H NMR (300 MHz, CDCl3) δ = 7.17 (dd, J = 8.4, 2.1 Hz, 1H), 7.10 (d, J = 2.1 Hz, 1H), 6.62 (d, J = 8.4 Hz, 
1H), 4.46 (hept, J = 6.1 Hz, 1H), 3.81 (s, 3H), 1.33 (d, J = 6.1 Hz, 6H). 
13
C NMR (75 MHz, CDCl3) δ = 151.3 
(Cq), 147.4 (Cq), 129.7 (CH), 121.1 (CH), 117.6 (CH), 82.8 (Cq), 71.6 (CH), 56.1 (CH3), 22.0 (CH3). IR (neat): 
2974, 1578, 1489, 1245, 1220, 1134, 1025, 824 cm
-1
. MS (EI) m/z (relative intensity) 292 (30) [M
+
], 249 
(100), 234 (50), 217 (5), 206 (15), 190 (5). HR-MS (EI) m/z calcd for C10H13IO2 [M
+
] 291.9960, found 
291.9953.  





1,2-Bis(4-isopropoxy-3-methoxyphenyl)ethyne (59c): Aryl iodide 173 (8.70 g, 30 mmol), Pd(PPh3)4 (1.04 g, 
6 mol %), CuI (285 mg, 10 mol %) were placed into a 250 mL Schlenk flask under a N2 atmosphere. Benzene 
(80 mL) and DBU (27 mL, 180 mmol) were added via cannula. Degassed H2O (121 mg, 45 mol %) and 
ethynyltrimethylsilane (2.10 mL, 15 mmol) were added by syringe sequentially. The mixture was kept in dark 
by aluminum foil and stirred at 60 ºC for 48 h. At ambient temperature, the mixture was diluted with CH2Cl2 
(400 mL) and washed with HCl (3 M, 3×75 mL), sat. aq. NH4Cl/NH3 (1/1, 3×75 mL) and brine (75 mL). The 
organic phase was dried over Na2SO4 and concentrated in vacuo. The residue was purified by silica gel 
column chromatography (n-hexane/EtOAc 4/1 to CH2Cl2) to afford the product 59c (3.99 g, 75%) as a white 
solid. 
M. p. = 176−177 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 7.06 (dd, J = 8.2, 1.9 Hz, 2H), 7.01 (d, J = 1.9 Hz, 2H), 
6.82 (d, J = 8.2 Hz, 2H), 4.53 (hept, J = 6.1 Hz, 2H), 3.84 (s, 6H), 1.35 (d, J = 6.1 Hz, 12H). 
13
C NMR (75 
MHz, CDCl3) δ = 149.8 (Cq), 147.6 (Cq), 124.5 (CH), 115.7 (Cq), 115.0 (CH), 114.8 (CH), 88.0 (Cq), 71.3 
(CH), 55.9 (CH3), 22.0 (CH3). IR (neat): 2976, 2916, 1509, 1241, 1214, 1135, 1036, 852 cm
-1
. MS (EI) m/z 
(relative intensity) 355 (10) [M+H
+
], 354 (30) [M
+
], 312 (15), 270 (100), 255 (20), 227 (20). HR-MS (EI) m/z 
calcd for C22H26O4 [M
+
] 354.1831, found 354.1828. 
















3-Isopropoxy-4-methoxyphenol (175): Under an argon atmosphere, m-CPBA (70%, 11.8 g, 48 mmol) was 
added portionwise to a solution of 174 (7.77 g, 40 mmol) in CH2Cl2 (120 mL) at 0 
o
C. After being stirred at 
23 
o
C for 3 h, to the mixture was added saturated aqueous NaHCO3 (80 mL). The mixture was diluted with 
H2O (50 mL) and the organic layer was separated. The aqueous layer was extracted with CH2Cl2 (3×80 mL). 
The combined extract was washed with brine (100 mL), dried over Na2SO4, and evaporated under reduced 
pressure. The residue was dissolved in MeOH (200 mL) and K2CO3 (13.8 g, 100 mmol) was added 
portionwise to the solution. After being stirred for 1 h, the mixture was evaporated under reduced pressure. 
H2O (150 mL) was added to the residue and the aqueous solution was extracted with EtOAc (3×100 mL). The 
extract was washed with brine (100 mL), dried over Na2SO4, evaporated under reduced pressure. The residue 
was purified by column chromatography on silica gel (n-hexane/EtOAc 15:1) to yield 175 (6.12 g, 84%) as a 
colorless solid.  
M. p. = 124−125 ºC.
 1
H NMR (400 MHz, CDCl3) δ = 6.71 (d, J = 8.6 Hz, 1H), 6.45 (d, J = 2.8, 1H), 6.33 (dd, 
J = 8.6, 2.8 Hz, 1H), 4.42 (hept, J = 6.1 Hz, 1H), 3.76 (s, 3H), 1.30 (d, J = 6.1 Hz, 6H). 
13
C NMR (100 MHz, 
CDCl3) δ = 150.2 (Cq), 148.1 (Cq), 144.2 (Cq), 113.5 (CH), 106.5 (CH), 104.1 (CH), 71.3 (CH), 56.8 (CH3), 
21.9 (CH3). IR (neat): 3424, 2977, 1606, 1504, 1460, 1287, 1221, 1126 cm
-1
. MS (EI) m/z (relative intensity) 
183 (10) [M+H
+
], 182 (50) [M
+
], 140 (70), 125 (100), 111 (10), 97 (30). HR-MS (EI) m/z calcd for C10H14O3 
[M
+
] 182.0943, found 182.0944. 
The analytical data are in accordance with those previously reported in the literature.
[122i]
 





2-Isopropoxy-1-methoxy-4-(methoxymethoxy)benzene (176): Under argon, a solution of 175 (3.64 g, 
20 mmol) in THF (20 mL) was added dropwise to A suspension of   NaH (60%, 2.40 g, 60  mmol) in THF (30 
mL) at 0 
o
C. After being stirred for 30 min, chloromethyl methyl ether (2.41 g, 30 mmol) was added and the 
mixture was stirred for 2 h at 0 °C and additional 1 h at ambient temperature. To the mixture was added 
saturated aqueous NH4Cl (80 mL) and extracted with EtOAc (3×80 mL). The extract was washed with brine 
(80 mL), dried over Na2SO4, and evaporated under reduced pressure. The residue was purified by column 
chromatography over silica gel (n-hexane/EtOAc 10/1) to give 176 as a colorless oil (3.62 g, 80%).  
1
H NMR (400 MHz, CDCl3) δ = 6.76 (d, J = 8.8 Hz, 1H), 6.63 (d, J = 2.8 Hz, 1H), 6.57 (dd, J = 8.8, 2.8 Hz, 
1H), 5.08 (s, 2H), 4.48 (hept, J = 6.1 Hz, 1H), 3.79 (s, 3H), 3.46 (s, 3H), 1.35 (d, J = 6.1 Hz, 6H). 
13
C NMR 
(100 MHz, CDCl3) δ = 151.6 (Cq), 148.1 (Cq), 145.6 (Cq), 112.8 (CH), 107.5 (CH), 105.9 (CH), 95.3 (CH2), 
71.4 (CH), 56.6 (CH3), 55.9 (CH3), 22.0 (CH3). IR (neat): 2975, 2931, 1595, 1503, 1224, 1150, 1009, 920 cm
-
1
. MS (EI) m/z (relative intensity) 227 (10) [M+H
+
], 226 (80) [M
+
], 195 (10), 184 (60), 154 (80), 139 (100). 
HR-MS (EI) m/z calcd for C12H18O4 [M
+
] 226.1205, found 226.1213. 




1-Bromo-4-isopropoxy-5-methoxy-2-(methoxymethoxy)benzene (177): A solution of NBS (2.8 g, 15.7 
mmol) in DMF (20 mL) was added dropwise to a solution of 176 (3.39 g, 15 mmol) in DMF (15 mL) at 0 °C. 
After being stirred for 30 min, to the reaction mixture was added H2O (30 mL) at the same temperature and 
allowed to warm to ambient temperature. The mixture was diluted with Et2O (250 mL), washed with H2O 
(3×40 mL) and brine (80 mL). The organic phase was dried over Na2SO4 and concentrated at ambient 
temperature. The residue was purified by column chromatography on silica gel (n-hexane/EtOAc 10/1) to 
yield S7 (4.07 g, 89%) as a pale yellow oil.  
1
H NMR (300 MHz, CDCl3) δ = 7.00 (s, 1H), 6.79 (s, 1H), 5.12 (s, 2H), 4.46 (hept, J = 6.1 Hz, 1H), 3.79 (s, 
3H), 3.51 (s, 3H), 1.33 (d, J = 6.1 Hz, 6H). 
13
C NMR (125 MHz, CDCl3) δ = 147.8 (Cq), 147.1 (Cq), 146.4 
(Cq), 116.6 (CH), 107.0 (CH), 103.2 (Cq), 96.3 (CH2), 72.1 (CH), 56.7 (CH3), 56.4 (CH3), 22.0 (CH3). IR 
(neat): 2974, 2903, 2833, 1495, 1374, 1206, 1149, 1010 cm
-1
. MS (EI) m/z (relative intensity) 304 (10) [M
+
], 









] 306.0290, found 306.0290. 
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A mixture of 177 (3.05 g, 10 mmol), Et3N (5.6 mL, 40 mmol), Pd(OAc)2 (112 mg, 5 mol %), DPEphos (538 
mg, 10 mol %), and 178 (3.84 g, 30 mmol) in 1,4-dioxane (20 mL) was heated at 100 °C for 16 h. At ambient 
temperature, to the mixture was added saturated NH4Cl (80 mL), and the aqueous solution was extracted with 
EtOAc (3×60 mL). The organic phase was dried over Na2SO4, filtered, and concentrated. The residue was 
purified by column chromatography (n-hexane/EtOAc/Et3N 100/10/1) to give 2a (2.92 g, 83%) as a pale 
yellow oil.  
1
H NMR (400 MHz, CDCl3) δ = 7.14 (s, 1H), 6.61 (s, 1H), 5.04 (s, 2H), 4.51 (hept, J = 6.1 Hz, 1H), 3.79 (s, 
3H), 3.48 (s, 3H), 1.31 (d, J = 6.1 Hz, 6H), 1.27 (s, 12H). 
13
C NMR (100 MHz, CDCl3) δ = 157.2 (Cq), 150.5 
(Cq), 145.3 (Cq), 119.0 (CH), 106.1 (CH), 97.1 (CH2), 83.0 (Cq), 70.9 (CH), 56.3 (CH3), 56.0 (CH3), 24.6 
(CH3), 21.7 (CH3). IR (neat): 2976, 2933, 1602, 1507, 1370, 1346, 1202, 1141 cm
-1
. MS (EI) m/z (relative 
intensity) 353 (10) [M+H
+
], 352 (100) [M
+
], 310 (10), 278 (30), 236 (30), 194 (80). HR-MS (EI) m/z calcd for 
C18H29BO6 [M
+
] 352.2057, found 352.2062. 
  
 Experimental Section  
120 
 










Methyl 4,5-bis(4-isopropoxy-3-methoxyphenyl)-1H-pyrrole-2-carboxylate (128a): Methyl 2-
acetamidoacrylate (127) (787 mg, 5.50 mmol), 1,2-bis(4-isopropoxy-3-methoxy-phenyl)ethyne (59c) (1.77 g, 
5.00 mmol), [RuCl2(p-cymene)]2 (153 mg, 5.0 mol %), AgSbF6 (343 mg, 20 mol %) and Cu(OAc)2·H2O (2.00 
g, 10.0 mmol) was placed into a 100 mL sealed tube under a N2 atmosphere. A solvent mixture of 
MeOH/DCE (20 mL/10 mL) was added via cannula. The reaction mixture was stirred at 110 °C for 24 h. At 
ambient temperature, the reaction mixture was dry-loaded onto silica gel and purified by column 
chromatography (n-hexane/EtOAc 4/1 to 2/1) to afford the desired product 128a (2.11g, 93%) as colorless 
solid.  M. p. = 70−71 ºC.
 1
H NMR (400 MHz, CDCl3) δ = 9.16 (s, 1H), 7.01 (d, J = 2.7 Hz, 1H), 6.93 (dd, J = 
8.2, 2.1 Hz, 1H), 6.87–6.77 (m, 5H), 4.56–4.43 (m, 2H), 3.84 (s, 3H), 3.67 (s, 3H), 3.63 (s, 3H), 1.35 (d, J = 
6.1 Hz, 6H), 1.34 (d, J = 6.1 Hz, 6H). 
13
C NMR (100 MHz, CDCl3) δ = 161.6 (Cq), 150.1 (Cq), 150.1 (Cq), 
147.2 (Cq), 145.9 (Cq), 133.1 (Cq), 128.6 (Cq), 124.8 (Cq), 123.5 (Cq), 121.4 (Cq), 120.7 (CH), 120.1 (CH), 
116.5 (CH), 115.9 (CH), 115.5 (CH), 112.6 (CH), 112.0 (CH), 71.5 (CH), 71.4 (CH), 55.8 (CH3), 55.7 (CH3), 
51.5 (CH3), 22.1 (CH3), 22.0 (CH3). IR (neat): 3296, 2975, 2934, 1680, 1517, 1465, 1204, 1106, 765 cm
-1
.  
MS (EI) m/z (relative intensity) 454 (100) [M+H
+
], 453 (80) [M
+
], 411 (30), 369 (100), 337 (80). HR-MS (EI) 
m/z calcd for C26H31NO6 [M
+
] 453.2151, found 453.2151.  
 
 
Methyl 1-acetyl-4,5-bis(4-isopropoxy-3-methoxyphenyl)-1H-pyrrole-2-carboxylate (128a'): 
Characterization data of 128a'. 
 M. p. = 143−144 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 7.14 (s, 1H), 6.88–6.84 (m, 2H), 6.82 (s, 1H), 6.78–
6.72 (m, 2H), 6.63 (s, 1H), 4.55 (hept, J = 6.1 Hz, 1H), 4.46 (hept, J = 6.1 Hz, 1H), 3.87 (s, 3H), 3.72 (s, 3H), 
3.56 (s, 3H), 2.31 (s, 3H), 1.37 (d, J = 6.1 Hz, 6H), 1.33 (d, J = 6.1 Hz, 6H). 
13
C NMR (75 MHz, CDCl3) δ = 
174.1 (Cq), 161.1 (Cq), 150.0 (Cq), 149.8 (Cq), 147.8 (Cq), 145.9 (Cq), 134.1 (Cq), 127.1 (Cq), 124.4 (Cq), 123.4 
(CH), 123.2 (Cq), 122.5 (Cq), 120.1 (CH), 117.9 (CH), 115.6 (CH), 114.9 (CH), 114.6 (CH), 111.8 (CH), 71.3 
(CH), 71.2 (CH), 56.0 (CH3), 55.5 (CH3), 51.8 (CH3), 28.8 (CH3), 22.1 (CH3), 22.0 (CH3). IR (neat): 2983, 
2934, 2827, 1749, 1691, 1470, 1227, 850, 769 cm
-1
. MS (EI) m/z (relative intensity) 496 (10) [M+H
+
], 495 (40) 





], 453 (60), 411 (40), 369 (100), 337 (60). HR-MS (EI) m/z calcd for C28H33NO7  [M
+




Methyl 3-bromo-4,5-bis(4-isopropoxy-3-methoxyphenyl)-1H-pyrrole-2-carboxylate (144a): to a solution 
of 128a (1.40g, 3.09 mmol) in DMF (40 mL) was added a solution of NBS (555 mg, 3.12 mmol) in DMF (5 
mL) dropwise within 10 min at 0 °C under a N2 atmosphere. The reaction mixture was stirred at 0 °C for 1 h. 
Then, the mixture was diluted with EtOAc (200 mL) and washed with H2O (3×60 mL) and brine (60 mL). The 
organic phase was dried over Na2SO4 and concentrated. The residue was purified by column chromatography 
over silica gel (n-hexane/EtOAc 5/1) to give 144a (1.61g, 98%) as a colorless solid. 
M. p. = 71−72 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 9.37 (s, 1H), 6.91–6.75 (m, 5H), 6.69 (d, J = 2.0 Hz, 1H), 
4.59–4.45 (m, 2H), 3.90 (s, 3H), 3.73 (s, 3H), 3.54 (s, 3H), 1.37 (d, J = 6.1 Hz, 6H), 1.34 (d, J = 6.1 Hz, 6H). 
13
C NMR (100 MHz, CDCl3) δ = 160.9 (Cq), 149.8 (Cq), 149.7 (Cq), 147.1 (Cq), 146.4 (Cq), 133.6 (Cq), 126.3 
(Cq), 124.2 (Cq), 123.6 (Cq), 123.1 (CH), 119.5 (CH), 118.9 (Cq), 115.2 (CH), 115.0 (CH), 114.6 (CH), 111.5 
(CH), 106.0 (Cq), 71.1 (CH), 71.1 (CH), 55.7 (CH3), 55.4 (CH3), 51.5 (CH3), 21.9 (CH3), 21.8 (CH3). IR 
(neat): 3284, 2975, 1671, 1518, 1467, 1383, 1233, 1106, 1032 cm
-1
. MS (EI) m/z (relative intensity) 533 (40) 
[M
+













methoxy)phenyl]-1H-pyrrole-2-carboxylate (145): 144a (1.06 g, 2.0 mmol), 2a (1.41 g, 4.0 mmol), 
Pd2(dba)3 (137 mg, 7.5 mol %), dppf (166 mg, 15 mol %) and Na2CO3 (1.40 g, 13.2 mmol) was placed into a 
100 mL sealed tube under a N2 atmosphere. A solvent mixture of DME/H2O (30 mL/2.4 mL) was added via 
cannula. The reaction mixture was kept in the dark and stirred at 110 °C for 24 h. After cooling down to 
ambient temperature, the mixture was evaporated, the residue was diluted with H2O (30 mL) and extracted 
with CH2Cl2 (4×30 mL). The extracts was washed with brine (2×30 mL), dried over Na2SO4, and evaporated. 
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The residue was purified by column chromatography over silica gel (n-hexane/EtOAc 2/1) to give 145 (1.18 g, 
87%) as a pale yellow solid.  
M. p. = 81−82 ºC. 
1
H NMR (600 MHz, CDCl3) δ = 9.23 (s, 1H), 6.92 (dd, J = 8.3, 2.1 Hz, 1H), 6.82 (d, J = 
8.3 Hz, 1H), 6.78 (s, 1H), 6.78 (d, J = 2.1 Hz, 1H), 6.65 (d, J = 8.2 Hz, 1H), 6.61 (s, 1H), 6.53 (dd, J = 8.2, 2.0 
Hz, 1H), 6.52 (d, J = 2.0 Hz, 1H), 4.75 (d, J = 6.9 Hz, 1H), 4.55–4.43 (m, 3H), 4.39 (hept, J = 6.1 Hz, 1H), 
3.68 (s, 3H), 3.62 (s, 3H), 3.54 (s, 3H), 3.44 (s, 3H), 3.21 (s, 3H), 1.34 (d, J = 6.1 Hz, 12H), 1.27 (d, J = 6.1 
Hz, 6H). 
 13
C NMR (75 MHz, CDCl3) δ = 161.7 (Cq), 149.9 (Cq), 149.8 (Cq), 149.8 (Cq), 147.1 (Cq), 147.0 
(Cq), 145.4 (Cq), 145.0 (Cq), 132.4 (Cq), 128.0 (Cq), 127.7 (Cq), 124.7 (Cq), 123.7 (Cq), 122.5 (CH), 119.6 (CH), 
118.8 (Cq), 117.1 (Cq), 116.1 (CH), 115.7 (CH), 115.3 (CH), 114.3 (CH), 112.0 (CH), 105.6 (CH), 96.5 (CH2), 
71.4 (CH), 71.3 (CH), 71.3 (CH), 56.4 (CH3), 55.6 (CH3), 55.5 (CH3), 55.4 (CH3), 51.3 (CH3), 22.0 (CH3), 
22.0 (CH3). IR (neat): 3530, 3314, 2976, 1670, 1506, 1440, 1214, 1107, 751 cm
-1
. MS (EI) m/z (relative 
intensity) 678 (50) [M+H
+
], 677 (100) [M
+
], 602 (30), 588 (10), 560 (10), 528 (10). HR-MS (ESI) m/z calcd 
for C38H48NO10 [M+H
+




(146a): Under N2, 145 (1.02 g, 1.50 mmol), TsOH·H2O (71 mg, 25 mol %) was placed into a 100 mL sealed 
tube. MeOH (20 mL) was added via cannula. The reaction mixture was stirred at 110 °C for 16 h. At ambient 
temperature, 40 mL saturated NaHCO3 solution was carefully added. A large amount of precipitate formed 
during this process. The solid was collected by filtration and further washed with cold H2O (2×5.0 mL) and n-
hexane (2×5.0 mL). The obtained pale brown solid 146a (776 mg, 86%) was analytic pure and didn’t need 
further purification.  
M. p. = 223−224 ºC.
 1
H NMR (400 MHz, CDCl3) δ = 10.49 (s, 1H), 7.08 (d, J = 2.1 Hz, 1H), 7.05–6.94 (m, 
3H), 6.94 (d, J = 1.7 Hz, 1H), 6.90 (s, 1H), 6.80 (d, J = 8.7 Hz, 1H), 6.77 (s, 1H), 4.61–4.48 (m, 3H), 3.75 (s, 
3H), 3.71 (s, 3H), 3.45 (s, 3H), 1.38 (d, J = 6.1 Hz, 12H), 1.35 (d, J = 6.1 Hz, 6H). 
13
C NMR (100 MHz, 
CDCl3) δ = 156.1 (Cq), 150.9 (Cq), 150.0 (Cq), 147.5 (Cq), 147.2 (Cq), 146.8 (Cq), 146.7 (Cq), 146.1 (Cq), 139.1 
(Cq), 129.0 (Cq), 127.9 (Cq), 123.5 (CH), 123.5 (Cq), 120.0 (CH), 117.2 (Cq), 116.5 (CH), 115.0 (Cq), 114.8 
(CH), 114.8 (CH), 111.3 (CH), 110.6 (Cq), 105.0 (CH), 103.8 (CH), 71.6 (CH), 71.5 (CH), 71.2 (CH), 56.1 
(CH3), 55.7 (CH3), 55.5 (CH3), 22.0 (CH3), 21.8 (CH3). IR (neat): 3275, 2972, 1685, 1521, 1460, 1257, 1146, 
870, 642 cm
-1
. MS (ESI) m/z (relative intensity) 624 (100) [M+Na
+
], 602 (80) [M+H
 +
], 563 (10), 525 (20), 
481 (30), 437 (50). HR-MS (ESI) m/z calcd for C35H40NO8 [M+H
+
] 602.2748, found 602.2747. 
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b]pyrrol-4(3H)-one (148a): Under N2, 146a (867 mg, 1.44 mmol) and Cs2CO3 (3.05 g, 9.36 mmol) were 
placed in a 100 mL sealed tube. 2-Bromo-1,1-dimethoxyethane (147) (1.60 g, 9.5 mmol) and DMF (30 mL) 
were added via cannula. The reaction mixture was stirred at 110 °C for 24 h. At ambient temperature, the 
mixture was diluted with EtOAc (250 mL) and washed with H2O (3×60 mL) and brine (60 mL). The organic 
phase was dried over Na2SO4 and concentrated. The residue was purified by column chromatography over 
silica gel (n-hexane/EtOAc 5/1) to give 148a (804 mg, 81%) as a colorless solid.  
M. p. = 162−163 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 6.92 (s, 1H), 6.91 (s, 1H), 6.92–6.78 (m, 4H), 6.79 (d, J 
= 8.8 Hz, 1H), 6.71 (d, J = 1.1 Hz, 1H), 4.85 (t, J = 5.5 Hz 1H), 4.62–4.41 (m, 5H), 3.65 (s, 3H), 3.63 (s, 3H), 
3.45 (s, 3H), 3.31 (s, 6H), 1.38 (d, J = 6.1  Hz, 6H), 1.33 (d, J = 6.1 Hz, 6H), 1.31 (d, J = 6.1 Hz, 6H). 
13
C 
NMR (125 MHz, CDCl3) δ = 155.6 (Cq), 150.1 (Cq), 149.5 (Cq), 147.4 (Cq), 147.2 (Cq), 146.5 (Cq), 146.2 (Cq), 
146.1 (Cq), 144.0 (Cq), 127.7 (Cq), 127.4 (Cq), 123.8 (CH), 123.4 (CH), 122.2 (Cq), 118.5 (Cq), 115.9 (CH), 
115.2 (CH), 115.0 (CH), 114.6 (Cq), 114.5 (CH), 110.2 (Cq), 105.3 (CH), 104.4 (CH), 103.5 (CH), 71.5 (CH), 
71.5 (CH), 71.2 (CH), 55.9 (CH3), 55.8 (CH3), 55.6 (CH3), 55.3 (CH3), 47.9 (CH2), 22.1 (CH3), 21.9 (CH3). 
IR (neat): 2975, 2931, 1703, 1517, 1463, 1257, 1107, 1031, 752 cm
-1
. MS (ESI) m/z (relative intensity) 712 
(100) [M+Na
+
], 690 (50) [M+H
 +
], 658 (80). HR-MS (ESI) m/z calcd for C39H48NO10 [M+H
+
] 690.3273, 




chromeno[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one (129c): Under N2, a solution of TfOH in CH2Cl2 
(1.0  M, 1.1 mL, 1.10 mmol) was added dropwise to a solution of 148a (508 mg, 0.73 mmol) in CH2Cl2 (25 
mL) within 10 min at 0 ºC. After stirring at 0 ºC for 30 min, the mixture was warmed to 23 ºC and stirred for 
additional 1 h. NaHCO3 (919 mg, 11 mmol) and EtOH (10 mL) were added sequentially. Then, the solvent 
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was removed and the residue was dry-loaded no silica gel and purified by column chromatography on silica 
gel (n-hexane/EtOAc 4/1) to yield 129c (429 mg, 94%) as a colorless solid.  
M. p. = 190−191 ºC.
 1
H NMR (400 MHz, CDCl3) δ = 9.08 (d, J = 7.3 Hz, 1H), 7.12–7.11 (m, 2H), 7.10–7.09 
(m, 2H), 7.02 (s, 1H), 6.91 (d, J = 7.3 Hz, 1H), 6.85 (s, 1H), 6.70 (s, 1H), 4.67–4.54 (m, 2H), 4.47 (hept, J = 
6.1 Hz, 1H), 3.81 (s, 3H), 3.40 (s, 3H), 3.39 (s, 3H), 1. 39–1.36 (m, 12H), 1.34–1.32 (m, 6H). 
13
C NMR (100 
MHz, CDCl3) δ = 155.2 (Cq), 151.2 (Cq), 150.0 (Cq), 148.3 (Cq), 147.6 (Cq), 147.0 (Cq), 146.4 (Cq), 146.3 (Cq), 
134.1 (Cq), 129.1 (Cq), 128.6 (Cq), 124.5 (Cq), 123.8 (CH), 122.9 (CH), 118.8 (Cq), 116.8 (CH), 115.0 (CH), 
112.1 (CH), 110.8 (Cq), 110.3 (CH), 109.8 (Cq), 107.6 (Cq), 105.5 (CH), 105.3 (CH), 103.2 (CH), 71.6 (CH), 
71.3 (CH), 71.0 (CH), 56.1 (CH3), 55.3 (CH3), 55.0 (CH3), 21.8 (CH3), 21.8 (CH3), 21.8 (CH3), 21.7 (CH3), 
21.7 (CH3), 21.7 (CH3). IR (neat): 3011, 2975, 2934, 1701, 1431, 1256, 1203, 1126, 1011 cm
-1
. MS (ESI) m/z 
(relative intensity) 626 (100) [M+H
+
], 524 (5), 348 (10). HR-MS (ESI) m/z calcd for C37H40NO8 [M+H
+
] 
626.2748, found 626.2744. 





a]isoquinolin-6-one (129b): To a solution of 129c (94 mg, 0.15 mmol) in CH2Cl2 (10 mL) was added BCl3 
(1.4 mL, 1.0 M in CH2Cl2, 1.40 mmol) under a N2 atmosphere at –78 ºC. After being stirred for 30 min at this 
temperature, the reaction mixture was allowed to warm to ambient temperature and stirred for additional 3 h. 
To the mixture was added saturated aqueous NaHCO3 (20 mL) and extracted with EtOAc (4×20 mL). The 
extract was washed with brine (20 mL), dried over Na2SO4, and evaporated under reduced pressure. The 
residue was purified by column chromatography on silica gel (EtOAc/MeOH 1/0 to 10/1) to yield 129b (72 
mg, 96%) as a pale green solid.  
M. p. ˃300 ºC.
 1
H NMR (400 MHz, DMSO-d6) δ = 9.92 (s, 1H), 9.81 (s, 1H), 9.32 (s, 1H), 8.98 (d, J = 7.4 Hz, 
1H), 7.18 (d, J = 7.4 Hz, 1H), 7.17 (s, 1H), 7.15 (d, J = 1.9 Hz, 1H), 7.13 (s, 1H), 7.09 (d, J = 8.0 Hz, 1H), 
6.99 (dd, J = 8.0, 1.9 Hz, 1H), 6.86 (s, 1H), 6.71 (s, 1H), 3.77 (s, 3H), 3.38 (s, 3H), 3.38 (s, 3H). 
13
C NMR 
(125 MHz, DMSO-d6) δ = 154.0 (Cq), 148.4 (Cq), 148.2 (Cq), 148.0 (Cq), 147.6 (Cq), 146.6 (Cq), 146.1 (Cq), 
144.3 (Cq), 133.8 (Cq), 128.7 (Cq), 125.3 (Cq), 124.4 (Cq), 123.6 (CH), 121.8 (CH), 117.4 (Cq), 116.2 (CH), 
115.0 (CH), 112.1 (CH), 111.3 (CH), 110.6 (Cq), 108.2 (Cq), 106.2 (Cq), 105.7 (CH), 105.3 (CH), 103.5 (CH), 
55.9 (CH3), 55.0 (CH3), 54.4 (CH3). IR (neat): 3385, 2933, 2837, 1672, 1595, 1431, 1273, 1154, 1014, 850 
cm
-1
. MS (ESI) m/z (relative intensity) 522 (100) [M+Na
+
], 500 (40) [M+H
 +
], 425 (10), 381 (20). HR-MS 
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(ESI) m/z calcd for C28H22NO8 [M+H
+
] 500.1340, found 500.1348; C28H21NO8Na [M+Na
+
] 522.1159, found 
522.1163. 






one (129a): To a solution of 129c (94 mg, 0.15 mmol) in CH2Cl2 (10 mL) was added BBr3 (2.25 mL, 1.0 M in 
CH2Cl2, 2.25 mmol) under a N2 atmosphere at –78 ºC. After being stirred for 30 min at this temperature, the 
reaction mixture was allowed to warm to ambient temperature and stirred for additional 16.5 h. After diluting 
with MeOH (5 mL), the solvent was removed under vacuum. The residue was dissolved in H2O (20 mL) and 
extracted with EtOAc (4×20 mL). The extracts was washed with brine (20 mL), dried over Na2SO4, and 
evaporated under reduced pressure. The residue was purified by column chromatography on silica gel 
(EtOAc/MeOH 10/1) to yield 129a (64 mg, 93%) as a pale green solid.  
M. p. ˃300 ºC.
 1
H NMR (400 MHz, DMSO-d6) δ = 9.98 (sbr, 1H), 9.76 (sbr, 1H), 9.41 (sbr, 1H), 9.19 (sbr, 2H), 
8.99 (d, J = 7.4 Hz, 1H), 8.90 (sbr, 1H), 7.14 (d, J = 7.4 Hz, 1H), 7.13 (s, 1H), 6.99 (d, J = 7.9 Hz, 1H), 6.95 (s, 
1H), 6.80 (s, 1H), 6.79 (d, J = 2.1 Hz, 1H), 6.71 (dd, J = 7.9, 2.1 Hz, 1H), 6.57 (s, 1H).
 13
C NMR (125 MHz, 
DMSO-d6) δ = 154.2 (Cq), 147.4 (Cq), 146.6 (Cq), 146.3 (Cq), 146.0 (Cq), 145.3 (Cq), 145.1 (Cq), 141.8 (Cq), 
133.7 (Cq), 128.6 (Cq), 125.3 (Cq), 123.6 (Cq), 121.3 (CH), 121.0 (CH), 117.9 (Cq), 117.4 (CH), 116.8 (CH), 
112.3 (CH), 111.2 (CH), 111.2 (Cq), 109.5 (CH), 109.4 (CH), 108.7 (Cq), 106.2 (Cq), 103.2 (CH). IR (neat): 
3363, 1670, 1428, 1274, 1153, 1030, 863, 753 cm
-1





], 441 (30), 425 (10), 413 (5). HR-MS (EI) m/z calcd for C25H16NO8 [M+H
+
] 458.0870, found 
458.0883; C25H15NO8Na [M+Na
+
] 480.0690, found 480.0703. 
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1,2-Bis(4-isopropoxy-3-methoxyphenyl)chromeno[3,4-b]pyrrol-4(3H)-one (146b): Under N2, 144a (1.06 g, 
2.0 mmol), 2b (414 mg, 3.0 mmol), Pd2(dba)3 (91.6 mg, 5.0 mol %), dppf (111 mg, 10 mol %) and Na2CO3 
(1.40 g, 13.2 mmol) were placed into a 100 mL sealed tube. A solvent mixture of DME/H2O (30 mL/2.4 mL) 
was added via cannula. The reaction mixture was kept in the dark and stirred at 110 °C for 36 h. After cooling 
down to ambient temperature, the mixture was evaporated, and the residue was diluted with H2O (30 mL) and 
extracted with CH2Cl2 (4×30 mL). The combined organic phase was washed with brine (2×30 mL), dried over 
Na2SO4, and evaporated. The residue was purified by column chromatography over silica gel (n-
hexane/EtOAc 3/1) to give 146b as a colorless solid (935 mg, 91%).  
M. p. = 245−247 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 10.93 (s, 1H), 7.43–7.27 (m, 3H), 7.12 (d, J = 2.2 Hz, 
1H), 7.10–6.96 (m, 3H), 7.00–6.90 (m, 2H), 6.81 (d, J = 8.5 Hz, 1H), 4.70–4.60 (m, 1H), 4.58–4.46 (m, 1H), 
3.78 (s, 3H), 3.75 (s, 3H), 1.44 (d, J = 6.0 Hz, 6H), 1.37 (d, J = 6.1 Hz, 6H).  
13
C NMR (75 MHz, CDCl3) δ = 
155.9 (Cq), 151.4 (Cq), 150.8 (Cq), 149.9 (Cq), 147.6 (Cq), 146.9 (Cq), 139.5 (Cq), 128.4 (Cq), 127.6 (Cq), 127.5 
(CH), 124.0 (CH), 123.6 (CH), 123.4 (Cq), 123.3 (CH), 120.2 (CH), 118.5 (Cq), 118.1 (Cq), 117.3 (CH), 116.0 
(CH), 115.9 (Cq), 114.7 (CH), 114.5 (CH), 111.4 (CH), 71.4 (CH), 71.1 (CH), 56.1 (CH3), 55.7 (CH3), 22.1 
(CH3), 22.1 (CH3). IR (neat): 3240, 2976, 1697, 1466, 1416, 1230, 1106, 772 cm
-1
. MS (EI) m/z (relative 
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intensity) 514 (20) [M+H
+
], 513 (40) [M
+
], 471 (10), 429 (100), 369 (10), 337 (10), 325 (10). HR-MS (EI) 
m/z calcd for C31H31NO6 [M
+




(148b): Under N2, 146b (514 mg, 1.0 mmol) and Cs2CO3 (2.11 g, 6.50 mmol) were placed into a 100 mL 
sealed tube. 2-Bromo-1,1-dimethoxyethane (147) (1.11 g, 6.60 mmol) and solvent DMF (15 mL) were added 
via cannula. The reaction mixture was stirred at 110 °C for 36 h. At ambient temperature, the mixture was 
diluted with EtOAc (200 mL) and washed with H2O (3×50 mL) and brine (50 mL). The organic phase was 
dried over Na2SO4 and concentrated. The residue was purified by column chromatography over silica gel (n-
hexane/EtOAc 6/1) to give 148b as a colorless solid (493 mg, 82%).  
M. p. = 169−170 ºC. 
 1
H NMR (600 MHz, CDCl3) δ = 7.48 (dd, J = 8.0, 1.6 Hz, 1H), 7.36 (dd, J = 8.3, 1.2 Hz, 
1H), 7.29–7.26 (m, 1H), 7.02–6.97 (m, 1H), 6.86–6.84 (m, 2H), 6.82 (d, J = 8.1 Hz, 1H), 6.79 (d, J = 8.1 Hz, 
1H), 6.77 (dd, J = 8.1, 2.0 Hz, 1H), 6.71 (d, J = 1.9 Hz, 1H), 4.85 (t, J = 5.5 Hz, 1H), 4.59–4.46 (m, 4H), 3.65 
(s, 3H), 3.64 (s, 3H), 3.31 (s, 6H), 1.40–1.27 (m, 12H). 
13
C NMR (125 MHz, CDCl3) δ = 155.2 (Cq), 151.3 
(Cq), 149.9 (Cq), 149.5 (Cq), 147.4 (Cq), 146.4 (Cq), 144.2 (Cq), 127.5 (CH), 127.0 (Cq), 127.0 (Cq), 123.8 (CH), 
123.6 (CH), 123.5 (CH), 123.3 (CH), 122.2 (Cq), 119.5 (Cq), 118.1 (Cq), 117.0 (CH), 115.4 (Cq), 115.3 (CH), 
115.3 (CH), 114.8 (CH), 114.5 (CH), 104.3 (CH), 71.3 (CH), 71.2 (CH), 55.9 (CH3), 55.8 (CH3), 55.4 (CH3), 
48.0 (CH2), 22.2 (CH3), 22.1 (CH3). IR (neat): 2975, 2934, 2833, 1706, 1462, 1439, 1255, 1050 cm
-1
. MS 
(ESI) m/z (relative intensity) 602 (30) [M+H
+
], 592 (40), 570 (100), 564 (10), 550 (5). HR-MS (ESI) m/z 
calcd for C35H40NO8 [M+H
+




a]isoquinolin-6-one (129d): Under N2, a solution of TfOH in CH2Cl2 (1.0 M, 1.0 mL, 1.0 mmol) was added 
dropwise to a solution of 148b (391 mg, 0.65 mmol) in CH2Cl2 (15 mL) within 10 min at 0 ºC. After stirring at 
0 ºC for 30 min, the mixture was warmed to 23 ºC and stirred for additional 1 h. NaHCO3 (819 mg, 9.75 mmol) 
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and EtOH (8.0 mL) were added sequentially. Then, the solvent was removed and the residue was dry-loaded 
on to silica gel and purified by column chromatography on silica gel (n-hexane/EtOAc 4/1) to yield 129d (318 
mg, 91%) as a colorless solid.  
M. p. = 177−178 ºC.
 1
H NMR (400 MHz, CDCl3) δ = 9.11 (d, J = 7.3 Hz, 1H), 7.35–7.28 (m, 1H), 7.31–7.23 
(m, 2H), 7.13–7.03 (m, 4H), 7.02 (s, 1H), 7.02–6.93 (m, 1H), 6.93 (d, J = 7.4 Hz, 1H), 4.69–4.59  (m, 2H), 
3.81 (s, 3H), 3.40 (s, 3H), 1.46 (d, J = 6.1 Hz, 3H), 1.41–1.37 (m, 9H). 
13
C NMR (100 MHz, CDCl3) δ = 
154.9 (Cq), 151.6 (Cq), 151.2 (Cq), 150.1 (Cq), 148.3 (Cq), 147.2 (Cq), 134.3 (Cq), 128.4 (Cq), 128.3 (Cq), 128.1 
(CH), 124.5 (Cq), 124.0 (CH), 123.6 (CH), 123.5 (CH), 122.8 (CH), 118.9 (Cq), 117.9 (Cq), 117.1 (CH), 116.4 
(CH), 114.7 (CH), 112.6 (CH), 112.0 (Cq), 110.3 (CH), 108.2 (Cq), 105.5 (CH), 71.3 (CH), 71.1 (CH), 56.0 
(CH3), 54.9 (CH3), 22.2 (CH3), 21.8 (CH3), 21.8 (CH3), 21.6 (CH3). IR (neat): 2976, 2933, 1701, 1473, 1398, 
1259, 1218, 1175, 745 cm
-1
. MS (ESI) m/z (relative intensity) 560 (20) [M+Na
+
], 538 (100) [M+H
+
], 478 (20), 
443 (10), 381 (20). HR-MS (ESI) m/z calcd for C33H32NO6 [M+H
+
] 538.2224, found 538.2234.  
 




Methyl 2-acetamidoacrylate (127) (472 mg, 3.30 mmol), 1,2-diphenylethyne (59c) (534 mg, 3.00 mmol), 
[RuCl2(p-cymene)]2 (46 mg, 2.5 mol %), AgSbF6 (103 mg, 10 mol %) and Cu(OAc)2·H2O (1.20 g, 6.0 mmol) 
were placed into a 100 mL sealed tube under a N2 atmosphere. A solvent mixture of MeOH/DCE (12 mL/6.0 
mL) was added via cannula. The reaction mixture was stirred at 110 °C for 24 h. At ambient temperature, the 
reaction mixture was dry-loaded onto silica gel and purified by column chromatography (n-hexane/EtOAc 
 Experimental Section  
130 
 
20/1) to afford the desired product 128b (740 mg, 89%) as a colorless solid and 128b´ (57 mg, 6%) as a pale 
yellow oil.  
 
Methyl 4,5-diphenyl-1H-pyrrole-2-carboxylate (128b):  
Clorless solid; M. p. = 169−170 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 9.55 (s, 1H), 7.44–7.36 (m, 2H), 7.35–
7.17 (m, 8H), 7.06 (d, J = 2.7 Hz, 1H), 3.83 (s, 3H).
 13
C NMR (75 MHz, CDCl3) δ = 161.8 (Cq), 135.3 (Cq), 
133.5 (Cq), 131.8 (Cq), 128.6 (CH), 128.4 (CH), 128.4 (CH), 128.0 (CH), 127.9 (CH), 126.3 (CH), 124.1 (Cq), 
122.0 (Cq), 116.8 (CH), 51.6 (CH3). IR (neat): 3258, 1669, 1440, 1226, 1203, 1009, 762, 692, 521 cm
-1
. MS 
(EI) m/z (relative intensity) 278 (20) [M+H
+
], 277 (100) [M
+
], 245 (80), 217 (70), 189 (40), 165 (10). HR-MS 
(EI) m/z calcd for C18H15NO2 [M
+
] 277.1103, found 277.1101. 




Methyl 1-acetyl-4,5-diphenyl-1H-pyrrole-2-carboxylate (128b´):  
Pale yellow oil; 
1
H NMR (300 MHz, CDCl3) δ = 7.42–7.28 (m, 5H), 7.25–7.11 (m, 6H), 3.88 (s, 3H), 2.32 (s, 
3H). 
13
C NMR (75 MHz, CDCl3) δ = 173.7 (Cq), 161.0 (Cq), 134.5 (Cq), 133.8 (Cq), 130.6 (Cq), 130.6 (CH), 
128.8 (CH), 128.5 (CH), 128.2 (CH), 127.9 (CH), 126.3 (CH), 124.7 (Cq), 122.9 (Cq), 118.2 (CH), 51.8 (CH3), 
28.8 (CH3). IR (neat): 3392, 1644, 1459, 1440, 1233, 1195, 759, 695 cm
-1
. MS (EI) m/z (relative intensity) 
320 (5) [M+H
+
], 319 (10) [M
+
], 277 (100), 245 (70), 217 (50), 189 (30). HR-MS (EI) m/z calcd for 
C20H17NO3 [M
+
] 319.1208, found 319.1214. 





Methyl 3-bromo-4,5-diphenyl-1H-pyrrole-2-carboxylate (144b): To a solution of 128b (693 mg, 2.50 
mmol) in DMF (30 mL), the solution of NBS (449 mg, 2.52 mmol) in DMF (5 mL) was added dropwise 
within 10 min at 0 °C under a N2 atmosphere. The reaction mixture was stirred at 0 °C for 1 h. Then, the 
mixture was diluted with EtOAc (200 mL) and washed with H2O (3×60 mL) and brine (60 mL). The organic 
phase was dried over Na2SO4 and concentrated. The residue was purified by column chromatography over 
silica gel (n-hexane/EtOAc 20/1) to give 144b (881 mg, 99%) as a colorless solid. 
M. p. = 190−191 ºC.
 1
H NMR (400 MHz, CDCl3) δ = 9.53 (s, 1H), 7.37–7.30 (m, 3H), 7.30–7.20 (m, 7H), 
3.89 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 160.9 (Cq), 133.5 (Cq), 133.3 (Cq), 130.8 (Cq), 130.7 (CH), 
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128.7 (CH), 128.3 (CH), 128.2 (CH), 127.5 (CH), 127.3 (CH), 125.1 (Cq), 119.8 (Cq), 106.0 (Cq), 51.8 (CH3). 
IR (neat): 3303, 1672, 1461, 1438, 1399, 1288, 1206, 774, 693, 537 cm
-1
. MS (EI) m/z (relative intensity) 355 
(80) [M
+









] 357.0187, found 357.0189. 
 
 
1,2-Diphenylchromeno[3,4-b]pyrrol-4(3H)-one (146c): Under N2, 144b (712 mg, 2.0 mmol), (2-
hydroxyphenyl)boronic acid (2b) (414 mg, 3.0 mmol), Pd2(dba)3 (91.6 mg, 5.0 mol %), dppf (111 mg, 10 
mol %) and Na2CO3 (1.40 g, 13.2 mmol) were placed into a 100 mL sealed tube. A solvent mixture of 
DME/H2O (30 mL/2.4 mL) was added via cannula. The reaction mixture was kept in the dark and stirred at 
110 °C for 36 h. After cooling to ambient temperature, the mixture was evaporated, and the residue was 
diluted with H2O (30 mL) and extracted with CH2Cl2 (4×30 mL). The extract was washed with brine (2×30 
mL), dried over Na2SO4, and evaporated. The residue was purified by column chromatography over silica gel 
(n-hexane/EtOAc 3/1) to give 146c as a colorless solid (526 mg, 78%).  
M. p. = 273−274 ºC.
 1
H NMR (400 MHz, CDCl3) δ = 10.27 (s, 1H), 7.51–7.38 (m, 6H), 7.37–7.25 (m, 7H), 
7.01 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H). 
13
C NMR (100 MHz, CDCl3) δ = 155.7 (Cq), 151.5 (Cq), 139.0 (Cq), 
134.3 (Cq), 131.0 (CH), 130.6 (Cq), 129.0 (CH), 128.8 (CH), 128.6 (CH), 127.9 (CH), 127.9 (Cq), 127.7 (CH), 
127.7 (CH), 124.0 (CH), 123.4 (CH), 119.1 (Cq), 118.3 (Cq), 117.5 (CH), 116.6 (Cq). IR (neat): 3231, 1692, 
1426, 1300, 1131, 977, 749, 703, 535 cm
-1
. MS (EI) m/z (relative intensity) 338 (80) [M+H
+
], 337 (100) [M
+
], 
322 (10), 308 (10), 291 (10), 280 (10). HR-MS (EI) m/z calcd for C23H15NO2 [M
+
] 337.1103, found 337.1097. 
 
 
3-(2,2-Dimethoxyethyl)-1,2-diphenylchromeno[3,4-b]pyrrol-4(3H)-one   (148c):    Under   N2,   146c   
(337 mg, 1.0 mmol) and Cs2CO3 (2.11 g, 6.5 mmol) were placed into a 100 mL sealed tube. 2-Bromo-1,1-
dimethoxyethane (147) (1.11 g, 6.6 mmol) and DMF (15 mL) were added via cannula. The reaction mixture 
was stirred at 110 °C for 36 h. At ambient temperature, the mixture was diluted with EtOAc (200 mL) and 
washed with H2O (3×50 mL) and brine (50 mL). The organic phase was dried over Na2SO4 and concentrated. 
The residue was purified by column chromatography over silica gel (n-hexane/EtOAc 6/1) to give 148c (264 
mg, 62%) as a colorless solid.  
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M. p. = 146−148 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 7.38 (ddd, J = 8.3, 1.4, 0.5 Hz, 1H), 7.36–7.30 (m, 2H), 
7.29–7.22 (m, 10H), 6.97 (ddd, J = 7.9, 7.2, 1.3 Hz, 1H), 4.75 (t, J = 5.5 Hz, 1H), 4.51 (d, J = 5.5 Hz, 2H), 
3.27 (s, 6H). 
13
C NMR (75 MHz, CDCl3) δ = 155.4 (Cq), 151.4 (Cq), 144.2 (Cq), 134.2 (Cq), 131.3 (CH), 
131.0 (CH), 129.8 (Cq), 128.6 (CH), 128.3 (CH), 128.2 (CH), 127.6 (CH), 127.3 (CH), 127.1 (Cq), 123.7 (CH), 
123.5 (CH), 120.0 (Cq), 118.1 (Cq), 117.1 (CH), 115.8 (Cq), 104.3 (CH), 55.3 (CH3), 47.9 (CH2). IR (neat): 
3060, 2927, 2838, 1713, 1607, 1454, 1074, 1048, 706 cm
-1
. MS (EI) m/z (relative intensity) 425 (20) [M
+
], 
410 (5), 394 (10), 364 (20), 337 (10), 320 (10), 75 (100). HR-MS (EI) m/z calcd for C27H23NO4 [M
+
] 
425.1627, found 425.1636. 
 
 
14-Phenyl-6H-chromeno[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one (129e): Following a modified 
procedure,
[11a]
 148c (44 mg, 0.10 mmol) was placed into a 25 mL sealed tube under a N2 atmosphere. A 
solvent mixture of CF3COOH/(CF3CO)2O (3.0 mL/1.0 mL) was added via cannula. The mixture was stirred at 
75 °C for 48 h. At ambient temperature, the excess anhydride and acid were removed by evaporation. NEt3 
(0.50 mL) was added and this mixture was dry-loaded onto silica gel and purified by column chromatography 
over silica gel (n-hexane/EtOAc 20/1) to give 129e (24 mg, 64%) as a colorless solid.  
M. p. ˃ 300 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 9.36 (d, J = 7.4 Hz, 1H), 7.72–7.69 (m, 1H), 7.67–7.62 (m, 
3H), 7.59–7.54 (m, 2H), 7.53–7.42 (m, 3H), 7.34 (ddd, J = 8.4, 7.1, 1.7 Hz, 1H), 7.25 (ddd, J = 8.5, 7.3, 1.3 
Hz, 1H), 7.14 (d, J = 7.4 Hz, 1H), 7.11 (ddd, J = 7.9, 1.7, 0.5 Hz, 1H), 7.00 (ddd, J = 8.1, 7.1, 1.4 Hz, 1H). 
13
C 
NMR (75 MHz, CDCl3) δ = 155.3 (Cq), 151.7 (Cq), 135.6 (Cq), 134.1 (Cq), 131.0 (CH), 129.9 (CH), 129.7 
(Cq), 128.7 (CH), 128.4 (CH), 128.2 (CH), 127.5 (CH), 127.3 (CH), 125.0 (Cq), 124.5 (CH), 124.4 (CH), 
124.1 (CH), 123.9 (CH), 117.9 (Cq), 117.4 (CH), 114.3 (Cq), 113.5 (CH), 109.4 (Cq). IR (neat): 3059, 3046, 
1426, 1701, 1409, 1368, 1178, 1048, 788 cm
-1
. MS (EI) m/z (relative intensity) 362 (30) [M+H
+
], 361 (100) 
[M
+
], 337 (10), 315 (10), 304 (10), 276 (5). HR-MS (EI) m/z calcd for C25H15NO2 [M
+
] 361.1103, found 
361.1092. 
The analytical data are in accordance with those previously reported in the literature.
[122b, 122g] 
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5.3.4 Cobalt-Catalyzed C–H Functionalizations by Imidate Assistance with Aryl and Alkyl Chlorides 
 
 
2-(4'-Methoxy-4-methyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole (131aa): The general procedure D was 
followed using oxazoline 130a (80.6 mg, 0.50 mmol) and aryl chloride 8a (92.7 mg, 0.65 mmol). Purification 
by column chromatography on silica gel (n-hexane/EtOAc 5:1) yielded 131aa (105.6 mg, 79%) as a colorless 
oil.  
1
H NMR (500 MHz, CDCl3) δ = 7.55 (s, 1H), 7.27 (d, J = 8.7 Hz, 2H), 7.26–7.22 (m, 2H), 6.89 (d, J = 8.7 Hz, 
2H), 4.12 (t, J = 9.6 Hz, 2H), 3.90 (t, J = 9.6 Hz, 2H), 3.82 (s, 3H), 2.37 (s, 3H). 
13
C NMR (125 MHz, CDCl3) 
δ = 166.3 (Cq), 158.6 (Cq), 138.5 (Cq), 136.4 (Cq), 133.6 (Cq), 131.2 (CH), 130.6 (CH), 130.1 (CH), 129.3 
(CH), 127.1 (Cq), 113.4 (CH), 67.8 (CH2), 55.2 (CH3), 54.9 (CH2), 20.9 (CH3). IR (ATR): 2934, 2835, 1647, 
1608, 1487, 1424, 1176, 819, 538 cm
-1
. MS (EI) m/z (relative intensity) 268 (10) [M+H
+
], 267 (40) [M
+
], 266 
(100), 251 (15), 222 (20). HR-MS (ESI) m/z calcd for C17H18NO2 [M+H
+
] 268.1332, found 268.1338.  





2-(4,4'-Dimethyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole (131ab): The general procedure D was followed 
using oxazoline 130a (80.6 mg, 0.50 mmol), aryl chloride 8b (82.3 mg, 0.65 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc 8:1) yielded 131ab (89.2 mg, 71%) as a colorless oil.  
1
H NMR (500 MHz, CDCl3) δ = 7.58–7.54 (m, 1H), 7.29–7.25 (m, 2H), 7.24 (d, J = 7.8 Hz, 2H), 7.16 (d, J = 
7.8 Hz, 2H), 4.12 (td, J = 9.5, 0.8 Hz, 2H), 3.90 (td, J = 9.5, 0.8 Hz, 2H), 2.38 (s, 3H), 2.36 (s, 3H). 
13
C NMR 
(125 MHz, CDCl3) δ = 166.3 (Cq), 138.8 (Cq), 138.2 (Cq), 136.6 (Cq), 136.5 (Cq), 131.2 (CH), 130.6 (CH), 
130.2 (CH), 128.6 (CH), 128.1 (CH), 127.1 (Cq), 67.8 (CH2), 55.0 (CH2), 21.2 (CH3), 20.9 (CH3). IR (ATR): 
2921, 2874, 1647, 1325, 1198, 975 cm
-1
. MS (EI) m/z (relative intensity) 252 (5) [M+H
+
], 251 (40) [M
+
], 250 
(100), 206 (40), 191 (15). HR-MS (EI) m/z calcd for C17H16NO [M-H]
+








2'-(4,5-Dihydrooxazol-2-yl)-N,N,4'-trimethyl-[1,1'-biphenyl]-4-amine (131ac): The general procedure D 
was followed using oxazoline 130a (80.6 mg, 0.50 mmol), aryl chloride 8c (101.1 mg, 0.65 mmol). 
Purification by column chromatography on silica gel (n-hexane/EtOAc 5:1) yielded 131ac (103.7 mg, 74%) as 
a colorless solid. 
M. p. = 126−127 °C. 
1
H NMR (500 MHz, CDCl3) δ = 7.52 (dd, J = 1.6, 0.8 Hz, 1H), 7.28–7.22 (m, 4H), 6.73 
(d, J = 8.9 Hz 2H), 4.15 (td, J = 9.5, 0.8 Hz, 2H), 3.92 (td, J = 9.5, 0.8 Hz, 2H), 2.96 (s, 6H), 2.36 (s, 3H). 
13
C 
NMR (125 MHz, CDCl3) δ = 166.8 (Cq), 149.5 (Cq), 138.9 (Cq), 135.7 (Cq), 131.1 (CH), 130.6 (CH), 130.0 
(CH), 129.1 (Cq), 128.9 (CH), 126.9 (Cq), 112.1 (CH), 67.9 (CH2), 54.9 (CH2), 40.6 (CH3), 20.9 (CH3). IR 
(ATR): 2876, 1651, 1608, 1530, 1488, 1358, 1193, 945, 808 cm
-1
. MS (EI) m/z (relative intensity) 281 (5) 
[M+H
+
], 280 (50) [M
+
], 279 (100), 263 (10), 235 (30). HR-MS (EI) m/z calcd for C18H19N2O [M-H]
+
 
279.1497, found 279.1487. 
 
 
2-{4'[-Methoxymethoxy]-4-methyl-[1,1'-biphenyl]-2-yl}-4,5-dihydrooxazole (131ad): The general 
procedure D was followed using oxazoline 130a (80.6 mg, 0.50 mmol), aryl chloride 8d (112.2 mg, 0.65 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 5:1) yielded 131ad (107.0 mg, 
72%) as a colorless solid.  
M. p. = 63−64 °C. 
1
H NMR (500 MHz, CDCl3) δ = 7.55 (d, J = 1.8 Hz, 1H), 7.27 (d, J = 8.8 Hz, 2H), 7.25–
7.22 (m, 2H), 7.02 (d, J = 8.8 Hz, 2H), 5.18 (s, 2H), 4.12 (td, J = 9.5, 0.8 Hz, 2H), 3.90 (td, J = 9.5, 0.8 Hz, 
2H), 3.48 (s, 3H), 2.37 (s, 3H).
 13
C NMR (125 MHz, CDCl3) δ = 166.2 (Cq), 156.3 (Cq), 138.3 (Cq), 136.5 (Cq), 
134.8 (Cq), 131.1 (CH), 130.6 (CH), 130.1 (CH), 129.3 (CH), 127.1 (Cq), 115.7 (CH), 94.5 (CH2), 67.8 (CH2), 
56.0 (CH3), 54.9 (CH2), 20.9 (CH3). IR (ATR): 2899, 1644, 1606, 1515, 1483, 1231, 1196, 1076, 827 cm
-1
. 
MS (EI) m/z (relative intensity) 298 (5) [M+H
+
], 297 (20) [M
+
], 296 (100), 266 (10), 252 (40). HR-MS (EI) 
m/z calcd for C18H18NO3 [M-H]
+








2-(4'-[{tert-Butyldimethylsilyl}oxy]-4-methyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole (131ae): The 
general procedure D was followed using oxazoline 130a (80.6 mg, 0.50 mmol), aryl chloride 8e (157.8 mg, 
0.65 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 5:1) yielded 131ae (104.7 
mg, 57%) as a colorless solid.  
M. p. = 97−98 °C. 
 1
H NMR (500 MHz, CDCl3) δ = 7.53 (dd, J = 1.4, 0.7 Hz, 1H), 7.31–7.23 (m, 2H), 7.20 (d, 
J = 8.7 Hz, 2H),6.82 (d, J = 8.7 Hz, 2H), 4.09 (td, J = 9.4, 0.9 Hz, 2H), 3.89 (td, J = 9.4, 0.9 Hz, 2H), 2.37 (s, 
3H), 0.98 (s, 9H), 0.20 (s, 6H). 
13
C NMR (125 MHz, CDCl3) δ = 166.4 (Cq), 154.7 (Cq), 138.6 (Cq), 136.4 
(Cq), 134.2 (Cq), 131.1 (CH), 130.5 (CH), 130.0 (CH), 129.2 (CH), 127.2 (Cq), 119.5 (CH), 67.7 (CH2), 54.9 
(CH2), 25.8 (CH3), 20.9 (CH3), 18.3 (Cq), -4.3 (CH3). IR (ATR): 2951, 2928, 1605, 1519, 1257, 913, 830, 776 
cm
-1
. MS (EI) m/z (relative intensity) 368 (5) [M+H
+
], 367 (25) [M
+
], 366 (100), 310 (10), 266 (10). HR-MS 
(EI) m/z calcd for C22H28NO2Si [M-H]
+
 366.1889, found 366.1880. 
 
 
2-(4-Methyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole (130af): The general procedure D was followed using 
oxazoline 130a (80.6 mg, 0.50 mmol), aryl chloride 8f (73.2 mg, 0.65 mmol) and ICyHCl (149i) (6.8 mg, 5.0 
mol %). Purification by column chromatography on silica gel (n-hexane/EtOAc 5:1) yielded 131af (79.5 mg, 
67%) as a colorless oil.  
1
H NMR (500 MHz, CDCl3) δ = 7.61–7.56 (m, 1H), 7.39–7.31 (m, 4H), 7.33–7.23 (m, 3H), 4.09 (td, J = 9.4, 
0.9 Hz, 2H), 3.89 (td, J = 9.5, 0.9 Hz, 2H), 2.39 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ = 166.1 (Cq), 141.1 
(Cq), 138.9 (Cq), 136.8 (Cq), 131.2 (CH), 130.6 (CH), 130.2 (CH), 128.2 (CH), 127.8 (CH), 127.2 (Cq), 126.8 
(CH), 67.8 (CH2), 55.0 (CH2), 20.9 (CH3). IR (ATR): 3025, 2877, 1647, 1480, 1192, 1081, 976, 700, 534 cm
-1
. 
MS (EI) m/z (relative intensity) 238 (5) [M+H
+
], 237 (40) [M
+
], 236 (100), 192 (50), 178 (20). HR-MS (EI) 
m/z calcd for C16H14NO [M-H]
+
 236.1075, found 236.1077. 










2-(3',4-Dimethyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole (131ag): The general procedure D was followed 
using oxazoline 130a (80.6 mg, 0.50 mmol), aryl chloride 8g (82.3 mg, 0.65 mmol) and ICyHCl (149i) (6.8 
mg, 5.0 mol %). Purification by column chromatography on silica gel (n-hexane/EtOAc 5:1) yielded 131ag 
(96.7 mg, 77%) as a colorless oil.  
1
H NMR (500 MHz, CDCl3) δ = 7.56 (dd, J = 1.6, 0.8 Hz, 1H), 7.29–7.26 (m, 2H), 7.26–7.21 (m, 1H), 7.18 
(dd, J = 1.6, 0.8 Hz, 1H), 7.16–7.13 (m, 1H), 7.11 (ddd, J = 7.5, 1.6, 0.8 Hz, 1H), 4.10 (td, J = 9.4, 0.9 Hz, 
2H), 3.90 (td, J = 9.4, 0.9 Hz, 2H), 2.38 (s, 3H), 2.37 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 166.4 (Cq), 
141.1 (Cq), 139.0 (Cq), 137.5 (Cq), 136.8 (Cq), 131.2 (CH), 130.6 (CH), 130.2 (CH), 129.0 (CH), 127.8 (CH), 
127.7 (CH), 127.2 (Cq), 125.4 (CH), 67.8 (CH2), 54.9 (CH2), 21.5 (CH3), 20.8 (CH3). IR (ATR): 2922, 2876, 
1648, 1348, 1270, 1196, 976, 786 cm
-1
. MS (EI) m/z (relative intensity) 251 (20) [M
+
], 250 (100) [M-H]
+
, 236 
(10), 206 (30), 191 (10). HR-MS (EI) m/z calcd for C17H16NO [M-H]
+
 250.1232, found 250.1235. 
 
 
2-(3'-Methoxy-4-methyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole (131ah): The general procedure D was 
followed using oxazoline 130a (80.6 mg, 0.50 mmol), aryl chloride 8h (92.7 mg, 0.65 mmol) and ICyHCl 
(149i) (6.8 mg, 5.0 mol %). Purification by column chromatography on silica gel (n-hexane/EtOAc 5:1) 
yielded 131ah (96.2 mg, 72%) as a colorless oil.  
1
H NMR (400 MHz, CDCl3) δ = 7.56 (dd, J = 1.5, 0.7 Hz, 1H), 7.30–7.25 (m, 3H), 6.95–6.89 (m, 2H), 6.85 
(ddd, J = 8.2, 2.6, 1.0 Hz, 1H), 4.11 (td, J = 9.6, 1.0 Hz, 2H), 3.90 (td, J = 9.6, 1.0 Hz, 2H), 3.80 (s, 3H), 2.38 
(s, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 166.3 (Cq), 159.3 (Cq), 142.6 (Cq), 138.8 (Cq), 137.0 (Cq), 131.2 
(CH), 130.6 (CH), 130.2 (CH), 128.9 (CH), 127.3 (Cq), 120.9 (CH), 113.8 (CH), 112.7 (CH), 67.9 (CH2), 55.2 
(CH3), 55.0 (CH2), 20.8 (CH3). IR (ATR): 2936, 1649, 1581, 1476, 1211, 1046, 948, 782, 698 cm
-1
. MS (EI) 
m/z (relative intensity) 267 (30) [M
+
], 266 (100) [M-H]
+
, 251 (10), 236 (15), 222 (20). HR-MS (EI) m/z calcd 
for C17H16NO2 [M-H
+








2-(2'-Methoxy-4-methyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole (131ai): The general procedure D was 
followed using oxazoline 130a (80.6 mg, 0.50 mmol) and aryl chloride 8i (92.7 mg, 0.65 mmol). Purification 
by column chromatography on silica gel (n-hexane/EtOAc 5:1) yielded 131ai (102.9 mg, 77%) as a colorless 
oil.  
1
H NMR (500 MHz, CDCl3) δ = 7.67 (dd, J = 1.9, 0.6 Hz, 1H), 7.31–7.26 (m, 2H), 7.21 (d, J = 7.4 Hz, 1H), 
7.20 (d, J = 7.4 Hz, 1H), 6.99 (ddd, J = 7.4, 1.1, 1.1 Hz, 1H), 6.87 (dd, J = 8.2, 1.1 Hz, 1H), 4.09 (dt, J = 9.5, 
0.8 Hz, 2H), 3.85 (t, J = 9.5 Hz, 2H), 3.71 (s, 3H), 2.38 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ = 166.0 (Cq), 
156.3 (Cq), 136.7 (Cq), 135.3 (Cq), 131.1 (CH), 131.1 (CH), 130.6 (Cq), 130.1 (CH), 129.9 (CH), 128.4 (CH), 
128.0 (Cq), 120.4 (CH), 110.1 (CH), 67.5 (CH2), 55.3 (CH3), 54.8 (CH2), 21.0 (CH3). IR (ATR): 2934, 2833, 
1645, 1483, 1242, 1050, 1003, 750 cm
-1
. MS (EI) m/z (relative intensity) 266 (5) [M-H]
+
, 250 (5), 236 (100), 
192 (30), 165 (20). HR-MS (ESI) m/z calcd for C17H18NO2 [M+H
+
] 268.1332, found 268.1334.  
 
 
2-(2',4-Dimethyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole (131aj): The general procedure D was followed 
using oxazoline 130a (80.5 mg, 0.50 mmol), aryl chloride 8j (82.3 mg, 0.65 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc 5:1) yielded 131aj (100.5 mg, 80%) as a colorless oil.  
1
H NMR (500 MHz, CDCl3) δ = 7.69 (d, J = 1.9 Hz, 1H), 7.27 (ddd, J = 7.8, 1.9, 0.8 Hz, 1H), 7.24–7.12 (m, 
3H), 7.13–7.07 (m, 2H), 4.10–3.92 (m, 2H), 3.81 (t, J = 9.0 Hz, 2H), 2.40 (s, 3H), 2.08 (s, 3H). 
13
C NMR 
(125 MHz, CDCl3) δ = 165.7 (Cq), 141.2 (Cq), 138.7 (Cq), 136.6 (Cq), 135.6 (Cq), 130.9 (CH), 130.4 (CH), 
130.1 (CH), 129.2 (CH), 128.9 (CH), 127.5 (Cq), 126.9 (CH), 124.9 (CH), 67.6 (CH2), 54.8 (CH2), 21.0 (CH3), 
20.1 (CH3). IR (ATR): 3019, 2923, 2875, 1645, 1479, 1191, 1080, 977, 755 cm
-1
. MS (EI) m/z (relative 
intensity) 250 (5) [M-H]
+
, 237 (20), 236 (100), 192 (30), 165 (20). HR-MS (ESI) m/z calcd for C17H18NO 
[M+H
+
] 252.1383, found 252.1386. 
 
 
2-(2',4,5'-Trimethyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole (131ak): The general procedure D was 
followed using oxazoline 130a (80.5 mg, 0.50 mmol) and aryl chloride 8k (91.4 mg, 0.65 mmol). Purification 
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by column chromatography on silica gel (n-hexane/EtOAc 5:1) yielded 131ak (98.2 mg, 74%) as a colorless 
oil.  
1
H NMR (500 MHz, CDCl3) δ = 7.68 (d, J = 1.8 Hz, 1H), 7.26 (dd, J = 7.8, 1.2 Hz, 1H), 7.10 (d, J = 7.8 Hz, 
1H), 7.06 (d, J = 7.7 Hz, 1H), 7.01 (dd, J = 7.7, 1.8 Hz, 1H), 6.93 (s, 1H), 4.10–3.96 (m, 2H), 3.82 (t, J = 9.6 
Hz, 2H), 2.39 (s, 3H), 2.30 (s, 3H), 2.04 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ = 165.8 (Cq), 141.0 (Cq), 
138.9 (Cq), 136.5 (Cq), 134.2 (Cq), 132.5 (Cq), 130.9 (CH), 130.5 (CH), 130.0 (CH), 129.6 (CH), 129.1 (CH), 
127.6 (CH), 127.5 (Cq), 67.6 (CH2), 54.8 (CH2), 21.0 (CH3), 21.0 (CH3), 19.6 (CH3). IR (ATR): 2920, 1645, 
1347, 1195, 1080, 977, 826 cm
-1
. MS (EI) m/z (relative intensity) 264 (5) [M-H]
+
, 251 (20), 250 (100), 206 
(30), 191 (20), 178 (20). HR-MS (ESI) m/z calcd for C18H20NO [M+H
+
] 266.1539, found 266.1543.  
 
 
2-(3',4,4'-Trimethyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole (131al): The general procedure D was 
followed using oxazoline 130a (80.6 mg, 0.50 mmol) and aryl chloride 8l (91.4 mg, 0.65 mmol). Purification 
by column chromatography on silica gel (n-hexane/EtOAc 5:1) yielded 131al (86.2 mg, 65%) as a colorless 
oil.  
1
H NMR (300 MHz, CDCl3) δ = 7.70 (d, J = 0.5 Hz, 1H), 7.28 (d, J = 8.3 Hz, 1H), 7.16–6.99 (m, 3H), 6.95 (s, 
1H), 4.15–3.95 (m, 2H), 3.84 (t, J = 9.0 Hz, 2H), 2.41 (s, 3H), 2.32 (s, 3H), 2.05 (s, 3H). 
13
C NMR (75 MHz, 
CDCl3) δ = 165.9 (Cq), 141.1 (Cq), 139.0 (Cq), 136.6 (Cq), 134.3 (Cq), 132.5 (Cq), 131.0 (CH), 130.6 (CH), 
130.1 (CH), 129.7 (CH), 129.2 (CH), 127.6 (CH), 127.6 (Cq), 67.6 (CH2), 54.8 (CH2), 20.9 (CH3), 20.9 (CH3), 
19.5 (CH3). IR (ATR): 2920, 1645, 1489, 1348, 1196, 1080, 977, 826 cm
-1
. MS (EI) m/z (relative intensity) 
264 (5) [M-H]
+
, 251 (20), 250 (100), 206 (30), 191 (10), 179 (20). HR-MS (ESI) m/z calcd for C18H20NO 
[M+H
+
] 266.1539, found 266.1542. 
 
 
2-(3',5'-Dimethoxy-4-methyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole (131am): The general procedure D 
was followed using oxazoline 130a (80.6 mg, 0.50 mmol), aryl chloride 8m (112.2 mg, 0.65 mmol) and 
ICyHCl (149i) (6.8 mg, 5.0 mol %). Purification by column chromatography on silica gel (n-hexane/EtOAc 
5:1) yielded 131am (98.1 mg, 66%) as a colorless oil.  
1
H NMR (300 MHz, CDCl3) δ = 7.56 (s, 1H), 7.29 (d, J = 1.2 Hz, 2H), 6.54 (dd, J = 2.2, 2.2 Hz, 2H), 6.43 (t, 
J = 2.2 Hz, 1H), 4.16 (td, J = 9.2, 1.3 Hz, 2H), 3.93 (td, J = 9.2, 1.3 Hz, 2H), 3.79 (s, 6H), 2.39 (s, 3H). 
13
C 
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NMR (75 MHz, CDCl3) δ = 166.3 (Cq), 160.3 (Cq), 143.2 (Cq), 138.8 (Cq), 137.1 (Cq), 131.2 (CH), 130.6 
(CH), 130.0 (CH), 127.3 (Cq), 106.4 (CH), 99.4 (CH), 67.9 (CH2), 55.3 (CH3), 55.0 (CH2), 20.8 (CH3). IR 
(ATR): 2935, 2836, 1590, 1453, 1422, 1201, 1150, 1062, 818, 690 cm
-1
. MS (EI) m/z (relative intensity) 297 
(30) [M
+
], 296 (100) [M-H]
+
, 282 (20), 266 (100), 252 (30), 238 (10), 210 (10). HR-MS (ESI) m/z calcd for 
C18H20NO3 [M+H
+
] 298.1438, found 298.1440. 
 
2-(3'-Fluoro-2',4-dimethyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole (131an): The general procedure D was 
followed using oxazoline 130a (80.6 mg, 0.50 mmol), aryl chloride 8n (94.0 mg, 0.65 mmol) and ICyHCl 
(149i) (6.8 mg, 5.0 mol %). Purification by column chromatography on silica gel (n-hexane/EtOAc 5:1) 
yielded 131an (68.7 mg, 51%) as a colorless oil.  
1
H NMR (300 MHz, CDCl3) δ = 7.70 (dd, J = 1.3, 0.7 Hz, 1H), 7.27 (ddd, J = 7.8, 1.9, 0.7 Hz, 1H), 7.16–7.05 
(m, 2H), 6.96 (ddd, J = 9.6, 8.2, 1.3 Hz, 1H), 6.89 (dd, J = 7.5, 1.3 Hz, 1H), 4.13–3.93 (m, 2H), 3.82 (t, J = 9.3 
Hz, 2H), 2.40 (s, 3H), 1.98 (d, J = 2.4 Hz, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 165.5 (Cq), 161.0 (d, 
1
JC-F = 
243.0 Hz, Cq), 143.7 (d, 
3
JC-F = 4.7 Hz, Cq), 137.4 (d, 
4
JC-F = 2.9 Hz, Cq), 137.2 (Cq), 131.1 (CH), 130.5 (CH), 
130.2 (CH), 127.6 (Cq), 125.8 (d, 
3
JC-F = 9.1 Hz, CH), 124.7 (d, 
4
JC-F = 3.1 Hz, CH), 123.2 (d, 
2
JC-F = 16.8 Hz, 
Cq), 113.5 (d, 
2
JC-F = 23.0 Hz, CH), 67.7 (CH2), 54.9 (CH2), 20.9 (CH3), 11.8 (d, 
3
JC-F = 4.7 Hz, CH3). 
19
F 
NMR (376 MHz, CDCl3): δ = -117.1 (m). IR (ATR): 2928, 1648, 1457, 1236, 1111, 1071, 977, 786 cm
-1
. MS 
(EI) m/z (relative intensity) 268 (5) [M-H]
+
, 255 (20), 254 (100), 210 (30), 196 (10), 183 (20). HR-MS (EI) 
m/z calcd for C17H15FNO [M-H]
+
 268.1138, found 268.1141. 
 
 
2-(2-{Benzo[d][1,3]dioxol-5-yl}-5-methylphenyl)-4,5-dihydrooxazole (3ao): The general procedure D was 
followed using oxazoline 130a (80.6 mg, 0.50 mmol) and aryl chloride 8o (101.8 mg, 0.65 mmol). 
Purification by column chromatography on silica gel (n-hexane/EtOAc 4:1) yielded 131ao (59.1 mg, 42%) as 
a colorless oil.  
1
H NMR (400 MHz, CDCl3) δ = 7.54 (dd, J = 1.6, 0.9 Hz, 1H), 7.27–7.23 (m, 1H), 7.21 (d, J = 7.8 Hz, 1H), 
6.84 (dd, J = 1.1 Hz, 1.1 Hz, 1H), 6.80 (d, J = 1.1 Hz, 2H), 5.96 (s, 2H), 4.15 (td, J = 9.5, 0.9 Hz, 2H), 3.91 (td, 
J = 9.5, 0.9 Hz, 2H), 2.37 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 166.2 (Cq), 147.3 (Cq), 146.7 (Cq), 138.5 
(Cq), 136.7 (Cq), 135.2 (Cq), 131.2 (CH), 130.7 (CH), 130.2 (CH), 127.2 (Cq), 121.7 (CH), 108.9 (CH), 107.9 
(CH), 101.0 (CH2), 67.8 (CH2), 54.9 (CH2), 20.8 (CH3). IR (ATR): 2878, 1648, 1475, 1336, 1218, 1034, 933, 





. MS (EI) m/z (relative intensity) 281 (30) [M
+
], 280 (100) [M-H]
+
, 237 (5), 236 (30), 223 (10), 
152 (20). HR-MS (ESI) m/z calcd for C17H15NO3Na [M+Na
+
] 304.0944, found 304.0943. 
 
 
2-(4'-Methoxy-3-methyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole (131ba): The general procedure D was 
followed using oxazoline 130b (80.6 mg, 0.50 mmol) and aryl chloride 8a (92.7 mg, 0.65 mmol). Purification 
by column chromatography on silica gel (n-hexane/EtOAc 8:1) yielded 131ba (97.6 mg, 73%) as a colorless 
oil.  
1
H NMR (500 MHz, CDCl3) δ = 7.35–7.31 (m, 2H), 7.30 (d, J = 7.7 Hz, 1H), 7.17 (d, J = 7.5 Hz, 2H), 6.89 (d, 
J = 7.7 Hz, 2H), 4.14 (t, J = 9.5 Hz, 2H), 3.86 (t, J = 9.5 Hz, 2H), 3.81 (s, 3H), 2.39 (s, 3H). 
13
C NMR (125 
MHz, CDCl3) δ = 164.4 (Cq), 158.7 (Cq), 141.5 (Cq), 137.3 (Cq), 133.6 (Cq), 129.4 (CH), 129.3 (CH), 128.5 
(CH), 128.0 (Cq), 127.1 (CH), 113.4 (CH), 67.2 (CH2), 55.2 (CH3), 55.1 (CH2), 19.9 (CH3). IR (ATR): 2957, 
1666, 1515, 1041 cm
-1
. MS (EI) m/z (relative intensity) 267 (30) [M
+
], 266 (100) [M-H]
+
, 251 (10), 222 (15), 
195 (10), 165 (10). HR-MS (ESI) m/z calcd for C17H18NO2 [M+H
+
] 268.1332, found 268.1335. 




2-(4'-Methoxy-4,5-dimethyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole (131ca): The general procedure D 
was followed using oxazoline 1c (87.6 mg, 0.50 mmol) and aryl chloride 8a (92.7 mg, 0.65 mmol). 
Purification by column chromatography on silica gel (n-hexane/EtOAc 5:1) yielded 131ca (101.3 mg, 72%) as 
a colorless oil.  
1
H NMR (300 MHz, CDCl3) δ = 7.53 (s, 1H), 7.27 (d, J = 8.7 Hz, 2H), 7.12 (s, 1H), 6.89 (d, J = 8.7 Hz, 2H), 
4.10 (td, J = 9.6, 1.3 Hz, 2H), 3.88 (td, J = 9.6, 1.3 Hz, 2H), 3.81 (s, 3H), 2.29 (s, 3H), 2.28 (s, 3H). 
13
C NMR 
(75 MHz, CDCl3) δ = 166.3 (Cq), 158.6 (Cq), 139.2 (Cq), 138.8 (Cq), 135.1 (Cq), 133.7 (Cq), 131.5 (CH), 131.2 
(CH), 129.3 (CH), 124.5 (Cq), 113.3 (CH), 67.6 (CH2), 55.1 (CH3), 54.8 (CH2), 19.6 (CH3), 19.0 (CH3). IR 
(ATR): 2936, 2834, 1646, 1608, 1490, 1242, 1176, 1031, 830 cm
-1
. MS (EI) m/z (relative intensity) 281 (20) 
[M
+
], 280 (100) [M-H]
+
, 265 (10), 236 (20), 223 (15), 165 (15). HR-MS (EI) m/z calcd for C18H18NO2 [M-H]
+
 
280.1338, found 280.1344. 
 




2-(4-Fluoro-4'-methoxy-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole (131da): The general procedure D was 
followed using oxazoline 130d (82.6 mg, 0.50 mmol) and aryl chloride 8a (92.7 mg, 0.65 mmol). Purification 
by column chromatography on silica gel (n-hexane/EtOAc 8:1) yielded 131da (95.0 mg, 70%) as a colorless 
oil.  
1
H NMR (300 MHz, CDCl3) δ = 7.52 (d, J = 7.1 Hz, 1H), 7.37–7.13 (m, 4H), 6.92 (d, J = 8.8 Hz, 2H), 4.07 (t, 
J = 9.4 Hz, 2H), 3.85 (t, J = 9.4 Hz, 2H), 3.81 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 164.9 (d, 
4
JC-F = 3.5 
Hz, Cq), 159.7 (d, 
1
JC-F = 245.2 Hz, Cq), 159.1 (Cq), 130.5 (d, 
5
JC-F = 1.6 Hz, CH), 130.4 (d, 
4
JC-F = 3.4 Hz, Cq), 
129.1 (d, 
3
JC-F = 17.3 Hz, Cq), 128.3 (d, 
2
JC-F = 8.8 Hz, CH), 126.1 (Cq), 125.6 (d, 
3
JC-F = 3.6 Hz, CH), 117.8 
(d, 
2
JC-F = 23.6 Hz, CH), 113.4 (CH), 67.9 (CH2), 55.2 (CH3), 54.9 (CH2). 
19
F NMR (376 MHz, CDCl3): δ = -
115.40 (dd, J = 9.4, 5.1 Hz). IR (ATR): 2935, 2836, 1517, 1452, 1242, 1177, 1035, 978, 830, 747 cm
-1
. MS 
(EI) m/z (relative intensity) 271 (20) [M
+
], 270 (100) [M-H]
+
, 255 (10), 226 (20), 170 (15), 157 (10). HR-MS 
(ESI) m/z calcd for C16H15FNO2 [M+H
+
] 272.1081, found 272.1084. 
 
 
2-(4'-Methoxy-4-methyl-[1,1'-biphenyl]-2-yl)-5-methyl-4,5-dihydrooxazole (131ea): The general 
procedure was followed using oxazoline 130e (87.6 mg, 0.50 mmol) and aryl chloride 8a (92.7 mg, 0.65 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 5:1) yielded 131ea (113.9 mg, 
81%) as a colorless oil.  
1
H NMR (300 MHz, CDCl3) δ = 7.53 (d, J = 0.8 Hz, 1H), 7.33–7.19 (m, 4H), 6.89 (d, J = 8.8 Hz, 2H), 4.56 
(tdd, J = 9.5, 7.4, 6.2 Hz, 1H), 3.99 (dd, J = 14.3, 9.5 Hz, 1H), 3.80 (s, 3H), 3.45 (dd, J = 14.3, 7.4 Hz, 1H), 
2.37 (s, 3H), 1.14 (d, J = 6.2 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 165.4 (Cq), 158.6 (Cq), 138.4 (Cq), 
136.3 (Cq), 133.5 (Cq), 130.9 (CH), 130.4 (CH), 130.1 (CH), 129.5 (CH), 127.5 (Cq), 113.2 (CH), 76.1 (CH), 
61.6 (CH2), 55.1 (CH3), 20.7 (CH3), 20.7 (CH3). IR (ATR): 2931, 1609, 1519, 1243, 1176, 1035, 819, 540 cm
-
1
. MS (EI) m/z (relative intensity) 281 (30) [M
+
], 280 (100) [M-H]
+
, 239 (30), 222 (20), 209 (10), 196 (10). 
HR-MS (EI) m/z calcd for C18H18NO2 [M-H
+
] 280.1338, found 280.1341. 
 




4-Ethyl-2-(4'-methoxy-4-methyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole (131fa): The general procedure 
D was followed using oxazoline 130f (94.6 mg, 0.50 mmol), aryl chloride 8a (92.7 mg, 0.65 mmol) and 
ICyHCl (149i) (6.8 mg, 5.0 mol %). Purification by column chromatography on silica gel (n-hexane/EtOAc 
5:1) yielded 131fa (94.5 mg, 64%) as a colorless oil.  
1
H NMR (300 MHz, CDCl3) δ = 7.54 (dd, J = 1.6, 0.8 Hz, 1H), 7.33–7.19 (m, 4H), 6.89 (d, J = 8.8 Hz 2H), 
4.23–4.01 (m, 2H), 3.82 (s, 3H), 3.74 (d, J = 7.3 Hz, 1H), 2.37 (s, 3H), 1.79–1.42 (m, 2H), 0.94 (t, J = 7.4 Hz, 
3H). 
13
C NMR (75 MHz, CDCl3) δ = 165.5 (Cq), 158.7 (Cq), 138.4 (Cq), 136.4 (Cq), 133.6 (Cq), 131.1 (CH), 
130.7 (CH), 130.1 (CH), 129.4 (CH), 127.4 (Cq), 113.3 (CH), 72.4 (CH2), 67.8 (CH), 55.2 (CH3), 28.3 (CH2), 
20.8 (CH3), 10.0 (CH3). IR (ATR): 2961, 2835, 1609, 1487, 1243, 1176, 1036, 819, 542 cm
-1
. MS (EI) m/z 
(relative intensity) 295 (30) [M
+
], 294 (100) [M-H]
+
, 280 (10), 240 (20), 225 (10), 209 (10). HR-MS (EI) m/z 
calcd for C19H20NO2 [M-H]
+
 294.1494, found 294.1489. 
 
  
2-(4'-Methoxy-4-methyl-[1,1'-biphenyl]-2-yl)-5,6-dihydro-4H-1,3-oxazine (131ga): The general procedure 
D was followed using oxazine 130g (87.6 mg, 0.50 mmol) and aryl chloride 8a (92.7 mg, 0.65 mmol). 
Purification by column chromatography on silica gel (n-hexane/EtOAc 5:1) yielded 131ga (67.5 mg, 48%) as 
a colorless solid.  
M. p. = 113−114 °C. 
1
H NMR (400 MHz, CDCl3) δ = 7.37–7.31 (m, 3H), 7.19 (d, J = 1.0 Hz, 2H), 6.89 (d, J 
= 8.8 Hz, 2H), 3.90 (t, J = 5.5 Hz, 2H), 3.82 (s, 3H), 3.48 (t, J = 5.9 Hz, 2H), 2.35 (s, 3H), 1.82 (tt, J = 11.5, 
5.9 Hz, 2H).
 13
C NMR (100 MHz, CDCl3) δ = 158.9 (Cq), 158.5 (Cq), 137.3 (Cq), 136.4 (Cq), 134.2 (Cq), 134.2 
(Cq), 130.1 (CH), 129.8 (CH), 129.8 (CH), 129.3 (CH), 113.4 (CH), 65.0 (CH2), 55.2 (CH3), 42.8 (CH2), 21.6 
(CH2), 20.8 (CH3).  
IR (ATR): 3002, 2932, 2860, 1659, 1294, 1099, 823, 548 cm
-1





, 252 (40), 222 (40), 209 (10), 181 (10). HR-MS (ESI) m/z calcd for C18H20NO2 [M+H
+
] 
282.1489, found 282.1490. 
 




2-[2-(4-Methoxyphenyl)-1-methyl-1H-indol-3-yl]-4,5-dihydrooxazole (131ha): The general procedure D 
was followed using oxazoline 130h (100.1 mg, 0.50 mmol) and aryl chloride 8a (92.7 mg, 0.65 mmol). 
Purification by column chromatography on silica gel (n-hexane/EtOAc 4:1) yielded 131ha (61.3 mg, 40%) as 
a colorless solid.  
M. p. = 163−164 °C. 
1
H NMR (500 MHz, CDCl3) δ = 8.31 (d, J = 7.8 Hz, 1H), 7.36–7.31 (m, 3H), 7.31–7.24 
(m, 2H), 6.99 (d, J = 8.8 Hz, 2H), 4.13 (td, J = 9.2, 1.0 Hz, 2H), 3.95 (td, J = 9.2, 1.0 Hz, 2H), 3.87 (s, 3H), 
3.54 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ = 162.0 (Cq), 159.7 (Cq), 143.0 (Cq), 136.9 (Cq), 131.8 (CH), 
126.6 (Cq), 123.7 (Cq), 122.4 (CH), 121.7 (CH), 121.3 (CH), 113.2 (CH), 109.3 (CH), 102.1 (Cq), 66.2 (CH2), 
55.2 (CH3), 54.6 (CH2), 30.8 (CH3). IR (ATR): 2926, 2866, 2836, 1629, 1466, 1240, 1176, 1000, 760 cm
-1
. 
MS (EI) m/z (relative intensity) 306 (40) [M
+
], 305 (100) [M-H]
+
, 290 (10), 262 (20), 205 (10), 192 (10). HR-
MS (EI) m/z calcd for C19H17N2O2 [M-H]
+
 305.1290, found 305.1294.  
 
 
2-(2-Decyl-6-methylphenyl)-4,5-dihydrooxazole (150a): A suspension of   Co(acac)2 (12.9 mg, 10.0 mol %), 
ICy·HCl (149g) (13.4 mg, 10.0 mol %), oxazoline 130b (80.6 mg, 0.50 mmol), alkyl chloride 68a (114.9 mg, 
0.65 mmol), and DMPU (1.0 mL) was stirred for 5 min at 0 °C. A solution of CyMgCl (1.0 M, 1.0 mL, 2.0 
equiv) in 2-methyltetrahydrofuran was added dropwise at the same temperature. Then, the mixture was stirred 
at 60 °C for 16 h. At ambient temperature, aq. NH4Cl (2.0 mL) and H2O (15 mL) were added. The reaction 
mixture was extracted with MTBE (3 × 20 mL). The combined organic phase was washed with brine (20 mL) 
and dried over Na2SO4. Evaporation of the solvents in vacuo and purification of the remaining residue by 




H NMR (300 MHz, CDCl3) δ = 7.19 (dd, J = 7.6, 7.6 Hz, 1H), 7.04–7.00 (m, 2H), 4.37 (td, J = 9.5, 1.0 Hz, 
2H), 4.06 (td, J = 9.5, 1.0 Hz, 2H), 2.69–2.52 (m, 2H), 2.30 (s, 3H), 1.73–1.44 (m, 2H), 1.33–1.25 (m, 14H), 
0.99–0.78 (m, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 164.7 (Cq), 141.9 (Cq), 136.9 (Cq), 129.2 (CH), 128.6 (Cq), 
127.3 (CH), 126.4 (CH), 67.0 (CH2), 55.2 (CH2), 33.7 (CH2), 31.9 (CH2), 31.4 (CH2), 29.6 (CH2), 29.6 (CH2), 
29.5 (CH2), 29.4 (CH2), 29.3 (CH2), 22.6 (CH2), 19.6 (CH3), 14.1 (CH3). IR (ATR): 2922, 2853, 1661, 1464, 
1250, 1041, 938, 786 cm
-1
. MS (EI) m/z (relative intensity) 301 (40) [M
+
], 300 (5) [M-H]
+
, 259 (10), 244 (10), 
202 (10), 188 (100). HR-MS (EI) m/z calcd for C20H31NO [M
+
] 301.2406, found 301.2402. 
 




2-(2-Cyclohexyl-6-methylphenyl)-4,5-dihydrooxazole (150b): A suspension of   Co(acac)2 (12.9 mg, 10.0 
mol %), ICy·HCl (149g) (13.4 mg, 10.0 mol %), oxazoline 130b (80.6 mg, 0.50 mmol), alkyl chloride 68b 
(77.1 mg, 0.65 mmol), and DMPU (1.0 mL) was stirred for 5 min at 0 °C. A solution of CyMgCl (1.0 M, 1.0 
mL, 2.0 equiv) in 2-methyltetrahydrofuran was added dropwise at the same temperature. Then the mixture 
was stirred at 60 °C for 16 h. At ambient temperature, aq. NH4Cl (2.0 mL) and H2O (15 mL) were added. The 
reaction mixture was extracted with MTBE (3 × 20 mL). The combined organic phase was washed with brine 
(20 mL) and dried over Na2SO4. Evaporation of the solvents in vacuo and purification of the remaining 





H NMR (500 MHz, CDCl3) δ = 7.23 (dd, J = 7.7, 7.7 Hz, 1H), 7.12 (d, J = 7.7 Hz, 1H), 7.01 (d, J = 7.7 Hz, 
1H), 4.38 (t, J = 9.5 Hz, 2H), 4.07 (t, J = 9.5 Hz, 2H), 2.56 (tt, J = 11.6, 3.2 Hz, 1H), 2.29 (s, 3H), 1.90–1.76 
(m, 4H), 1.71 (dtt, J = 12.3, 3.1, 1.6 Hz, 1H), 1.43–1.17 (m, 5H). 
13
C NMR (125 MHz, CDCl3) δ = 164.8 (Cq), 
146.7 (Cq), 136.7 (Cq), 129.4 (CH), 128.3 (Cq), 127.2 (CH), 123.2 (CH), 67.1 (CH2), 55.2 (CH2), 41.8 (CH), 
34.3 (CH2), 27.0 (CH2), 26.2 (CH2), 19.7 (CH3). IR (ATR): 2923, 2850, 1659, 1465, 1249, 1041, 936, 783  
cm
-1
. MS (EI) m/z (relative intensity) 243 (30) [M
+
], 242 (15) [M-H]
+
, 228 (10), 215 (40), 200 (30), 172 (100). 
HR-MS (EI) m/z calcd for C16H21NO [M-H]
 +




A suspension of   Co(acac)2 (12.9 mg, 10.0 mol %), ICy·HCl (149g) (13.4 mg, 10.0 mol %), aryl oxazoline 
130a (80.6 mg, 0.50 mmol), aryl chlorides 8a (85.6 mg, 0.60 mmol) and 8f (67.5 mg, 0.60 mmol) and DMPU 
(1.0 mL) was stirred for 5 min at 0 °C. A solution of CyMgCl (1.0 M, 1.0 mL, 2.0 equiv) in 2-
methyltetrahydrofuran was added dropwise at the same temperature. Then the mixture was stirred at 60 °C for 
16 h. At ambient temperature, aq. NH4Cl (2.0 mL) and H2O (15 mL) were added. The reaction mixture was 
extracted with MTBE (3 × 20 mL). The combined organic phase was washed with brine (20 mL) and dried 
over Na2SO4. Evaporation of the solvents in vacuo and purification of the remaining residue by column 
chromatography on silica gel (n-hexane/EtOAc 8:1) yielded product 131af (21.3 mg, 18%) and 131aa (4.0 mg, 
3%). 





A suspension of   Co(acac)2 (6.4 mg, 5.0 mol %), ICy·HCl (149g) (6.7 mg, 5.0 mol %), aryl chloride 8a (71.3 
mg, 0.50 mmol), aryl oxazolines 130d (99.1 mg, 0.60 mmol) and 130a (96.7 mg, 0.60 mmol) and DMPU (1.0 
mL) was stirred for 5 min at 0 °C. A solution of CyMgCl (1.0 M, 1.0 mL, 2.0 equiv) in 2-
methyltetrahydrofuran was added dropwise at the same temperature. Then the mixture was stirred at 23 °C for 
16 h. At ambient temperature, aq. NH4Cl (2.0 mL) and H2O (15 mL) were added. The reaction mixture was 
extracted with MTBE (3 × 20 mL). The combined organic phase was washed with brine (20 mL) and dried 
over Na2SO4. Evaporation of the solvents in vacuo and purification of the remaining residue by column 
chromatography on silica gel (n-hexane/EtOAc 5:1) yielded product 131da (65.1 mg, 48%). The product 
131aa was not detected. 
 
A suspension of   Co(acac)2 (6.4 mg, 5.0 mol %), ICy·HCl (149g) (6.7 mg, 5.0 mol %), aryl oxazoline 130a 
(80.6 mg, 0.50 mmol), alkyl chloride 68a (106.0 mg, 0.60 mmol) and aryl chloride 8a (85.6 mg, 0.60 mmol) 
and DMPU (1.0 mL) was stirred for 5 min at 0 °C. A solution of CyMgCl (1.0 M, 1.0 mL, 2.0 equiv) in 2-
methyltetrahydrofuran was added dropwise at the same temperature. Then the mixture was stirred at 23 °C for 
16 h. At ambient temperature, aq. NH4Cl (2.0 mL) and H2O (15 mL) were added. The reaction mixture was 
extracted with MTBE (3 × 20 mL). The combined organic phase was washed with brine (20 mL) and dried 
over Na2SO4. Evaporation of the solvents in vacuo and purification of the remaining residue by column 
chromatography on silica gel (n-hexane/EtOAc 5:1) yielded product 131aa (46.8 mg, 35%). Only traces of 
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Kinetic Isotope Effect Experiments 
Synthesis of Deuterated Substrate [D]4-130b
 
 
To a 60 mL Sealed tube was added 130b (967 mg, 6.0 mmol), [Ru(p-cymene)(O2CMes)2] (168 mg, 5.0 mol 
%), K2CO3 (1.66 g, 12.0 mmol), D2O (0.80 mL), and PhMe (8.0 mL) under argon atmosphere. The mixture 
was stirred at 140 °C for 48 h. At ambient temperature, the reaction mixture was diluted with EtOAc (50 mL), 
dried with K2CO3 and concentrated in vacuo. The crude product was purified by column chromatography (n-
hexane/EtOAc = 2:1) to give the deuterated product as a pale yellow oil (843 mg, 85%). 
1
H-NMR analysis 
showed 80% deuterium incorporation in the ortho-position. The same procedure was repeated again. The 
substrate (843 mg, 5.1 mmol) was dissolved in PhMe (6.0 mL), [Ru(p-cymene)(O2CMes)2] (143 mg, 5.0 mol 
%), K2CO3 (1.41 g, 10.2 mmol) and D2O (0.60 mL) was added. This mixture was stirred at 140 °C for 48 h. 
Following the same work-up procedure as above, the deuterated product [D]4-130b was isolated as a pale 
yellow oil (725 mg, 86%). 
1
H-NMR analysis showed 91% deuterium incorporation in the ortho-position.  
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1) Parallel Experiments 
 
Two independent reactions with 130b or deuterated substrate [D]4-130b under the standard conditions were 
performed. A suspension of   Co(acac)2 (6.4 mg, 5.0 mol %), ICy·HCl (149g) (6.7 mg, 5.0 mol %), aryl 
chloride 8a (92.7 mg, 0.65 mmol), substrate 130b (80.6 mg, 0.50 mmol) or [D]4-130b (82.6 mg, 0.50 mmol), 
internal standard 1,3,5-trimethoxybenzene (16.8 mg, 0.10 mmol) and DMPU (1.0 mL) were stirred at 0 °C for 
5 min. A solution of CyMgCl (1.0 M, 1.0 mL, 2.0 equiv) in 2-methyltetrahydrofuran was added dropwise at 
the same temperature. An aliquot (0.1 mL) was removed by syringe every 5 min. The appearance of the 
product 131ba or [D]3-131ba was monitored by GC analysis to provide the following conversions. 
t [min] 10 15 20 25 30 
131ba [%] 38 50 59 61 68 










y = 1.42x + 26.8 
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2) Competition Experiment 
 
A suspension of   Co(acac)2 (6.4 mg, 5.0 mol %), ICy·HCl (149g) (6.7 mg, 5.0 mol %), aryl chloride 8a (71.3 
mg, 0.50 mmol), substrate 130b (80.6 mg, 0.50 mmol) and [D]4-130b (82.6 mg, 0.50 mmol) in DMPU (1.0 
mL) were stirred at 0 °C for 5 min. A solution of CyMgCl (1.0 M, 1.0 mL, 2.0 equiv) in 2-
methyltetrahydrofuran was added dropwise at the same temperature. Then the mixture was stirred at 23 °C for 
1 h. Then aq. NH4Cl (2.0 mL) and H2O (15 mL) were added. The reaction mixture was extracted with MTBE 
(3 × 20 mL). The combined organic phase was washed with brine (20 mL) and dried over Na2SO4. 
Evaporation of the solvents in vacuo and purification of the remaining residue by column chromatography on 
silica gel (n-hexane/EtOAc 5:1) yielded product [D]n-131ba (24 mg, 18%) as a colorless oil. The KIE value of 
the competition experiment was estimated to be 1.0 by 
1
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Procedure for Gram-Scale Reaction 
 
A suspension of   Co(acac)2 (102.9 mg, 5.0 mol %), ICy·HCl (149g) (107.5 mg, 10.0 mol %), aryl oxazoline 
130a (1.29 g, 8.0 mmol), alkyl chlorides 8i (1.48 g, 10.4 mmol), and DMPU (8.0 mL) was stirred for 5 min at 
0 °C. A solution of CyMgCl (1.0 M, 16 mL, 2.0 equiv) in 2-methyltetrahydrofuran was added dropwise at the 
same temperature. Then, the mixture was stirred at 23 °C for 16 h. At ambient temperature, aq. NH4Cl (20.0 
mL) and H2O (80 mL) were added. The reaction mixture was extracted with MTBE (3 × 100 mL). The 
combined organic phase was washed with brine (100 mL) and dried over Na2SO4. Evaporation of the solvents 
in vacuo and purification of the remaining residue by column chromatography on silica gel (n-hexane/EtOAc 




Diversification of Oxazolines 131 
 
 





A 25 mL round-bottomed flask was charged with the oxazoline 131aa (534.7 mg, 2.0 mmol), THF (3.0 mL), 
Hünig’s base (51.7 mg, 0.4 mmol), and methyl chloroformate (378.0 mg, 4.0 mmol). The reaction mixture 
was then heated to 65 °C and stirred for 30 min before being cooled to 0 °C. Then, LiAlH4 (228 mg, 6.0 mmol) 
was added, followed by MeOH (192.2 mg, 6.0 mmol), the reaction was then warmed to ambient temperature 
and stirred for 1 h. The reaction mixture was cooled to 0 °C and carefully quenched with HCl (1.0 N, 2.5 mL) 
and H2O (2.5 mL). After 15 min, the reaction mixture was diluted with H2O (25 mL). The reaction mixture 
was extracted with MTBE (3 × 30 mL). The combined organic phase was washed with brine (50 mL) and 
dried over Na2SO4. Evaporation of the solvents in vacuo and purification of the remaining residue by column 
chromatography (n-hexane/EtOAc 5:1) yielded product 150a (273.9 mg, 60%) as colorless solid.  
M. p. = 97−98 °C. 
1
H NMR (500 MHz, CDCl3) δ = 7.34 (dd, J = 2.4, 0.7 Hz, 1H), 7.28 (d, J = 8.8 Hz 2H), 
7.18–7.13 (m, 2H), 6.94 (d, J = 8.8 Hz 2H), 4.58 (s, 2H), 3.83 (s, 3H), 2.39 (s, 3H). 
13
C NMR (125 MHz, 
CDCl3) δ = 158.7 (Cq), 138.1 (Cq), 137.8 (Cq), 137.1 (Cq), 133.0 (Cq), 130.2 (CH), 130.1 (CH), 129.1 (CH), 
128.3 (CH), 113.6 (CH), 63.2 (CH2), 55.2 (CH3), 21.1 (CH3). IR (ATR): 3329, 2912, 1609, 1484, 1244, 1033, 
840, 532 cm
-1
. MS (EI) m/z (relative intensity) 229 (10) [M+H
+
], 228 (100) [M
 +
], 210 (40), 195 (60), 185 (10), 
152 (30). HR-MS (EI) m/z calcd for C15H16O2 [M
+





A 25 mL round-bottomed flask was charged with the oxazoline 131ai (534.7 mg, 2.0 mmol), THF (3.0 mL), 
Hünig’s base (51.7 mg, 0.4 mmol), and methyl chloroformate (378.0 mg, 4.0 mmol). The reaction mixture 
was then heated to 65 °C and stirred for 30 min before being cooled to 0 °C. Then, LiAlH4 (228 mg, 6.0 mmol) 
was added, followed by MeOH (192.2 mg, 6.0 mmol), the reaction was then warmed to ambient temperature 
and stirred for 1 h. The reaction mixture was cooled to 0 °C and carefully quenched with HCl (1.0 N, 2.5 mL) 
and H2O (2.5 mL). After 15 min of stirring, the reaction mixture was diluted with H2O (25 mL).The reaction 
mixture was extracted with MTBE (3 × 30 mL). The combined organic phase was washed with brine (50 mL) 
and dried over Na2SO4. Evaporation of the solvents in vacuo and purification of the remaining residue by 
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H NMR (300 MHz, CDCl3) δ = 7.42–7.32 (m, 2H), 7.23–7.09 (m, 3H), 7.08–6.95 (m, 2H), 4.41 (d, J = 11.7 
Hz, 2H), 3.75 (s, 3H), 2.43 (s, 3H), 2.38 (br, 1H). 
13
C NMR (75 MHz, CDCl3) δ = 156.3 (Cq), 139.0 (Cq), 
137.5 (Cq), 134.4 (Cq), 131.3 (CH), 130.1 (CH), 129.7 (Cq), 129.0 (CH), 128.8 (CH), 128.3 (CH), 120.9 (CH), 
110.9 (CH), 63.5 (CH2), 55.6 (CH3), 21.1 (CH3). IR (ATR): 3392, 2938, 1734, 1596, 1481, 1230, 1051, 749 
cm
-1
. MS (EI) m/z (relative intensity) 229 (10) [M+H
+
], 228 (100) [M
+
], 210 (20), 195 (60), 185 (10), 152 (30). 
HR-MS (EI) m/z calcd for C15H16O2 [M
+






A 25 mL round-bottomed flask was charged with the oxazoline 131aa (534.7 mg, 2.0 mmol), THF (3.0 mL), 
Hünig’s base (51.7 mg, 0.4 mmol), and methyl chloroformate (378.0 mg, 4.0 mmol). The reaction mixture 
was then heated to 65 °C and stirred for 45 min, before being cooled to ambient temperature. Then the solvent 
was removed and the residue was purified by column chromatography on silica gel (n-hexane/EtOAc 5:1) to 
afford 131aa
,
 (521.0 mg, 72%) as a white solid.
  
M. p. = 89−90 °C. 
1
H NMR (400 MHz, CDCl3) δ = 7.28–7.15 (m, 5H), 6.92–6.85 (m, 2H), 3.87 (t, J = 7.0 Hz, 
2H), 3.81 (s, 3H), 3.48 (s, 3H), 3.49 (t, J = 7.0 Hz, 2H), 2.39 (s, 3H).
 13
C NMR (100 MHz, CDCl3) δ =172.7 
(Cq), 159.2 (Cq), 153.9 (Cq), 136.7 (Cq), 136.1 (Cq), 135.9 (Cq), 132.3 (Cq), 130.8 (CH), 129.6 (CH), 129.3 
(CH), 127.5 (CH), 113.7 (CH), 55.3 (CH3), 53.6 (CH3), 45.9 (CH2), 40.7 (CH2), 21.0 (CH3). IR (ATR): 2967, 
2839, 1741, 1687, 1443, 1337, 1196, 846 cm
-1
. MS (EI) m/z (relative intensity) 362 (50) [M+H
+
], 326 (30), 
286 (10), 225 (100), 197 (10). HR-MS (EI) m/z calcd for C19H20ClNO4 [M+H
 +






A 25 mL round-bottomed flask was charged with the oxazoline 131ai (534.7 mg, 2.0 mmol), THF (3.0 mL), 
Hünig’s base (51.7 mg, 0.4 mmol), and methyl chloroformate (378.0 mg, 4.0 mmol). The reaction mixture 
was then heated to 65 °C and stirred for 45 min, before being cooled to ambient temperature. Then, the 
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solvent was removed and the residue was purified by column afford 131ai
,
 (549.9 mg, 76%) as a white solid. 
M. p. = 117−118 °C. 
1
H NMR (400 MHz, CDCl3) δ = 7.36–7.34 (m, 1H), 7.33–7.26 (m, 2H), 7.15 (d, J = 7.8 
Hz, 1H), 7.12 (dd, J = 7.5, 1.8 Hz, 1H), 6.96 (ddd, J = 7.5, 7.5, 1.1 Hz, 1H), 6.88 (dd, J = 8.3, 1.1 Hz, 1H), 
3.72 (t, J = 7.2 Hz, 2H), 3.69 (s, 3H), 3.44 (s, 3H), 3.41 (t, J = 7.2 Hz, 2H), 2.40 (s, 3H). 
13
C NMR (100 MHz, 
CDCl3) δ = 172.5 (Cq), 156.3 (Cq), 153.9 (Cq), 137.2 (Cq), 136.5 (Cq), 132.8 (Cq), 131.0 (CH), 131.0 (CH), 
130.4 (CH), 129.3 (CH), 128.5 (Cq), 128.3 (CH), 120.6 (CH), 110.4 (CH), 55.2 (CH3), 53.4 (CH3), 46.1 (CH2), 
40.5 (CH2), 21.1 (CH3). IR (ATR): 2954, 2839, 1722, 1661, 1442, 1342, 1261, 755 cm
-1
. MS (EI) m/z 
(relative intensity) 362 (40) [M+H
+
], 326 (10), 301 (5), 225 (100), 173 (10), 149 (5). HR-MS (ESI) m/z calcd 
for C19H20ClNO4Na [M+Na
+




A 20 mL seal tube was charged with amide 131ai
,
 (361.8 mg, 1.0 mmol), aqueous HCl (5.0 mL, 37%) and 
then stirred at 140 °C for 24 h. The mixture was allowed to cool to ambient temperature. H2O (20 mL) was 
carefully added and the mixture was extracted with EtOAc (3 × 20 mL). The combined organic phase was 
dried over Na2SO4. Evaporation of the solvents in vacuo and purification of the remaining residue by column 
chromatography on silica gel (n-hexane/EtOAc 10:1) yielded product 153 (195.5 mg, 93%) as a white solid. 
M. p. = 130−131 °C. 
1
H NMR (300 MHz, CDCl3) δ = 8.17 (s, 1H), 8.04–7.95 (m, 2H), 7.61 (dd, J = 8.2, 1.6 
Hz, 1H), 7.43 (ddd, J = 8.2, 7.0, 1.6 Hz, 1H), 7.36–7.26 (m, 2H), 2.47 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 
= 161.3 (Cq), 151.0 (Cq), 139.2 (Cq), 136.0 (CH), 132.2 (Cq), 130.3 (CH), 129.9 (CH), 124.4 (CH), 122.5 (CH), 
121.6 (CH), 121.1 (Cq), 118.2 (Cq), 117.7 (CH), 21.3 (CH3). IR (ATR): 2919, 1719, 1611, 1477, 1305, 1175, 
1112, 744 cm
-1
. MS (EI) m/z (relative intensity) 211 (10) [M+H
+
], 210 (100) [M
+
], 181 (30), 165 (15), 152 
(30). HR-MS (EI) m/z calcd for C14H10O2 [M
+
] 210.0681, found 210.0673. 






A 20 mL seal tube was charged with the amide 131ai
,
 (180.9 mg, 0.5 mmol), PhSNa (330.4 mg, 2.5 mmol) 
and MeOH (2.0 mL). The mixture was stirred at 85 °C for 24 h. At ambient temperature, the solvent was 
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removed and the residue was purified by column chromatography on silica gel (n-hexane/EtOAc 2:1) to yield 
product 151 (1.56 g, 73%) as colorless oil.  
1
H NMR (300 MHz, CDCl3) δ = 7.55 (dd, J = 1.3, 0.6 Hz, 1H), 7.40–7.09 (m, 9H), 7.01 (ddd, J = 7.5, 7.5, 1.1 
Hz, 1H), 6.91 (dd, J = 8.3, 1.0 Hz, 1H), 5.93 (t, J = 5.4 Hz, 1H), 3.74 (s, 3H), 3.31 (t, J = 6.4 Hz, 2H), 2.67 (t, 
J = 6.5 Hz, 2H), 2.40 (s, 3H).
 13
C NMR (125 MHz, CDCl3) δ = 169.0 (Cq), 156.3 (Cq), 137.4 (Cq), 135.7 (Cq), 
134.7 (Cq), 132.8 (Cq), 130.8 (CH), 130.7 (CH), 130.7 (CH), 129.6 (CH), 129.3 (CH), 129.2 (Cq), 128.9 (CH), 
128.9 (CH), 126.3 (CH), 120.9 (CH), 110.7 (CH), 55.4 (CH3), 38.4 (CH2), 33.2 (CH2), 21.1 (CH3). IR (ATR): 
3417, 2935, 1719, 1644, 1503, 1249, 1024, 736 cm
-1
. HR-MS (ESI) m/z calcd for C23H23NO2SNa [M+Na
+
] 
400.1342, found 400.1332. 
 
4'-Methoxy-4-methyl-[1,1'-biphenyl]-2-carboxylic acid (152) 
 
A 20 mL seal tube was charged with amide 131aa
,
 (361.8 mg, 1.0 mmol), HCl (5.0 mL, 37%) and then stirred 
at 140 °C for 24 h. The mixture was allowed to cool to ambient temperature. H2O (20 mL) was carefully 
added and the mixture was extracted with EtOAc (3 × 20 mL). The combined organic phase was dried over 
Na2SO4. Evaporation of the solvents in vacuo and purification of the remaining residue by column 
chromatography (n-hexane/EtOAc 10:1) and then by HPLC yielded product 152 (172.0 mg, 71%) as a pale 
yellow solid.  
M. p. = 108−109 °C.
 1
H NMR (300 MHz, CDCl3) δ = 10.28 (br, H),7.73 (dd, J = 1.3, 0.6 Hz, 1H), 7.37–7.30 
(m, 1H), 7.27–7.19 (m, 3H), 6.90 (d, J = 8.8 Hz, 2H), 3.82 (s, 3H), 2.40 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 
= 173.8 (Cq), 158.9 (Cq), 140.1 (Cq), 136.6 (Cq), 133.3 (Cq), 132.8 (CH), 131.1 (CH), 131.1 (CH), 129.6 (CH), 
129.0 (Cq), 113.5 (CH), 55.2 (CH3), 20.8 (CH3). IR (ATR): 2947, 1678, 1608, 1285, 1038, 823 cm
-1
. MS (EI) 
m/z (relative intensity) 243 (20) [M+H
+
], 242 (100) [M
+
], 225 (20), 181 (20), 153 (20). HR-MS (EI) m/z calcd 
for C15H14O3 [M
+
] 242.0943, found 242.0941. 
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5.3.5 Oxazoline-Assisted C–H Amidation by Cobalt(III) Catalysis 
 
N-[2-(4,5-Dihydrooxazol-2-yl)-5-methylphenyl]benzamide (133ia): The general procedure E was followed 
using oxazoline 130i (81 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and NaOAc (8.2 
mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-hexane/EtOAc 5:1) 
yielded 133ia (95 mg, 68%) as a white solid.  
M. p. = 149−150 °C. 
1
H NMR (400 MHz, CDCl3) δ = 13.00 (s, 1H), 8.82 (s, 1H), 8.10 (d, J = 8.1 Hz, 2H), 
7.77 (d, J = 8.0 Hz, 1H), 7.58–7.45 (m, 3H), 6.92 (dd, J = 8.0, 1.4 Hz, 1H), 4.41–4.33 (m, 2H), 4.19–4.14 (m, 
2H), 2.43 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 166.0 (Cq), 164.9 (Cq), 143.4 (Cq), 140.0 (Cq), 135.3 (Cq), 
131.5 (CH), 129.1 (CH), 128.5 (CH), 127.7 (CH), 123.3 (CH), 120.3 (CH), 111.0 (Cq), 66.1 (CH2), 54.6 (CH2), 
22.1 (CH3). IR (ATR): 3055, 2982, 2915, 1677, 1363, 1155, 1103, 1055, 817, 754 cm
-1
. MS (EI) m/z (relative 
intensity) 281 (20) [M+H
+
], 280 (55), 263 (25), 203 (100), 160 (50). HR-MS (EI) m/z calcd for C17H16N2O2 
[M
+





N-[2-(4,5-Dihydrooxazol-2-yl)phenyl]benzamide (133ja): The general procedure E was followed using 
oxazoline 130j (74 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and NaOAc (8.2 
mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-hexane/EtOAc 11:2) 
yielded 133ja (95 mg, 71%) as a white solid.  
M. p. = 143–145 °C. 
1
H NMR (400 MHz, CDCl3) δ = 13.03 (s, 1H), 8.97 (dd, J = 8.5, 1.2 Hz, 1H), 8.10 (d, J 
= 8.1 Hz, 2H), 7.91 (dd, J = 7.9, 1.7 Hz, 1H), 7.59–7.45 (m, 4H), 7.12 (ddd, J = 7.9, 7.3, 1.2 Hz, 1H), 4.42 (td, 
J = 9.4, 1.1 Hz, 2H), 4.21 (td, J = 9.4, 1.1 Hz, 2H). 
13
C NMR (100 MHz, CDCl3) δ = 166.2 (Cq), 165.1 (Cq), 
140.4 (Cq), 135.5 (Cq), 132.8 (CH), 131.8 (CH), 129.4 (CH), 128.7 (CH), 127.9 (CH), 122.5 (CH), 120.1 (CH), 
113.7 (Cq), 66.4 (CH2), 54.9 (CH2). IR (ATR): 3026, 1614, 1446, 1303, 1058, 943, 748, 703, 674 cm
-1
. MS 
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(EI) m/z (relative intensity) 266 (56) [M
+
], 189 (96), 146 (42), 105 (100), 77 (75), 51 (12). HR-MS (ESI) m/z 
calcd for C16H13N2O2 [M-H]
-
: 265.0983, found: 265.0991. 





N-[2-(4,5-Dihydrooxazol-2-yl)-5-ethylphenyl]benzamide (133ka): The general procedure E was followed 
using oxazoline 130k (88 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and NaOAc (8.2 
mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-hexane/EtOAc 7:1) 
yielded 133ka (95 mg, 65%) as a white solid.  
M. p. = 122–124 °C. 
1
H NMR (300 MHz, CDCl3) δ = 13.02 (s, 1H), 8.87 (dq, J = 1.8, 0.6 Hz, 1H), 8.17–8.05 
(m, 2H), 7.81 (d, J = 8.1 Hz, 1H), 7.61–7.43 (m, 3H), 6.96 (ddt, J = 8.1, 1.7, 0.6 Hz, 1H), 4.40 (td, J = 9.1, 1.0 
Hz, 2H), 4.19 (td, J = 9.1, 1.0 Hz, 2H), 2.74 (q, J = 7.6 Hz, 2H), 1.30 (t, J = 7.6 Hz, 3H). 
13
C NMR (125 
MHz, CDCl3) δ = 166.1 (Cq), 165.0 (Cq), 149.8 (Cq), 140.3 (Cq), 135.5 (Cq), 131.6 (CH), 129.3 (CH), 128.6 
(CH), 127.8 (CH), 122.2 (CH), 119.4 (CH), 111.3 (Cq), 66.3 (CH2), 54.8 (CH2), 29.6 (CH2), 15.5 (CH3). IR 
(ATR): 3065, 2962, 1620, 1580, 1296, 1242, 1052, 698, 678 cm
-1
. MS (EI) m/z (relative intensity) 294 (49) 
[M
+






N-[2-(4,5-Dihydrooxazol-2-yl)-5-isopropylphenyl]benzamide (133la): The general procedure E was 
followed using oxazoline 130l (95 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 
equiv), [Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and 
NaOAc (8.2 mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-
hexane/EtOAc 5:1) yielded 133la (103 mg, 67%) as a white solid.  
M. p. = 137−139 °C. 
1
H NMR (400 MHz, CDCl3) δ = 13.00 (s, 1H), 8.89 (d, J = 1.8 Hz, 1H), 8.13–8.05 (m, 
2H), 7.80 (d, J = 8.2 Hz, 1H), 7.56–7.43 (m, 3H), 6.97 (ddd, J = 8.2, 1.8, 0.5 Hz, 1H), 4.42–4.31 (m, 2H), 
4.18–4.13 (m, 2H), 2.98 (hept, J = 6.9 Hz, 1H), 1.29 (d, J = 6.9 Hz, 6H). 
13
C NMR (100 MHz, CDCl3) δ = 
166.1 (Cq), 164.9 (Cq), 154.3 (Cq), 140.2 (Cq), 135.4 (Cq), 131.5 (CH), 129.2 (CH), 128.5 (CH), 127.7 (CH), 
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120.6 (CH), 118.0 (CH), 111.3 (Cq), 66.2 (CH2), 54.6 (CH2), 34.6 (CH), 23.7 (CH3). IR (ATR): 3027, 2959, 
2869, 1663, 1624, 1426, 1289, 1239, 1050, 694 cm
-1
. MS (EI) m/z (relative intensity) 308 (60) [M
+
], 291 (25), 
231 (100), 188 (40), 105 (60). HR-MS (EI) m/z calcd for C19H20N2O2 [M
+
] 308.1512, found 308.1524. 
 
 
N-[2-(4,5-Dihydrooxazol-2-yl)-5-methoxyphenyl]benzamide (133ma): The general procedure E was 
followed using oxazoline 130m (89 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 
equiv), [Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and 
NaOAc (8.2 mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-
hexane/EtOAc 2:1) yielded 133ma (111 mg, 75%) as a white solid. 
M. p. = 178−179 °C. 
1
H NMR (600 MHz, CDCl3) δ = 13.15 (s, 1H), 8.66 (d, J = 2.6 Hz, 1H), 8.11–8.06 (d, J 
= 8.2 Hz, 2H), 7.78 (d, J = 8.8 Hz, 1H), 7.54–7.51 (m, 1H), 7.50–7.46 (m, 2H), 6.63 (dd, J = 8.8, 2.6 Hz, 1H), 
4.36 (td, J = 9.2, 0.9 Hz, 2H), 4.19–4.11 (td, J = 9.2, 0.9 Hz, 2H), 3.89 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 
= 166.3 (Cq), 164.8 (Cq), 162.9 (Cq), 142.0 (Cq), 135.2 (Cq), 131.7 (CH), 130.5 (CH), 128.6 (CH), 127.7 (CH), 
109.7 (CH), 106.4 (Cq), 104.0 (CH), 66.1 (CH2), 55.5 (CH3), 54.5 (CH2). IR (ATR): 3062, 2882, 1636, 1613, 
1411, 1283, 1242, 1143, 938, 753 cm
-1
. MS (EI) m/z (relative intensity) 296 (5) [M
+
], 267 (25), 240 (10), 219 
(10), 105 (100), 77 (60). HR-MS: (EI) m/z calcd for C17H16N2O3 [M
+
] 296.1161, found 296.1167. 
 
 
N-[5-(tert-Butoxy)-2-(4,5-dihydrooxazol-2-yl)phenyl]benzamide (133na): The general procedure E was 
followed using oxazoline 130n (110 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 
equiv), [Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and 
NaOAc (8.2 mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-
hexane/EtOAc 7.5:1) yielded 133na (84 mg, 50%) as a white solid.  
M. p. = 120–122 °C. 
1
H NMR (500 MHz, CDCl3) δ = 13.05 (s, 1H), 8.76 (d, J = 2.4 Hz, 1H), 8.13–8.07 (d, J 
= 8.1 Hz, 2H), 7.77 (d, J = 8.7 Hz, 1H), 7.57–7.45 (m, 3H), 6.70 (dd, J = 8.7, 2.4 Hz, 1H), 4.36 (td, J = 9.3, 
0.9 Hz, 2H), 4.15 (td, J = 9.3, 0.9 Hz, 2H), 1.49 (s, 9H). 
13
C NMR (125 MHz, CDCl3) δ = 166.3 (Cq), 164.9 
(Cq), 159.8 (Cq), 141.2 (Cq), 135.4 (Cq), 131.7 (CH), 130.0 (CH), 127.8 (CH), 127.8 (CH), 116.8 (CH), 113.1 
(CH), 108.0 (Cq), 79.6 (Cq), 66.2 (CH2), 54.6 (CH2), 29.1 (CH3). IR (ATR): 2978, 2935, 2877, 1630, 1578, 
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1362, 1257, 1239, 707 cm
-1
. MS (EI) m/z (relative intensity) 338 (7) [M
+
], 282 (67), 205 (100), 162 (19), 105 
(83), 77 (53), 57 (24). HR-MS (EI) m/z calcd for C20H22N2O3 [M
+
]: 338.1630, found: 338.1627. 
 
 
N-[4-(4, 5-Dihydrooxazol-2-yl)-[1,1'-biphenyl]-3-yl]benzamide (133oa): The general procedure E was 
followed using oxazoline 130o (112 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 
equiv), [Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and 
NaOAc (8.2 mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-
hexane/EtOAc 6:1) yielded 133oa (127 mg, 74%) as a white solid.  
M. p. = 170–171 °C. 
1
H NMR (300 MHz, CDCl3) δ = 13.08 (s, 1H), 9.34 (d, J = 1.8 Hz, 1H), 8.12 (d, J = 8.1 
Hz, 2H), 7.95 (d, J = 8.2 Hz, 1H), 7.80–7.69 (m, 2H), 7.62–7.32 (m, 7H), 4.41 (td, J = 9.2, 0.9 Hz, 2H), 4.21 
(td, J = 9.2, 0.9 Hz, 2H). 
13
C NMR (100 MHz, CDCl3) δ = 166.3 (Cq), 165.0 (Cq), 145.3 (Cq), 140.7 (Cq), 
140.2 (Cq), 135.4 (Cq), 131.8 (CH), 129.8 (CH), 128.9 (CH), 128.7 (CH), 128.2 (CH), 127.9 (CH), 127.5 (CH), 
121.1 (CH), 118.5 (CH), 112.5 (Cq), 66.4 (CH2), 54.9 (CH2). IR (ATR): 3056, 1618, 1569, 1409, 1249, 1064, 
697, 678 cm
-1
. MS (EI) m/z (relative intensity) 342 (64) [M
+
], 265 (100), 222 (35), 166 (15), 105 (55), 77 (57). 
HR-MS (EI) m/z calcd for C22H18N2O2 [M
+
]: 342.1368, found: 342.1364. 
 
 
N-[2-(4,5-Dihydrooxazol-2-yl)-5-(trifluoromethyl)phenyl]benzamide (133pa): The general procedure E 
was followed using oxazoline 130p (108 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 
1.2 equiv), [Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and 
NaOAc (8.2 mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-
hexane/EtOAc 85:15) yielded 133pa (106 mg, 63%) as a white solid.  
M. p. = 191–193 °C. 
1
H NMR (300 MHz, CDCl3) δ = 13.10 (s, 1H), 9.34 (d, J = 1.8 Hz, 1H), 8.08 (d, J = 8.0 
Hz, 2H), 8.02–7.93 (m, 1H), 7.63–7.44 (m, 3H), 7.33 (ddd, J = 8.3, 1.8, 0.7 Hz, 1H), 4.46 (td, J = 9.3, 1.3 Hz, 
2H), 4.24 (td, J = 9.3, 1.3 Hz, 2H). 
13
C NMR (100 MHz, CDCl3) δ = 166.2 (Cq), 164.2 (Cq), 140.6 (Cq), 134.7 
(Cq), 134.1 (q, 
2
JC-F = 32.7 Hz, Cq), 132.0 (CH), 129.8 (CH), 128.7 (CH), 127.7 (CH), 123.6 (q, 
1
JC-F = 273.1 
Hz, Cq), 118.7 (q, 
3
JC-F = 3.8 Hz, CH), 116.9 (q, 
3
JC-F = 4.2 Hz, CH), 116.0 (Cq), 66.5 (CH2), 54.8 (CH2). 
19
F 
NMR (282 MHz, CDCl3): δ = -63.2 (s). IR (ATR): 3016, 1622, 1588, 1426, 1333, 1118, 1081, 1055, 922, 899, 





. MS (EI) m/z (relative intensity) 334 (28) [M
+
], 257 (36), 214 (14), 158 (7), 105 (100), 77 (44), 51 
(6). HR-MS (ESI) m/z calcd for C17H14N2O2F3 [M+H
+
]: 335.1002, found: 335.1005.  
 
 
N-[2-(4,5-Dihydrooxazol-2-yl)-5-fluorophenyl]benzamide (133qa): The general procedure E was followed 
using oxazoline 130q (83 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and NaOAc (8.2 
mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-hexane/EtOAc 85:15) 
yielded 133qa (101 mg, 71%) as a white solid.  
M. p. = 163–165 °C. 
1
H NMR (300 MHz, CDCl3) δ = 13.16 (s, 1H), 8.79 (dd, J = 12.2, 2.6 Hz, 1H), 8.08 (d, 
J = 8.0 Hz, 2H), 7.88 (dd, J = 8.9, 6.5 Hz, 1H), 7.62–7.43 (m, 3H), 6.80 (ddd, J = 8.9, 7.6, 2.6 Hz, 1H), 4.41 
(td, J = 9.2, 1.3 Hz, 2H), 4.19 (td, J = 9.2, 1.3 Hz, 2H). 
13
C NMR (100 MHz, CDCl3) δ = 166.2 (Cq), 165.0 (d, 
1
JC-F = 249.0 Hz, Cq), 164.4 (Cq), 142.1 (d, 
3
JC-F = 12.8 Hz, Cq), 134.9 (Cq), 131.9 (CH), 131.1 (d, 
3
JC-F = 10.4 
Hz, CH), 128.6 (CH), 127.8 (CH), 109.8 (d, 
4
JC-F = 2.9 Hz, Cq), 109.5 (d, 
2
JC-F = 22.5 Hz, CH), 107.3 (d, 
2
JC-F 
= 28.8 Hz, CH), 66.3 (CH2), 54.6 (CH2). 
19
F NMR (282 MHz, CDCl3): δ = -104.2 (m). IR (ATR): 3111, 2975, 
1614, 1599, 1544, 1430, 1255, 705 cm
-1
. MS (EI) m/z (relative intensity) 284 (33) [M
+
], 207 (84), 164 (30), 
105 (100), 77 (45), 44 (10). HR-MS (ESI) m/z calcd for C16H14N2O2F [M+H
+
]: 285.1034, found: 285.1038. 
 
N-[5-Chloro-2-(4, 5-dihydrooxazol-2-yl)phenyl]benzamide (133ra): The general procedure E was followed 
using oxazoline 130r (74 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and NaOAc (8.2 
mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-hexane/EtOAc 11:2) 
yielded 133ra (95 mg, 65%) as a white solid.  
M. p. = 186−187 °C. 
1
H NMR (400 MHz, CDCl3) δ = 13.04 (s, 1H), 9.05 (d, J = 2.1 Hz, 1H), 8.06 (d, J = 8.2 
Hz, 2H), 7.79 (d, J = 8.5 Hz, 1H), 7.56–7.51 (m, 1H), 7.51–7.45 (m, 2H), 7.06 (dd, J = 8.5, 2.1 Hz, 1H), 4.40 
(td, J = 9.2, 1.1 Hz, 2H), 4.18 (td, J = 9.2, 1.1 Hz, 2H). 
13
C NMR (100 MHz, CDCl3) δ = 166.1 (Cq), 164.4 
(Cq), 141.0 (Cq), 138.7 (Cq), 134.9 (Cq), 131.9 (CH), 130.2 (CH), 128.6 (CH), 127.7 (CH), 122.6 (CH), 119.9 
(CH), 111.8 (Cq), 66.3 (CH2), 54.7 (CH2). IR (ATR): 3063, 2880, 1674, 1613, 1579, 1358, 1281, 1237, 1057, 









Cl), 223 (55), 180 (25), 124 (10), 105 (100), 77 




] 300.0666, found 300.0659. 
 
 
N-[5-Bromo-2-(4,5-dihydrooxazol-2-yl)phenyl]benzamide (133sa): The general procedure E was followed 
using oxazoline 130s (113 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and NaOAc (8.2 
mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-hexane/EtOAc 11:2) 
yielded 133sa (88 mg, 51%) as a white solid.  
M. p. = 139−140 °C. 
1
H NMR (400 MHz, CDCl3) δ = 13.02 (s, 1H), 9.21 (d, J = 2.0 Hz, 1H), 8.08–8.01 (d, J 
= 8.2 Hz, 2H), 7.71 (d, J = 8.5 Hz, 1H), 7.56–7.51 (m, 1H), 7.51–7.45 (m, 2H), 7.22 (dd, J = 8.5, 2.0 Hz, 1H), 
4.40 (td, J = 9.3, 1.2 Hz, 2H), 4.17 (td, J = 9.3, 1.2 Hz, 2H). 
13
C NMR (100 MHz, CDCl3) δ = 166.1 (Cq), 
164.5 (Cq), 141.0 (Cq), 134.8 (Cq), 131.9 (CH), 130.3 (CH), 128.6 (CH), 127.7 (CH), 127.3 (Cq), 125.5 (CH), 
122.8 (CH), 112.2 (Cq), 66.3 (CH2), 54.7 (CH2). IR (ATR): 3062, 2935, 1672, 1626, 1443, 1039, 856, 753, 
523 cm
-1








Br), 269 (31) (
81
Br), 267 (32) 
(
79








Methyl 3-benzamido-4-(4, 5-dihydrooxazol-2-yl)benzoate (133ta): The general procedure E was followed 
using oxazoline 130t (103 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and NaOAc (8.2 
mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-hexane/EtOAc 5:1) 
yielded 133ta (115 mg, 71%) as a white solid.  
M. p. = 148−149 °C. 
1
H NMR (300 MHz, CDCl3) δ = 12.98 (s, 1H), 9.57 (d, J = 1.6 Hz, 1H), 8.07 (d, J = 7.9 
Hz, 2H), 7.93 (d, J = 8.2 Hz, 1H), 7.75 (dd, J = 8.2, 1.6 Hz, 1H), 7.56–7.44 (m, 3H), 4.42 (td, J = 9.4, 1.3 Hz, 
2H), 4.20 (td, J = 9.4, 1.3 Hz, 2H), 3.93 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 166.5 (Cq), 166.0 (Cq), 164.4 
(Cq), 140.2 (Cq), 134.9 (Cq), 133.6 (Cq), 131.8 (CH), 129.3 (CH), 128.6 (CH), 127.7 (CH), 123.2 (CH), 120.7 
(CH), 116.8 (Cq), 66.4 (CH2), 54.8 (CH2), 52.4 (CH3). IR (ATR): 3115, 3053, 2952, 1721, 1617, 1579, 1288, 
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1258, 1101, 745 cm
-1
. MS (EI) m/z (relative intensity) 324 (19) [M
+
], 307 (5), 293 (5), 247 (20), 220 (40), 105 
(100). HR-MS (EI) m/z calcd for C18H16N2O4 [M
+
] 324.1110, found 324.1107. 
 
 
N-[5-Cyano-2-(4,5-dihydrooxazol-2-yl)phenyl]benzamide (133ua): The general procedure E was followed 
using oxazoline 130u (91 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and NaOAc (8.2 
mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-hexane/EtOAc 3:1) 
yielded 133ua (99 mg, 68%) as a white solid.  
M. p. = 203−204 °C. 
1
H NMR (400 MHz, CDCl3) δ =13.06 (s, 1H), 9.33 (d, J = 1.6 Hz, 1H), 8.03 (d, J = 8.1 
Hz, 2H), 7.95 (d, J = 8.2 Hz, 1H), 7.59–7.52 (m, 1H), 7.52–7.46 (m, 2H), 7.33 (dd, J = 8.2, 1.6 Hz, 1H), 4.46 
(td, J = 9.5, 1.1 Hz, 2H), 4.24 (td, J = 9.6, 1.1 Hz, 2H). 
13
C NMR (100 MHz, CDCl3) δ = 166.3 (Cq), 163.9 
(Cq), 140.6 (Cq), 134.4 (Cq), 132.2 (CH), 129.9 (CH), 128.7 (CH), 127.7 (CH), 125.3 (CH), 123.2 (CH), 118.2 
(Cq), 116.7 (Cq), 115.8 (Cq), 66.7 (CH2), 54.9 (CH2). IR (ATR): 3065, 3025, 1677, 1616, 1579, 1414, 1289, 
1240, 1059, 693 cm
-1
. MS (EI) m/z (relative intensity) 292 (5) [M+H
+
], 291 (25) [M
+
], 214 (35), 171 (15), 115 
(10), 105 (100), 77 (60). HR-MS: (ESI) m/z calcd for C17H14N3O2 [M+H
+
] 292.1081, found 292.1079. 
 
 
N-[4-Chloro-2-(4,5-dihydrooxazol-2-yl)phenyl]benzamide (133va): The general procedure E was followed 
using oxazoline 130v (86 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and NaOAc (8.2 
mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-hexane/EtOAc 5:1) 
yielded 133va (101 mg, 67%) as a white solid.  
M. p. = 140−141 °C. 
1
H NMR (400 MHz, CDCl3) δ = 12.88 (s, 1H), 8.90 (d, J = 9.0 Hz, 1H), 8.01 (d, J = 8.2 
Hz, 2H), 7.77 (d, J = 2.6 Hz, 1H), 7.54–7.45 (m, 1H), 7.49–7.40 (m, 2H), 7.39 (dd, J = 9.0, 2.6 Hz, 1H), 4.34 
(td, J = 9.4, 1.0 Hz, 2H), 4.12 (td, J = 9.4, 1.0 Hz, 2H). 
13
C NMR (100 MHz, CDCl3) δ = 165.8 (Cq), 163.8 
(Cq), 138.6 (Cq), 134.8 (Cq), 132.2 (CH), 131.7 (CH), 128.8 (CH), 128.5 (CH), 127.6 (CH), 127.2 (Cq), 121.0 
(CH), 114.7 (Cq), 66.3 (CH2), 54.6 (CH2). IR (ATR): 3048, 2969, 1666, 1615, 1579, 1474, 1230, 1057, 950, 
693   cm
-1




Cl), 307 (5), 223 (30), 180 (15), 124 (15), 105 




] 300.0666, found 300.0655. 




N-[2-(4,5-Dihydrooxazol-2-yl)-4-(trifluoromethyl)phenyl]benzamide (133wa): The general procedure E 
was followed using oxazoline 130w (108 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 
1.2 equiv), [Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and 
NaOAc (8.2 mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-
hexane/EtOAc 7:1) yielded 133wa (108 mg, 65%) as a white solid.  
M. p. = 184–187 °C. 
1
H NMR (300 MHz, CDCl3) δ = 13.17 (s, 1H), 9.11 (dt, J = 8.9, 0.7 Hz, 1H), 8.19 (dt, J 
= 2.3, 0.6 Hz, 1H), 8.09 (d, J = 8.1 Hz, 2H), 7.75 (ddt, J = 8.9, 2.3, 0.6 1H), 7.64–7.45 (m, 3H), 4.48 (td, J = 
9.1, 1.6 Hz, 2H), 4.26 (td, J = 9.1, 1.6 Hz, 2H). 
13
C NMR (125 MHz, CDCl3) δ = 166.2 (Cq), 164.0 (Cq), 142.8 
(Cq), 134.7 (Cq), 132.0 (CH), 129.2 (q, 
3
JC-F = 3.4 Hz, CH), 128.6 (CH), 127.7 (CH), 126.5 (q, 
3
JC-F = 4.0 Hz, 
CH), 124.9 (q, 
1
JC-F = 271.3 Hz, Cq), 124.2 (q, 
2
JC-F = 33.4 Hz, Cq), 119.9 (CH), 113.4 (Cq), 66.6 (CH2), 54.8 
(CH2). 
19
F NMR (282 MHz, CDCl3) δ = -62.2 (s). IR (ATR): 3013, 1627, 1308, 1237, 1107, 1082, 1058, 952, 
695 cm
-1
. MS (EI) m/z (relative intensity) 334 (38) [M
+
], 257 (57), 214 (21), 158 (10), 105 (100), 77 (64). 
HR-MS (EI) m/z calcd for C17H13N2O2F3 [M
+
]: 334.0929, found: 334.0923. 
 
 
N-[5-Methyl-2-(5-methyl-4,5-dihydrooxazol-2-yl)phenyl]benzamide (133xa): The general procedure E 
was followed using oxazoline 130x (88 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 
equiv), [Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and 
NaOAc (8.2 mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-
hexane/EtOAc 8:1) yielded 133xa (125 mg, 85%) as a white solid.  
M. p. = 126–128 °C. 
1
H NMR (400 MHz, CDCl3) δ = 13.06 (s, 1H), 8.83 (dq, J = 1.1, 0.6 Hz, 1H), 8.16–8.06 
(m, 2H), 7.78 (d, J = 8.0 Hz, 1H), 7.59–7.45 (m, 3H), 6.97–6.88 (m, 1H), 4.81 (ddq, J = 9.4, 7.4, 6.2 Hz, 1H), 
4.26 (dd, J = 14.2, 9.4 Hz, 1H), 3.73 (dd, J = 14.2, 7.4 Hz, 1H), 2.44 (s, 3H), 1.44 (d, J = 6.2 Hz, 3H). 
13
C 
NMR (100 MHz, CDCl3) δ = 166.2 (Cq), 164.5 (Cq), 143.5 (Cq), 140.2 (Cq), 135.6 (Cq), 131.7 (CH), 129.3 
(CH), 128.7 (CH), 127.9 (CH), 123.4 (CH), 120.5 (CH), 111.4 (Cq), 75.0 (CH), 61.3 (CH2), 22.2 (CH3), 21.1 
(CH3). IR (ATR): 3063, 2974, 1622, 1585, 1295, 1243, 1062, 1049, 696, 677 cm
-1
. MS (EI) m/z (relative 
intensity) 294 (22) [M
+
], 217 (100), 160 (29), 105 (34), 77 (44). HR-MS (EI) m/z calcd for C18H18N2O2 [M
+
]: 
294.1368, found: 294.1370. 




N-[5-Methyl-2-(5-phenyl-4,5-dihydrooxazol-2-yl)phenyl]benzamide (133ya): The general procedure E was 
followed using oxazoline 130y (119 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 
equiv), [Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and 
NaOAc (8.2 mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-
hexane/EtOAc 8:1) yielded 133ya (131 mg, 74%) as a white solid.  
M. p. = 131–133 °C. 
1
H NMR (400 MHz, CDCl3) δ = 12.99 (s, 1H), 8.88 (t, J = 1.1 Hz, 1H), 8.16–8.06 (m, 
2H), 7.90 (d, J = 8.0 Hz, 1H), 7.61–7.45 (m, 3H), 7.45–7.30 (m, 5H), 6.96 (ddd, J = 8.0, 1.7, 0.8 Hz, 1H), 5.64 
(dd, J = 10.1, 7.7 Hz, 1H), 4.60 (dd, J = 14.5, 10.1 Hz, 1H), 4.13 (dd, J = 14.5, 7.7 Hz, 1H), 2.46 (s, 3H). 
13
C 
NMR (100 MHz, CDCl3) δ = 166.2 (Cq), 164.6 (Cq), 143.8 (Cq), 140.7 (Cq), 140.4 (Cq), 135.5 (Cq), 131.7 
(CH), 129.5 (CH), 129.0 (CH), 128.7 (CH), 128.6 (CH), 127.9 (CH), 125.8 (CH), 123.6 (CH), 120.6 (CH), 
111.0 (Cq), 79.6 (CH), 62.9 (CH2), 22.3 (CH3). IR (ATR): 3066, 2965, 1618, 1294, 1055, 759, 707, 694, 677 
cm
-1
. MS (EI) m/z (relative intensity) 356 (40) [M
+
], 279 (45), 238 (25), 160 (61), 119 (27), 105 (99), 77 (100). 
HR-MS (EI) m/z calcd for C23H20N2O2 [M
+
]: 356.1525, found: 356.1533. 
 
 
N-[2-(5,5-Dimethyl-4,5-dihydrooxazol-2-yl)-5-methylphenyl]benzamide (133za): The general procedure E 
was followed using oxazoline 130z (95 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 
equiv), [Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and 
NaOAc (8.2 mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-
hexane/EtOAc 8:1) yielded 133za (132 mg, 86%) as a white solid.  
M. p. = 103–105 °C. 
1
H NMR (400 MHz, CDCl3) δ = 13.13 (s, 1H), 8.87–8.81 (m, 1H), 8.16–8.07 (m, 2H), 
7.78 (d, J = 8.0 Hz, 1H), 7.58–7.45 (m, 3H), 6.93 (ddd, J = 8.0, 1.7, 0.8 Hz, 1H), 3.89 (s, 2H), 2.44 (s, 3H), 
1.50 (s, 6H). 
13
C NMR (100 MHz, CDCl3) δ = 166.1 (Cq), 163.9 (Cq), 143.3 (Cq), 140.2 (Cq), 135.6 (Cq), 
131.6 (CH), 129.2 (CH), 128.6 (CH), 127.9 (CH), 123.3 (CH), 120.4 (CH), 111.7 (Cq), 82.9 (Cq), 66.6 (CH2), 
27.4 (CH3), 22.2 (CH3). IR (ATR): 3065, 2974, 2873, 1620, 1583, 1298, 1059, 695, 677 cm
-1
. MS (EI) m/z 
(relative intensity) 308 (53) [M
+
], 275 (21), 231 (100), 160 (93), 134 (14), 105 (72), 77 (69), 51 (9). HR-MS 
(ESI) m/z calcd for C19H21N2O2 [M+H
+
]: 309.1598, found: 309.1598.  




N-[2-(5,6-Dihydro-4H-1,3-oxazin-2-yl)-4-methylphenyl]benzamide (133aaa): The general procedure E 
was followed using oxazine 130aa (88 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 
equiv), [Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and 
NaOAc (8.2 mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-
hexane/EtOAc 8:1) yielded 133aaa (97 mg, 66%) as a white solid.  
M. p. = 127–129 °C. 
1
H NMR (300 MHz, CDCl3) δ = 13.87 (s, 1H), 8.81 (d, J = 8.5 Hz, 1H), 8.07–7.97 (m, 
2H), 7.72 (d, J = 2.1 Hz, 1H), 7.58–7.41 (m, 3H), 7.27 (dd, J = 8.5, 2.1 Hz, 1H), 4.42 (t, J = 5.4 Hz, 2H), 3.73 
(t, J = 5.9 Hz, 2H), 2.34 (s, 3H), 2.04 (tt, J = 5.9, 5.4 Hz, 2H). 
13
C NMR (125 MHz, CDCl3) δ = 165.7 (Cq), 
157.1 (Cq), 137.9 (Cq), 136.1 (Cq), 132.3 (CH), 131.5 (Cq), 131.4 (CH), 128.6 (CH), 128.4 (CH), 127.6 (CH), 
120.1 (CH), 118.3 (Cq), 65.5 (CH2), 42.1 (CH2), 21.7 (CH2), 21.0 (CH3). IR (ATR): 2853, 1641, 1595, 1525, 
1349, 1237, 822, 701, 543 cm
-1
. MS (EI) m/z (relative intensity) 294 (54) [M
+
], 217 (100), 189 (11), 160 (61), 
105 (52), 77 (61). HR-MS (ESI) m/z calcd for C18H19N2O2 [M+H
+
]: 295.1441, found: 295.1444.  
 
 
N-(2-(4,5-dihydrooxazol-2-yl)-5-methylphenyl)-3-methylbenzamide(133ib): The general procedure E was 
followed using oxazine 130i (88 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132b (106 mg, 0.60 mmol, 1.2 
equiv), [Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and 
NaOAc (8.2 mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-
hexane/EtOAc 8:1) yielded 133ib (63 mg, 43%) as a white solid. 
M. p. = 145−146 °C.
 1
H NMR (300 MHz, CDCl3)  δ = 12.95 (s, 1H), 8.80 (s, 1H), 7.93 – 7.83 (m, 2H), 7.74 
(d, J = 8.0 Hz, 1H), 7.40 – 7.29 (m, 2H), 6.89 (ddt, J = 8.0, 1.5, 0.7 Hz, 1H), 4.35 (td, J = 9.4, 1.3 Hz, 2H), 
4.13 (td, J = 9.4, 1.3 Hz, 2H), 2.42 (s, 3H), 2.41 (s, 3H).
 13
C NMR (75 MHz, CDCl3) δ = 166.1 (Cq), 164.9 
(Cq), 143.3 (Cq), 140.0 (Cq), 138.2 (Cq), 135.2 (Cq), 132.2 (CH), 129.1 (CH), 128.5 (CH), 128.4 (CH), 124.7 
(CH), 123.2 (CH), 120.2 (CH), 110.9 (Cq), 66.1 (CH2), 54.5 (CH2), 22.0 (CH3), 21.4 (CH3). IR (neat): 3066, 
2914, 1681, 1619, 1583, 1362, 1299, 1103, 802, 765, 500 cm
-1
. MS (EI) m/z (relative intensity) 294 (40) [M
 +
], 









N-[2-(4,5-Dihydrooxazol-2-yl)-5-methylphenyl]-3-fluorobenzamide (133ic): The general procedure E was 
followed using oxazoline 133i (81mg, 0.50 mmol, 1.0 equiv), dioxazolone 132c (109 mg, 0.60 mmol, 1.2 
equiv), [Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and 
NaOAc (8.2 mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-
hexane/EtOAc 5:1) yielded 133ic (98 mg, 66%) as a white solid.  
M. p. = 163−164 °C. 
1
H NMR (300 MHz, CDCl3) δ = 13.03 (s, 1H), 8.76 (s, 1H), 7.88–7.84 (m, 1H), 7.81–
7.73 (m, 2H), 7.44 (td, J = 8.0, 5.6 Hz, 1H), 7.23–7.17 (m, 1H), 6.93–6.90 (m, 1H), 4.41–4.33 (m, 2H), 4.19–
4.12 (m, 2H), 2.41 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 165.0 (Cq), 164.5 (d, 
4
JC-F = 2.6 Hz, Cq), 162.8 (d, 
1
JC-F = 246.8 Hz, Cq), 143.5 (Cq), 139.7 (Cq), 137.6 (d, 
3
JC-F = 6.8 Hz, Cq), 130.1 (d, 
3
JC-F = 7.9 Hz, CH), 129.1 
(CH), 123.6 (CH), 123.3 (d, 
4
JC-F = 3.0 Hz, CH), 120.3 (CH), 118.5 (d, 
2
JC-F = 21.4 Hz, CH), 114.9 (d, 
2
JC-F = 
23.0 Hz, CH), 111.0 (Cq), 66.2 (CH2), 54.5 (CH2), 22.1 (CH3). 
19
F-NMR (282 MHz, CDCl3) δ = –112.1 (m). 
IR (ATR): 3055, 2915, 2881, 1624, 1588, 1420, 1359, 1297, 1059, 726 cm
-1
. MS (EI) m/z (relative intensity) 
298 (70) [M
+
], 281 (15), 267 (10), 203 (100), 160 (70), 123 (40). HR-MS (EI) m/z calcd for C17H15FN2O2 [M
+
] 
298.1118, found 294.1121. 
 
 
N-(2-(4,5-dihydrooxazol-2-yl)-5-methylphenyl)thiophene-3-carboxamide(133id): The general procedure E 
was followed using oxazoline 130i (81mg, 0.50 mmol, 1.0 equiv), dioxazolone 132d (102 mg, 0.60 mmol, 1.2 
equiv), [Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %) and 
NaOAc (8.2 mg, 0.10 mmol, 20 mol %). Purification by column chromatography on silica gel (n-
hexane/EtOAc 5:1) yielded 133id (51 mg, 36%) as a white solid.  
M. p. = 168−169 °C. 
1
H NMR (300 MHz, CDCl3) δ = 13.02 (s, 1H), 8.68 (s, 1H), 7.76 (dd, J = 3.8, 1.1 Hz, 
1H), 7.72 (d, J = 8.0 Hz, 1H), 7.51 (dd, J = 5.0, 1.1 Hz, 1H), 7.10 (dd, J = 5.0, 3.8 Hz, 1H), 6.87 (dd, J = 8.0, 
1.4, 1H), 4.40–4.31 (m, 2H), 4. 18–4.11 (m, 2H), 2.38 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 164.9 (Cq), 
160.6 (Cq), 143.4 (Cq), 141.2 (Cq), 139.7 (Cq), 130.8 (CH), 129.0 (CH), 128.4 (CH), 127.7 (CH), 123.2 (CH), 
120.1 (CH), 110.6 (Cq), 66.1 (CH2), 54.5 (CH2), 22.0 (CH3). IR (neat): 3113, 2959, 1621, 1587, 1553, 1413, 
1352, 1298, 1060, 725, 509, 456 cm
-1
. MS (EI) m/z (relative intensity) 286 (90) [M
 +
], 269 (30), 255 (20), 225 
(30), 203 (70), 160 (50), 111 (100). HR-MS (EI) m/z calcd for C15H14N2O2S [M
 +
] 286.0776, found 286.0765. 




N-[4-Methoxy-1-(pyridin-2-yl)-1H-indol-2-yl]benzamide (154aa): The general procedure F was followed 
using indole 102a (112 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (5.9 mg, 0.0125 mmol, 2.5 mol %), AgSbF6 (8.6 mg, 0.025 mmol, 5.0 mol %) and NaOAc 
(2.1 mg, 0.025 mmol, 5.0 mol %) at 70 °C. Purification by column chromatography on silica gel (n-
hexane/EtOAc 3:1) yielded 154aa (165 mg, 96%) as a pale yellow solid. 
M. p. = 152–154 °C. 
1
H NMR (500 MHz, CDCl3) δ = 11.75 (s, 1H), 8.61 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 
7.97–7.86 (m, 3H), 7.75 (dt, J = 8.3, 1.0 Hz, 1H), 7.58–7.45 (m, 3H), 7.41 (s, 1H), 7.30–7.18 (m, 2H), 7.11 (t, 
J = 8.1 Hz, 1H), 6.66 (dd, J = 7.9, 0.6 Hz, 1H), 3.98 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ = 163.5 (Cq), 
153.4 (Cq), 152.2 (Cq), 148.2 (CH), 139.5 (CH), 134.5 (Cq), 133.5 (Cq), 133.2 (Cq), 131.9 (CH), 128.8 (CH), 
127.1 (CH), 122.7 (CH), 120.9 (CH), 119.9 (Cq), 118.2 (CH), 104.0 (CH), 102.7 (CH), 91.2 (CH), 55.7 (CH3). 
IR (ATR): 3057, 2954, 1666, 1538, 1470, 1437, 1250, 1090, 764, 686. MS (EI) m/z (relative intensity) 343 
(69) [M
+
], 281 (6), 238 (27), 207 (20), 169 (7), 105 (100), 77 (40), 44 (11). HR-MS (ESI) m/z calcd for 
C21H18N3O2 [M+H
+
]: 344.1394, found: 344.1394.  
 
 
N-[1-(Pyridin-2-yl)-1H-indol-2-yl]benzamide (154ba): The general procedure F was followed using indole 
substrate 102b (97 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (5.9 mg, 0.0125 mmol, 2.5 mol %), AgSbF6 (8.6 mg, 0.025 mmol, 5.0 mol %) and NaOAc 
(2.1 mg, 0.025 mmol, 5.0 mol %) at 70 °C. Purification by column chromatography on silica gel (n-
hexane/EtOAc 3:1) yielded 154ba (150 mg, 94%) as a pale yellow solid.  
M. p. = 101−102 °C. 
1
H NMR (400 MHz, CDCl3) δ = 11.88 (s, 1H), 8.59 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 
7.95–7.91 (m, 2H), 7.88 (ddd, J = 8.3, 7.4, 1.9 Hz, 1H), 7.73 (dt, J = 8.3, 0.9 Hz, 1H), 7.63–7.60 (m, 1H), 
7.59–7.56 (m, 1H), 7.55–7.51 (m, 1H), 7.50–7.45 (m, 2H), 7.31 (s, 1H), 7.26–7.14 (m, 3H). 
13
C NMR (100 
MHz, CDCl3) δ = 163.5 (Cq), 151.9 (Cq), 148.1 (CH), 139.4 (CH), 134.8 (Cq), 134.1 (Cq), 131.8 (CH), 131.9 
(Cq), 129.5 (Cq), 128.7 (CH), 126.9 (CH), 122.0 (CH), 121.7 (CH), 120.7 (CH), 120.5 (CH), 117.8 (CH), 
110.4 (CH), 93.6 (CH). IR (ATR): 3199, 3061, 3010, 1672, 1586, 1570, 1528, 1328, 789, 777 cm
-1
. MS (EI) 
m/z (relative intensity) 313 (90) [M
+
], 285 (5), 208 (20), 181 (30), 105 (100), 77 (60). HR-MS (EI) m/z calcd 
for C20H15N3O [M
+
] 313.1215, found 313.1207. 




N-[5-Methoxy-1-(pyridin-2-yl)-1H-indol-2-yl]benzamide (154ca): The general procedure F was followed 
using indole substrate 102c (112 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (5.9 mg, 0.0125 mmol, 2.5 mol %), AgSbF6 (8.6 mg, 0.025 mmol, 5.0 mol %) and NaOAc 
(2.1 mg, 0.025 mmol, 5.0 mol %) at 70 °C. Purification by column chromatography on silica gel (n-
hexane/EtOAc 2:1) yielded 154ca (168 mg, 98%) as a pale yellow solid.  
M. p. = 151−152 °C. 
1
H NMR (300 MHz, CDCl3) δ = 12.00 (s, 1H), 8.55 (dd, J = 5.0, 1.6 Hz, 1H), 7.91 (ddd, 
J = 7.0, 1.9, 1.0 Hz, 2H), 7.91–7.78 (m, 1H), 7.67 (d, J = 8.3 Hz, 1H), 7.55–7.39 (m, 4H), 7.23 (s, 1H), 7.24–
7.13 (m, 1H), 7.06 (d, J = 2.5 Hz, 1H), 6.77 (dd, J = 8.9, 2.5 Hz, 1H), 3.84 (s, 3H). 
13
C NMR (75 MHz, 
CDCl3) δ = 163.5 (Cq), 155.5 (Cq), 152.1 (Cq), 147.9 (CH), 139.3 (CH), 135.4 (Cq), 134.1 (Cq), 131.8 (CH), 
130.5 (Cq), 128.7 (CH), 126.9 (CH), 126.4 (Cq), 120.3 (CH), 117.2 (CH), 111.3 (CH), 110.5 (CH), 103.0 (CH), 
93.5 (CH), 55.6 (CH3). IR (ATR): 3192, 3062, 2829, 1668, 1586, 1570, 1467, 1280, 776, 689 cm
-1
. MS (EI) 
m/z (relative intensity) 344 (20) [M+H
+
], 343 (70) [M
+
], 303 (5), 238 (30), 211 (15), 198 (20), 105 (100). HR-
MS (EI) m/z calcd for C20H17N3O2 [M
+
] 343.1321, found 343.1328. 
 
 
N-[5-Fluoro-1-(pyridin-2-yl)-1H-indol-2-yl]benzamide (154da): The general procedure F was followed 
using indole substrate 102d (106 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (5.9 mg, 0.0125 mmol, 2.5 mol %), AgSbF6 (8.6 mg, 0.025 mmol, 5.0 mol %) and NaOAc 
(2.1 mg, 0.025 mmol, 5.0 mol %) at 70 °C. Purification by column chromatography on silica gel (n-
hexane/EtOAc 3:1) yielded 154da (154 mg, 93%) as a pale yellow solid.  
M. p. = 148−149 °C. 
1
H NMR (300 MHz, CDCl3) δ = 11.87 (s, 1H), 8.58–8.56 (m, 1H), 7.94–7.83 (m, 3H), 
7.63 (dt, J = 8.3, 0.9 Hz, 1H), 7.56–7.39 (m, 4H), 7.28–7.16 (m, 3H), 6.83 (td, J = 9.0, 2.6 Hz, 1H). 
13
C NMR 
(75 MHz, CDCl3) δ = 163.6 (Cq), 158.9 (d, 
1
JC-F = 237.1 Hz, Cq), 151.7 (Cq), 148.1 (CH), 139.5 (CH), 136.2 
(Cq), 133.9 (Cq), 131.9 (CH), 130.4 (d, 
3
JC-F = 10.5 Hz, Cq), 128.7 (CH), 128.1 (Cq), 126.9 (CH), 120.8 (CH), 
117.5 (CH), 111.2 (d, 
3
JC-F = 9.4 Hz, CH), 109.2 (d, 
2
JC-F = 25.6 Hz, CH), 105.8 (d, 
2
JC-F = 24.1 Hz, CH), 93.3 
(d, 
4
JC-F = 4.1 Hz, CH). 
19
F-NMR (282 MHz, CDCl3) δ = –121.7 (m). IR (ATR): 3217, 3053, 1676, 1587, 
1471, 1295, 1130, 1103, 840, 697 cm
-1
. MS (EI) m/z (relative intensity) 332 (20) [M+H
+
], 331 (100) [M
+
], 303 
(5), 226 (20), 199 (30), 105 (100), 77 (60). HR-MS (EI) m/z calcd for C20H14FN3O [M
+
] 331.1121, found 
331.1124. 




N-[5-Bromo-1-(pyridin-2-yl)-1H-indol-2-yl]benzamide (154ea): The general procedure F was followed 
using indole substrate 102e (136 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (5.9 mg, 0.0125 mmol, 2.5 mol %), AgSbF6 (8.6 mg, 0.025 mmol, 5.0 mol %) and NaOAc 
(2.1 mg, 0.025 mmol, 5.0 mol %) at 70 °C. Purification by column chromatography on silica gel (n-
hexane/EtOAc 3:1) yielded 154ea (186 mg, 95%) as a pale yellow solid.  
M. p. = 140−141 °C. 
1
H NMR (300 MHz, CDCl3) δ = 11.81 (s, 1H), 8.59 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 
7.94–7.84 (m, 3H), 7.67–7.59 (m, 2H), 7.56–7.43 (m, 3H), 7.37 (d, J = 8.7 Hz, 1H), 7.29–7.23 (m, 1H), 7.21–
7.15 (m, 2H). 
13
C NMR (75 MHz, CDCl3) δ = 163.6 (Cq), 151.5 (Cq), 148.2 (CH), 139.6 (CH), 135.8 (Cq), 
133.9 (Cq), 132.0 (CH), 131.3 (Cq), 130.5 (Cq), 128.7 (CH), 127.0 (CH), 124.2 (CH), 122.9 (CH), 121.1 (CH), 
117.7 (CH), 115.0 (Cq), 111.8 (CH), 92.7 (CH). IR (ATR): 3186, 3053, 3023, 1667, 1583, 1440, 1290, 1206, 
872, 783, 637, 402 cm
-1








Br), 363 (5) 
(
79
Br), 288 (10) (
81
Br), 259 (10) (
79





] 391.0320, found 391.0310. 
 
 
N-[5-Iodo-1-(pyridin-2-yl)-1H-indol-2-yl]benzamide (154fa): The general procedure F was followed using 
indole substrate 102f (160 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (5.9 mg, 0.0125 mmol, 2.5 mol %), AgSbF6 (8.6 mg, 0.025 mmol, 5.0 mol %) and NaOAc 
(2.1 mg, 0.025 mmol, 5.0 mol %) at 70 °C. Purification by column chromatography on silica gel (n-
hexane/EtOAc 3:1) yielded 154fa (180 mg, 82%) as a pale yellow solid.  
M. p. = 159−160 °C. 
1
H NMR (300 MHz, CDCl3) δ = 11.80 (s, 1H), 8. 61–8.59 (m, 1H), 7.94–7.84 (m, 4H), 
7.63 (dt, J = 8.3, 0.9 Hz, 1H), 7.56–7.43 (m, 3H), 7.39–7.34 (m, 1H), 7.31–7.23 (m, 2H), 7.17 (s, 1H). 
13
C 
NMR (75 MHz, CDCl3) δ = 163.6 (Cq), 151.5 (Cq), 148.2 (CH), 139.6 (CH), 135.4 (Cq), 133.9 (Cq), 132.0 
(CH), 131.9 (Cq), 131.0 (Cq), 129.9 (CH), 129.1 (CH), 128.8 (CH), 127.0 (CH), 121.1 (CH), 117.8 (CH), 
112.3 (CH), 92.5 (CH), 85.5 (Cq). IR (ATR): 3169, 3060, 1667, 1583, 1529, 1455, 1257, 990, 792, 750 cm
-1
. 
MS (EI) m/z (relative intensity) 440 (20) [M+H
+
], 439 (70) [M
+
], 411 (5), 334 (10), 206 (20), 105 (100), 77 
(60). HR-MS (EI) m/z calcd for C20H14IN3O [M
+
] 439.0182, found 439.0188. 
 




Methyl 2-benzamido-1-(pyridin-2-yl)-1H-indole-6-carboxylate (154ga): The general procedure F was 
followed using indole 102g (126 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (5.9 mg, 0.0125 mmol, 2.5 mol %), AgSbF6 (8.6 mg, 0.025 mmol, 5.0 mol %) and NaOAc 
(2.1 mg, 0.025 mmol, 5.0 mol %) at 70 °C. Purification by column chromatography on silica gel (n-
hexane/EtOAc 3:1 to 3:2) yielded 154ga (169 mg, 91%) as an off-white solid.  
M. p. = 180–183 °C. 
1
H NMR (500 MHz, CDCl3) δ = 11.95 (s, 1H), 8.67 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 8.32 
(dt, J = 1.5, 0.8 Hz, 1H), 8.02 (ddd, J = 8.3, 7.5, 1.9 Hz, 1H), 7.97–7.87 (m, 3H), 7.82 (dt, J = 8.2, 0.9 Hz, 1H), 
7.63 (dd, J = 8.2, 0.6 Hz, 1H), 7.57 (ddt, J = 8.2, 6.4, 1.3 Hz, 1H), 7.52 (ddt, J = 8.2, 6.6, 1.4 Hz, 2H), 7.39–
7.32 (m, 2H), 3.93 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ = 168.0 (Cq), 163.9 (Cq), 151.7 (Cq), 148.4 (CH), 
140.1 (CH), 137.9 (Cq), 134.1 (Cq), 133.9 (Cq), 132.3 (CH), 131.5 (Cq), 129.0 (CH), 127.3 (CH), 123.6 (CH), 
123.4 (Cq), 121.5 (CH), 120.1 (CH), 118.5 (CH), 112.6 (CH), 93.9 (CH), 52.1 (CH3). IR (ATR): 3059, 2952, 
1703, 1673, 1530, 1436, 1262, 1219, 998, 786 cm
-1
. MS (EI) m/z (relative intensity) 371 (34) [M
+
], 281 (17), 
253 (8), 207 (54), 105 (100), 77 (30), 44 (18). HR-MS (ESI) m/z calcd for C22H18N3O3 [M+H
+
]: 372.1343, 
found: 372.1332.  
 
 
N-[1-(4-Methylpyridin-2-yl)-1H-indol-2-yl]benzamide (154ha): The general procedure F was followed 
using indole 102h (104 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (5.9 mg, 0.0125 mmol, 2.5 mol %), AgSbF6 (8.6 mg, 0.025 mmol, 5.0 mol %) and NaOAc 
(2.1 mg, 0.025 mmol, 5.0 mol %) at 70 °C. Purification by column chromatography on silica gel (n-
hexane/EtOAc 5:1) yielded 154ha (159 mg, 97%) as an off-white solid.  
M. p. = 166–169 °C. 
1
H NMR (500 MHz, CDCl3) δ = 11.92 (s, 1H), 8.52–8.46 (m, 1H), 7.97–7.91 (m, 2H), 
7.66–7.58 (m, 3H), 7.58–7.50 (m, 2H), 7.50–7.46 (m, 1H), 7.29 (s, 1H), 7.28–7.16 (m, 2H), 7.11 (ddd, J = 5.2, 
1.5, 0.8 Hz, 1H), 2.49 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ = 163.8 (Cq), 152.2 (Cq), 151.4 (Cq), 147.9 
(CH), 135.1 (Cq), 134.4 (Cq), 132.0 (CH), 132.0 (Cq), 129.8 (Cq), 128.9 (CH), 127.2 (CH), 122.2 (CH), 122.1 
(CH), 121.7 (CH), 120.8 (CH), 118.6 (CH), 110.7 (CH), 93.6 (CH), 21.6 (CH3). IR (ATR): 3228, 3044, 1672, 
1523, 1459, 1259, 805, 685, 636, 447 cm
-1
. MS (EI) m/z (relative intensity) 327 (60) [M
+
], 222 (26), 195 (26), 
105 (100), 77 (41), 44 (33). HR-MS (ESI) m/z calcd for C21H18N3O [M+H
+
]: 328.1444, found: 328.1447.  
 




N-[1-(5-Methylpyridin-2-yl)-1H-indol-2-yl]benzamide (154ia): The general procedure F was followed 
using indole 102i (104 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (5.9 mg, 0.0125 mmol, 2.5 mol %), AgSbF6 (8.6 mg, 0.025 mmol, 5.0 mol %) and NaOAc 
(2.1 mg, 0.025 mmol, 5.0 mol %) at 70 °C. Purification by column chromatography on silica gel (n-
hexane/EtOAc 5:1) yielded 154ia (151 mg, 92%) as a pale yellow solid.  
M. p. = 171–173 °C. 
1
H NMR (300 MHz, CDCl3) δ = 11.80 (s, 1H), 8.45 (dp, J = 2.3, 0.8 Hz, 1H), 8.00–7.86 
(m, 2H), 7.75 (ddd, J = 8.4, 2.4, 0.7 Hz, 1H), 7.67 (dd, J = 8.4, 0.8 Hz, 1H), 7.65–7.61 (m, 1H), 7.60–7.47 (m, 
4H), 7.28 (t, J = 0.5 Hz, 1H), 7.24–7.13 (m, 2H), 2.44 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ = 163.6 (Cq), 
149.9 (Cq), 148.2 (CH), 140.1 (CH), 134.9 (Cq), 134.4 (Cq), 132.0 (Cq), 131.9 (CH), 130.7 (Cq), 129.6 (Cq), 
128.8 (CH), 127.2 (CH), 121.9 (CH), 121.7 (CH), 120.7 (CH), 117.6 (CH), 110.5 (CH), 93.5 (CH), 18.2 (CH3). 
IR (ATR): 3183, 3049, 1683, 1539, 1477, 1455, 783, 690, 650, 637 cm
-1
. MS (EI) m/z (relative intensity) 327 
(60) [M
+
], 281 (24), 253 (13), 207 (76), 105 (100), 77 (35), 44 (22). HR-MS (ESI) m/z calcd for C21H18N3O 
[M+H
+
]: 328.1444, found: 328.1444. 
 
 
N-[1-(Pyrimidin-2-yl)-1H-indol-2-yl]benzamide (154ja): The general procedure F was followed using 
indole substrate 102j (98 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (5.9 mg, 0.0125 mmol, 2.5 mol %), AgSbF6 (8.6 mg, 0.025 mmol, 5.0 mol %) and NaOAc 
(2.1 mg, 0.025 mmol, 5.0 mol %) at 70 °C. Purification by column chromatography on silica gel (n-
hexane/EtOAc 2:1) yielded 154ja (148 mg, 94%) as a pale yellow solid.  
M. p. = 137−138 °C. 
1
H NMR (300 MHz, CDCl3) δ = 12.99 (s, 1H), 8.63–8.59 (m, 1H), 8.57–8.55 (m, 2H), 
7.94–7.87 (m, 2H), 7.55–7.41 (m, 4H), 7.37 (s, 1H), 7.17 (pd, J = 7.2, 1.5 Hz, 2H), 6.95 (t, J = 4.8 Hz, 1H). 
13
C NMR (75 MHz, CDCl3) δ = 163.5 (Cq), 158.6 (Cq), 157.3 (CH), 135.5 (Cq), 134.4 (Cq), 132.5 (Cq), 131.7 
(CH), 129.9 (Cq), 128.7 (CH), 126.9 (CH), 123.0 (CH), 122.4 (CH), 119.7 (CH), 116.5 (CH), 115.9 (CH), 
95.6 (CH). IR (ATR): 3015, 1667, 1587, 1492, 1348, 1253, 791, 703, 588, 444 cm
-1
. MS (EI) m/z (relative 
intensity), 315 (5) [M+H
+
], 314 (40) [M
+
], 231 (10), 210 (20), 105 (100). HR-MS (EI) m/z calcd for 
C19H14N4O [M
+
] 314.1168, found 314.1165. 
 




3-Methyl-N-[1-(pyridin-2-yl)-1H-indol-2-yl]benzamide (154bb): The general procedure F was followed 
using indole substrate 102b (97 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132b (106 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (5.9 mg, 0.0125 mmol, 2.5 mol %), AgSbF6 (8.6 mg, 0.025 mmol, 5.0 mol %) and NaOAc 
(2.1 mg, 0.025 mmol, 5.0 mol %) at 70 °C. Purification by column chromatography on silica gel (n-
hexane/EtOAc 3:1) yielded 154bb (160 mg, 98%) as a pale yellow solid.  
M. p. = 112−113 °C. 
1
H NMR (300 MHz, CDCl3) δ = 11.88 (s, 1H), 8.59–8.57 (m, 1H), 7.88 (ddd, J = 8.4, 
7.4, 2.0 Hz, 1H), 7.77–7.67 (m, 3H), 7.64–7.54 (m, 2H), 7.41–7.28 (m, 3H), 7.27–7.12 (m, 3H), 2.43 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 163.7 (Cq), 151.9 (Cq), 147.9 (CH), 139.3 (CH), 138.5 (Cq) 134.8 (Cq), 134.0 
(Cq), 132.6 (CH), 131.7 (Cq), 129.5 (Cq), 128.5 (CH), 127.8 (CH), 123.8 (CH), 121.9 (CH), 121.6 (CH), 120.7 
(CH), 120.5 (CH), 117.8 (CH), 110.4 (CH), 93.5 (CH), 21.4 (CH3). IR (ATR): 3180, 3047, 1687, 1570, 1456, 
1342, 1210, 772, 733, 688 cm
-1
. MS (EI) m/z (relative intensity) 328 (20) [M+H
+
], 327 (100) [M
+
], 299 (10), 
208 (20), 181 (35), 181 (35), 119 (100). HR-MS (EI) m/z calcd for C21H17N3O2 [M
+




3-Fluoro-N-[1-(pyridin-2-yl)-1H-indol-2-yl]benzamide (154bc): The general procedure F was followed 
using indole substrate 102b (97 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132c (109 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (5.9 mg, 0.0125 mmol, 2.5 mol %), AgSbF6 (8.6 mg, 0.025 mmol, 5.0 mol %) and NaOAc 
(2.1 mg, 0.025 mmol, 5.0 mol %) at 100 °C. Purification by column chromatography on silica gel (n-
hexane/EtOAc 3:1) yielded 154bc (126 mg, 76%) as a pale yellow solid.  
M. p. = 105−106 °C. 
1
H NMR (300 MHz, CDCl3) δ = 11.98 (s, 1H), 8.59 (dd, J = 5.0, 1.7 Hz, 1H), 7. 92–
7.86 (m, 1H), 7.76–7.71 (m, 1H), 7.69–7.55 (m, 4H), 7.44 (td, J = 8.0, 5.6 Hz, 1H), 7.28–7.20 (m, 3H), 7.21–
7.12 (m, 2H). 
13
C NMR (75 MHz, CDCl3) δ = 164.4 (d, 
1
JC-F = 247.9 Hz, Cq), 162.1 (d, 
4
JC-F = 2.7 Hz, Cq), 
151.9 (Cq), 148.0 (CH), 139.5 (CH), 136.4 (d, 
3
JC-F = 6.9 Hz, Cq), 134.5 (Cq), 131.7 (Cq), 130.3 (d, 
3
JC-F = 7.9 
Hz, CH), 129.4 (Cq), 122.4 (d, 
4
JC-F = 3.1 Hz, CH), 122.1 (CH), 121.8 (CH), 120.7 (CH), 120.6 (CH), 118.8 (d, 
2
JC-F = 21.3 Hz, CH), 117.7 (CH), 114.3 (d, 
2
JC-F = 23.1 Hz, CH), 110.5 (CH), 93.8 (CH). 
19
F-NMR (282 MHz, 
CDCl3) δ = –114.4. IR (ATR): 3057, 3022, 1685, 1583, 1540, 1322, 1208, 873, 712, 637 cm
-1
. MS (EI) m/z 
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(relative intensity) 332 (30) [M+H
+
], 331 (100) [M
+
], 303 (10), 208 (50), 181 (50), 123 (70), 95 (40). HR-MS 
(EI) m/z calcd for C20H14FN3O [M
 +
] 331.1121, found 331.1134. 
 
 
3-Chloro-N-[1-(pyridin-2-yl)-1H-indol-2-yl]benzamide (154be): The general procedure F was followed 
using indole substrate 102b (97 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132e (119 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (5.9 mg, 0.0125 mmol, 2.5 mol %), AgSbF6 (8.6 mg, 0.025 mmol, 5.0 mol %) and NaOAc 
(2.1 mg, 0.025 mmol, 5.0 mol %) at 100 °C. Purification by column chromatography on silica gel (n-
hexane/EtOAc 3:1) yielded 154be (113 mg, 65%) as a pale yellow solid.  
M. p. = 145−146 °C. 
1
H NMR (400 MHz, CDCl3) δ = 12.02 (s, 1H), 8.60 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 
7.95–7.85 (m, 2H), 7.81–7.72 (m, 2H), 7.62–7.56 (m, 2H), 7.49 (ddd, J = 8.0, 2.1, 1.1 Hz, 1H), 7.40 (t, J = 7.8 
Hz, 1H), 7.28–7.23 (m, 2H), 7.21–7.13 (m, 2H). 
13
C NMR (100 MHz, CDCl3) δ = 162.0 (Cq), 152.0 (Cq), 
148.0 (CH), 139.5 (CH), 135.9 (Cq), 134.8 (Cq), 134.5 (Cq), 131.7 (Cq), 131.8 (CH), 130.0 (CH), 129.5 (Cq), 
127.4 (CH), 125.1 (CH), 122.1 (CH), 121.9 (CH), 120.7 (CH), 120.7 (CH), 117.7 (CH), 110.6 (CH), 93.8 
(CH). IR (ATR): 3055, 1689, 1569, 1545, 1341, 1259, 866, 733, 707, 671 cm
-1
. MS (EI) m/z (relative 
intensity) 347 (100) [M
+





] 347.0825, found 347.0827. 
 
 
N-[1-(Pyridin-2-yl)-1H-indol-2-yl]thiophene-3-carboxamide (154bd): The general procedure F was 
followed using indole substrate 102b (97 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132d (101 mg, 0.60 mmol, 
1.2 equiv), [Cp*Co(CO)I2] (5.9 mg, 0.0125 mmol, 2.5 mol %), AgSbF6 (8.6 mg, 0.025 mmol, 5.0 mol %) and 
NaOAc (2.1 mg, 0.025 mmol, 5.0 mol %) at 70 °C. Purification by column chromatography on silica gel (n-
hexane/EtOAc 3:1) yielded 154bd (153 mg, 96%) as a pale yellow solid.  
M. p. = 128−129 °C. 
1
H NMR (400 MHz, CDCl3) δ = 11.85 (s, 1H), 8.59 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.87 
(ddd, J = 8.3, 7.4, 2.0 Hz, 1H), 7.70 (dt, J = 8.3, 1.0 Hz, 1H), 7.62–7.53 (m, 3H), 7.50 (dd, J = 5.0, 1.2 Hz, 
1H), 7.25–7.19 (m, 2H), 7.19–7.12 (m, 2H), 7.09 (dd, J = 5.0, 3.7 Hz, 1H). 
13
C NMR (100 MHz, CDCl3) δ = 
158.1 (Cq), 151.8 (Cq), 148.0 (CH), 139.4 (CH), 139.1 (Cq), 134.3 (Cq), 131.7 (Cq), 130.6 (CH), 129.4 (Cq), 
128.4 (CH), 127.8 (CH), 122.0 (CH), 121.7 (CH), 120.6 (CH), 120.5 (CH), 117.6 (CH), 110.5 (CH), 93.5 
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(CH). IR (ATR): 3148, 3071, 1639, 1568, 1531, 1455, 1362, 1321, 844, 777, 727 cm
-1
. MS (EI) m/z (relative 
intensity), 320 (10) [M+H
+
], 319 (30), 291 (10), 208 (70), 181 (70), 111 (100). HR-MS (EI) m/z calcd for 
C18H13N3OS [M
+
] 319.0779, found 319.0782. 
 
 
N-[1-(Pyridin-2-yl)-1H-indol-2-yl]tetradecanamide (154bf): The general procedure F was followed using 
indole substrate 102b (97 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132f (162 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (5.9 mg, 0.0125 mmol, 2.5 mol %), AgSbF6 (8.6 mg, 0.025 mmol, 5.0 mol %) and NaOAc 
(2.1 mg, 0.025 mmol, 5.0 mol %) at 70 °C. Purification by column chromatography on silica gel (n-
hexane/EtOAc 6:1) yielded 154bf (205 mg, 98%) as a pale yellow solid.  
M. p. = 89−90 °C. 
1
H NMR (300 MHz, CDCl3) δ = 10.65 (s, 1H), 8.54 (dd, J = 5.0, 1.9 Hz, 1H), 7.87 (td, J = 
7.9, 1.9 Hz, 1H), 7.67 (d, J = 8.3 Hz, 1H), 7.60–7.46 (m, 2H), 7.28–7.06 (m, 4H), 2.37 (t, J = 7.3 Hz, 2H), 
1.69 (p, J = 7.3 Hz, 2H), 1.36–1.19 (m, 20H), 0.93–0.82 (m, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 170.0 (Cq), 
151.7 (Cq), 148.2 (CH), 139.2 (CH), 134.2 (Cq), 131.6 (Cq), 129.4 (Cq), 121.8 (CH), 121.5 (CH), 120.7 (CH), 
120.4 (CH), 118.1 (CH), 110.2 (CH), 93.4 (CH), 37.7 (CH2), 31.8 (CH2), 29.7 (CH2), 29.6 (CH2), 29.5 (CH2), 
29.4 (CH2), 29.4 (CH2), 29.3 (CH2), 29.3 (CH2), 29.1 (CH2), 25.3 (CH2), 22.6 (CH2), 14.0 (CH3). IR (ATR): 
3327, 3059, 2916, 2849, 1668, 1533, 1438, 1320, 1207, 738 cm
-1
. MS (EI) m/z (relative intensity), 420 (10) 
[M+H
+
], 419 (40) [M
+
], 361 (5), 209 (100), 181 (70), 169 (10). HR-MS (ESI) m/z calcd for C13H38N3O 
[M+H
+
] 420.3009, found 420.3002. 
 
 
N-[3-Methyl-1-(pyridin-2-yl)-1H-indol-2-yl]benzamide (154ka): The general procedure F was followed 
using indole substrate 102k (97 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (17 mg, 0.050 mmol, 10 mol %) and NaOAc (4.1 
mg, 0.050 mmol, 10 mol %) at 100 °C. Purification by column chromatography on silica gel (n-hexane/EtOAc 
3:1) yielded 154ka (105 mg, 64%) as a pale yellow solid.  
M. p. = 144−145 °C. 
1
H NMR (300 MHz, CDCl3) δ = 10.07 (s, 1H), 8.41–8.38 (m, 1H), 8.01–7.89 (m, 2H), 
7.78 (td, J = 7.8, 1.9 Hz, 1H), 7.60–7.56 (m, 1H), 7.55–7.42 (m, 5H), 7.25–7.17 (m, 2H), 7.11 (ddd, J = 7.5, 
5.0, 1.0 Hz, 1H), 2.22 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 164.7 (Cq), 150.9 (Cq), 148.4 (CH), 138.7 (CH), 
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133.9 (Cq), 133.4 (Cq), 131.9 (CH), 128.9 (Cq), 128.6 (CH), 128.4 (Cq), 127.4 (CH), 122.7 (CH), 121.0 (CH), 
120.8 (CH), 119.1 (CH), 119.0 (CH), 109.8 (CH), 107.9 (Cq), 9.2 (CH3). IR (ATR): 3151, 1676, 1591, 1471, 
1455, 1245, 1217, 894, 740, 691 cm
-1
. MS (EI) m/z (relative intensity) 328 (20) [M+H
+
], 327 (100) [M
+
], 222 
(100), 207 (20), 195 (30), 169 (5). HR-MS (EI) m/z calcd for C21H17N3O2 [M
 +
] 327.1372, found 327.1379. 
 
 
N-[3-Methyl-1-(pyrimidin-2-yl)-1H-indol-2-yl]benzamide (154la): The general procedure F was followed 
using indole 102l (105 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (98 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (17 mg, 0.050 mmol, 10 mol %) and NaOAc (4.1 
mg, 0.050 mmol, 10 mol %) at 100 °C. Purification by column chromatography on silica gel (n-hexane/EtOAc 
8:2 to 6:4) yielded 154la (106 mg, 65%) as a white solid.  
M. p. = 159–160 °C. 
1
H NMR (300 MHz, CDCl3) δ = 10.88 (s, 1H), 8.70 (d, J = 4.8 Hz, 2H), 8.56–8.46 (m, 
1H), 7.99 (d, J = 6.9 Hz, 2H), 7.61–7.43 (m, 4H), 7.34–7.20 (m, 2H), 7.04 (t, J = 4.8 Hz, 1H), 2.31 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ = 158.1 (Cq), 157.9 (CH), 157.9 (Cq), 134.5 (Cq), 134.2 (Cq), 132.0 (CH), 
130.0 (Cq), 129.1 (Cq), 128.8 (CH), 127.5 (CH), 123.6 (CH), 122.5 (CH), 118.5 (CH), 116.1 (CH), 114.9 
(CH), 110.3 (Cq), 10.2 (CH3). IR (ATR): 1673, 1562, 1503, 1429, 1272, 740, 710, 624 cm
-1
. MS (EI) m/z 
(relative intensity) 328 (58) [M
+
], 223 (95), 207 (26), 153 (12) 105 (100), 77 (51), 44 (55). HR-MS (ESI) m/z 
calcd for C20H17N4O [M+H
+
]: 329.1397, found: 329.1396.  
 
 
N-[1-(Pyridin-2-yl)-1H-pyrrol-2-yl]benzamide (155aa): The general procedure F was followed using 
substrate 102m (72 mg, 0.50 mmol, 1.0 equiv), dioxazolone 132a (101 mg, 0.60 mmol, 1.2 equiv), 
[Cp*Co(CO)I2] (11.9 mg, 0.025 mmol, 5.0 mol %), AgSbF6 (17 mg, 0.050 mmol, 10 mol %) and NaOAc (4.1 
mg, 0.050 mmol, 10 mol %) at 100 °C. Purification by column chromatography on silica gel (n-hexane/EtOAc 
3:1) yielded 155aa (72 mg, 55%) as a pale yellow solid.  
M. p. = 105−106 °C. 
1
H NMR (300 MHz, CDCl3) δ = 12.68 (s, 1H), 8.43 (ddd, J = 5.0, 1.9, 0.9 Hz, 1H), 
7.98–7.92 (m, 2H), 7.80 (ddd, J = 8.5, 7.4, 1.9 Hz, 1H), 7.53–7.43 (m, 3H), 7.37 (dt, J = 8.5, 0.9 Hz, 1H), 7.14 
(ddd, J = 7.4, 5.0, 0.9 Hz, 1H), 6.95 (dd, J = 3.6, 1.8 Hz, 1H), 6.91 (dd, J = 3.5, 1.8 Hz, 1H), 6.32 (td, J = 3.6, 
0.5 Hz, 1H). 
13
C NMR (125 MHz, CDCl3) δ = 162.8 (Cq), 153.4 (Cq), 146.8 (CH), 139.5 (CH), 134.7 (Cq), 
131.4 (CH), 130.8 (Cq), 128.6 (CH), 126.9 (CH), 119.8 (CH), 113.4 (CH), 112.6 (CH), 110.8 (CH), 100.2 
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(CH). IR (ATR): 3162, 3057, 3024, 1662, 1572, 1539, 1490, 1469, 1283, 775 cm
-1
. MS (EI) m/z (relative 
intensity) 264 (20) [M+H
+
], 263 (100) [M
+
], 158 (100), 131 (20), 105 (100). HR-MS (EI) m/z calcd for 
C16H13N3O2 [M
+
] 263.1059, found 263.1050. 
 
 
Methyl 3-benzamido-4-(1H-pyrazol-1-yl)benzoate(156aa): The general procedure F was followed by using 
phenyl pyrozol 117a (101 mg, 0.5 mmol), 3-phenyl-1,4,2-dioxazol-5-one (132a) (98 mg, 0.6 mmol, 1.2 equiv). 
Purification by column chromatography on silica gel (n-hexane /EtOAc 2:1) yielded 156aa (135 mg, 84%) as 
a white solid.  
M. p. = 154−155 °C.
 1
H NMR (300 MHz, CDCl3) δ = 11.66 (s, 1H), 9.35 (d, J = 1.9 Hz, 1H), 7.96–7.90 (m, 
3H), 7.85 (dd, J = 1.9, 0.6 Hz, 1H), 7.81 (dd, J = 8.4, 1.9 Hz, 1H), 7.55–7.42 (m, 3H), 7.39 (d, J = 8.4 Hz, 1H), 
6.50 (dd, J = 2.5, 1.9 Hz, 1H), 3.90 (s, 3H).
 13
C NMR (75 MHz, CDCl3) δ = 166.0 (Cq), 165.2 (Cq), 141.4 
(CH), 134.4 (Cq), 131.9 (CH), 131.6 (Cq), 131.2 (Cq), 130.2 (CH), 129.2 (Cq), 128.6 (CH), 127.2 (CH), 125.2 
(CH), 124.0 (CH), 121.3 (CH), 107.7 (CH), 52.2 (CH3). IR (ATR): 3241, 3141, 2946, 1715, 1671, 1590, 1437, 
1228, 763, 698 cm
-1
. MS (EI) m/z (relative intensity), 322 (5) [M+H
+
], 321 (40) [M
 +
], 290 (10), 189 (10), 105 
(100). HR-MS (EI) m/z calcd for C18H15N3O3 [M
+
] 321.1113, found 321.1109. 
 
 
N-(2-(1H-indazol-1-yl)-5-methylphenyl)benzamide(156ba): The general procedure F was followed by 
using phenyl pyrozol 117b (104 mg, 0.5 mmol), 3-phenyl-1,4,2-dioxazol-5-one 132a (98 mg, 0.6 mmol, 1.2 
equiv). Purification by column chromatography on silica gel (n-hexane /EtOAc 2:1) yielded 156ba (154 mg, 
94%) as a white solid.  
M. p. = 115−116 °C.
 1
H NMR (300 MHz, CDCl3) δ = 10.17 (s, 1H), 8.57–8.51 (m, 1H), 8.33 (d, J = 0.9 Hz, 
1H), 7. 85–7.78 (m, 3H), 7.58 (dt, J = 8.6, 0.9 Hz, 1H), 7.51–7.36 (m, 5H), 7. 25–7.19 (m, 1H), 7. 10–7.06 (m, 
1H), 2.49 (s, 3H).
 13
C NMR (75 MHz, CDCl3) δ = 164.8 (Cq), 139.8 (Cq), 138.4 (Cq), 135.5 (CH), 134.5 (Cq), 
132.5 (Cq), 131.6 (CH), 128.5 (CH), 127.7 (CH), 126.9 (CH), 126.2 (Cq), 124.7 (CH), 124.1 (Cq), 123.9 (CH), 
123.5 (CH), 121.9 (CH), 121.1 (CH), 110.6 (CH), 21.4 (CH3). IR (ATR): 3342, 1673, 1592, 1531, 1497, 1464, 
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1414, 1347, 1299 cm
-1




], 327 (100) [M
+
], 222 (30), 195 (10), 
105 (100). HR-MS (EI) m/z calcd for C21H17N3O [M
 +
] 327.1372, found 327.1373. 
 
 
N-(4-methyl-2-(4-methylpyridin-2-yl)phenyl)benzamide (157aa): The general procedure F was followed 
by using phenyl pyridine 9a (92 mg, 0.5 mmol), 3-phenyl-1,4,2-dioxazol-5-one 132a (98 mg, 0.6 mmol, 1.2 
equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1) yielded 157aa (144 mg, 
95%) as a white solid.  




H NMR (300 MHz, CDCl3) δ = 13.25 (s, 1H), 8.68 (d, J = 8.4 Hz, 1H), 8.47 (d, J = 5.1 
Hz, 1H), 8.03–7.99 (m, 2H), 7.55 (s, 1H), 7.50–7.41 (m, 4H), 7.24 (dd, J = 8.5, 2.1 Hz, 1H), 7.05–7.02 (m, 
1H), 2.38 (s, 3H), 2.37 (s, 3H).
 13
C NMR (75 MHz, CDCl3) δ = 165.1 (Cq), 157.9 (Cq), 148.9 (Cq), 146.8 (CH), 
135.7 (Cq), 135.6 (Cq), 132.7 (Cq), 131.2 (CH), 130.5 (CH), 129.0 (CH), 128.4 (CH), 127.2 (CH), 125.5 (Cq), 
123.5 (CH), 122.8 (CH), 121.6 (CH), 21.3 (CH3), 20.9 (CH3). IR (ATR): 2974, 1664, 1592, 1517, 1448, 1316, 
1298, 1177, 819 cm
-1
. MS (EI) m/z (relative intensity), 303 (10) [M+H
+
], 302 (60) [M
 +
], 258 (10), 225 (100), 
105 (60). HR-MS (EI) m/z calcd for C20H18N2O [M
 +
] 302.1419, found 302.1421. 
 
 
N-(5-(tert-butyl)-2-(pyridin-2-yl)phenyl)benzamide(157ba): The general procedure F was followed by 
using phenyl pyridine 9b (105 mg, 0.5 mmol), 3-phenyl-1,4,2-dioxazol-5-one 132a (98 mg, 0.6 mmol, 1.2 
equiv). Purification by column chromatography on silica gel (n-hexane /EtOAc 2:1) yielded 157ba (152 mg, 
92%) as a white solid. 




H NMR (300 MHz, CDCl3) δ = 13.54 (s, 1H), 9.00 (d, J = 2.1 Hz, 1H), 8.58 (dt, J = 4.9, 
1.5 Hz, 1H), 8.12–8.03 (m, 2H), 7.76–7.67 (m, 2H), 7.64 (d, J = 8.3 Hz, 1H), 7. 51–7.45 (m, 3H), 7.26–7.12 
(m, 2H), 1.42 (s, 9H).
 13
C NMR (75 MHz, CDCl3) δ = 165.4 (Cq), 157.9 (Cq), 153.5 (Cq), 146.9 (CH), 138.0 
(Cq), 137.5 (CH), 135.7 (Cq), 131.3 (CH), 128.4 (CH), 128.1 (CH), 127.2 (CH), 122.3 (Cq), 122.2 (CH), 121.4 
(CH), 120.5 (CH), 118.7 (CH), 34.9 (Cq), 31.1 (CH3). IR (ATR): 2956, 1665, 1574, 1556, 1526, 1465, 1245, 
703 cm
-1




], 330 (30) [M
 +
], 315 (10), 253 (30), 105 (100). 
HR-MS (EI) m/z calcd for C20H18N2O [M
 +
] 330.1732, found 330.1737. 
 




N-(5-Methoxy-2-(pyrimidin-2-yl)phenyl)benzamide(157ca): The general procedure F was followed by 
using phenyl pyrimidine 9c (93 mg, 0.5 mmol), 3-phenyl-1,4,2-dioxazol-5-one 132a (98 mg, 0.6 mmol, 1.2 
equiv). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1) yielded 157ca (90 mg, 
59%) as a white solid. 




H NMR (300 MHz, CDCl3) δ = 13.76 (s, 1H), 8.74 (d, J = 4.8, 2H), 8.65 (d, J = 2.7 Hz, 
1H), 8.59 (d, J = 9.0 Hz, 1H), 8.13–8.01 (m, 2H), 7.61–7.41 (m, 3H), 7.11 (dd, J = 4.8, 0.5 Hz, 1H), 6.74 (dd, 
J = 9.0, 2.7 Hz, 1H), 3.92 (s, 3H).
 13
C NMR (75 MHz, CDCl3) δ = 166.0 (Cq), 164.9 (Cq), 162.7 (Cq), 156.2 
(CH), 142.0 (Cq), 135.9 (Cq), 131.9 (CH), 131.6 (CH), 128.6 (CH), 127.4 (CH), 117.6 (CH), 115.4 (Cq), 110.5 
(CH), 104.5 (CH), 55.5 (CH3). IR (ATR): 3236, 3027, 2842, 2233, 1672, 1574, 1390, 1189 cm
-1
. MS (EI) m/z 




], 305 (100) [M
 +
], 228 (90), 155 (30), 105 (100). HR-MS (EI) m/z calcd 
for C18H15N3O2 [M
 +
] 305.1164, found 305.1166. 
 
Reactions with Radical Scavengers: 
 
Reaction with TEMPO 
130i (81 mg, 0.50 mmol, 1.0 equiv), 132a (98 mg, 0.60 mmol, 1.2 equiv), [Cp*Co(CO)I2] (11.9 mg, 0.025 
mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %), NaOAc (8.2 mg, 0.10 mmol, 20 mol %) and 
TEMPO (78 mg, 0.50 mmol, 1.0 equiv) were placed into a 25 mL Schlenk tube equipped with a septum under 
N2 atmosphere. DCE (2.0 mL) was introduced via cannula. The reaction mixture was stirred at 100 °C for 16 h. 
After cooling to ambient temperature, the reaction mixture was dry loaded onto silica gel and purified by flash 
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Reaction with 1,1-Diphenylethylene 
130i (81 mg, 0.50 mmol, 1.0 equiv), 132a (98 mg, 0.60 mmol, 1.2 equiv), [Cp*Co(CO)I2] (11.9 mg, 0.025 
mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %), NaOAc (8.2 mg, 0.10 mmol, 20 mol %) and 1,1-
diphenylethylene (90 mg, 0.50 mmol, 1.0 equiv) were placed into a 25 mL Schlenk tube equipped with a 
septum under N2 atmosphere. DCE (2.0 mL) was introduced via cannula. The reaction mixture was stirred at 
100 °C for 16 h. After cooling to ambient temperature, the reaction mixture was dry loaded onto silica gel and 
purified by flash column chromatography (n-hexane/EtOAc = 7:1) to yield the product 133ia (95 mg, 67%) as 
a white solid. 
 
Reaction with BHT 
130i (81 mg, 0.50 mmol, 1.0 equiv), 132a (98 mg, 0.60 mmol, 1.2 equiv), [Cp*Co(CO)I2] (12 mg, 0.025 
mmol, 5 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %), NaOAc (8.2 mg, 0.10 mmol, 20 mol %) and 2,6-
bis(1,1-dimethylethyl)-4-methylphenol (110 mg, 0.50 mmol, 1.0 equiv) were placed into a 25 mL Schlenk 
tube equipped with a septum under N2 atmosphere. DCE (2.0 mL) was introduced via cannula. The reaction 
mixture was stirred at 100 °C for 16 h. After cooling to ambient temperature, the reaction mixture was dry 
loaded onto silica gel and purified by flash column chromatography (n-hexane/EtOAc = 7:1) to yield the 




133i (81 mg, 0.50 mmol, 1.0 equiv), 132a (98 mg, 0.60 mmol, 1.2 equiv), [Cp*Co(CO)I2] (12 mg, 0.025 
mmol, 5.0 mol %), AgSbF6 (34 mg, 0.10 mmol, 20 mol %), and NaOAc (8.2 mg, 0.10 mmol, 20 mol %) were 
placed into a 25 mL Schlenk tube equipped with a septum under N2 atmosphere. DCE (2.0 mL) was 
introduced via cannula. The reaction mixture was stirred at 100 °C for 2.5 min. (No detectable formation of 
133ia was observed by GC-MS analysis of an aliquot of the reaction mixture). Mercury (100 mg, 0.50 mmol, 
1.0 equiv) was then added via syringe. The reaction mixture was stirred at 100 °C for 16 h. After cooling to 
ambient temperature, the reaction mixture was dry loaded onto silica gel and purified by flash column 
chromatography (n-hexane/EtOAc = 7:1) to yield the product 133ia (92 mg, 66%) as a white solid. 
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H/D Exchange Experiments  
Cobalt-Catalyzed H/D Exchange in Substrate 130i with CD3OD as the Co-solvent in the Absence of 
132a: 
 
A suspension of   oxazoline 130i (81 mg, 0.50 mmol), [Cp*Co(CO)I2] (11.9 mg, 5.0 mol %), AgSbF6 (34 mg, 
20 mol %) and NaOAc (8.2 mg, 10 mol %) in a solvent mixture of DCE (2.0 mL) and CD3OD (0.10 mL) was 
stirred at 100 °C for 16 h under argon atmosphere. After cooling to ambient temperature, the reaction mixture 
was evaporated in vacuo and the remaining residue was purified by column chromatography on silica gel (n-
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Cobalt-Catalyzed H/D Exchange in Substrate 130j with CD3OD as the Co-solvent in the absence of 132a: 
 
A suspension of   2-phenyl-4,5-dihydrooxazole (130j) (74 mg, 0.50 mmol), [Cp*Co(CO)I2] (11.9 mg, 5.0 mol 
%), AgSbF6 (34 mg, 20 mol %) and NaOAc (8.2 mg, 20 mol %) in a solvent mixture of DCE (2.0 mL) and 
CD3OD (0.10 mL) was stirred at 100 °C for 4 h under argon atmosphere. After cooling to ambient temperature, 
the reaction mixture was evaporated in vacuo and the residue was purified by column chromatography on 
silica gel (n-hexane/EtOAc) to yield [D]n-130j (59 mg, 80%) as a pale yellow oil. The D-incorporation in 
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Cobalt-Catalyzed H/D Exchange in Substrate 130i with CD3OD as the Co-solvent in the Presence of 
132a: 
 
A suspension of   oxazoline 130i (81 mg, 0.50 mmol), 132a (98 mg, 0.60 mmol), [Cp*Co(CO)I2] (11.9 mg, 
5.0 mol %), AgSbF6 (34 mg, 20 mol %) and NaOAc (8.2 mg, 20 mol %) in a solvent mixture of DCE (2.0 mL) 
and CD3OD (0.10 mL) was stirred at 100 °C for 16 h under argon atmosphere. After cooling to ambient 
temperature, the reaction mixture was evaporated in vacuo and the remaining residue was purified by column 
chromatography on silica gel (n-hexane/EtOAc) and then by GPC to yield [D]n-133ia (49 mg, 35%) as a white 
solid. The D-incorporation in [D]n-133ia was estimated by 
1
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Kinetic Isotope Effects Experiments  
Synthesis of Deuterated Substrate [D]2-130i 
 
To a 25 mL Schlenk flask was added 130i (967 mg, 6.0 mmol), [Ru(p-cymene)(MesCO2)2] (168 mg, 5.0 
mol %), K2CO3 (1.66 g, 12.0 mmol), D2O (0.80 mL), and PhMe (8.0 mL) under argon atmosphere. The 
mixture was stirred at 130 °C for 48 h. After cooling to ambient temperature, the reaction mixture was diluted 
with EtOAc, dried with K2CO3 and concentrated in vacuo. The crude product was purified by silica gel 
column chromatography (n-hexane/EtOAc 2:1) to give the deuterated product as a pale yellow solid (871 mg, 
89%). 
1
H-NMR analysis showed 88% Deuterium incorporation in the ortho-positions. The same procedure 
was repeated again: The substrate (871 mg, 5.34 mmol) was dissolved in PhMe (6.0 mL), [Ru(p-
cymene)(MesCO2)2] (149 mg, 5.0 mol %), K2CO3 (1.48 g, 10.7 mmol) and D2O (0.60 mL) was added. This 
mixture was stirred at 130 °C for 48 h. Following the same work-up procedure as above, the deuterated 
product [D]2-130i was isolated as a pale yellow solid (748 mg, 86%). 
1
H-NMR analysis showed 92% 
Deuterium incorporation in the ortho-positions. 
 





Two independent reactions with 130i or deuterated substrate [D]2-130i under the standard conditions were 
performed: Suspensions of dioxazolone 132a (196 mg, 1.2 mmol), substrate 130i (161 mg, 1.0 mmol) or [D]2-
130i (163 mg, 1.0 mmol), [Cp*Co(CO)I2] (23.0 mg, 5.0 mol %), AgSbF6 (68.7 mg, 20 mol %), NaOAc (16.4 
mg, 20 mol %) and internal standard n-dodecane (101 mg, 0.60 mmol) in DCE (4.0 mL) were stirred at 
100 °C for 15 min, 20 min, 25 min, 30 min, 40 min, 50 min under an atmosphere of argon, respectively. The 
conversion to the products 133ia or [D]1-133ia was monitored by GC analysis. 
 
 
t [min] 15 20 25 30 40 50 
3aa [%] 3.3 11.2 19.8 27.0 43.4 55.6 







y = 1,5124x - 18,654 
 




























130i (81 mg, 0.50 mmol) and [D]2-130i (82 mg, 0.50 mmol) were added to one test tube with stirring bar, 
followed by dioxazolone 132a (82 mg, 0.50 mmol), [Cp*Co(CO)I2] (12 mg, 5.0 mol %), AgSbF6 (34 mg, 20 
mol %), NaOAc (16.4 mg, 20 mol %) and DCE (2.0 mL), and the mixture was stirred at 100 °C for 16 h under 
argon. After cooling to ambient temperature, the volatiles were removed under reduced pressure and the 
mixture was purified by flash chromatography on silica gel to afford the amidation product [D]n-133ia (36 mg, 
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Intermolecular Competition Experiment between oxazolines 130q and 130m 
  
 
A suspension of   3-phenyl-1,4,2-dioxazol-5-one (132a) (81 mg, 0.50 mmol), oxazoline 130m (89 mg, 0.50 
mmol), oxazoline 130q (108 mg, 0.50 mmol), [Cp*Co(CO)I2] (11.9 mg, 5.0 mol %), AgSbF6 (34 mg, 20 
mol %) and NaOAc (8.2 mg, 20 mol %) in DCE (2.0 mL) was stirred at 100 °C for 16 h under an atmosphere 
of argon. At ambient temperature, 1,3,5-trimethoxybenzene (16.8 mg, 0.10 mmol) was added as internal 





Intermolecular Competition Experiment between amidation reagents 132b and 132c 
 
A suspension of   oxazoline 130i (81 mg, 0.50 mmol), amidation reagent 132b (88 mg, 0.50 mmol), 132c (82 
mg, 0.50 mmol), [Cp*Co(CO)I2] (11.9 mg, 5.0 mol %), AgSbF6 (34 mg, 20 mol %) and NaOAc (8.2 mg, 20 
mol %) in DCE (2.0 mL) was stirred at 100 °C for 16 h under an atmosphere of argon. After cooling to 
ambient temperature, the reaction mixture was dry loaded onto silica gel and purified by column 
chromatography (n-hexane/EtOAc 6:1) to afford a mixture of 133ib and 133ic (34 mg). The ratio of the two 
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Procedures for Gram-Scale Reactions 
 
To a 100 mL Schlenk flask was added substrates 130i (6.0 mmol, 967 mg), 132a (1.17 g, 7.2 mmol), 
[Cp*Co(CO)I2] (138 mg, 5.0 mol %), AgSbF6 (412 mg, 20 mol %), NaOAc (98 mg, 20 mol %) and DCE (24 
mL). This mixture was stirred at 100 °C for 24 h under an atmosphere of argon. After cooling to ambient 
temperature, the reaction mixture was dry loaded onto silica gel and purified by flash column chromatography 
(n-hexane/EtOAc = 6:1) to afford the desired product 133ia as white solid (1.04 g, 62%). 
 
 
To a 100 mL Schlenk tube were added substrates 102b (6.0 mmol, 1.16 g), 132a (1.17 g, 7.2 mmol), 
[Cp*Co(CO)I2] (28 mg, 1.0 mol %), AgSbF6 (41 mg, 2.0 mol %), NaOAc (9.8 mg, 2.0 mol %) and DCE (24 
mL). This mixture was stirred at 70 °C for 24 h under an atmosphere of argon. After cooling to ambient 
temperature, the reaction mixture was dry loaded onto silica gel and purified by flash column chromatography 
(n-hexane/EtOAc 2:1) to afford the desired product 154ba as white solid (1.84 g, 98%). 
 
Diversification of 2-Amidoaryloxazolines 3 
 
 
N-[2-(4,5-Dihydrooxazol-2-yl)-5-methylphenyl]-2-hydroxybenzamide (158): Following a modified 
procedure,
[151]
 133ia (0.20 mmol, 56 mg), H2O (72 mg, 4.0 mmol), Cu(OAc)2 (36 mg, 0.20 mmol), Na2CO3 
(21 mg, 0.20 mmol), and DMSO (4.0 mL) were added to a 25 mL Schlenk tube. The reaction tube was 
evacuated and backfilled with O2 6 times. After stirring at 80 °C for 6 h, the reaction mixture was diluted with 
EtOAc (20 mL) and washed with NH4OH (25%, 20 mL) and brine (20 mL). The organic fraction was dried 
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over Na2SO4 and concentrated in vacuo. The crude product was purified by column chromatography on silica 
gel (n-hexane/EtOAc 5:1) to give the hydroxylated product 158 as a white solid (53 mg, 89%).  
M. p. = 144−145 °C. 
1
H NMR (300 MHz, CDCl3) δ = 13.17 (s, 1H), 12.44 (s, 1H), 8.62 (s, 1H), 7.89 (dd, J = 
8.1, 1.6 Hz, 1H), 7.76 (d, J = 8.1 Hz, 1H), 7.40 (ddd, J = 8.6, 7.2, 1.6 Hz, 1H), 6.99 (dd, J = 8.6, 1.2 Hz, 1H), 
6.96–6.85 (m, 2H), 4.39 (td, J = 9.3, 1.3 Hz, 2H), 4.17 (td, J = 9.3, 1.3 Hz, 2H), 2.41 (s, 3H). 
13
C NMR (75 
MHz, CDCl3) δ = 169.7 (Cq), 165.0 (Cq), 162.3 (Cq), 143.4 (Cq), 139.1 (Cq), 134.2 (CH), 129.2 (CH), 126.9 
(CH), 123.9 (CH), 120.7 (CH), 118.8 (CH), 118.5 (CH), 115.6 (Cq), 111.4 (Cq), 66.3 (CH2), 54.5 (CH2), 22.1 
(CH3). IR (ATR): 2981, 2908, 1628, 1581, 1313, 1261, 1149, 813, 742, 517 cm
-1
. MS (EI) m/z (relative 
intensity) 296 (50) [M
+
], 280(10), 203 (25), 176 (100), 160 (20), 145 (20), 121 (20). HR-MS (EI) m/z calcd 
for C17H16N2O3 [M
+
] 296.1161, found 296.1166. 
 
 
2-[(7-Phenylquinazolin-4-yl)amino]ethan-1-ol (159): To a 5 mL sealed tube was added 133oa (51 mg, 0.15 
mmol), KOH (336 mg, 6.0 mmol), EtOH (2.0 mL). The reaction mixture was irradiated with microwave at 
100 °C for 30 min under air. Upon completion, the reaction mixture was diluted with H2O (20 mL) and 
extracted with EtOAc (4 × 20 mL). The organic phase was dried over Na2SO4 and concentrated in vacuo. 
Following a modified procedure,
[12]
 the residue was then dissolved in EtOH (2.0 mL), and formamidine 
acetate (47 mg, 3.0 equiv) was added. The reaction mixture was heated at 90 °C for 1 hour. After cooling to 
ambient temperature, the reaction mixture was dry loaded onto silica gel and purified by column 
chromatography (DCM/MeOH 10:1) to yield the product 159 (29 mg, 74%) as an off-white solid.  
M. p. = 209−210 °C. 
1
H NMR (400 MHz, DMSO-d6) δ = 8.48 (s, 1H), 8.34 (d, J = 8.6 Hz, 1H), 8.29–8.24 (m, 
1H), 7.91 (d, J = 1.8 Hz, 1H), 7.85–7.82 (m, 3H), 7.56–7.49 (m, 2H), 7.47–7.40 (m, 1H), 4.79 (s, 1H), 3.76–
3.59 (m, 4H). 
13
C NMR (100 MHz, DMSO-d6) δ = 159.3 (Cq), 155.4 (CH), 149.5 (Cq), 143.8 (Cq), 138.8 (Cq), 
129.0 (CH), 128.2 (CH), 127.0 (CH), 124.5 (CH), 124.2 (CH), 123.5 (CH), 114.0 (Cq), 59.2 (CH2), 43.3 (CH2). 
IR (ATR): 3337, 3061, 2830, 1584, 1428, 1347, 1064, 755, 512 cm
-1
. MS (EI) m/z (relative intensity) 265 (15) 
[M
+









2-(4, 5-Dihydrooxazol-2-yl)-5-methylaniline (S8) 
133ia (140 mg, 0.50 mmol), KOH (1.12 g, 20 mmol), EtOH (10 mL) were added to a 50 mL sealed tube. The 
reaction mixture was stirred at 80 °C for 24 h under air. After cooling to ambient temperature, the reaction 
mixture was diluted with H2O (20 mL) and extracted with EtOAc (4 × 20 mL). The organic phase was dried 
over Na2SO4 and concentrated in vacuo. The crude product was purified by flash column chromatography on 
silica gel (n-hexane/EtOAc 5:1) to give 178 as a pale yellow solid (83 mg, 93%).  
M. p. = 93−94 °C. 
1
H NMR (400 MHz, CDCl3) δ = 7.56 (d, J = 8.0 Hz, 1H), 6.50–6.45 (m, 2H), 5.96 (br, 2H), 
4.28 (td, J = 9.3, 1.0 Hz, 2H), 4.06 (td, J = 9.3, 1.0 Hz, 2H), 2.25 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 
164.8 (Cq), 148.4 (Cq), 142.4 (Cq), 129.5 (CH), 117.4 (CH), 115.9 (CH), 106.8 (Cq), 65.6 (CH2), 54.9 (CH2), 
21.5 (CH3). IR (ATR): 3426, 3308, 2979, 2876, 1607, 1366, 1247, 1047, 810, 680 cm
-1
. MS (EI) m/z (relative 
intensity) 176 (100) [M
+
], 145 (40), 132 (25), 118 (10), 104 (10). HR-MS (EI) m/z calcd for C17H16N2O3 [M
+
] 
176.0950, found 176.0949. 
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5.3.6 Cobalt-Catalyzed Oxidase C−H/N−H Alkyne Annulation 
 
 
2-[3-n-Hexyl-1-oxoisoquinolin-2(1H)-yl] pyridine 1-oxide (134ae): The general procedure G was followed, 
using aromatic amide 85a (107 mg, 0.50 mmol) and alkyne 59e (66 mg, 0.60 mmol). Purification by column 
chromatography on silica gel (CH2Cl2/acetone 2:1) yielded 134ae (124 mg, 77%) as a colorless solid.  
M. p. = 100–101 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 8.38–8.24 (m, 2H), 7.64–7.58 (m, 1H), 7.48–7.37 (m, 
3H), 7.36–7.31 (m, 2H), 6.41 (s, 1H), 2.40–2.24 (m, 1H), 2.21–2.06 (m, 1H), 1.57–1.46 (m, 2H), 1.29–1.11 
(m, 6H), 0.82 (t, J = 7.0 Hz, 3H). 
13
C NMR (125 MHz, CDCl3) δ = 162.5 (Cq), 144.4 (Cq), 142.5 (Cq), 140.5 
(CH), 137.3 (Cq), 133.0 (CH), 128.0 (CH), 127.8 (CH), 126.1 (CH), 125.9 (CH), 125.6 (CH), 125.3 (CH), 
124.3 (Cq), 104.8 (CH), 31.8 (CH2), 31.2 (CH2), 28.6 (CH2), 27.4 (CH2), 22.2 (CH2), 13.8 (CH3). IR (ATR): 
2962, 2856, 1662, 1624, 1591, 1561, 1467, 1308, 994, 820 cm
-1
. MS (EI) m/z (relative intensity) 323 (10) 
[M+H
+
], 322 (50) [M
+
], 306 (30), 305 (100), 265 (20), 251 (60), 234 (95). HR-MS (EI) m/z calcd for 
C20H22N2O2 [M
+
] 322.1681, found 322.1672. 
 
 
2-[1-Oxo-3-(p-tolyl) isoquinolin-2(1H)-yl] pyridine 1-oxide (134af): The general procedure G was followed, 
using aromatic amide 85a (107 mg, 0.50 mmol) and alkyne 59f (70 mg, 0.60 mmol). Purification by column 
chromatography on silica gel (CH2Cl2/acetone 2:1) yielded 134af (149 mg, 91%) as a colorless solid.  
M. p. = 238–239 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 8.39–8.36 (m, 1H), 8.19–8.12 (m, 1H), 7.70–7.59 (m, 
1H), 7.52–7.36 (m, 2H), 7.31–7.20 (m, 2H), 7.14–7.00 (m, 3H), 7.00–6.94 (m, 2H), 6.53 (s, 1H), 2.22 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ = 161.8 (Cq), 145.5 (Cq), 142.6 (Cq), 139.8 (CH), 138.9 (Cq), 137.0 (Cq), 133.2 
(CH), 131.9 (Cq), 128.8 (CH), 128.2 (CH), 127.6 (CH), 127.5 (CH), 126.8 (CH), 126.1 (CH), 125.3 (CH), 
125.0 (CH), 124.7 (Cq), 107.8 (CH), 21.1 (CH3). IR (ATR): 3062, 1657, 1621, 1600, 1480, 1422, 1260, 1141, 
890, 758 cm
-1
. MS (EI) m/z (relative intensity) 329 (5) [M+H
+
], 328 (10) [M
+
], 312 (30), 283 (30), 208 (25), 
195 (100), 165 (50). HR-MS (EI) m/z calcd for C21H16N2O2 [M
+
] 328.1212, found 328.1213. 
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2-[3-{(1,3-Dioxoisoindolin-2-yl)methyl}-1-oxoisoquinolin-2(1H)-yl] pyridine 1-oxide (134ag): The general 
procedure G was followed, using aromatic amide 85a (107 mg, 0.50 mmol) and alkyne 59g (111 mg, 0.60 
mmol). The crude product was directly purified by column chromatography on silica gel (n-hexane/EtOAc 2:1 
→ CH2Cl2/acetone 1:1) without aqueous work up yielding 134ag (187 mg, 94%) as a colorless solid.  
M. p. = 232–233 ºC. 
1
H NMR (400 MHz, CDCl3) δ = 8.37–8.28 (m, 2H), 7.83–7.76 (m, 2H), 7.75–7.68 (m, 
2H), 7.66 (ddd, J = 7.9, 7.2, 1.4 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.49–7.43 (m, 2H), 7.40 (ddd, J = 7.7, 6.4, 
2.4 Hz, 1H), 7.35 (dd, J = 7.7, 7.7 Hz, 1H), 6.75 (s, 1H), 4.75 (dd, J = 15.7, 1.0 Hz, 1H), 4.46 (d, J = 15.7 Hz, 
1H). 
13
C NMR (100 MHz, CDCl3) δ = 167.1 (Cq), 162.3 (Cq), 143.3 (Cq), 140.9 (CH), 136.5 (Cq), 136.0 (Cq), 
134.3 (CH), 133.4 (CH), 131.7 (Cq), 128.5 (CH), 128.3 (CH), 127.4 (CH), 126.4 (CH), 126.3 (CH), 125.8 
(CH), 125.2 (Cq), 123.4 (CH), 108.6 (CH), 38.9 (CH2). IR (ATR): 3513, 2283, 3062, 1717, 1668, 1635, 1603, 
1420, 1386, 1115, 725 cm
-1
. MS (EI) m/z (relative intensity) 398 (2) [M+H
+
], 380 (15), 303 (10), 264 (10), 
234 (100), 205 (20), 160 (40). HR-MS (EI) m/z calcd for C23H15N3O4 [M
+
] 397.1063, found 397.1076. 
 
 
2-[1-Oxo-3-(triisopropylsilyl)isoquinolin-2(1H)-yl] pyridine 1-oxide (134ah): The general procedure G 
was followed, using aromatic amide 85a (107 mg, 0.50 mmol) and alkyne 59h (109 mg, 0.60 mmol). 
Purification by column chromatography on silica gel (CH2Cl2/acetone 2:1) yielded 134ah (164 mg, 83%) as a 
colorless solid.  
M. p. = 175–177 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 8.38–8.35 (m, 1H), 8.27 (dd, J = 6.4, 1.5 Hz, 1H), 
7.71–7.63 (m, 1H), 7.54–7.42 (m, 3H), 7.37–7.27 (m, 2H), 6.83 (s, 1H), 1.10–1.03 (m, 18H), 0.97–0.83 (m, 
3H). 
13
C NMR (125 MHz, CDCl3) δ = 163.1 (Cq), 147.2 (Cq), 141.6 (Cq), 140.3 (CH), 136.3 (Cq), 132.9 (CH), 
127.9 (CH), 127.8 (CH), 127.5 (CH), 126.1 (CH), 126.0 (CH), 125.8 (Cq), 124.3 (CH), 118.7 (CH), 19.1 
(CH3), 18.6 (CH3), 12.3 (CH). IR (ATR): 2942, 2866, 1650, 1488, 1427, 1334, 1261, 950, 882, 747 cm
-1
. MS 
(EI) m/z (relative intensity) 395 (30) [M+H
+
], 394 (100) [M
+
], 386 (10), 385 (40), 379 (25), 377 (60), 369 (60). 
HR-MS (ESI) m/z calcd for C23H31N2O2Si [M+H
+




2-[6-Methoxy-1-oxo-3-n-pentylisoquinolin-2(1H)-yl] pyridine 1-oxide (134bi): The general procedure G 
was followed, using aromatic amide 85b (122 mg, 0.50 mmol) and alkyne 59i (58 mg, 0.60 mmol). 
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Purification by column chromatography on silica gel (CH2Cl2/acetone 1:1) yielded 134bi (147 mg, 88%) as a 
colorless solid.  
M. p. = 202–203 ºC. 
1
H NMR (500 MHz, CDCl3) δ = 8.34–8.28 (m, 1H), 8.19 (d, J = 8.8 Hz, 1H), 7.42–7.37 
(m, 1H), 7.33–7.26 (m, 2H), 6.92 (dd, J = 8.9, 2.5 Hz, 1H), 6.80 (d, J = 2.5 Hz, 1H), 6.32 (s, 1H), 3.83 (s, 3H), 
2.31–2.19 (m, 1H), 2.15–2.01 (m, 1H), 1.55–1.40 (m, 2H), 1.23–1.10 (m, 4H), 0.78 (t, J = 7.0 Hz, 3H). 
13
C 
NMR (125 MHz, CDCl3) δ = 163.3 (Cq), 162.0 (Cq), 144.3 (Cq), 143.1 (Cq), 140.3 (CH), 139.5 (Cq), 129.9 
(CH), 127.9 (CH), 125.8 (CH), 125.3 (CH), 117.9 (Cq), 115.4 (CH), 106.6 (CH), 104.6 (CH), 55.3 (CH3), 31.7 
(CH2), 31.0 (CH2), 27.0 (CH2), 22.0 (CH2), 13.7 (CH3). IR (ATR): 3049, 2926, 2866, 1697, 1665, 1632, 1598, 
1485, 1252, 866 cm
-1
. MS (EI) m/z (relative intensity) 395 (2) [M+H
+
], 394 (5) [M
+
], 378 (60), 359 (20), 249 
(100), 235 (60), 206 (20). HR-MS (EI) m/z calcd for C20H22N2O3 [M
+
], 338.1630, found 338.1632. 
 
 
2-[6-Methyl-1-oxo-3-phenylisoquinolin-2(1H)-yl] pyridine 1-oxide (134cj): The general procedure G was 
followed, using aromatic amide 85a (114 mg, 0.50 mmol) and alkyne 59j (61 mg, 0.60 mmol). Purification by 
column chromatography on silica gel (CH2Cl2/acetone 2:1) yielded 134cj (158 mg, 96%) as a colorless solid.  
M. p. = 224–225 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 8.26 (d, J = 8.0 Hz, 1H), 8.16–8.13 (m, 1H), 7.37–7.33 
(m, 2H), 7.27–7.24 (m, 2H), 7.21–7.13 (m, 3H), 7.10–7.05 (m, 2H), 7.02–6.96 (m, 1H), 6.48 (s, 1H), 2.44 (s, 
3H). 
13
C NMR (125 MHz, CDCl3) δ = 161.7 (Cq), 145.4 (Cq), 143.9 (Cq), 142.5 (Cq), 139.8 (CH), 137.0 (Cq), 
134.8 (Cq), 128.8 (CH), 128.5 (CH), 128.1 (CH), 128.0 (CH), 127.8 (CH), 127.6 (CH), 126.0 (CH), 125.3 
(CH), 124.9 (CH), 122.5 (Cq), 107.8 (CH), 21.7 (CH3). IR (ATR): 3055, 1658, 1627, 1607, 1482, 1433, 1369, 
1262, 773, 694 cm
-1
. MS (EI) m/z (relative intensity) 329 (5) [M+H
+
], 328 (20) [M
+
], 311 (10), 283 (15), 208 
(20), 181 (100), 165 (30). HR-MS (EI) m/z calcd for C21H16N2O2 [M
 +




2-[1-Oxo-3-phenylisoquinolin-2(1H)-yl] pyridine 1-oxide (134aj): The general procedure G was followed, 
using aromatic amide 85a (107 mg, 0.50 mmol) and alkyne 59j (61 mg, 0.60 mmol). Purification by column 
chromatography on silica gel (CH2Cl2/acetone 2:1) yielded 134aj (149 mg, 95%) as a colorless solid.  
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M. p. = 226–227 ºC. 
1
H NMR (500 MHz, CDCl3) δ = 8.41–8.38 (m, 1H), 8.18–8.14 (m, 1H), 7.68–7.64 (m, 
1H), 7.52 (dt, J = 7.9, 0.9 Hz, 1H), 7.48–7.44 (m, 1H), 7.41–7.36 (m, 2H), 7.25–7.17 (m, 3H), 7.12–7.09 (m, 
2H), 7.04–7.00 (m, 1H), 6.57 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ = 161.8 (Cq), 145.4 (Cq), 142.5 (Cq), 
139.9 (CH), 136.9 (Cq), 134.7 (Cq), 133.2 (CH), 128.9 (CH), 128.2 (CH), 128.1 (CH), 127.8 (CH), 127.5 (CH), 
126.9 (CH), 126.2 (CH), 125.3 (CH), 125.0 (CH), 124.8 (Cq), 107.9 (CH). IR (ATR): 3073, 1658, 1622, 1602, 
1482, 1425, 1256, 1142, 889, 760 cm
-1
. MS (EI) m/z (relative intensity) 315 (5) [M+H
+
], 314 (20) [M
+
], 298 
(20), 269 (30), 194 (30), 181 (100), 165 (30). HR-MS (EI) m/z calcd for C2H14N2O2 [M
+




2-[6-Bromo-1-oxo-3-phenylisoquinolin-2(1H)-yl] pyridine 1-oxide (134dj): The general procedure G was 
followed, using aromatic amide 85d (146 mg, 0.50 mmol), alkyne 59j (61 mg, 0.60 mmol). Purification by 
column chromatography on silica gel (CH2Cl2/acetone 2:1) yielded 134dj (187 mg, 95%) as a colorless solid.  
M. p. = 210–212 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 8.25 (d, J = 8.6 Hz, 1H), 8.21–8.17 (m, 1H), 7.70 (d, J 
= 1.9 Hz, 1H), 7.57 (dd, J = 8.6, 1.9 Hz, 1H), 7.40–7.35 (m, 2H), 7.25–7.17 (m, 3H), 7.17–7.09 (m, 2H), 
7.08–7.02 (m, 1H), 6.49 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ = 161.5 (Cq), 145.2 (Cq), 144.1 (Cq), 140.0 
(CH), 138.5 (Cq), 134.5 (Cq), 130.4 (CH), 130.2 (CH), 129.3 (CH), 128.7 (CH), 128.6 (Cq), 128.3 (CH), 127.9 
(CH), 127.6 (CH), 125.6 (CH), 125.0 (CH), 123.6 (Cq), 106.8 (CH). IR (ATR): 3055, 1666, 1628, 1589, 1490, 
1470, 1366, 1255, 763, 681 cm
-1









376 (25), 349 (25) (
81
Br), 347 (25) (
81









2-[6-Iodo-1-oxo-3-phenylisoquinolin-2(1H)-yl] pyridine 1-oxide (134ej): The general procedure G was 
followed, using aromatic amide 85e (170 mg, 0.50 mmol) and alkyne 59j (61 mg, 0.60 mmol). Purification by 
column chromatography on silica gel (CH2Cl2/acetone 2:1) yielded 134ej (200 mg, 91%) as a colorless solid.  
M. p. = 249–250 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 8.19 (d, J = 6.5 Hz, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.93 
(d, J = 1.6 Hz, 1H), 7.77 (dd, J = 8.4, 1.7 Hz, 1H), 7.39–7.33 (m, 2H), 7.25–7.17 (m, 3H), 7.17–7.08 (m, 2H), 
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7.07–7.02 (m, 1H), 6.46 (s, 1H). 
13
C NMR (75 MHz, CDCl3) δ = 161.7 (Cq), 145.2 (Cq), 143.9 (Cq), 140.1 
(CH), 138.4 (Cq), 136.0 (CH), 135.1 (CH), 134.5 (Cq), 129.8 (CH), 129.3 (CH), 128.3 (CH), 127.9 (CH), 
127.6 (CH), 125.6 (CH), 125.1 (CH), 124.1 (Cq), 106.6 (CH), 101.4 (Cq). IR (ATR): 3055, 1666, 1626, 1599, 
1583, 1490, 1428, 1365, 892 cm
-1
. MS (EI) m/z (relative intensity) 440 (20) [M
+
], 424 (15), 395 (15), 320 (20), 
208 (20), 296 (10), 268 (10), 181 (100). HR-MS (EI) m/z calcd for C20H13IN2O2 [M
+





6-[3-{(4-Methoxybenzyl) oxy} propyl]-3, 4-dimethyl-2-oxo-2H-[1, 2'-bipyridine] 1'-oxide (134fk): The 
general procedure G was followed, using aromatic amide 85f (147 mg, 0.50 mmol), alkyne 59k (127 mg, 0.60 
mmol) and Co(OAc)2 (18 mg, 20 mol %). Purification by column chromatography on silica gel 
(CH2Cl2/acetone 2:1) yielded 134fk (106 mg, 54%) as a colorless solid.  
M. p. = 105–106 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 8.29 (dd, J = 4.7, 3.1 Hz, 1H), 7.37–7.22 (m, 3H), 7.12 
(d, J = 8.8 Hz, 2H), 6.81 (d, J = 8.8 Hz, 2H), 5.92 (s, 1H), 4.28 (s, 2H), 3.77 (s, 3H), 3.42–3.20 (m, 2H), 2.37–
2.16 (m, 2H), 2.13 (s, 3H), 2.02 (s, 3H), 1.71 (tt, J = 6.8, 6.8 Hz, 2H). 
13
C NMR (75 MHz, CDCl3) δ = 162.7 
(Cq), 159.1 (Cq), 147.5 (Cq), 144.5 (Cq), 143.8 (Cq), 140.5 (CH), 130.2 (Cq), 129.1 (CH), 127.5 (CH), 125.8 
(CH), 125.4 (CH), 123.8 (Cq), 113.6 (CH), 108.8 (CH), 72.3 (CH2), 68.3 (CH2), 55.2 (CH3), 28.4 (CH2), 27.6 
(CH2), 20.0 (CH3), 12.2 (CH3). IR (ATR): 3051, 2918, 2849, 1652, 1593, 1510, 1243, 1098, 1030, 763 cm
-1
. 
MS (EI) m/z (relative intensity) 394 (5) [M
+
], 377 (10), 273 (15), 241 (40), 229 (60), 213 (30), 121 (100). HR-
MS (ESI) m/z calcd for C23H27N2O4 [M+H
+
] 395.1965, found 395.1958. 
 
 
2-[3-(Ethoxycarbonyl)-1-oxoisoquinolin-2(1H)-yl] pyridine 1-oxide (134al): The general procedure G was 
followed, using amide 85a (107 mg, 0.50 mmol) and alkyne 59l (59 mg, 0.60 mmol). Purification by column 
chromatography on silica gel (CH2Cl2/acetone 2:1) yielded 134al (138 mg, 89%) as a colorless solid.  
M. p. = 172–173 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 8.39 (dd, J = 8.0, 0.7 Hz, 1H), 8.24 (d, J = 6.3 Hz, 1H), 
7.76–7.69 (m, 1H), 7.67–7.62 (m, 1H), 7.60–7.55 (m, 2H), 7.46 (s, 1H), 7.43–7.35 (m, 1H), 7.36–7.27 (m, 
1H), 4.20 (q, J = 7.1 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H). 
13
C NMR (125 MHz, CDCl3) δ = 161.5 (Cq), 161.3 
(Cq), 144.3 (Cq), 139.7 (CH), 134.8 (Cq), 133.6 (CH), 131.3 (Cq), 129.2 (CH), 128.6 (CH), 127.8 (CH), 127.4 
(Cq), 127.0 (CH), 125.6 (CH), 124.8 (CH), 112.7 (CH), 61.9 (CH2), 13.8 (CH3). IR (ATR): 3113, 2991, 2903, 
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1718, 1665, 1479, 1432, 1248, 785, 690 cm
-1
. MS (EI) m/z (relative intensity) 311 (10) [M+H
+
], 310 (30) [M
+
], 






2-[3-(2-(Benzoyloxy)ethyl)-1-oxoisoquinolin-2(1H)-yl]pyridine 1-oxide (134am): The general procedure G 
was followed, using amide 85a (107 mg, 0.50 mmol) and alkyne 59m (104 mg, 0.60 mmol). Purification by 
column chromatography on silica gel (CH2Cl2/acetone 2:1) yielded 134am (178 mg, 92%) as a colorless solid.  
M. p. = 143–144 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 8.44–8.40 (m, 1H), 8.38–8.32 (m, 1H), 8.00–7.93 (m, 
2H), 7.69–7.63 (m, 1H), 7.59–7.51 (m, 2H), 7.50–7.37 (m, 6H), 6.56 (s, 1H), 4.58–4.42 (m, 2H), 2.90 (dt, J = 
16.0, 6.9 Hz, 1H), 2.68 (dt, J = 16.0, 6.9 Hz, 1H). 
13
C NMR (125 MHz, CDCl3) δ = 166.2 (Cq), 162.6 (Cq), 
144.0 (Cq), 140.8 (CH), 138.2 (Cq), 137.0 (Cq), 133.4 (CH), 133.2 (CH), 129.7 (Cq), 129.6 (CH), 128.4 (CH), 
128.2 (CH), 128.2 (CH), 126.8 (CH), 126.3 (CH), 125.9 (CH), 125.7 (CH), 124.8 (Cq), 106.4 (CH), 61.9 
(CH2), 31.5 (CH2). IR (ATR): 3061, 1718, 1671, 1632, 1598, 1492, 1245, 1098, 860, 710 cm
-1
. MS (EI) m/z 
(relative intensity) 370 (5), 264 (60), 247 (100), 234 (70), 219 (10), 205 (10), 171 (30), 131 (70). HR-MS 
(ESI) m/z calcd for C23H18N2O4K [M+K
+
], 425.0898, found 425.0896. 
 
 
2-[3-(8-Carboxyoctyl)-1-oxoisoquinolin-2(1H)-yl] pyridine 1-oxide (134an): The general procedure G was 
followed, using amide 85a (107 mg, 0.50 mmol) and alkyne 59n (109 mg, 0.60 mmol). The crude product was 
directly purified by column chromatography on silica gel (n-hexane/EtOAc 2:1 → CH2Cl2/MeOH 10:1) 
without aqueous work up yielding 134an (172 mg, 87%) as a colorless solid.  
M. p. = 191–192 ºC. 
1
H NMR (300 MHz, DMSO-d6) δ = 11.90 (sbr, 1H), 8.48 (dd, J = 6.4, 1.5 Hz, 1H), 8.16–
8.10 (m, 1H), 7.80 (dd, J = 7.8, 2.4 Hz, 1H), 7.74 (dd, J = 7.0, 1.3 Hz, 1H), 7.66 (d, J = 7.5 Hz, 1H), 7.61–
7.45 (m, 3H), 6.61 (s, 1H), 2.32–2.03 (m, 4H), 1.55–1.36 (m, 4H), 1.27–1.06 (m, 8H). 
13
C NMR (125 MHz, 
DMSO-d6) δ = 174.3 (Cq), 161.5 (Cq), 143.3 (Cq), 142.9 (Cq), 139.9 (CH), 137.2 (Cq), 133.3 (CH), 128.3 (CH), 
127.0 (CH), 126.7 (CH), 126.2 (CH), 125.9 (CH), 125.5 (CH), 123.8 (Cq), 104.0 (CH), 33.6 (CH2), 31.4 (CH2), 
28.4 (CH2), 28.3 (CH2), 28.3 (CH2), 28.2 (CH2), 26.9 (CH2), 24.3 (CH2). IR (ATR): 3061, 2926, 2851, 1697, 
1671, 1632, 1495, 1436, 1231, 775, cm
-1
. MS (EI) m/z (relative intensity) 395 (2) [M+H
+
], 394 (5) [M
+
], 378 
(60), 359 (20), 249 (100), 235 (60), 206 (20). HR-MS (EI) m/z calcd for C23H26N2O4 [M
+
], 394.1893, found 
394.1883. 
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The general procedure G was followed, using amide 85c (107 mg, 0.50 mmol) and alkyne 59d (107 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1 → CH2Cl2/acetone 1:1) 
yielded 134cd (149 mg, 74%) and 134cd
,
 (37 mg, 19%) as colorless solids.  
The general procedure H was followed, using amide 85c (107 mg, 0.50 mmol) and alkyne 59d (107 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1) 134cd
,
 (142 mg, 73%) 
was obtained as colorless solid. 
 
2-[6-Methyl-1-oxo-3, 4-diphenylisoquinolin-2(1H)-yl] pyridine 1-oxide (134cd):  
M. p. = 247–248 ºC. 
1
H NMR (400 MHz, CDCl3) δ = 8.40 (d, J = 8.1 Hz, 1H), 8.10 (dd, J = 6.5, 1.4 Hz, 1H), 
7.44–7.39 (m, 1H), 7.30 (ddd, J = 8.1, 1.7, 0.6 Hz, 1H), 7.25–7.22 (m, 2H), 7.16–7.09 (m, 3H), 7.06–7.03 (m, 




C NMR (100 MHz, CDCl3) δ 
= 161.3 (Cq), 145.6 (Cq), 143.8 (Cq), 139.7 (CH), 139.7 (Cq), 138.0 (Cq), 135.7 (Cq), 133.6 (Cq), 131.5 (CH), 
131.3 (CH), 130.1 (CH), 128.4 (CH), 128.4 (CH), 128.3 (CH), 128.2 (CH), 128.2 (CH), 127.9 (CH), 127.7 
(CH), 127.6 (CH), 127.0 (CH), 126.9 (CH), 125.5 (CH), 125.1 (CH), 124.7 (CH), 122.8 (Cq), 119.2 (Cq), 22.0 
(CH3). IR (ATR): 3056, 1657, 1606, 1481, 1431, 1340, 1323, 760, 711 cm
-1
. MS (EI) m/z (relative intensity) 
405 (5) [M+H
+
], 404 (10) [M
+
], 388 (15), 299 (20), 284 (50), 241 (10), 181 (100). HR-MS (EI) m/z calcd for 
C27H20N2O2 [M
+
] 404.1525, found 404.1510. 
 
 
6-Methyl-3, 4-diphenyl-2-(pyridin-2-yl) isoquinolin-1(2H)-one (134cd
,
):  
M. p. = 230–232 ºC. 
1
H NMR (500 MHz, CDCl3) δ = 8.43 (d, J = 8.1 Hz, 1H), 8.35 (ddd, J = 4.9, 2.0, 0.9 Hz, 
1H), 7.55 (dd, J = 7.7, 7.7 Hz, 1H), 7.32 (dd, J = 8.2, 1.6 Hz, 1H), 7.19 (m, 3H), 7.17–7.08 (m, 3H), 7.08–7.00 
(m, 2H), 6.97–6.82 (m, 5H), 2.34 (s, 3H). 
13
C NMR (125 MHz, CDCl3) δ = 162.5 (Cq), 152.7 (Cq), 148.9 
(CH), 143.2 (Cq), 140.0 (Cq), 137.8 (Cq), 137.4 (CH), 136.1 (Cq), 134.4 (Cq), 131.6 (CH), 131.6 (CH), 128.4 
(CH), 128.1 (CH), 127.9 (CH), 127.1 (CH), 126.9 (CH), 126.7 (CH), 125.3 (CH), 124.9 (CH), 123.3 (Cq), 
122.7 (CH), 118.7 (Cq), 22.0 (CH3). IR (ATR): 3059, 1651, 1616, 1589, 1470, 1432, 1324, 758, 698, 585 cm
-1
. 
MS (EI) m/z (relative intensity) 389 (30) [M+H
+
], 388 (100) [M
+
], 387 (35) [M–H
+
], 359 (20), 283 (15), 178 
(10), 78 (35). HR-MS (EI) m/z calcd for C27H20N2O [M
+
] 388.1576, found 388.1585. 
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The general procedure G was followed, using amide 85a (107 mg, 0.50 mmol) and alkyne 59d (109 mg, 0.60 
mmol), Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1 → CH2Cl2/acetone 1:1) 
yielded 134ad (135 mg, 69%) and 134ad
,
 (49 mg, 26%) as colorless solids.  
The general procedure H was followed, using amide 85a (107 mg, 0.50 mmol), alkyne 59d (109 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 1:1) yielded 134ad
,
 (157 mg, 
84%) as colorless solid.  
 
2-[1-Oxo-3, 4-Diphenylisoquinolin-2(1H)-yl) pyridine 1-oxide] (134ad):  
M. p. = 264–265 ºC. 
 1
H NMR (300 MHz, CDCl3) δ = 8.52 (dd, J = 7.9, 1.5 Hz, 1H), 8.12 (dd, J = 6.3, 1.5 Hz, 
1H), 7.57 (dd, J = 7.6, 7.6 Hz, 1H), 7.49 (dd, J = 7.7, 1.2 Hz, 1H), 7.47–7.40 (m, 1H), 7.27–7.20 (m, 3H), 
7.16–7.11 (m, 3H), 7.07–7.01 (m, 2H), 7.01–6.87 (m, 5H). 
 13
C NMR (75 MHz, CDCl3) δ = 161.5 (Cq), 145.6 
(Cq), 139.8 (CH), 139.6 (Cq), 138.0 (Cq), 135.6 (Cq), 133.5 (Cq), 133.1 (CH), 131.5 (CH), 131.3 (CH), 130.1 
(CH), 128.5 (CH), 128.4 (CH), 128.3 (CH), 128.3 (CH), 127.9 (CH), 127.8 (CH), 127.7 (CH), 127.1 (CH), 
127.0 (CH), 127.0 (CH), 125.7 (CH), 125.2 (CH), 125.0 (Cq), 124.8 (CH), 119.4 (Cq). IR (ATR): 3056, 1666, 
1594, 1490, 1431, 1277, 699. cm
-1
. MS (EI) m/z (relative intensity) 391 (10) [M+H
+
], 374 (70), 345 (30), 285 
(30), 270 (60), 181 (100). HR-MS (ESI) m/z calcd for C26H19N2O2 [M+H
+







M. p. = 251–252 ºC. 
1
H NMR (500 MHz, CDCl3) δ = 8.55 (dd, J = 8.1, 1.4 Hz, 1H), 8.37–8.32 (m, 1H), 
7.57–7.52 (m, 2H), 7.48 (ddd, J = 8.2, 7.1, 1.3 Hz, 1H), 7.25–7.22 (m, 1H), 7.22–7.16 (m, 3H), 7.16–7.11 (m, 
3H), 7.05–6.90 (m, 3H), 6.89–6.84 (m, 3H). 
13
C NMR (125 MHz, CDCl3) δ = 162.4 (Cq), 152.6 (Cq), 148.9 
(CH), 139.9 (Cq), 137.6 (Cq), 137.4 (CH), 135.9 (Cq), 134.1 (Cq), 132.5 (CH), 131.4 (CH), 131.4 (CH), 127.9 
(CH), 127.8 (CH), 127.1 (CH), 126.9 (CH), 126.7 (CH), 126.7 (CH), 125.5 (CH), 125.4 (Cq), 124.8 (CH), 
122.7 (CH), 118.7 (Cq). IR (ATR): 3059, 1657, 1589, 1467, 1321, 1156, 996, 777, 590 cm
-1
. MS (EI) m/z 
(relative intensity) 375 (30) [M+H
+
], 374 (100) [M
+
], 373 (40) [M–H
+
], 345 (30), 269 (20), 165 (12), 78 (20). 
HR-MS (EI) m/z calcd for C26H18N2O [M
+
] 374.1419, found 374.1416. 
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The general procedure G was followed, using amide 85g (141 mg, 0.50 mmol) and alkyne 59d (107 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1 → CH2Cl2/acetone 1:1) 
yielded 134gd (104 mg, 44%) and 134gd
,
 (122 mg, 53%) as colorless solids. 
The general procedure H was followed, using amide 85g (141 mg, 0.50 mmol) and alkyne 59d (107 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1) yielded 134gd
,
 (208 mg, 
94%) as a colorless solid.  
 
2-[1-Oxo-3, 4-diphenyl-6-(trifluoromethyl)isoquinolin-2(1H)-yl] pyridine 1-oxide (134gd):  
M. p. = 254–255 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 8.63 (d, J = 8.4 Hz, 1H), 8.15 (dd, J = 6.4, 1.5 Hz, 1H), 
7.70 (dd, J = 8.4, 1.7 Hz, 1H), 7.50 (s, 1H), 7.46–7.37 (m, 1H), 7.32–7.25 (m, 1H), 7.24–7.22 (m, 1H), 7.21–
7.17 (m, 2H), 7.16–7.10 (m, 1H), 7.09–7.03 (m, 2H), 7.03–6.87 (m, 5H).
 13
C NMR (125 MHz, CDCl3) δ = 
160.6 (Cq), 145.1 (Cq), 141.3 (Cq), 139.8 (CH), 138.2 (Cq), 134.6 (q, 
2
JC-F = 34.3 Hz, Cq), 134.5 (Cq), 133.1 
(Cq), 131.4 (CH), 131.0 (CH), 129.9 (CH), 129.4 (CH), 128.6 (CH), 128.6 (CH), 128.3 (CH), 128.0 (CH), 
127.9 (CH), 127.7 (CH), 127.5 (CH), 127.3 (Cq), 127.2 (CH), 125.4 (CH), 124.8 (CH), 123.5 (q, 
1
JC-F = 272.7 
Hz, Cq), 122.9 (q, 
3
JC-F = 4.4 Hz, CH), 122.9 (q, 
3
JC-F = 4.4 Hz, CH), 119.1 (Cq). 
19
F NMR (283 MHz, CDCl3) 
δ = – 63.08 (S). IR (ATR): 3055, 1669, 1433, 1314, 1277, 1168, 1129, 1065, 699 cm
-1
. MS (EI) m/z (relative 
intensity) 459 (10) [M+H
+
], 442 (40), 413 (15), 353 (25), 338 (60), 181 (100), 78 (80). HR-MS (EI) m/z calcd 
for C27H17F3N2O2 [M
+
] 458.1242, found 458.1249. 
 
 
3, 4-Diphenyl-2-(pyridin-2-yl)-6-(trifluoromethyl) isoquinolin-1(2H)-one (134gd
,
):  
M. p. = 203–205 ºC. 
1
H NMR (400 MHz, CDCl3) δ = 8.65 (d, J = 8.4 Hz, 1H), 8.39 (ddd, J = 4.9, 1.9, 0.8 Hz, 
1H), 7.70 (ddd, J = 8.4, 1.7, 0.6 Hz, 1H), 7.60 (dd, J = 7.8, 7.8 Hz 1H), 7.51 (m, 1H), 7.25–7.15 (m, 4H), 
7.14–7.05 (m, 3H), 7.04–6.87 (m, 5H). 
13
C NMR (100 MHz, CDCl3) δ = 161.8 (Cq), 152.3 (Cq), 149.2 (CH), 
141.7 (Cq), 137.9 (Cq), 137.7 (CH), 135.0 (Cq), 134.3 (q, 
2
JC-F = 32.4 Hz, Cq), 133.8 (Cq), 131.4 (CH), 130.8 
(CH), 129.2 (CH), 128.3 (CH), 127.7 (Cq), 127.6 (CH), 127.4 (CH), 127.2 (CH), 124.8 (CH), 123.7 (q, 
1
J C-F = 
273.3 Hz, Cq), 123.1 (CH), 122.9 (q, 
3
J C-F = 3.7 Hz, CH), 122.9 (q, 
3
J C-F = 3.6 Hz, CH), 118.6 (Cq). 
19
F NMR 
(283 MHz, CDCl3) δ = – 63.00 (S). IR (ATR): 1660, 1591, 1472, 1432, 1330, 1171, 1132, 1067, 756, 600 cm
-1
. 
MS (EI) m/z (relative intensity) 443 (30) [M+H
+
], 442 (100) [M
+
], 441 (35) [M–H
+
], 413 (20), 365 (10), 337 
(15), 78 (30). HR-MS (EI) m/z calcd for C27H17F3N2O [M
+
] 442.1293, found 442.1292. 




The general procedure G was followed, using amide 85b (122 mg, 0.50 mmol) and alkyne 59d (107 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1→CH2Cl2/acetone 1:1) 
yielded 134bd (174 mg, 83%) and 134bd
,
 (26 mg, 13%) as colorless solids.  
The general procedure H was followed, using amide 85b (141 mg, 0.50 mmol) and alkyne 59d (107 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1) yielded 134bd
,
 (101 mg, 
50%) as a colorless solid.  
 
2-[6-Methoxy-1-oxo-3,4-diphenylisoquinolin-2(1H)-yl] pyridine 1-oxide (134bd):  
M. p. = 241–242 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 8.43 (d, J = 8.9 Hz, 1H), 8.11 (dd, J = 6.4, 1.4 Hz, 1H), 
7.45–7.38 (m, 1H), 7.25–7.21 (m, 2H), 7.16–7.09 (m, 3H), 7.08–6.99 (m, 3H), 6.98–6.87 (m, 5H), 6.59 (d, J = 
2.5 Hz, 1H), 3.69 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 163.4 (Cq), 161.1 (Cq), 145.6 (Cq), 140.3 (Cq), 
140.2 (Cq), 139.7 (CH), 135.6 (Cq), 133.6 (Cq), 131.5 (CH), 131.2 (CH), 130.5 (CH), 130.0 (CH), 128.4 (CH), 
128.3 (CH),  128.3 (CH), 128.0 (CH), 127.8 (CH), 127.7 (CH), 127.1 (CH), 127.0 (CH), 125.2 (CH), 124.8 
(CH), 119.1 (Cq), 118.8 (Cq), 115.3 (CH), 108.0 (CH), 55.3 (CH3). IR (ATR): 3052, 1654, 1604, 1431, 1333, 
1240, 860. cm
-1
. MS (EI) m/z (relative intensity) 421 (10) [M+H
+
], 420 (20) [M
+
], 404 (100), 300 (80), 181 
(90). HR-MS (ESI) m/z calcd for C27H21N2O3 [M+H
+






M. p. = 251–252 ºC. 
1
H NMR (500 MHz, CDCl3) δ = 8.46 (d, J = 8.9 Hz, 1H), 8.34 (sbr, 1H), 7.55 (dd, J = 
7.7, 7.7 Hz, 1H), 7.21–7.15 (m, 3H), 7.14–7.09 (m, 3H), 7.06 (dd, J = 8.9, 2.5 Hz, 1H), 7.02 (dd, J = 7.5, 4.8 
Hz, 1H), 6.95 (sbr, 2H), 6.90–6.83 (m, 3H), 6.60 (d, J = 2.5 Hz, 1H), 3.68 (s, 3H). 
13
C NMR (125 MHz, CDCl3) 
δ = 163.0 (Cq), 162.2 (Cq), 152.7 (Cq), 148.9 (CH), 140.6 (Cq), 139.8 (Cq), 137.3 (CH), 136.1 (Cq), 134.4 (Cq), 
131.5 (CH), 131.5 (CH), 130.2 (CH), 127.9 (CH), 127.2 (CH), 126.9 (CH), 126.8 (CH), 125.0 (CH), 122.7 
(CH), 119.3 (Cq), 118.5 (Cq), 115.4 (CH), 107.6 (CH), 55.2 (CH3). IR (ATR): 3058, 1654, 1589, 1432, 1325, 
1288, 1026, 857, 758, 691 cm
-1
. MS (EI) m/z (relative intensity) 405 (40) [M+H
+
], 404 (100) [M
+
], 403 (40) 
[M–H
+
], 375 (10), 181 (10), 152 (10), 78 (20). HR-MS (EI) m/z calcd for C27H20N2O2 [M
+
] 404.1525, found 
404.1514. 
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The general procedure G was followed, using amide 85d (146 mg, 0.50 mmol) and alkyne 59d (107 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1 → CH2Cl2/acetone 1:1) 
yielded 134dd (143 mg, 61%) and 134dd
,
 (70 mg, 31%) as colorless solid. 
The general procedure H was followed, using amide 85d (146 mg, 0.50 mmol) and alkyne 59d (107 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1) yielded 134dd
,
 (120 mg, 
53%) as colorless solid. 
 
2-[6-Bromo-1-oxo-3, 4-diphenylisoquinolin-2(1H)-yl] pyridine 1-oxide (134dd):  
M. p. = 249–250 ºC. 
 1
H NMR (300 MHz, CDCl3) δ = 8.35 (d, J = 8.6 Hz, 1H), 8.14–8.09 (m, 1H), 7.58 (dd, 
J = 8.6, 1.9 Hz, 1H), 7.43–7.35 (m, 2H), 7.30–7.23 (m, 1H), 7.22–7.14 (m, 3H), 7.14–7.09 (m, 1H), 7.08–7.01 
(m, 2H), 7.01–6.86 (m, 5H).
 13
C NMR (75 MHz, CDCl3) δ = 161.0 (Cq), 145.3 (Cq), 141.1 (Cq), 139.8 (CH), 
139.5 (Cq), 134.7 (Cq), 133.2 (Cq), 131.4 (CH), 131.1 (CH), 130.3 (CH), 130.1 (CH), 129.9 (CH), 128.6 (Cq), 
128.6 (CH), 128.5 (CH), 128.2 (CH), 128.2 (CH), 128.0 (CH), 127.9 (CH), 127.7 (CH), 127.3 (CH), 127.2 
(CH), 125.4 (CH), 124.9 (CH), 123.8 (Cq), 118.4 (Cq). IR (ATR): 3056, 1662, 1591, 1490, 1432, 1261, 701 
cm
-1








Br), 350 (30) (
81
Br), 348 (30) (
79
Br), 









M. p. = 243–245 ºC. 
1
H NMR (400 MHz, CDCl3) δ = 8.40–8.36 (m, 2H), 7.62–7.55 (m, 2H), 7.37 (dd, J = 
2.0, 0.5 Hz, 1H), 7.24–7.21 (m, 1H), 7.21–7.13 (m, 3H), 7.12–7.04 (m, 3H), 7.01–6.85 (m, 5H). 
13
C NMR 
(100 MHz, CDCl3) δ = 162.2 (Cq), 152.4 (Cq), 149.1 (CH), 141.5 (Cq), 139.3 (Cq), 137.6 (CH), 135.3 (Cq), 
135.3 (Cq), 134.0 (Cq), 131.5 (CH), 131.5 (CH), 130.2 (CH), 130.0 (CH), 128.2 (CH), 128.1 (CH), 127.5 (CH), 
127.2 (CH), 127.1 (CH), 124.8 (CH), 124.3 (Cq), 123.0 (CH), 118.0 (Cq). IR (ATR): 3061, 1653, 1588, 1470, 
1318, 1148, 924, 757, 701, 586 cm
-1









Br), 425 (10) (
81
Br), 425 (10) (
79





] 452.0524, found 452.0514. 
 
The general procedure G was followed, using amide 85a (146 mg, 0.50 mmol) and alkyne 59o (107 mg, 0.60 
mmol) at 80 ºC for 16 h. Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1 → 
CH2Cl2/acetone 1:1) yielded 134ao (128 mg, 60%) and 134ao
,
 (60 mg, 29%) as colorless solids. 
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The general procedure H was followed, using amide 85a (107 mg, 0.50 mmol) and alkyne 59o (129 mg, 0.60 
mmol) at 80 ºC for 16 h. Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1) yielded 
134ao
,
 (160 mg, 78%) as a colorless solid. 
 
2-[3, 4-Bis (4-fluorophenyl)-1-oxoisoquinolin-2(1H)-yl] pyridine 1-oxide (134ao):  
M. p. = 291–292 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 8.51 (dd, J = 7.9, 1.0 Hz, 1H), 8.13 (dd, J = 6.2, 1.2 Hz, 
1H), 7.64–7.55 (m, 1H), 7.51 (ddd, J = 8.3, 7.2, 1.3 Hz, 1H), 7.47–7.40 (m, 1H), 7.22–7.11 (m, 3H), 7.11–
7.00 (m, 3H), 6.99–6.81 (m, 3H), 6.70–6.62 (m, 2H). 
13
C NMR (125 MHz, CDCl3) δ = 162.2 (d, 
1
JC-F = 249.0 
Hz, Cq), 161.7 (d, 
1
JC-F = 246.7 Hz, Cq), 161.3 (Cq), 145.2 (Cq), 139.8 (CH), 139.0 (Cq), 137.7 (Cq), 133.2 
(CH), 133.1 (d, 
3
JC-F = 8.0 Hz, CH), 132.7 (d, 
3
JC-F = 8.0 Hz, CH), 131.8 (d, 
3
JC-F = 8.3 Hz, CH), 131.3 (d, 
4
JC-F 
= 3.5 Hz, Cq), 130.7 (d, 
3
JC-F = 8.3 Hz, CH), 129.4 (d, 
4
JC-F = 3.5 Hz, Cq), 128.4 (CH), 127.8 (CH), 127.2 (CH), 
125.5 (CH), 125.4 (CH), 125.1 (Cq), 124.9 (CH), 118.7 (Cq), 115.4 (d, 
2
JC-F = 21.3 Hz, CH), 115.1 (d, 
2
JC-F = 
21.5 Hz, CH), 115.0 (d, 
2
JC-F = 21.5 Hz, CH), 114.4 (d, 
2
JC-F = 21.8 Hz, CH). 
19
F NMR (283 MHz, CDCl3) δ = 
– (111.4–111.5) (m), – (114.4–114.5) (m). IR (ATR): 3056, 1662, 1600, 1505, 1218, 1157, 774, 537 cm
-1
. MS 
(EI) m/z (relative intensity) 411 (30) [M+H
+
], 410 (100) [M
+
], 409 (40) [M–H
+
], 381 (40), 287 (20), 183 (10). 
HR-MS (EI) m/z calcd for C26H16F2N2O [M
+
] 410.1231, found 410.1219. 
 
3, 4-Bis (4-fluorophenyl)-2-(pyridin-2-yl) isoquinolin-1(2H)-one (134ao
,
):  
M. p. = 283–284 ºC. 
 1
H NMR (400 MHz, CDCl3) δ = 8.57–8.52 (m, 1H), 8.38 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 
7.65–7.57 (m, 2H), 7.52 (ddd, J = 8.3, 7.2, 1.3 Hz, 1H), 7.23–7.20 (m, 2H), 7.13–7.06 (m, 3H), 6.97–6.86 (m, 
4H), 6.64–6.59 (m, 2H).
 13
C NMR (100 MHz, CDCl3) δ = 162.4 (Cq), 161.7 (d, 
1
JC-F = 246.8 Hz, Cq), 161.4 (d, 
1
JC-F = 248.6 Hz, Cq), 152.5 (Cq), 149.1 (CH), 139.3 (Cq), 137.7 (CH), 137.5 (Cq), 133.0 (d, 
3
JC-F = 8.0 Hz, 
CH), 133.0 (d, 
3
JC-F = 8.0 Hz, CH), 132.8 (CH), 131.8 (d, 
4
JC-F = 3.5 Hz, Cq), 130.2 (d, 
4
JC-F = 3.6 Hz, Cq), 
128.2 (CH), 127.1 (CH), 125.5 (Cq), 125.4 (CH), 124.8 (CH), 123.0 (CH), 118.2 (Cq), 115.2 (d, 
2
JC-F = 21.5 
Hz, CH), 114.3 (d, 
2
JC-F = 21.6 Hz, CH). 
19
F NMR (376 MHz, CDCl3) δ = – (112.8–112.9) (m), – (114.6–
114.7) (m). IR (ATR): 3054, 1658, 1615, 1603, 1589, 1324, 1217, 1147, 836, 799 cm
-1
. MS (EI) m/z (relative 
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intensity) 427 (5) [M+H
+
], 426 (10) [M
+
], 410 (20), 402 (10), 306 (60), 277 (20), 199 (100). HR-MS (EI) m/z 
calcd for C26H16F2N2O2 [M
+
] 426.1180, found 426.1189. 
 
The general procedure G was followed, using amide 85a (107 mg, 0.50 mmol) and alkyne 59p (49 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1 → CH2Cl2/acetone 1:1) 
yielded 134ap (84 mg, 57%) and 134ap
,
 (5 mg, 4%) as colorless solid. 
The general procedure H was followed, using amide 85a (107 mg, 0.50 mmol) and alkyne 59p (49 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1) yielded 134ap
,
 (86 mg, 
62%) as a colorless solid. 
 
2-[3, 4-Diethyl-1-oxoisoquinolin-2(1H)-yl] pyridine 1-oxide (134ap):  
M. p. = 195–196 ºC.
 1
H NMR (400 MHz, CDCl3) δ = 8.37 (dd, J = 8.0, 8.0 Hz, 1H), 8.35–8.32 (m, 1H), 7.67 
(d, J = 1.1 Hz, 1H), 7.66 (dd, J = 2.1, 1.1 Hz, 1H), 7.45–7.42 (m, 1H), 7.39 (ddd, J = 8.0, 5.2, 3.1 Hz, 1H), 
7.35–7.32 (m, 2H), 2.76 (m, 2H), 2.65 (dd, J = 15.3, 7.6 Hz, 1H), 2.04 (dd, J = 15.3, 7.6 Hz, 1H), 1.24 (t, J = 
7.6 Hz, 3H), 1.00 (t, J = 7.6 Hz, 3H).
 13
C NMR (100 MHz, CDCl3) δ = 162.1 (Cq), 145.0 (Cq), 140.4 (CH), 
139.6 (Cq), 137.3 (Cq), 133.0 (CH), 128.5 (CH), 128.0 (CH), 125.9 (CH), 125.9 (CH), 125.2 (CH), 125.1 (Cq), 
122.9 (CH), 115.4 (Cq), 22.8 (CH2), 20.3 (CH2), 14.6 (CH3), 13.6 (CH3). IR (ATR): 3107, 2968, 1651, 1614, 
1593, 1260, 784, 704 cm
-1
. MS (EI) m/z (relative intensity) 295 (5) [M+H
+
], 294 (40) [M
+
], 277 (100), 247 
(70), 237 (20), 219 (20), 133 (90). HR-MS (EI) m/z calcd for C18H18N2O2 [M
+
] 294.1368, found 294.1361. 
 
3, 4-Diethyl-2-(pyridin-2-yl) isoquinolin-1(2H)-one (134ap
,
):  
M. p. = 114–115 ºC. 
1
H NMR (500 MHz, CDCl3) δ = 8.67 (ddd, J = 4.7, 1.9, 1.0 Hz, 1H), 8.44 (ddd, J = 8.0, 
1.5, 0.7 Hz, 1H), 7.89 (dd, J = 7.7, 7.7 Hz, 1H), 7.74–7.66 (m, 2H), 7.46–7.37 (m, 3H), 2.81 (q, J = 7.5 Hz, 
2H), 2.41 (q, J = 7.5 Hz, 2H), 1.27 (t, J = 7.5 Hz, 3H), 1.01 (t, J = 7.5 Hz, 3H).
 13
C NMR (125 MHz, CDCl3) δ 
= 163.0 (Cq), 152.9 (Cq), 149.6 (CH), 140.1 (Cq), 138.1 (CH), 137.0 (Cq), 132.6 (CH), 128.3 (CH), 125.8 (CH), 
125.4 (Cq), 124.6 (CH), 123.6 (CH), 122.7 (CH), 114.8 (Cq), 22.9 (CH2), 20.2 (CH2), 14.6 (CH3), 13.7 (CH3). 
IR (ATR): 3064, 2976, 1650, 1465, 1327, 993, 897, 775, 676 cm
-1
. MS (EI) m/z (relative intensity) 279 (10) 
[M+H
+
], 278 (50) [M
+
], 277 (100) [M–H
+
], 263 (30), 249 (40), 247 (30), 234 (15). HR-MS (ESI) m/z calcd 
for C18H18N2NaO [M+Na
+
] 301.1311, found 301.1314. 
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The general procedure G was followed, using amide 85a (107 mg, 0.50 mmol) and alkyne 59q (100 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1 → CH2Cl2/acetone 1:1) 
yielded 134aq (85 mg, 45%) and 134aq
,
 (31 mg, 17%) as colorless solids. 
The general procedure H was followed, using amide 85a (107 mg, 0.50 mmol) and alkyne 59q (100 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1) yielded 134aq
,
 (110 mg, 
61%) as a colorless solid.  
 
2-[1-Oxo-3, 4-di-n-pentylisoquinolin-2(1H)-yl] pyridine 1-oxide (134aq):  
M. p. = 121–122 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 8.42–8.37 (m, 2H), 7.74–7.64 (m, 2H), 7.51–7.41 (m, 
2H), 7.41–7.34 (m, 2H), 2.81–2.53 (m, 3H), 2.03–1.93 (m, 1H), 1.71–1.57 (m, 2H), 1.54–1.24 (m, 6H), 1.19–
1.03 (m, 4H), 0.93 (t, J = 7.0 Hz, 3H), 0.78 (t, J = 6.7 Hz, 3H).
 13
C NMR (75 MHz, CDCl3) δ = 162.2 (Cq), 
145.2 (Cq), 140.5 (CH), 138.8 (Cq), 137.6 (Cq), 133.0 (CH), 128.6 (CH), 128.2 (CH), 125.9 (CH), 125.8 (CH), 
125.1 (CH), 125.1 (Cq), 123.0 (CH), 114.6 (Cq), 32.2 (CH2), 31.7 (CH2), 29.9 (CH2), 29.7 (CH2), 28.7 (CH2), 
27.5 (CH2), 22.5 (CH2), 21.8 (CH2), 14.0 (CH3), 13.8 (CH3). IR (ATR): 2957, 2923, 2855, 1651, 1592, 1426, 
1259, 765, 703 cm
-1
. MS (EI) m/z (relative intensity) 379 (5) [M+H
+
], 378 (30) [M
+
], 361 (80), 321 (20), 307 
(30), 251 (100), 247 (50). HR-MS (EI) m/z calcd for C24H30N2O2 [M
+




3, 4-Di-n-pentyl-2-(pyridin-2-yl) isoquinolin-1 (2H)-one (134aq
,
):  
M. p. = 104–105 ºC. 
 1
H NMR (500 MHz, CDCl3) δ = 8.67 (dd, J = 5.4, 1.8 Hz, 1H), 8.43 (dd, J = 7.9, 1.0 Hz, 
1H), 7.88 (dd, J = 7.8, 7.8 Hz, 1H), 7.72–7.65 (m, 2H), 7.46–7.37 (m, 3H), 2.75–2.69 (m, 2H), 2.40–2.24 (m, 
2H), 1.63 (m, 2H), 1.52–1.34 (m, 6H), 1.10–1.07 (m, 4H), 0.93 (t, J = 7.1 Hz, 3H), 0.76 (t, J = 7.1 Hz, 3H).
 
13
C NMR (125 MHz, CDCl3) δ = 163.0 (Cq), 152.9 (Cq), 149.5 (CH), 139.2 (Cq), 138.0 (CH), 137.3 (Cq), 
132.5 (CH), 128.3 (CH), 125.7 (CH), 125.3 (Cq), 124.7 (CH), 123.5 (CH), 122.8 (CH), 113.9 (Cq), 32.2 (CH2), 
31.7 (CH2), 29.9 (CH2), 29.7 (CH2), 28.6 (CH2), 27.3 (CH2), 22.4 (CH2), 21.7 (CH2), 14.0 (CH3), 13.7 (CH3). 
IR (ATR): 2926, 2868, 1651, 1555, 1486, 1325, 995, 768, 695 cm
-1
. MS (EI) m/z (relative intensity) 363 (15) 
[M+H
+
], 362 (65) [M
+
], 361 (80) [M–H
+
], 319 (55), 305 (100), 291 (40), 247 (40). HR-MS (ESI) m/z calcd 
for C24H29N2O [M–H
+
] 361.2280, found 361.2271. 
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The general procedure G was followed, using amide 85i (114 mg, 0.50 mmol) and alkyne 59d (107 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1 → CH2Cl2/acetone 1:1) 
and then by GPC yielded 134id
,
 (66 mg, 34%) and 134id (59 mg, 29%) as colorless solids. 
The general procedure H was followed, using amide 85i (114 mg, 0.50 mmol) and alkyne 59d (107 mg, 0.60 
mmol), Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1) yielded 134id
,
 (150 mg, 
77%) as a colorless solid. 
 
2-[8-Methyl-1-oxo-3, 4-diphenylisoquinolin-2(1H)-yl] pyridine 1-oxide (134id):  
M. p. = 272–273 ºC.
 1
H NMR (300 MHz, CDCl3) δ = 8.16–8.11 (m, 1H), 7.48–7.41 (m, 1H), 7.39 (d, J = 8.1 
Hz, 1H), 7.30–7.19 (m, 3H), 7.18–7.09 (m, 3H), 7.08–6.98 (m, 4H), 6.97–6.85 (m, 4H), 2.94 (s, 3H). 
13
C 
NMR (125 MHz, CDCl3) δ = 162.1 (Cq), 146.0 (Cq), 142.7 (Cq), 139.8 (CH), 139.7 (Cq), 139.5 (Cq), 136.3 
(Cq), 133.6 (Cq), 132.2 (CH), 131.6 (CH), 131.4 (CH), 130.2 (CH), 130.0 (CH), 128.3 (CH), 128.2 (CH), 
128.2 (CH), 128.0 (CH), 127.8 (CH), 127.6 (CH), 127.0 (CH), 126.9 (CH), 125.0 (CH), 124.7 (CH), 124.2 
(CH), 123.5 (Cq), 119.5 (Cq), 24.1 (CH3). IR (ATR): 3053, 2920, 1660, 1590, 1488, 1339, 1304, 1275, 808, 
744 cm
-1
. MS (EI) m/z (relative intensity) 405 (5) [M+H
+
], 404 (20) [M
+
], 388 (40), 371 (20), 359 (20), 310 
(10), 284 (50), 284 (50), 181 (100). HR-MS (ESI) m/z calcd for C27H21N2O2 [M+H
+




8-Methyl-3, 4-diphenyl-2-(pyridin-2-yl) isoquinolin-1(2H)-one (134id
,
):  
M. p. = 281–283 ºC. 
1
H NMR (400 MHz, CDCl3) δ = 8.40 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.58–7.53 (m, 1H), 
7.39 (dd, J = 8.2, 8.2 Hz, 1H), 7.25 (dd, J = 7.4, 7.4 Hz, 1H), 7.21–7.09 (m, 6H), 7.08–7.02 (m, 2H), 6.98–
6.84 (m, 5H), 2.96 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 163.5 (Cq), 153.2 (Cq), 149.1 (CH), 142.4 (Cq), 
139.9 (Cq), 139.5 (Cq), 137.5 (CH), 136.7 (Cq), 134.3 (Cq), 131.8 (CH), 131.6 (CH), 131.6 (CH), 130.1 (CH), 
127.9 (CH), 127.1 (CH), 126.9 (CH), 126.7 (CH), 125.0 (CH), 124.0 (CH), 123.9 (Cq), 122.7 (CH), 118.9 (Cq), 
24.2 (CH3). IR (ATR): 3059, 2923, 1653, 1557, 1488, 1434, 1149, 997, 695, 593 cm
-1
. MS (EI) m/z (relative 
intensity) 389 (30) [M+H
+
], 388 (100) [M
+
], 387 (40) [M–H
+
], 371 (20), 359 (20), 310 (10), 78 (15). HR-MS 
(EI) m/z calcd for C27H20N2O [M
+
] 388.1576, found 388.1589. 
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The general procedure G was followed, using amide 85h (116 mg, 0.50 mmol) and alkyne 59d (107 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1 → CH2Cl2/acetone 1:1) 
yielded 134hd (131 mg, 64%) and 134hd
,
 (49 mg, 25%) as colorless solids. 
The general procedure H was followed, using amide 85h (116 mg, 0.50 mmol) and alkyne 59d (107 mg, 0.60 
mmol), Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1) yielded 134hd
,
 (108 mg, 
55%) as colorless solid. 
 
2-[6-Fluoro-1-oxo-3, 4-diphenylisoquinolin-2(1H)-yl] pyridine 1-oxide (134hd):  
M. p. = 243–244 ºC 
 1
H NMR (300 MHz, CDCl3) δ = 8.53 (dd, J = 8.9, 5.9 Hz, 1H), 8.14 (dd, J = 6.5, 1.4 Hz, 
1H), 7.46–7.38 (m, 1H), 7.30–7.24 (m, 1H), 7.24–7.21 (m, 1H), 7.21–7.15 (m, 3H), 7.15–7.03 (m, 3H), 7.03–
6.93 (m, 4H), 6.92–6.83 (m, 2H).
 13
C NMR (100 MHz, CDCl3) δ = 165.8 (d, 
1
JC-F = 252.9 Hz, Cq), 160.7 (Cq), 
141.1 (Cq), 140.7 (d, 
3
JC-F = 9.9 Hz, Cq), 139.8 (CH), 135.0 (Cq), 133.3 (Cq), 131.6 (d, 
3
JC-F = 10.1 Hz, CH), 
131.4 (CH), 131.1 (CH), 129.9 (CH), 128.5 (CH), 128.5 (CH), 128.4 (CH), 127.9 (CH), 127.9 (CH), 127.8 
(CH), 127.3 (CH), 127.1 (CH), 125.3 (CH), 124.7 (CH), 121.7 (Cq), 121.7 (Cq), 118.9 (d, 
4
JC-F = 3.2 Hz, Cq), 
115.5 (d, 
2
JC-F = 23.4 Hz, CH), 111.2 (d, 
2
JC-F = 23.4 Hz, CH).
 19
F NMR (282 MHz, CDCl3) δ = – 104.10 (ddd, 
J = 10.4, 8.3, 5.9 Hz). IR (ATR): 3063, 1664, 1608, 1472, 1434, 1328, 1259, 868, 759, 712 cm
-1
. HR-MS 
(ESI) m/z calcd for C26H18F1N2O2 [M+H
+





M. p. = 206–208 ºC. 
1
H NMR (400 MHz, CDCl3) δ = 8.54 (dd, J = 8.8, 5.9 Hz, 1H), 8.37 (ddd, J = 4.9, 1.9, 
0.9 Hz, 1H), 7.58 (dd, J = 7.6, 7.6, 1H), 7.23–7.14 (m, 5H), 7.13–7.05 (m, 3H), 7.00–6.83 (m, 6H). 
13
C NMR 
(100 MHz, CDCl3) δ = 165.6 (d, 
1
JC-F = 254.7 Hz, Cq), 161.9 (Cq), 152.5 (Cq), 149.1 (CH), 141.4 (Cq), 140.4 
(d. 
3
JC-F = 9.8 Hz, Cq), 137.6 (CH), 135.5 (Cq), 134.0 (Cq), 131.4 (CH), 131.4 (CH), 131.3 (d, 
3
JC-F = 8.4 Hz, 
CH), 128.2 (CH), 127.5 (CH), 127.2 (CH), 127.1 (CH), 124.9 (CH), 123.0 (CH), 122.1 (d, 
4
JC-F = 1.7 Hz, Cq), 
118.4 (d, 
4
JC-F = 3.1 Hz, Cq), 115.5 (d, 
2
JC-F = 23.6 Hz, CH) 111.9 (d, 
2
JC-F = 23.4 Hz, CH). 
19
F NMR (283 
MHz, CDCl3) δ = – 105.03 (ddd, J = 10.5, 8.1, 6.0 Hz). IR (ATR): 3057, 1659, 1612, 1470, 1436, 1323, 1181, 
950, 785, 701 cm
-1
. MS (EI) m/z (relative intensity) 393 (30) [M+H
+
], 392 (100) [M
+
], 391 (50) [M–H
+
], 363 
(20), 287 (15), 181 (10), 78 (20). HR-MS (EI) m/z calcd for C26H17FN2O [M
+
] 392.1325, found 392.1325. 
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The general procedure G was followed, using amide 85j (121 mg, 0.50 mmol) and alkyne 59d (107 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1 → CH2Cl2/acetone 1:1) 
yielded 134jd (168 mg, 80%) and 134jd
,
 (29 mg, 14%) as colorless solids. 
When The general procedure H was followed, using amide 85j (121 mg, 0.50 mmol), alkyne 59d (107 mg, 
0.60 mmol), purification by column chromatography on silica gel (n-hexane/EtOAc 2:1) yielded 134jd
,
 (157 
mg, 78%) as a colorless solid. 
 
2-[6, 7-Dimethyl-1-oxo-3, 4-diphenylisoquinolin-2(1H)-yl] pyridine 1-oxide (134jd):  
M. p. = 272–273 ºC
  1
H NMR (300 MHz, CDCl3) δ = 8.26 (s, 1H), 8.11 (dd, J = 6.4, 1.5 Hz, 1H), 7.44–7.38 
(m, 1H), 7.24–7.19 (m, 1H), 7.18–7.08 (m, 3H), 7.07–6.98 (m, 3H), 6.98–6.86 (m, 6H), 2.37 (s, 3H), 2.25 (s, 
3H). 
13
C NMR (75 MHz, CDCl3) δ = 161.4 (Cq), 145.8 (Cq), 143.1 (Cq), 139.8 (CH), 138.8 (Cq), 136.5 (Cq), 
136.1 (Cq), 135.9 (Cq), 133.8 (Cq), 131.6 (CH), 131.3 (CH), 130.2 (CH), 128.6 (CH), 128.5 (CH), 128.2 (CH), 
128.2 (CH), 128.0 (CH), 127.8 (CH), 127.6 (CH), 127.0 (CH), 126.9 (CH), 126.1 (CH), 125.1 (CH), 124.7 
(CH), 123.1 (Cq), 119.2 (Cq), 20.4 (CH3), 19.7 (CH3). IR (ATR): 3054, 2234, 1651, 1591, 1487, 1331, 1264, 
752 cm
-1
. MS (EI) m/z (relative intensity) 418 (10) [M
+
], 402 (20), 313 (25), 298 (40), 181 (100). HR-MS 
(ESI) m/z calcd for C28H22N2O2 [M
+
] 418.1681, found 418.1672.  
 
6, 7-Dimethyl-3, 4-diphenyl-2-(pyridin-2-yl) isoquinolin-1(2H)-one (134jd
,
):  
M. p. = 240–241 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 8.39–8.35 (m, 1H), 8.30 (s, 1H), 7.58 (dd, J = 7.7, 7.7 
Hz, 1H), 7.25–7.10 (m, 6H), 7.08–7.03 (m, 1H), 7.00–6.92 (m, 3H), 6.89–6.86 (m, 3H), 2.41 (s, 3H), 2.28 (s, 
3H). 
13
C NMR (75 MHz, CDCl3) δ = 162.5 (Cq), 152.9 (Cq), 148.9 (CH), 142.6 (Cq), 139.1 (Cq), 137.4 (CH), 
136.4 (Cq), 136.3 (Cq), 135.9 (Cq), 134.5 (Cq), 131.6 (CH), 131.0 (CH), 128.2 (CH), 127.8 (CH), 127.1 (CH), 
126.9 (CH), 126.7 (CH), 126.0 (CH), 125.0 (CH), 123.6 (Cq), 122.7 (CH), 118.7 (Cq), 20.4 (CH3), 19.7 (CH3). 
IR (ATR): 3054, 2918, 1659, 1617, 1586, 1487, 1465, 1431, 1321, 715 cm
-1
. MS (EI) m/z (relative intensity) 
403 (35) [M+H
+
], 402 (100) [M
+
], 401 (30) [M–H
+
], 373 (20), 297 (15), 181 (10). HR-MS (ESI) m/z calcd for 
C28H22N2O [M
+
] 402.1732, found 402.1723. 
 
The general procedure G was followed, using amide 85k (114 mg, 0.50 mmol) and alkyne 59d (107 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1 → CH2Cl2/acetone 1:1) 
and then by GPC yielded 134kd (144 mg, 71%) and 134kd
,
 (45 mg, 23%) as colorless solids. 
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The general procedure H was followed, using amide 85k (114 mg, 0.50 mmol) and alkyne 59d (107 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1) yielded 134kd
,
 (172 mg, 
78%) as a colorless solid.  
 
2-(7-Methyl-1-oxo-3, 4-diphenylisoquinolin-2(1H)-yl) pyridine 1-oxide (134kd):  




H NMR (400 MHz, CDCl3) δ = 8.32 (dd, J = 1.2, 0.6 Hz, 1H), 8.13 (d, J = 6.4 Hz, 1H), 
7.44–7.38 (m, 2H), 7.27–7.20 (m, 2H), 7.16–7.10 (m, 4H), 7.07–7.03 (m, 2H), 7.01 – 6.94 (m, 3H), 6.93–6.88 
(m, 2H), 2.47 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 161.5 (Cq), 139.9 (CH), 138.7 (Cq), 137.2 (Cq), 137.2 
(Cq), 135.8 (Cq), 135.7 (Cq), 134.5 (CH), 133.7 (Cq), 131.6 (CH), 131.3 (CH), 130.2 (CH), 128.7 (CH), 128.3 
(CH), 128.3 (CH), 128.0 (CH), 127.9 (CH), 127.8 (CH), 127.7 (CH), 127.1 (CH), 127.0 (CH), 125.8 (CH), 
125.2 (CH), 125.0 (Cq), 124.7 (CH), 119.4 (Cq), 21.3 (CH3). IR (ATR): 3053, 3002, 2918, 1655, 1593, 1510, 
1488, 1436, 1243, 761 cm
-1
. HR-MS (ESI) m/z calcd for C27H21N2O2 [M+H
+





M. p. = 180–181 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 8.40–8.31 (m, 2H), 7.57 (dd, J = 7.7, 7.7 Hz, 1H), 7.39 
(dd, J = 8.3, 2.0 Hz, 1H), 7.22–7.02 (m, 8H), 6.99–6.81 (m, 5H), 2.48 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ = 
162.6 (Cq), 152.8 (Cq), 149.0 (CH), 139.1 (Cq), 137.4 (CH), 137.0 (Cq), 136.3 (Cq), 135.5 (Cq), 134.4 (Cq), 
134.1 (CH), 131.6 (CH), 131.6 (CH), 127.9 (CH), 127.7 (CH), 127.1 (CH), 127.0 (CH), 126.8 (CH), 125.6 
(CH), 125.4 (Cq), 125.0 (CH), 122.8 (CH), 118.9 (Cq), 21.3 (CH3). IR (ATR): 3055, 2919, 1654, 1587, 1432, 
1316, 997, 833, 760 cm
-1
. MS (EI) m/z (relative intensity) 389 (30) [M+H
+
], 388 (100) [M
+
], 387 (30) [M–H
+
], 
359 (20), 283 (15), 181 (10), 78 (30). HR-MS (EI) m/z calcd for C27H20N2O [M
+
] 388.1576, found 388.1587. 
 
The general procedure G was followed, using amide 85a (107 mg, 0.50 mmol) and alkyne 59b (70 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1 → CH2Cl2/acetone 1:1) 
yielded 134ab (13:1 mixture of isomers, only the major isomer could be isolated by column chromatography) 
(120 mg, 73%) and 134ab
,
 (5 mg, 3%) as colorless solids. 
The general procedure H was followed, using amide 85a (107 mg, 0.50 mmol) and alkyne 59b (70 mg, 0.60 
mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc 2:1) yielded 134ab
,
 (16:1 
mixture of isomers, only the major isomer could be isolated by column chromatography) (114 mg, 73%) as a 
colorless solid. 




2-[4-Methyl-1-oxo-3-phenylisoquinolin-2(1H)-yl] pyridine 1-oxide (134ab):  
M. p. = 227–228 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 8.48 (dt, J = 8.0, 1.0 Hz, 1H), 8.11–8.05 (m, 1H), 7.78–
7.68 (m, 2H), 7.55–7.46 (m, 2H), 7.26–7.11 (m, 4H), 7.09–6.93 (m, 3H), 2.08 (s, 3H). 
13
C NMR (125 MHz, 
CDCl3) δ = 161.3 (Cq), 145.6 (Cq), 139.7 (CH), 138.5 (Cq), 137.9 (Cq), 133.9 (Cq), 133.1 (CH), 129.7 (CH), 
128.8 (CH), 128.5 (CH), 128.4 (CH), 128.2 (CH), 127.9 (CH), 127.6 (CH), 126.8 (CH), 125.3 (Cq), 125.1 
(CH), 124.5 (CH), 123.6 (CH), 111.2 (Cq), 14.6 (CH3). IR (ATR): 3048, 1652, 1622, 1590, 1489, 1430, 1337, 
1263, 761 cm
-1
. MS (EI) m/z (relative intensity) 329 (5) [M+H
+
], 328 (20) [M
+
], 312 (10), 283 (10), 208 (50), 
193 (25), 181 (100), 165 (20). HR-MS (EI) m/z calcd for C21H16N2O2 [M
+





M. p. = 162–163 ºC. 
 1
H NMR (300 MHz, CDCl3) δ = 8.54 (dd, J = 8.0, 8.0 Hz, 1H), 8.37–8.34 (m, 1H), 
7.78–7.73 (m, 2H), 7.59 –7.55 (m, 1H), 7.55–7.51 (m, 1H), 7.21–7.09 (m, 6H), 7.06–7.02 (m, 1H), 2.11 (s, 
3H). 
13
C NMR (125 MHz, CDCl3) δ = 162.4 (Cq), 152.8 (Cq), 148.9 (CH), 139.1 (Cq), 137.7 (Cq), 137.3 (CH), 
134.7 (Cq), 132.7 (CH), 130.5 (CH), 128.3 (CH), 127.8 (CH), 127.6 (CH), 126.7 (CH), 125.8 (Cq), 124.9 (CH), 
123.4 (CH), 122.6 (CH), 110.5 (Cq), 14.5 (CH3). IR (ATR): 3059, 2917, 1650, 1586, 1483, 1463, 1324, 776, 
688 cm
-1
. MS (EI) m/z (relative intensity) 313 (25) [M+H
+
], 312 (100) [M
+
], 311 (45) [M–H
+
], 283 (70), 269 
(30), 206 (15). HR-MS (EI) m/z calcd for C21H16N2O [M
+
] 312.1263, found 312.1260. 
 
Procedure for Gram-Scale Reactions 
 
To a 50 mL Schlenk flask was added amide 85b (1.22 g, 5.0 mmol), alkyne 59i (577 mg, 6.0 mmol), PivOH 
(1.02 g, 10.0 mmol), Co(OAc)2 (88 mg, 10 mol %). The Schlenk flask was evacuated and refilled with O2 
three times with a balloon. TFE (20 mL) was added via cannula and the mixture was stirred in a pre-heated (60 
ºC) oil bath for 16 h (The O2 balloon was connected to the Schlenk flask until the reaction was finished). At 
ambient temperature, the reaction was stopped by adding saturated aqueous NaHCO3 (40 mL). The mixture 
was extracted with CH2Cl2 (4×30 mL) and the organic phase dried over Na2SO4. Evaporation of the solvent 
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and purification by column chromatography on silica gel (CH2Cl2/acetone 3:1) afforded the corresponding 
product 134bi (1.44 g, 85%) as a colorless solid. 
 
 
To a 50 mL Schlenk flask was added aromatic amides 85a (1.07 g, 5.0 mmol), alkyne 59j (613 mg, 6.0 mmol), 
PivOH (1.02 g, 10.0 mmol), Co(OAc)2 (88 mg, 10 mol %). The Schlenk flask was evacuated and refilled with 
O2 three times with a balloon. TFE (20 mL) was added via cannula and the mixture was stirred in a pre-heated 
(60 ºC) oil bath for 16 h (The O2 balloon was connected to the Schlenk flask until the reaction was finished). 
At ambient temperature, the reaction was stopped by adding saturated aqueous NaHCO3 (40 mL). The mixture 
was extracted with CH2Cl2 (4×30 mL) and the organic phase dried over Na2SO4. Evaporation of the solvents 
and purification by column chromatography on silica gel (CH2Cl2/acetone 3:1) afforded the corresponding 
product 134aj (1.41 g, 90%) as a colorless solid. 
 
 
Intermolecular Competition Experiments  
1) Intermolecular Competition Experiment between aromatic amides 85c and 85h. 
 
The general procedure H was followed, using amides 85c (114 mg, 0.50 mmol), 85h (116 mg, 0.50 mmol) 
and alkyne 59j (51 mg, 0.50 mmol). Purification by column chromatography on silica gel (n-hexane/EtOAc) 
gave a mixture (133 mg) of 134cj
,
 (46%) and 134hj
,
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2) Intermolecular Competition Experiment between alkyne 59r and 59s. 
 
The general procedure G was followed, using amide 85a (107 mg, 0.50 mmol) and alkynes 59r (58 mg, 0.50 
mmol) and 59s (60 mg, 0.50 mmol). Purification by column chromatography on silica gel (CH2Cl2/acetone 2:1) 
gave a mixture (159 mg) of 134ar (59%) and 134as (37%) as a colorless solid. 
 
 
H/D Exchange Experiment 
1) Cobalt-Catalyzed H/D Exchange in Substrate 85a with D2O as the Co-solvent in the Absence of 
Alkyne 
 
Under an atmosphere of ambient air, to a 25 mL Schlenk tube were added amide 85a (107 mg, 0.50 mmol), 
PivOH (102 mg, 1.0 mmol), Co(OAc)2 (8.9 mg, 10 mol %). The Schlenk tube was evacuated and refilled with 
O2 three times with a balloon. TFE (1.8 mL) and D2O (0.2 mL) was added via cannula. Then the mixture was 
stirred in a pre-heated (60 ºC) oil bath for 16 h (The O2 balloon was connected to the Schlenk tube until the 
reaction was finished). At ambient temperature, the reaction was stopped by adding saturated aqueous 
NaHCO3 (15 mL) and extracted with CH2Cl2 (4×10 mL) and dried over Na2SO4. Evaporation of the solvents 
and purification by column chromatography on silica gel (CH2Cl2/acetone 2:1) gave [D]n-85a´ (105 mg, 98%) 
as a colorless solid. The D-incorporation was estimated based on 
1
H-NMR spectroscopy.  






2) Cobalt-Catalyzed H/D Exchange with D2O as the Co-solvent in the Presence of Alkyne 59j 
 
The general procedure G was followed, using 85a (107 mg, 0.50 mmol), 59j (61 mg, 0.60 mmol), Co(OAc)2 
(9.0 mg, 10 mol %) and PivOH (102 mg, 1.0 mmol) in a solvent mixture of CF3CH2OH (1.8 mL) and 
CD3OD( 0.2 mL). Purification by column chromatography (CH2Cl2 /acetone: 2:1→1:1) yielded [D]n-134aj 
(145 mg, 92%) as a colorless solid. The D-incorporation was estimated by 
1
H-NMR spectroscopy.  





Kinetic Isotope Effect Experiments 
1) Intramolecular Competition Experiment 
 
The general procedure G was followed, using [D]1-85a (107 mg, 0.50 mmol) and 59j (61 mg, 0.60 mmol). 
Purification by column chromatography (CH2Cl2/acetone: 2:1→1:1) yielded [D]n-134aj (127 mg, 81%) as a 
colorless solid. The D-incorporation in [D]n-134aj was estimated by 
1
H-NMR spectroscopy.  
 





2) Intermolecular Competition Experiment 
 
The general procedure H was followed, using aromatic amide 85a (107 mg, 0.50 mmol), [D]5-85a (109 mg, 
0.50 mmol) and alkyne 59j (51 mg, 0.50 mmol). Purification by column chromatography (n-hexane /EtOAc 
2:1→1:1) yielded a mixture of 134aj and [D]4-134aj (92 mg, 61%) as a colorless solid. The D-incorporation 
in [D]n-134aj was estimated by 
1
H-NMR spectroscopy. 





Oxygen up-take Studies 
1) O2-uptake Study with Terminal Alkyne 2a 
 
The general procedure G was followed, using aromatic amide 85a (200 mg, 0.93 mmol), alkyne 59j (114 mg, 
1.12 mmol), PivOH (190 mg, 1.86 mmol) and Co(OAc)2 (16.5 mg, 10 mol %). The Schlenk tube was 
connected to a burette with a reservoir filled with oxygen-saturated water. The mixture was stirred at 60 ºC 
and the changes in volume were determined, as shown in Table S-2. At ambient temperature, the reaction was 
stopped by adding saturated aqueous NaHCO3 (30 mL). This mixture was extracted with CH2Cl2 (4×20 mL) 
and dried over Na2SO4. Evaporation of the solvent and purification by column chromatography on silica gel 
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Table S-1: O2-uptake Study. 
t / h V / mL ∆V / mL n / mmol 
0 21.7 0 0 
0.083 21.8 0 0 
0.167 21.7 0 0 
0.217 21.4 0.3 0.013 
0.250 21.1 0.6 0.027 
0.283 21.0 0.7 0.031 
0.333 20.7 1.0 0.045 
0.417 19.8 1.9 0.085 
0.500 19.0 2.7 0.120 
0.583 18.5 3.2 0.143 
0.667 17.9 3.8 0.170 
0.750 17.6 4.1 0.183 
0.833 17.4 4.3 0.192 
0.917 17.2 4.5 0.201 
1.000 17.0 4.7 0.210 
1.083 16.7 5.0 0.223 
1.167 16.5 5.2 0.232 
1.333 16.0 5.7 0.254 
1.500 15.7 6.0 0.268 
1.667 15.4 6.3 0.281 
1.833 15.0 6.7 0.299 
2.000 14.8 6.9 0.308 
2.167 14.3 7.4 0.330 
2.500 13.7 8.0 0.357 
2.833 12.9 8.8 0.393 
3.167 12.5 9.2 0.411 
3.500 12.3 9.4 0.420 
3.750 12.0 9.7 0.433 
4.667 11.0 10.7 0.478 
5.000 10.8 10.9 0.486 
5.417 10.7 11.0 0.491 
6.000 10.8 10.9 0.487 
6.250 10.8 10.9 0.487 
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Figure S-1: O2-uptake with terminal alkyne 59j. 
 
2) O2-uptake Study with Internal Alkyne 59d 
 
The general procedure G was followed, using aromatic amide 85a (207 mg, 1.00 mmol), alkyne 59d (214 mg, 
1.20 mmol), PivOH (204 mg, 2.0 mmol) and Co(OAc)2 (18 mg, 10 mol %). The Schlenk tube was connected 
to a burette with a reservoir filled with O2-saturated water. The mixture was stirred at 60 ºC and the changes in 
volume were determined as shown in Table S-3. At ambient temperature, the reaction was stopped with 
saturated aqueous NaHCO3 (30 mL). This mixture was extracted with CH2Cl2 (4×20 mL) and dried over 
Na2SO4. Evaporation of the solvents and purification by column chromatography on silica gel (n-
hexane/EtOAc 2:1→CH2Cl2/acetone 2:1) yielded 134ad (285 mg, 73%) and 134ad
,
 (65 mg, 17%) as colorless 
solids. 
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Table S-2: O2-uptake Study. 
t / h V / mL ∆V / mL n / mmol 
0 23.5 0 0 
0.083 23.5 0 0 
0.167 23.5 0 0 
0.250 23.5 0 0 
0.333 23.5 0 0 
0.417 23.2 0.3 0.013 
0.500 23.1 0.4 0.018 
0.583 23.0 0.5 0.022 
0.667 23.0 0.5 0.022 
0.750 22.9 0.6 0.027 
0.833 22.7 0.8 0.036 
0.917 22.6 0.9 0.040 
1.000 22.5 1.0 0.045 
1.167 22.4 1.1 0.049 
1.333 22.3 1.2 0.054 
1.500 22.1 1.4 0.062 
1.667 22.0 1.5 0.067 
1.833 21.8 1.7 0.076 
2.000 21.6 1.9 0.085 
2.167 21.4 2.1 0.094 
2.500 21.4 2.1 0.094 
3.500 20.8 2.7 0.120 
3.667 20.6 2.9 0.129 
4.667 20.1 3.4 0.152 
5.417 19.3 4.2 0.187 
5.917 18.9 4.6 0.205 
6.333 18.5 5.0 0.223 
6.667 18.4 5.1 0.228 
7.667 17.7 5.8 0.259 
8.167 17.4 6.1 0.272 
8.833 17.0 6.5 0.290 
9.333 16.6 6.9 0.308 
9.917 16.3 7.2 0.321 
12.000 15.5 8.0 0.357 
12.333 15.4 8.1 0.362 
13.333 14.9 8.6 0.384 
16.000 14.5 9 0.402 































Figure S-2: O2-uptake with internal alkyne 59d. 
 
Removal of Directing Group 
 
 
6-Methoxy-3-n-pentylisoquinolin-1(2H)-one (165bi): To a 25 mL Schlenk tube was added 134bi (169 mg, 
0.50 mmol), KOtBu (168 mg, 1.50 mmol) and DMSO (5.0 mL) under an atmosphere of N2. The reaction 
mixture was heated to 80 ºC for 16 h. At ambient temperature, the reaction mixture was diluted with  EtOAc 
(100 mL) and washed with H2O (30 mL) and brine (30 mL). The organic phase was dried over Na2SO4, 
evaporation of the solvents and purification by column chromatography on silica gel (n-hexane/EtOAc: 
2:1→1:1) afforded 165bi (96 mg, 78%) as a pale yellow solid.  
M. p. = 120–121 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 11.78 (s, 1H), 8.29 (d, J = 8.9 Hz, 1H), 6.99 (dd, J = 
8.9, 2.5 Hz, 1H), 6.82 (d, J = 2.5 Hz, 1H), 6.23 (s, 1H), 3.88 (s, 3H), 2.63 (t, J = 7.6 Hz, 2H), 1.76 (m, 2H), 
1.46–1.27 (m, 4H), 0.90 (t, J = 7.0 Hz, 3H). 
13
C NMR (125 MHz, CDCl3) δ = 164.5 (Cq), 162.8 (Cq), 143.2 
(Cq), 140.9 (Cq), 129.1 (CH), 118.2 (Cq), 115.3 (CH), 106.1 (CH), 103.5 (CH), 55.3 (CH3), 33.3 (CH2), 31.2 
(CH2), 28.0 (CH2), 22.3 (CH2), 13.9 (CH3). IR (ATR): 2930, 1632, 1602, 1497, 1454, 1434, 1371, 1245, 1166, 
863 cm
-1
. MS (EI) m/z (relative intensity) 246 (10) [M+H
+
], 245 (40) [M
+
], 202 (20), 189 (100), 161 (20), 146 
(10). HR-MS (EI) m/z calcd for C15H19NO2 [M
+
], 245.1416, found 245.1417. 
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Synthesis of Di-Methoxyrosettacin 170 
 
 
2-[6,7-Dimethoxy-3-(3-((4-methoxybenzyl)oxy)propyl)-1-oxoisoquinolin-2(1H)-yl] pyridine 1-oxide 
(134lk): The general procedure G was followed, by using amide 85l (1.37 g, 5.0 mmol), alkyne 59k (1.22 g, 
6.0 mmol), PivOH (1.02 g, 10.0 mmol) and Co(OAc)2 (88 mg, 10 mol %) in TFE (20 mL). Purification by 
column chromatography on silica gel (CH2Cl2/acetone 3:1) afforded the product 134lk (1.69 g, 71%) as a 
colorless solid.  
M. p. = 164–165 ºC. 
1
H NMR (300 MHz, CDCl3) δ = 8.40–8.33 (m, 1H), 7.71 (s, 1H), 7.49–7.39 (m, 1H), 
7.36–7.29 (m, 2H), 7.20–7.14 (m, 2H), 6.89–6.82 (m, 2H), 6.82 (s, 1H), 6.33 (s, 1H), 4.34 (s, 2H), 4.00 (s, 
3H), 3.95 (s, 3H), 3.80 (s, 3H), 3.47–3.28 (m, 2H), 2.54–2.25 (m, 2H), 1.85–1.75 (m, 2H).
 13
C NMR (125 
MHz, CDCl3) δ =161.9 (Cq), 159.1 (Cq), 154.1 (Cq), 148.8 (Cq), 144.6 (Cq), 140.6 (CH), 140.4 (Cq), 133.0 (Cq), 
130.4 (Cq), 129.2 (CH), 128.0 (CH), 125.9 (CH), 125.3 (CH), 118.1 (Cq), 113.7 (CH), 108.1 (CH), 106.0 (CH), 
104.9 (CH), 72.4 (CH2), 68.4 (CH2), 56.1 (CH3), 56.1 (CH3) 55.3 (CH3), 28.7 (CH2), 27.7 (CH2). IR (ATR): 
3048, 2945, 2857, 1664, 1596, 1248, 1160, 1031, 754 cm
-1
. MS (EI) m/z (relative intensity) 460 (20), 355 (10), 
340 (20), 339 (70), 323 (35), 309 (40), 295 (60), 121 (100). HR-MS (ESI) m/z calcd for C27H29N2O6 [M+H
+
], 
477.2020, found 477.2018. 
 
 
6, 7-Dimethoxy-3-[3-{(4-methoxybenzyl)oxy}propyl]isoquinolin-1(2H)-one (165lk): to a 100 mL Schlenk 
tube was added 134lk (1.67 g, 3.50 mmol), KOt-Bu (1.18 g, 10.50 mmol) and DMSO (35 mL) under an 
atmosphere of N2, the reaction mixture was heated to 80 ºC for 16 h. At ambient temperature, the reaction was 
diluted with EtOAc (200 mL) and washed with H2O (40 mL) and brine (40 mL). The organic phase was dried 
over Na2SO4. Evaporation of the solvent and purification by column chromatography on silica gel (n-
hexane/EtOAc: 2:1→1:1) afforded 165lk (1.13 g, 84%) as a pale yellow solid.  
M. p. = 136–137 ºC. 
 1
H NMR (400 MHz, CDCl3) δ = 10.10 (s, 1H), 7.72 (s, 1H), 7.30 (d, J = 8.8 Hz, 2H), 
6.88 (d, J = 8.8 Hz, 2H), 6.81 (s, 1H), 6.17 (s, 1H), 4.48 (s, 2H), 3.98 (s, 3H), 3.97 (s, 3H), 3.80 (s, 3H), 3.52 
(t, J = 5.9 Hz, 2H), 2.69 (t, J = 7.2 Hz, 2H), 2.05–1.94 (m, 2H).
 13
C NMR (125 MHz, CDCl3) δ = 163.3 (Cq), 
159.2 (Cq), 153.7 (Cq), 148.6 (Cq), 139.4 (Cq), 134.1 (Cq), 130.2 (Cq), 129.5 (CH), 118.3 (Cq), 113.8 (CH), 
107.1 (CH), 105.8 (CH), 103.6 (CH), 72.7 (CH2), 68.3 (CH2), 56.1 (CH3), 56.0 (CH3), 55.2 (CH3), 30.1 (CH2), 
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28.3 (CH2). IR (ATR): 2935, 1636, 1608, 1498, 1395, 1249, 1219, 994, 825 cm
-1
. MS (EI) m/z (relative 
intensity) 384 (10) [M+H
+
], 383 (40) [M
+
], 339 (10), 262 (20), 247 (15), 232 (25), 219 (20), 121 (100).HR-
MS (ESI) m/z calcd for C22H25NO5 [M
 +
], 383.1733, found 383.1724. 
 
 
3-(3-Hydroxypropyl)-6, 7-dimethoxyisoquinolin-1(2H)-one (166): to a solution of ether 165lk (958 mg, 2.5 
mmol) in EtOH (20 mL) was added Pd/C (96 mg, 10 mol %). The reaction mixture was set under hydrogen 
atmosphere (1 atm H2) and heated to 50 ºC for 24 h. The reaction mixture was filtered through Celite, and 
after removal of the solvent the crude product was purified by column chromatography on silica gel 
(CH2Cl2/MeOH 10:1) to give 166 (579 mg, 88 %) as a colorless solid.  
M. p. = 252–253 ºC. 
 1
H NMR (300 MHz, DMSO-d6) δ = 11.01 (sbr, 1H), 7.50 (s, 1H), 7.04 (s, 1H), 6.24 (s, 
1H), 4.49 (sbr, 1H), 3.86 (s, 3H), 3.83 (s, 3H), 3.44 (t, J = 6.6 Hz, 2H), 2.56–2.45 (m, 2H), 1.81–1.71 (m, 2H). 
13
C NMR (125 MHz, DMSO-d6) δ = 161.8 (Cq), 153.1 (Cq), 147.9 (Cq), 140.6 (Cq), 133.6 (Cq), 117.7 (Cq), 
106.6 (CH), 106.3 (CH), 101.7 (CH), 59.8 (CH2), 55.6 (CH3), 55.4 (CH3), 31.1 (CH2), 28.8 (CH2). IR (ATR): 
3373, 2937, 1626, 1602, 1552, 1500, 1263, 1221, 877, 658 cm
-1
. MS (EI) m/z (relative intensity) 364 (20) 
[M+H
+
], 363 (90) [M
+
], 248 (10), 232 (20), 219 (100), 204 (30), 188 (10), 174 (10). HR-MS (EI) m/z calcd 
for C14H17NO4 [M
+
], 263.1158, found 263.1153. 
 
 
7, 8-Dimethoxy-2, 3-dihydropyrrolo [1, 2-b] isoquinolin-5(1H)-one (167):
[134] 
a 50 mL flask was charged 
with compound 166 (527 mg, 2.0 mmol), PPh3 (787 mg, 3.0 mmol), and THF (15 mL). Diisopropyl 
azodicarboxylate (0.6 mL, 3.0 mmol) in THF (5.0 mL) was added dropwise at 0 ºC. Upon completion of the 
addition, the mixture was allowed to warm to ambient temperature and was stirred for 16 h. The solvent was 
removed and the residue purified by column chromatography on silica gel (n-hexane/EtOAc 2:1) to afford 167 
(461 mg, 94%) as a colorless solid. 
 
M. p. = 190–191 ºC. 
 1
H NMR (300 MHz, DMSO-d6) δ = 7.73 (s, 1H), 6.79 (s, 1H), 6.31 (s, 1H), 4.15 (t, J = 
7.2 Hz, 2H), 3.97 (s, 3H), 3.95 (s, 3H), 3.06 (t, J = 7.6 Hz, 2H), 2.22–2.12 (m, 2H).
 13
C NMR (75 MHz, CDCl3) 
δ = 160.7 (Cq), 153.0 (Cq), 148.2 (Cq), 142.2 (Cq), 133.5 (Cq), 118.3 (Cq), 107.0 (CH), 105.5 (CH), 99.7 (CH), 
56.0 (CH3), 55.8 (CH3), 47.9 (CH2), 31.0 (CH2), 21.9 (CH2). IR (ATR): 3055, 2891, 2824, 1660, 1596, 1506, 
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1454, 1252, 1119, 997 cm
-1
. MS (EI) m/z (relative intensity) 246 (20) [M+H
+
], 245 (100) [M
+
], 230 (75), 202 
(40), 200 (25), 172(20), 159 (15). HR-MS (EI) m/z calcd for C14H15NO3 [M
+




7, 8-Dimethoxy-2, 3-dihydropyrrolo [1, 2-b] isoquinoline-1, 5-dione (168):
[134] 
a mixture of compound 167 
(368 mg, 1.5 mmol) and SeO2 (200 mg, 1.8 mmol) in 1,4-dioxane (15 mL) and H2O (0.5 mL) was heated at 
110 
º
C for 6 h. At ambient temperature, the reaction mixture was diluted with CH2Cl2(40 mL), filtered through 
Celite, and the filtrate was concentrated in vacuo. The residue was dissolved in CH2Cl2 (20 mL), Li2CO3 (222 
mg, 3.0 mmol) and 4 Å molecular sieve (1.10 g) was added. PCC (647 mg, 3.0 mmol) was added in one 
portion at 0 ºC. The mixture was allowed to warm to ambient temperature and stirred for 24 h. The reaction 
mixture was then diluted with CH2Cl2(40 mL) and filtered through Celite. The filtrate was concentrated in 
vacuo. The residue was purified by column chromatography on silica gel (n-hexane/EtOAc 3:1) to give 168 
(280 mg, 72%) as an off-white solid. 
 
M. p. = 249–250 ºC. 
1
H NMR (500 MHz, CDCl3) δ = 7.84 (s, 1H), 7.19 (s, 1H), 7.06 (s, 1H), 4.37 (t, J = 7.1 
Hz, 2H), 4.05 (s, 3H), 4.02 (s, 3H), 2.93 (t, J = 7.1 Hz, 2H). 
13
C NMR (125 MHz, CDCl3) δ = 197.6 (Cq), 
160.3 (Cq), 153.5 (Cq), 151.5 (Cq), 133.4 (Cq), 131.2 (Cq), 123.1 (Cq), 108.4 (CH), 107.3 (CH), 104.7 (CH), 
56.4 (CH3), 56.2 (CH3), 41.5 (CH2), 34.1 (CH2).  IR (ATR): 3062, 2928, 2830, 1720, 1643, 1508, 1462, 1093, 
653 cm
-1
. MS (EI) m/z (relative intensity) 260 (20) [M+H
+
], 259 (100) [M
+
], 244 (30), 214 (40), 188 (30), 
160(35), 117 (20). HR-MS (EI) m/z calcd for C14H13NO4 [M
+




8, 9-Dimethoxybenzo[6, 7]indolizino[1, 2-b] quinolin-11(13H)-one (170):
[134]
 a mixture of ketone 168 (52 
mg, 0.20 mmol), 2-aminobenzylidene-p-tolylamine (169) (46 mg, 0.22 mmol), and p-toluenesulfonic acid 
monohydrate (2.6 mg 0.014 mmol) in PhMe (2.0 mL) was stirred at 125 ºC for 16 h in a 20 mL sealed tube. 
Then, the reaction mixture was allowed to cool to ambient temperature. The solvents were removed in vacuo. 
The residue was purified by column chromatography on silica gel (EtOAc/acetone 1:1) to give 170 (66 mg, 
96%) as an off-white solid.  
M. p. = 301–303 ºC. 
1
H NMR (300 MHz, DMSO-d6, 120
 
ºC) δ = 8.55 (s, 1H), 8.13 (d, J = 8.5 Hz, 1H), 8.07–
8.02 (m, 1H), 7.85–7.80 (m, 1H), 7.79 (s, 1H), 7.65 (ddd, J = 8.2, 6.9, 1.3 Hz, 1H), 7.55 (s, 1H), 7.43 (s, 1H), 
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5.31 (d, J = 1.3 Hz, 2H), 3.98 (s, 3H), 3.95 (s, 3H). 
13
C NMR (75 MHz, DMSO-d6, 120
 
ºC) δ = 158.6 (Cq), 
153.1 (Cq), 153.0 (Cq), 149.3 (Cq), 147.7 (Cq), 138.4 (Cq), 132.2 (Cq), 130.2 (CH), 129.1 (CH), 128.8 (Cq), 
128.2 (CH), 127.6 (CH), 127.2 (Cq), 126.2 (CH), 119.5 (Cq), 108.3 (CH), 107.5 (CH), 98.9 (CH), 55.5 (CH3), 
55.5 (CH3), 48.7 (CH2). IR (neat): 3059, 3006, 2924, 1651, 1597, 1504, 1446, 1272, 1023, 789  cm
-1
. MS (EI) 
m/z (relative intensity) 345 (2) [M+H
+
], 344 (15) [M
+
], 329 (10), 301 (10), 229 (5), 121 (5), 84 (60), 66 (100). 
HR-MS (EI) m/z calcd for C21H16N2O3 [M
+
], 344.1161, found 344.1157.
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